[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fI42A7zLNslrQUpb_iP-YfRL5tGb3Dk9EXwJYxc3lSZo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":85,"rows":92},"City of Hope Medical Center",[4],655,false,326,8,1077751,273,217,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Breast Cancer",41,{"name":18,"count":19},"Acute Myeloid Leukemia",28,{"name":21,"count":22},"Myelodysplastic Syndrome",27,{"name":24,"count":25},"Unspecified Adult Solid Tumor, Protocol Specific",26,{"name":27,"count":25},"Lymphoma",{"name":29,"count":30},"Malignant Solid Neoplasm",24,{"name":32,"count":33},"Leukemia",21,{"name":35,"count":36},"Acute Lymphoblastic Leukemia",18,[38,43,47,52,57,62,67,72,76,80],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT00544115","Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","2007-03-13","busulfan",{"nctId":44,"briefTitle":45,"date":46,"intervention":42},"NCT00534430","Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer","2010-04-12",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT00544830","Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","2011-03-16","Bicalutamide",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT00609791","Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer","2011-10-25","paclitaxel albumin-stabilized nanoparticle formulation",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT00544466","Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies","2013-08-01","fludarabine phosphate",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT01318317","Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma","2013-10-03","Filgrastim",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT01199562","Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant","2013-12-30","DNA analysis",{"nctId":73,"briefTitle":74,"date":70,"intervention":75},"NCT00295893","Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer","cyclophosphamide",{"nctId":77,"briefTitle":78,"date":79,"intervention":71},"NCT00977457","Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery","2016-07-13",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT01463072","Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer","2017-05-17","Nab-paclitaxel",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,231,249,485,556,640,677,755,783,1537,1665,1815,2089,2264,2519,2656,2837,3004,3128,3214,3372,3478,3528,3599,3674,3735,3781,3836,3940,4020,4100,4150,4204,4238,4275,4305,4340,4405,4448,4510,4560,4644,4688,4726,4775,4801,4837,4863,4889,4938,4964,4996,5094,5140,5174,5218,5257,5287,5317,5354,5385,5411,5437,5463,5500,5522,5554,5576,5598,5620,5642,5664,5686,5717,5739,5761,5796,5818,5840,5862,5884,5912,5944,5966,5988,6038,6097,6127,6183,6213,6275,6301,6336,6367,6400,6431,6453,6475,6501,6523,6541,6559,6577,6601,6625,6643,6669,6687,6714,6732,6750,6768,6786,6804,6827,6855,6873,6897,6915,6933,6951,6976,6994,7012,7030,7048,7066,7095,7113,7131,7149,7167,7185,7203,7221,7244,7262,7280,7298,7316,7334,7359,7377,7395,7413,7431,7449,7473,7491,7519,7537,7555,7605,7635,7720,7754,7799,7825,7851,7916,7949,7987,8025,8055,8077,8099,8125,8153,8186,8218,8240,8262,8284,8446,8476,8502,8548,8574,8596,8618,8657,8717,8748,8774,8796,8818,8853,8875,8904,8926,8944,8962,8985,9003,9021,9039,9057,9075,9093,9111,9143,9161,9179,9197,9215,9233,9257,9275,9293,9311,9335,9359,9382,9400,9422,9440,9458,9476,9499,9517,9541,9567,9585,9603,9621,9639,9667,9685,9703,9727,9745,9763,9781,9804,9822,9840,9864,9888,9906,9924,9947,9969,9987,10005,10031,10049,10067,10085,10103,10125,10149,10172,10190,10208,10230,10248,10270,10288,10306,10411,10433,10457,10481,10504,10527,10549,10607,10640,10673,10691,10709,10727,10750,10777,10804,10822,10866,10904,10960,10990,11024,11050,11088,11114,11140,11166,11192,11214,11245,11270,11292,11314,11336,11358,11383,11405,11431,11467,11503,11529,11557,11579,11601,11619,11643,11661,11679,11697,11715,11743,11767,11793,11811,11835,11858,11876,11894,11917,11935,11953,11981,12003,12021,12045,12063,12088,12106,12130,12148,12166,12184,12202,12231,12253,12283,12313,12335,12357,12407,12429,12447,12465,12488,12506,12530,12548,12566,12584,12602,12620,12638,12656,12674,12692,12710,12728,12746,12764,12782,12800,12818,12836,12854,12872,12890,12908,12926,12950,12968,12986,13010,13034,13058,13081,13105,13128,13146,13170,13188,13211,13229,13247,13265,13283,13301,13319,13337,13355,13376,13394,13412,13430,13452,13476,13499,13522,13572,13606,13632,13668,13690,13708,13732,13756,13780,13804,13822,13851,13869,13891,13916],{"intervention":94,"totalTrials":95,"cells":96},"trastuzumab",9,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":196,"PHASE4":198,"NA":215},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":195,"soonestReadout":70},[104,117,127,149,161,171,181],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":113},"NCT00182793","Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer","COMPLETED",[88],"2014-10","2005-07",32,[15],[94,114,75,115,116],"carboplatin","melphalan","thiotepa",{"nctId":118,"briefTitle":119,"status":107,"phases":120,"primaryCompletion":121,"completion":121,"start":122,"conditions":123,"interventions":125},"NCT00005857","Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy",[88],"2002-10","2000-08",[124],"Prostate Cancer",[94,126],"docetaxel",{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":147},"NCT01730833","Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer","ACTIVE_NOT_RECRUITING",[88],"2021-01-12","2026-05-20","2013-07-17",63,[137,138,139,140,141,142,143,144,145,146],"HER2-positive Breast Cancer","Recurrent Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Stage IV Breast Cancer","Breast Adenocarcinoma","Inflammatory Breast Carcinoma",[148,94,56],"pertuzumab",{"nctId":150,"briefTitle":151,"status":130,"phases":152,"primaryCompletion":153,"completion":154,"start":155,"enrollment":36,"conditions":156,"interventions":158},"NCT02827877","Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer",[88],"2020-07-02","2026-09-25","2016-07-15",[157,141,142,143],"HER2 Positive Breast Carcinoma",[159,160],"Pertuzumab","Trastuzumab",{"nctId":73,"briefTitle":74,"status":130,"phases":162,"primaryCompletion":70,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":167},[88],"2026-08-11","2005-09-27",121,[15],[75,126,168,160,169,170],"doxorubicin hydrochloride","Carboplatin","Paclitaxel",{"nctId":172,"briefTitle":173,"status":107,"phases":174,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":179},"NCT00086957","Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer",[87,88],"2015-08","2004-01",31,[15],[94,126,180],"gefitinib",{"nctId":182,"briefTitle":183,"status":130,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":193},"NCT01273610","Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer",[88],"2018-02-22","2026-05-19","2011-04-20",40,[190,191,192],"Breast Neoplasms","HER2\u002FNeu Positive","Geriatric Health Services",[194,160],"Lapatinib",4,{"trials":197,"activeCount":99},[],{"trials":199,"activeCount":214,"soonestReadout":205},[200],{"nctId":201,"briefTitle":202,"status":203,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":212},"NCT05376878","An Investigational Scan (64Cu-DOTA-Trastuzumab PET\u002FMRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis","RECRUITING",[90],"2026-05-26","2022-12-21",10,[209,210,211],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Metastatic Malignant Neoplasm in the Brain",[160,213],"Trastuzumab Deruxtecan",1,{"trials":216,"activeCount":214,"soonestReadout":221},[217],{"nctId":218,"briefTitle":219,"status":130,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":207,"conditions":224,"interventions":229},"NCT02226276","Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer",[91],"2021-12-07","2026-09-29","2015-01-07",[225,137,226,227,138,228,144],"Bone Metastases","Liver Metastases","Lung Metastases","Soft Tissue Metastases",[94,230],"ado-trastuzumab emtansine",{"intervention":213,"totalTrials":214,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":247},{"trials":234,"activeCount":99},[],{"trials":236,"activeCount":99},[],{"trials":238,"activeCount":99},[],{"trials":240,"activeCount":99},[],{"trials":242,"activeCount":214,"soonestReadout":205},[243],{"nctId":201,"briefTitle":202,"status":203,"phases":244,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":245,"interventions":246},[90],[209,210,211],[160,213],{"trials":248,"activeCount":99},[],{"intervention":250,"totalTrials":251,"cells":252},"fluorouracil",14,{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":364,"PHASE3":460,"PHASE4":472,"NA":474},{"trials":254,"activeCount":99},[],{"trials":256,"activeCount":363,"soonestReadout":296},[257,277,291,310,350],{"nctId":258,"briefTitle":259,"status":107,"phases":260,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":267},"NCT00873275","Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer",[87],"2012-09-25","2025-02-26","2009-03-11",11,[266],"Colorectal Cancer",[268,269,250,270,271,272,273,274,275,276],"bevacizumab","FOLFOX regimen","leucovorin calcium","oxaliplatin","ursodiol","RNA analysis","gene expression analysis","polymerase chain reaction","western blotting",{"nctId":278,"briefTitle":279,"status":107,"phases":280,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":289},"NCT01205022","Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",[87],"2014-01","2011-04",3,[285,286,287,288],"Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer","Stage IV Rectal Cancer",[290,270,250,268],"irinotecan hydrochloride",{"nctId":292,"briefTitle":293,"status":294,"phases":295,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":304},"NCT07363408","Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced\u002FMetastatic Colorectal Cancer","NOT_YET_RECRUITING",[87],"2027-07-21","2026-07-21",30,[300,301,302,303],"Advanced Microsatellite Stable Colorectal Carcinoma","Metastatic Microsatellite Stable Colorectal Carcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8",[305,306,307,308,309],"Fluorouracil","Irinotecan","Ivonescimab","Leucovorin Calcium","Muzastotug",{"nctId":311,"briefTitle":312,"status":203,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":344},"NCT04329494","PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer",[87],"2028-01-05","2020-08-21",49,[318,319,320,321,322,323,324,325,326,327,328,329,330,331,303,332,333,334,335,336,337,338,339,340,341,342,343],"Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVB Gastric Cancer AJCC v8","Malignant Uterine Neoplasm","Metastatic Appendix Carcinoma","Metastatic Colorectal Carcinoma","Metastatic Gastric Carcinoma","Metastatic Malignant Neoplasm in the Peritoneum","Metastatic Malignant Solid Neoplasm","Metastatic Ovarian Carcinoma","Pathologic Stage IV Gastric Cancer AJCC v8","Peritoneal Carcinomatosis","Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8","Stage IV Appendix Carcinoma AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Uterine Corpus Cancer AJCC v8","Stage IVA Appendix Carcinoma AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVA Ovarian Cancer AJCC v8","Stage IVA Uterine Corpus Cancer AJCC v8","Stage IVB Appendix Carcinoma AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVB Ovarian Cancer AJCC v8","Stage IVB Uterine Corpus Cancer AJCC v8","Stage IVC Appendix Carcinoma AJCC v8","Stage IVC Colorectal Cancer AJCC v8",[345,346,305,306,347,348,349],"Cisplatin","Doxorubicin","Leucovorin","Mitomycin","Oxaliplatin",{"nctId":351,"briefTitle":352,"status":107,"phases":353,"primaryCompletion":354,"completion":354,"start":355,"enrollment":25,"conditions":356,"interventions":361},"NCT02041481","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",[87],"2018-01-19","2014-06",[285,286,357,358,359,360],"Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Rectal Cancer",[362,270,250,271],"MEK inhibitor MEK162",2,{"trials":365,"activeCount":363,"soonestReadout":402},[366,375,388,398,415,428,448],{"nctId":367,"briefTitle":368,"status":369,"phases":370,"primaryCompletion":371,"completion":371,"start":372,"enrollment":214,"conditions":373,"interventions":374},"NCT01320683","Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer","TERMINATED",[88],"2014-12","2011-03",[226,285,286,357,358,359,360],[271,270,250,268,290],{"nctId":376,"briefTitle":377,"status":107,"phases":378,"primaryCompletion":379,"completion":380,"start":381,"enrollment":177,"conditions":382,"interventions":384},"NCT00544414","Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer",[88],"2017-02-14","2024-07-02","2000-06-07",[383],"Head and Neck Cancer",[385,126,250,386,270,274,387],"cisplatin","gemcitabine hydrochloride","protein expression analysis",{"nctId":389,"briefTitle":390,"status":107,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":316,"conditions":394,"interventions":396},"NCT00002842","Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer",[88],"2014-05","1994-09",[266,395],"Metastatic Cancer",[397,250,270],"floxuridine",{"nctId":399,"briefTitle":400,"status":130,"phases":401,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":411},"NCT05627635","FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer",[87,88],"2026-06-23","2023-05-03",20,[406,407,301,408,409,303,410],"Metastatic Colon Adenocarcinoma","Metastatic Colorectal Adenocarcinoma","Metastatic Rectal Adenocarcinoma","Stage IV Colon Cancer AJCC v8","Stage IV Rectal Cancer AJCC v8",[412,413,414,305,308,349],"Balstilimab","Bevacizumab","Botensilimab",{"nctId":416,"briefTitle":417,"status":369,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":214,"conditions":421,"interventions":425},"NCT02508077","FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer",[88],"2017-09-13","2016-02-16",[422,423,424],"Recurrent Colorectal Carcinoma","Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer",[305,426,308,427],"Irinotecan Hydrochloride","Panitumumab",{"nctId":429,"briefTitle":430,"status":107,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":445},"NCT01231399","Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer",[87,88],"2016-07","2012-02",6,[436,437,438,439,440,441,442,443,444],"Adenocarcinoma of the Esophagus","Adenocarcinoma of the Gastroesophageal Junction","Diffuse Adenocarcinoma of the Stomach","Intestinal Adenocarcinoma of the Stomach","Mixed Adenocarcinoma of the Stomach","Recurrent Esophageal Cancer","Recurrent Gastric Cancer","Stage IV Esophageal Cancer","Stage IV Gastric Cancer",[250,270,271,446,447],"everolimus","microarray analysis",{"nctId":449,"briefTitle":450,"status":203,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":25,"conditions":454,"interventions":458},"NCT06780787","FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery",[88],"2027-11-05","2025-05-20",[455,456,457],"Rectal Adenocarcinoma","Stage IIA Rectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8",[412,414,459,305,308,349],"Capecitabine",{"trials":461,"activeCount":214,"soonestReadout":466},[462],{"nctId":463,"briefTitle":464,"status":294,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT07271355","Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial",[89],"2031-02-28","2026-07-01",129,[322,323,325,331,343,470],"Unresectable Colorectal Carcinoma",[413,305,426,308,348],{"trials":473,"activeCount":99},[],{"trials":475,"activeCount":99},[476],{"nctId":477,"briefTitle":478,"status":479,"phases":480,"primaryCompletion":481,"start":281,"enrollment":99,"conditions":482,"interventions":483},"NCT01941173","Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy","WITHDRAWN",[91],"2014-07",[285,286,357,358,359,360],[484,270,290,250],"ziv-aflibercept",{"intervention":413,"totalTrials":486,"cells":487},7,{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":520,"PHASE3":546,"PHASE4":552,"NA":554},{"trials":489,"activeCount":99},[],{"trials":491,"activeCount":214,"soonestReadout":496},[492,512,516],{"nctId":493,"briefTitle":494,"status":130,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":510},"NCT04227028","Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC",[87],"2026-04-21","2020-03-09",5,[500,501,502,503,504,505,506,507,508,509],"Locally Advanced Lung Non-Small Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Recurrent Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[413,511],"Brigatinib",{"nctId":258,"briefTitle":259,"status":107,"phases":513,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":514,"interventions":515},[87],[266],[268,269,250,270,271,272,273,274,275,276],{"nctId":278,"briefTitle":279,"status":107,"phases":517,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":518,"interventions":519},[87],[285,286,287,288],[290,270,250,268],{"trials":521,"activeCount":363,"soonestReadout":402},[522,526,530],{"nctId":367,"briefTitle":368,"status":369,"phases":523,"primaryCompletion":371,"completion":371,"start":372,"enrollment":214,"conditions":524,"interventions":525},[88],[226,285,286,357,358,359,360],[271,270,250,268,290],{"nctId":399,"briefTitle":400,"status":130,"phases":527,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":528,"interventions":529},[87,88],[406,407,301,408,409,303,410],[412,413,414,305,308,349],{"nctId":531,"briefTitle":532,"status":203,"phases":533,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":539},"NCT07288034","Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial",[88],"2028-10-08","2026-04-08",535,[538,505,507],"Lung Non-Small Cell Carcinoma",[540,541,542,413,543,544,545],"Adagrasib","Anti-PD-L1 Monoclonal Antibody","Anti-PD1 Monoclonal Antibody","Chemotherapy","Durvalumab","Tremelimumab",{"trials":547,"activeCount":214,"soonestReadout":466},[548],{"nctId":463,"briefTitle":464,"status":294,"phases":549,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":550,"interventions":551},[89],[322,323,325,331,343,470],[413,305,426,308,348],{"trials":553,"activeCount":99},[],{"trials":555,"activeCount":99},[],{"intervention":270,"totalTrials":251,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":596,"PHASE3":626,"PHASE4":632,"NA":634},{"trials":559,"activeCount":99},[],{"trials":561,"activeCount":214,"soonestReadout":296},[562,566,570,588,592],{"nctId":258,"briefTitle":259,"status":107,"phases":563,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":564,"interventions":565},[87],[266],[268,269,250,270,271,272,273,274,275,276],{"nctId":278,"briefTitle":279,"status":107,"phases":567,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":568,"interventions":569},[87],[285,286,287,288],[290,270,250,268],{"nctId":571,"briefTitle":572,"status":107,"phases":573,"primaryCompletion":574,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":585},"NCT02015819","Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas",[87],"2017-10-07","2014-10-07",16,[578,579,580,581,582,583,584],"Adult Anaplastic Astrocytoma","Adult Anaplastic Oligodendroglioma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Recurrent Adult Brain Tumor","Anaplastic Oligoastrocytoma",[586,587,270],"E. coli CD-expressing genetically modified neural stem cells","flucytosine",{"nctId":292,"briefTitle":293,"status":294,"phases":589,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":590,"interventions":591},[87],[300,301,302,303],[305,306,307,308,309],{"nctId":351,"briefTitle":352,"status":107,"phases":593,"primaryCompletion":354,"completion":354,"start":355,"enrollment":25,"conditions":594,"interventions":595},[87],[285,286,357,358,359,360],[362,270,250,271],{"trials":597,"activeCount":363,"soonestReadout":402},[598,602,606,610,614,618,622],{"nctId":367,"briefTitle":368,"status":369,"phases":599,"primaryCompletion":371,"completion":371,"start":372,"enrollment":214,"conditions":600,"interventions":601},[88],[226,285,286,357,358,359,360],[271,270,250,268,290],{"nctId":376,"briefTitle":377,"status":107,"phases":603,"primaryCompletion":379,"completion":380,"start":381,"enrollment":177,"conditions":604,"interventions":605},[88],[383],[385,126,250,386,270,274,387],{"nctId":389,"briefTitle":390,"status":107,"phases":607,"primaryCompletion":392,"completion":392,"start":393,"enrollment":316,"conditions":608,"interventions":609},[88],[266,395],[397,250,270],{"nctId":399,"briefTitle":400,"status":130,"phases":611,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":612,"interventions":613},[87,88],[406,407,301,408,409,303,410],[412,413,414,305,308,349],{"nctId":416,"briefTitle":417,"status":369,"phases":615,"primaryCompletion":419,"completion":419,"start":420,"enrollment":214,"conditions":616,"interventions":617},[88],[422,423,424],[305,426,308,427],{"nctId":429,"briefTitle":430,"status":107,"phases":619,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":620,"interventions":621},[87,88],[436,437,438,439,440,441,442,443,444],[250,270,271,446,447],{"nctId":449,"briefTitle":450,"status":203,"phases":623,"primaryCompletion":452,"completion":452,"start":453,"enrollment":25,"conditions":624,"interventions":625},[88],[455,456,457],[412,414,459,305,308,349],{"trials":627,"activeCount":214,"soonestReadout":466},[628],{"nctId":463,"briefTitle":464,"status":294,"phases":629,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":630,"interventions":631},[89],[322,323,325,331,343,470],[413,305,426,308,348],{"trials":633,"activeCount":99},[],{"trials":635,"activeCount":99},[636],{"nctId":477,"briefTitle":478,"status":479,"phases":637,"primaryCompletion":481,"start":281,"enrollment":99,"conditions":638,"interventions":639},[91],[285,286,357,358,359,360],[484,270,290,250],{"intervention":348,"totalTrials":283,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":650,"PHASE3":667,"PHASE4":673,"NA":675},{"trials":643,"activeCount":99},[],{"trials":645,"activeCount":214,"soonestReadout":314},[646],{"nctId":311,"briefTitle":312,"status":203,"phases":647,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":648,"interventions":649},[87],[318,319,320,321,322,323,324,325,326,327,328,329,330,331,303,332,333,334,335,336,337,338,339,340,341,342,343],[345,346,305,306,347,348,349],{"trials":651,"activeCount":214,"soonestReadout":656},[652],{"nctId":653,"briefTitle":654,"status":203,"phases":655,"primaryCompletion":656,"completion":656,"start":657,"enrollment":298,"conditions":658,"interventions":665},"NCT05672108","Phase II Trial of Lung Chemoemobolization",[88],"2027-10-28","2023-05-12",[538,659,660,661,662,663,664],"Mediastinal Neoplasm","Pleural Neoplasm","Lung Metastases From Any Primary","Endobronchial Metastases","Colon Cancer","Sarcoma",[666,348],"Ethiodized Oil",{"trials":668,"activeCount":214,"soonestReadout":466},[669],{"nctId":463,"briefTitle":464,"status":294,"phases":670,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":671,"interventions":672},[89],[322,323,325,331,343,470],[413,305,426,308,348],{"trials":674,"activeCount":99},[],{"trials":676,"activeCount":99},[],{"intervention":290,"totalTrials":95,"cells":678},{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":720,"PHASE3":741,"PHASE4":747,"NA":749},{"trials":680,"activeCount":99},[],{"trials":682,"activeCount":214,"soonestReadout":701},[683,687,697,713],{"nctId":278,"briefTitle":279,"status":107,"phases":684,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":685,"interventions":686},[87],[285,286,287,288],[290,270,250,268],{"nctId":688,"briefTitle":689,"status":107,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":695},"NCT00547547","High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer",[87],"2012-08","2006-04",22,[24],[696,290],"capecitabine",{"nctId":698,"briefTitle":699,"status":130,"phases":700,"primaryCompletion":701,"completion":154,"start":702,"enrollment":36,"conditions":703,"interventions":711},"NCT02192359","Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas",[87],"2022-02-21","2016-04-05",[704,705,706,707,708,709,710],"Recurrent Anaplastic Astrocytoma","Recurrent Anaplastic Oligoastrocytoma","Recurrent Anaplastic Oligodendroglioma","Recurrent Glioblastoma","Recurrent Gliosarcoma","Recurrent Malignant Glioma","Recurrent WHO Grade III Glioma",[712,306,426],"Carboxylesterase-expressing Allogeneic Neural Stem Cells",{"nctId":714,"briefTitle":715,"status":479,"phases":716,"primaryCompletion":392,"enrollment":99,"conditions":717,"interventions":718},"NCT02055196","Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas",[87],[578,579,580,581,582,583],[719,290],"carboxylesterase-expressing allogeneic neural stem cells",{"trials":721,"activeCount":99},[722,726,730],{"nctId":367,"briefTitle":368,"status":369,"phases":723,"primaryCompletion":371,"completion":371,"start":372,"enrollment":214,"conditions":724,"interventions":725},[88],[226,285,286,357,358,359,360],[271,270,250,268,290],{"nctId":416,"briefTitle":417,"status":369,"phases":727,"primaryCompletion":419,"completion":419,"start":420,"enrollment":214,"conditions":728,"interventions":729},[88],[422,423,424],[305,426,308,427],{"nctId":731,"briefTitle":732,"status":369,"phases":733,"primaryCompletion":734,"start":735,"enrollment":486,"conditions":736,"interventions":737},"NCT00544778","Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma",[88],"2011-11","2001-08",[664],[738,739,168,740,290,387],"filgrastim","dexrazoxane hydrochloride","ifosfamide",{"trials":742,"activeCount":214,"soonestReadout":466},[743],{"nctId":463,"briefTitle":464,"status":294,"phases":744,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":745,"interventions":746},[89],[322,323,325,331,343,470],[413,305,426,308,348],{"trials":748,"activeCount":99},[],{"trials":750,"activeCount":99},[751],{"nctId":477,"briefTitle":478,"status":479,"phases":752,"primaryCompletion":481,"start":281,"enrollment":99,"conditions":753,"interventions":754},[91],[285,286,357,358,359,360],[484,270,290,250],{"intervention":756,"totalTrials":214,"cells":757},"Extended Release Metformin Hydrochloride",{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":764,"PHASE4":779,"NA":781},{"trials":759,"activeCount":99},[],{"trials":761,"activeCount":99},[],{"trials":763,"activeCount":99},[],{"trials":765,"activeCount":214,"soonestReadout":770},[766],{"nctId":767,"briefTitle":768,"status":203,"phases":769,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":778},"NCT06763328","Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy",[89],"2029-06-16","2024-12-16",200,[774,775,776,777],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Invasive Breast Carcinoma",[756],{"trials":780,"activeCount":99},[],{"trials":782,"activeCount":99},[],{"intervention":784,"totalTrials":785,"cells":786},"Cyclophosphamide",58,{"EARLY_PHASE1":787,"PHASE1":799,"PHASE2":1235,"PHASE3":1512,"PHASE4":1514,"NA":1516},{"trials":788,"activeCount":214,"soonestReadout":793},[789],{"nctId":790,"briefTitle":791,"status":203,"phases":792,"primaryCompletion":793,"completion":793,"start":794,"enrollment":795,"conditions":796,"interventions":798},"NCT04380831","TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis",[86],"2026-12-22","2022-02-24",15,[797],"Systemic Scleroderma",[784],{"trials":800,"activeCount":1001,"soonestReadout":1065},[801,824,839,852,862,872,884,895,904,914,924,944,958,982,995,1006,1018,1029,1061,1076,1086,1095,1105,1122,1136,1150,1166,1178,1187,1201,1213,1224],{"nctId":802,"briefTitle":803,"status":130,"phases":804,"primaryCompletion":805,"completion":805,"start":806,"enrollment":177,"conditions":807,"interventions":820},"NCT02159495","Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia and Persistent\u002FRecurrent Blastic Plasmacytoid Dendritic Cell Neoplasm",[87],"2026-08-06","2015-12-15",[808,809,810,811,812,813,814,18,815,816,817,818,819],"Adult Acute Myeloid Leukemia in Remission","Acute Biphenotypic Leukemia","Early Relapse of Acute Myeloid Leukemia","Late Relapse of Acute Myeloid Leukemia","Recurrent Adult Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia","Blastic Plasmacytoid Dendritic Cell Neoplasm","Adult Acute Lymphoblastic Leukemia","Interleukin-3 Receptor Subunit Alpha Positive","Minimal Residual Disease","Refractory Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia",[75,821,822,823],"Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes","Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes","Fludarabine Phosphate",{"nctId":825,"briefTitle":826,"status":130,"phases":827,"primaryCompletion":828,"completion":828,"start":829,"enrollment":9,"conditions":830,"interventions":836},"NCT03655002","IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer",[87],"2027-03-02","2019-02-21",[831,832,833,834,835],"Recurrent Hepatocellular Carcinoma","Refractory Liver Carcinoma","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IVA Hepatocellular Carcinoma AJCC v8","Stage IVB Hepatocellular Carcinoma AJCC v8",[784,837,838],"Cytokine-based Biologic Agent IRX-2","Nivolumab",{"nctId":840,"briefTitle":841,"status":130,"phases":842,"primaryCompletion":205,"completion":205,"start":843,"enrollment":693,"conditions":844,"interventions":846},"NCT03118492","Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis",[87],"2017-05-24",[845],"Secondary Myelofibrosis",[784,847,848,849,850,851],"Fludarabine","Glycosylated Recombinant Human G-CSF AVI-014","Melphalan","Mycophenolate Mofetil","Tacrolimus",{"nctId":853,"briefTitle":854,"status":130,"phases":855,"primaryCompletion":856,"completion":856,"start":857,"enrollment":36,"conditions":858,"interventions":860},"NCT05707273","CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission",[87],"2026-07-24","2023-04-26",[859],"B Acute Lymphoblastic Leukemia",[861,784,847],"Autologous Anti-CD19 CAR-expressing T Lymphocytes",{"nctId":863,"briefTitle":864,"status":107,"phases":865,"primaryCompletion":866,"completion":866,"start":867,"enrollment":795,"conditions":868,"interventions":869},"NCT00003927","Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer",[87],"2023-03-21","1999-05-18",[15],[738,870,75,168,871],"amifostine trihydrate","paclitaxel",{"nctId":873,"briefTitle":874,"status":107,"phases":875,"primaryCompletion":109,"completion":109,"start":876,"enrollment":9,"conditions":877,"interventions":881},"NCT00550784","Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",[87],"2001-01",[878,879,880],"Fallopian Tube Cancer","Ovarian Cancer","Peritoneal Cavity Cancer",[738,385,75,115,871,882,883,274],"topotecan hydrochloride","TdT-mediated dUTP nick end labeling assay",{"nctId":885,"briefTitle":886,"status":107,"phases":887,"primaryCompletion":888,"completion":888,"start":889,"enrollment":890,"conditions":891,"interventions":892},"NCT00641381","Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma",[87],"2026-02-13","2000-05-10",25,[27],[893,75,894],"carmustine","etoposide",{"nctId":896,"briefTitle":897,"status":107,"phases":898,"primaryCompletion":433,"completion":433,"start":899,"enrollment":900,"conditions":901,"interventions":902},"NCT00551889","Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer",[87],"2001-09",57,[24],[903,75],"celecoxib",{"nctId":905,"briefTitle":906,"status":907,"phases":908,"primaryCompletion":909,"completion":909,"start":910,"enrollment":911,"conditions":912,"interventions":913},"NCT03467386","Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia","SUSPENDED",[87],"2026-09-06","2018-03-19",56,[18],[784,66,851],{"nctId":915,"briefTitle":916,"status":107,"phases":917,"primaryCompletion":175,"completion":175,"start":918,"enrollment":919,"conditions":920,"interventions":922},"NCT00002854","High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer",[87],"1994-12",33,[921],"Cancer",[738,114,385,75,894,740,923,871],"mesna",{"nctId":925,"briefTitle":926,"status":130,"phases":927,"primaryCompletion":928,"completion":928,"start":929,"enrollment":207,"conditions":930,"interventions":937},"NCT02337985","Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma",[87],"2026-09-08","2015-11-20",[931,932,933,934,935,936],"AIDS-Related Burkitt Lymphoma","AIDS-Related Diffuse Large B-cell Lymphoma","AIDS-Related Plasmablastic Lymphoma","AIDS-Related Primary Effusion Lymphoma","HIV Infection","AIDS Related Non-Hodgkin Lymphoma",[938,939,940,941,942,784,66,943],"Prednisone","Rituximab","Etoposide","Doxorubicin Hydrochloride","Vincristine Sulfate","Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem\u002FProgenitor Cells",{"nctId":945,"briefTitle":946,"status":203,"phases":947,"primaryCompletion":948,"completion":948,"start":949,"enrollment":25,"conditions":950,"interventions":953},"NCT07133997","Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia",[87],"2028-06-01","2026-06-01",[951,952],"Recurrent B Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia",[954,955,784,956,957],"Asparaginase Erwinia chrysanthemi","Blinatumomab","Venetoclax","Vincristine",{"nctId":959,"briefTitle":960,"status":130,"phases":961,"primaryCompletion":962,"completion":962,"start":963,"enrollment":964,"conditions":965,"interventions":979},"NCT02153580","Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",[87],"2026-09-02","2014-09-24",37,[966,967,968,969,970,971,972,973,974,975,976,977,978],"B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma","B-Cell Prolymphocytic Leukemia","High Grade B-Cell Lymphoma, Not Otherwise Specified","Post-Transplant Lymphoproliferative Disorder","Recurrent Adult Burkitt Lymphoma","Recurrent Chronic Lymphocytic Leukemia","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Follicular Lymphoma","Recurrent Hairy Cell Leukemia","Recurrent Lymphoplasmacytic Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Small Lymphocytic Lymphoma",[980,981,784,940,823],"Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn\u002Fmem-enriched T-lymphocytes","Bendamustine Hydrochloride",{"nctId":983,"briefTitle":984,"status":107,"phases":985,"primaryCompletion":986,"completion":986,"start":987,"enrollment":36,"conditions":988,"interventions":993},"NCT01074060","Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma",[87],"2013-02","2010-04",[989,990,991,992],"Refractory Multiple Myeloma","Stage I Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma",[994,738,75],"plerixafor",{"nctId":996,"briefTitle":997,"status":294,"phases":998,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1004},"NCT07583303","BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation",[87],"2027-04-16","2026-12-14",19,[1003,818],"Recurrent Acute Myeloid Leukemia",[784,847,1005],"Single Agent Therapy",{"nctId":1007,"briefTitle":1008,"status":203,"phases":1009,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":36,"conditions":1012,"interventions":1016},"NCT04510051","CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children",[87],"2027-02-24","2020-12-04",[1013,1014,1015],"Malignant Brain Neoplasm","Recurrent Malignant Brain Neoplasm","Refractory Malignant Brain Neoplasm",[784,847,1017],"IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes",{"nctId":1019,"briefTitle":1020,"status":203,"phases":1021,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":919,"conditions":1025,"interventions":1027},"NCT05225363","Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer",[87],"2026-10-05","2027-06-05","2022-05-05",[1026],"Platinum-Resistant Ovarian Carcinoma",[1028,784,847],"Chimeric Antigen Receptor T-cells",{"nctId":1030,"briefTitle":1031,"status":479,"phases":1032,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":99,"conditions":1035,"interventions":1058},"NCT06626256","STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma",[87],"2027-10-30","2025-12-05",[1036,1037,1038,1039,1040,1041,1042,323,326,1043,1044,1045,1046,1047,302,1048,1049,1050,303,1051,1052,1053,470,1054,1055,1056,1057],"Locally Advanced Cervical Carcinoma","Locally Advanced Colorectal Carcinoma","Locally Advanced Malignant Solid Neoplasm","Locally Advanced Melanoma","Locally Advanced Pancreatic Ductal Adenocarcinoma","Locally Advanced Renal Cell Carcinoma","Metastatic Cervical Carcinoma","Metastatic Melanoma","Metastatic Pancreatic Ductal Adenocarcinoma","Metastatic Renal Cell Carcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Cervical Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage IV Cervical Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Unresectable Cervical Carcinoma","Unresectable Malignant Solid Neoplasm","Unresectable Melanoma","Unresectable Pancreatic Ductal Adenocarcinoma","Unresectable Renal Cell Carcinoma",[1059,784,847,1060],"Aldesleukin","Therapeutic Tumor Infiltrating Lymphocytes",{"nctId":1062,"briefTitle":1063,"status":130,"phases":1064,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":251,"conditions":1068,"interventions":1074},"NCT03873805","PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer",[87],"2022-08-20","2027-03-18","2019-08-20",[1069,1070,1071,1072,1073],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8",[1075,784,847,823],"Autologous Anti-PSCA-CAR-4-1BB\u002FTCRzeta-CD19t-expressing T-lymphocytes",{"nctId":1077,"briefTitle":1078,"status":203,"phases":1079,"primaryCompletion":1080,"completion":1080,"start":1081,"enrollment":404,"conditions":1082,"interventions":1084},"NCT05625594","Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn\u002FMem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma",[87],"2026-05-21","2023-06-29",[1083],"Central Nervous System Lymphoma",[1085,784,847],"CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn\u002Fmem T-lymphocytes",{"nctId":1087,"briefTitle":1088,"status":107,"phases":1089,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":498,"conditions":1092,"interventions":1093},"NCT00569985","Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma",[87],"2019-11-12","2007-06",[27],[1094,893,75,894],"lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells",{"nctId":1096,"briefTitle":1097,"status":203,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":298,"conditions":1101,"interventions":1104},"NCT03710421","CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma",[87],"2027-02-23","2019-04-23",[1102,1103],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[784,847],{"nctId":1106,"briefTitle":1107,"status":130,"phases":1108,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":283,"conditions":1111,"interventions":1117},"NCT03249831","A Blood Stem Cell Transplant for Sickle Cell Disease",[87],"2027-01-25","2019-01-04",[1112,1113,1114,1115,1116],"Sickle Cell Disease","Sickle Cell Disorder","Hemoglobinopathies","Thalassemia","Anemia, Sickle Cell",[784,1118,1119,851,1120,1121],"Pentostatin","Rabbit anti-thymocyte globulin","Mycophenolate mofetil","CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant",{"nctId":1123,"briefTitle":1124,"status":130,"phases":1125,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":30,"conditions":1128,"interventions":1130},"NCT05157971","Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia",[87],"2027-04-12","2022-03-17",[859,1129],"Ph-Like Acute Lymphoblastic Leukemia",[784,1131,1132,1133,1134,1135,938,956,942],"Cytarabine","Daunorubicin Hydrochloride","Mercaptopurine","Methotrexate","Pegaspargase",{"nctId":1137,"briefTitle":1138,"status":907,"phases":1139,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1146},"NCT04177004","Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant",[87],"2026-10-27","2021-04-30",53,[1144,1145],"Allogeneic Hematopoietic Stem Cell Transplant Recipient","Hematopoietic and Lymphoid Cell Neoplasm",[784,940,1147,1148,1149,851],"Goat Milk","Palifermin","Sirolimus",{"nctId":1151,"briefTitle":1152,"status":294,"phases":1153,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":404,"conditions":1156,"interventions":1163},"NCT07278856","Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas",[87],"2027-03-31","2026-04-27",[1157,1158,1159,1160,1161,1162],"Follicular Helper T-Cell Lymphoma","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","Follicular Helper T-Cell Lymphoma, Follicular-Type","Follicular Helper T-Cell Lymphoma, Not Otherwise Specified","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified",[784,346,66,1164,938,1165,957],"Pegfilgrastim","Ruxolitinib Phosphate",{"nctId":1167,"briefTitle":1168,"status":203,"phases":1169,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":30,"conditions":1172,"interventions":1175},"NCT06447987","Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia",[87],"2026-12-05","2024-11-06",[1173,1174],"Recurrent Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia",[1176,1177,784,847],"CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn\u002Fmem-enriched T-lymphocytes","Cetuximab",{"nctId":1179,"briefTitle":1180,"status":479,"phases":1181,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":99,"conditions":1184,"interventions":1186},"NCT03531281","Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant",[87],"2022-12-30","2018-12-30",[1145,1185],"Hematopoietic Cell Transplantation Recipient",[784,940,1147,1148,1149,851],{"nctId":1188,"briefTitle":1189,"status":107,"phases":1190,"primaryCompletion":453,"completion":453,"start":1191,"enrollment":177,"conditions":1192,"interventions":1200},"NCT02446964","Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia",[87],"2015-06-25",[1193,1194,1195,1196,812,1197,1198,1199],"Adult Acute Lymphoblastic Leukemia in Complete Remission","Acute Myeloid Leukemia in Remission","Previously Treated Myelodysplastic Syndrome","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Childhood Acute Lymphoblastic Leukemia in Complete Remission",[784,823,850,851],{"nctId":1202,"briefTitle":1203,"status":479,"phases":1204,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":99,"conditions":1207,"interventions":1210},"NCT06572631","Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor",[87],"2026-12-12","2025-06-07",[1003,1208,818,1209],"Recurrent Myelodysplastic Syndrome","Refractory Myelodysplastic Syndrome",[1211,784,1212,847],"Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001","Decitabine",{"nctId":1214,"briefTitle":1215,"status":203,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":434,"conditions":1219,"interventions":1222},"NCT05757310","A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia",[87],"2027-06-18","2024-11-15",[1220,1221],"Recurrent Severe Aplastic Anemia","Refractory Severe Aplastic Anemia",[1223,784,1118],"Anti-Thymocyte Globulin",{"nctId":1225,"briefTitle":1226,"status":203,"phases":1227,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":795,"conditions":1230,"interventions":1232},"NCT06996119","Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant",[87],"2027-05-25","2026-05-25",[18,1231,21],"Graft Versus Host Disease",[1233,784,1234,847,849,850,851],"Busulfan","Emapalumab",{"trials":1236,"activeCount":207,"soonestReadout":41},[1237,1258,1267,1279,1289,1307,1311,1322,1334,1344,1355,1365,1376,1387,1398,1419,1433,1442,1446,1459,1481,1491,1503],{"nctId":1238,"briefTitle":1239,"status":130,"phases":1240,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":1244,"conditions":1245,"interventions":1255},"NCT03113500","Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma",[88],"2021-07-16","2026-07-07","2017-05-25",48,[1246,1247,1248,1249,1250,1251,1252,1253,1254,1161,1162],"Adult T-Cell Leukemia\u002FLymphoma","Anaplastic Large Cell Lymphoma, ALK-Negative","Anaplastic Large Cell Lymphoma, ALK-Positive","Angioimmunoblastic T-Cell Lymphoma","Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma","Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma","Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma","Enteropathy-Associated T-Cell Lymphoma","Hepatosplenic T-Cell Lymphoma",[1256,784,346,941,940,1257,938],"Brentuximab Vedotin","Etoposide Phosphate",{"nctId":1259,"briefTitle":1260,"status":107,"phases":1261,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1266},"NCT00562978","Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients",[87,88],"2018-05-21","2000-05-16",54,[27],[738,75,894],{"nctId":1268,"briefTitle":1269,"status":203,"phases":1270,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":1273,"conditions":1274,"interventions":1277},"NCT06815003","Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning",[88],"2028-10-15","2025-04-18",35,[35,18,1275,1231,21,1276],"Chronic Myelomonocytic Leukemia","Myeloproliferative Neoplasm",[784,847,849,851,1278],"Vedolizumab",{"nctId":1280,"briefTitle":1281,"status":107,"phases":1282,"primaryCompletion":1283,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1288},"NCT00576979","Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia",[87,88],"2016-05-30","2026-01-07","2008-03-04",51,[32],[75,894],{"nctId":1290,"briefTitle":1291,"status":107,"phases":1292,"primaryCompletion":433,"completion":433,"start":1293,"enrollment":111,"conditions":1294,"interventions":1302},"NCT00589563","Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer",[88],"2007-05",[1295,1231,1296,32,27,1297,1298,1299,1300,845,1301],"Chronic Myeloproliferative Disorders","Infection","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms","Precancerous Condition","Small Intestine Cancer",[1303,75,894,61,115,1304,1305,1306],"anti-thymocyte globulin","methotrexate","sirolimus","tacrolimus",{"nctId":105,"briefTitle":106,"status":107,"phases":1308,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":1309,"interventions":1310},[88],[15],[94,114,75,115,116],{"nctId":1312,"briefTitle":1313,"status":479,"phases":1314,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":99,"conditions":1317,"interventions":1320},"NCT03100877","Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma",[87,88],"2020-05-24","2018-01",[1318,1319],"Plasma Cell Leukemia in Remission","Plasma Cell Myeloma",[784,66,1321,849,1148],"Lenalidomide",{"nctId":1323,"briefTitle":1324,"status":107,"phases":1325,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1264,"conditions":1328,"interventions":1330},"NCT00112827","Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma",[87,88],"2019-02-15","2004-11",[989,1329,990,991,992],"Smoldering Multiple Myeloma",[115,738,1331,1332,75,1333],"fluorescence in situ hybridization","cytogenetic analysis","lenalidomide",{"nctId":1335,"briefTitle":1336,"status":107,"phases":1337,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":16,"conditions":1341,"interventions":1342},"NCT00003042","Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer",[88],"2010-02-09","2025-11-06","1997-05-30",[15],[738,385,75,168,115,923,871,1343],"tamoxifen citrate",{"nctId":1345,"briefTitle":1346,"status":203,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1142,"conditions":1350,"interventions":1353},"NCT06918431","Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[88],"2029-03-30","2025-10-10",[1351,1352],"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Lymphoblastic Lymphoma",[954,784,1131,1131,1132,1354,1133,1134,939,942],"Dexamethasone",{"nctId":1356,"briefTitle":1357,"status":107,"phases":1358,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1363},"NCT00559104","Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",[88],"2011-07","1998-10",60,[27],[893,75,894,1364],"G-CSF",{"nctId":39,"briefTitle":40,"status":130,"phases":1366,"primaryCompletion":41,"completion":1367,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1373},[88],"2027-03-29","2001-10-16",260,[1295,1231,32,27,1297,1298,1371,1372],"Myelodysplastic\u002FMyeloproliferative Diseases","Precancerous\u002FNonmalignant Condition",[42,75,1374,894,61,115,1304,1375,1305,1306],"cyclosporine","mycophenolate mofetil",{"nctId":1377,"briefTitle":1378,"status":107,"phases":1379,"primaryCompletion":1380,"completion":1381,"start":1382,"enrollment":1383,"conditions":1384,"interventions":1386},"NCT00538031","Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",[88],"2011-04-21","2019-09-13","2003-12-22",52,[878,880,1385],"Recurrent Ovarian Epithelial Cancer",[75,903],{"nctId":1388,"briefTitle":1389,"status":203,"phases":1390,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1396},"NCT06042569","Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial",[88],"2030-03-20","2024-09-16",174,[774,775,776,1395],"HER2-Negative Breast Carcinoma",[784,1397],"Docetaxel",{"nctId":1399,"briefTitle":1400,"status":107,"phases":1401,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":1406,"interventions":1417},"NCT03128359","High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant",[88],"2020-08-01","2021-09-15","2017-05-30",38,[1407,1408,1409,1410,1411,1231,1412,1413,1414,21,1276,1415,1102,1103,1416],"Acute Leukemia","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Diffuse Large B-Cell Lymphoma","Follicular Lymphoma","Hodgkin Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Secondary Myelodysplastic Syndrome",[1233,784,823,1418,850,851],"Melphalan Hydrochloride",{"nctId":1420,"briefTitle":1421,"status":130,"phases":1422,"primaryCompletion":205,"completion":205,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1432},"NCT02094794","Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML",[88],"2014-05-12",108,[1426,1427,1428,1429,1430,1431,1196,812,1197,1198],"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",[894,75],{"nctId":1434,"briefTitle":1435,"status":130,"phases":1436,"primaryCompletion":402,"completion":402,"start":1437,"enrollment":919,"conditions":1438,"interventions":1440},"NCT04262843","Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia",[88],"2020-02-07",[35,18,1439,21],"High Risk Myelodysplastic Syndrome",[784,847,823,1441,850,851],"Granulocyte Colony-Stimulating Factor",{"nctId":73,"briefTitle":74,"status":130,"phases":1443,"primaryCompletion":70,"completion":163,"start":164,"enrollment":165,"conditions":1444,"interventions":1445},[88],[15],[75,126,168,160,169,170],{"nctId":1447,"briefTitle":1448,"status":203,"phases":1449,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":404,"conditions":1452,"interventions":1456},"NCT05672173","Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation",[88],"2026-09-10","2023-06-02",[1453,1454,1455],"Recurrent Transformed Chronic Lymphocytic Leukemia","Refractory Transformed Chronic Lymphocytic Leukemia","Richter Syndrome",[784,847,1457,1458,838],"Ibrutinib","Lisocabtagene Maraleucel",{"nctId":1460,"briefTitle":1461,"status":107,"phases":1462,"primaryCompletion":1463,"completion":1463,"start":1464,"enrollment":95,"conditions":1465,"interventions":1479},"NCT03918499","IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer",[87,88],"2023-02-09","2019-04-19",[318,1466,319,1467,320,1468,1469,1470,328,1471,1472,1473,330,1474,1475,1476,1477,1478],"Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Metastatic Gastric Adenocarcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Recurrent Gastric Adenocarcinoma","Recurrent Gastroesophageal Junction Adenocarcinoma",[784,837,1480],"Pembrolizumab",{"nctId":1482,"briefTitle":1483,"status":130,"phases":1484,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":404,"conditions":1487,"interventions":1489},"NCT05364762","Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants",[88],"2026-05-22","2022-11-23",[35,18,1275,21,1276,1488,845],"Primary Myelofibrosis",[784,1490,851],"Itacitinib",{"nctId":1492,"briefTitle":1493,"status":107,"phases":1494,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":1498,"interventions":1499},"NCT00004088","Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma",[88],"2018-01-09","1999-04-13",77,[1297],[738,1500,42,75,115,1501,1502],"recombinant interferon alfa","pamidronate disodium","thalidomide",{"nctId":1504,"briefTitle":1505,"status":107,"phases":1506,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":1510,"interventions":1511},"NCT00004092","Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer",[88],"2013-12","1999-05",72,[15],[738,114,75,168,871,116],{"trials":1513,"activeCount":99},[],{"trials":1515,"activeCount":99},[],{"trials":1517,"activeCount":99},[1518,1526],{"nctId":1519,"briefTitle":1520,"status":107,"phases":1521,"primaryCompletion":1522,"completion":1522,"start":1523,"enrollment":298,"conditions":1524,"interventions":1525},"NCT00544570","High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma",[91],"2007-12","1998-04",[27],[738,893,75,894,115],{"nctId":1527,"briefTitle":1528,"status":107,"phases":1529,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":207,"conditions":1533,"interventions":1534},"NCT00547196","AlloHCT From Matched Unrelated Donors in Pts w\u002F Advanced Hematologic Malignancies & Disorders",[91],"2009-11-11","2024-05-28","2005-08-16",[32,27,1298],[738,1233,784,1535,1536,849,850],"Cyclosporine","Fludarabine phosphate",{"intervention":847,"totalTrials":404,"cells":1538},{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1633,"PHASE3":1659,"PHASE4":1661,"NA":1663},{"trials":1540,"activeCount":99},[],{"trials":1542,"activeCount":1632,"soonestReadout":1065},[1543,1547,1558,1562,1572,1576,1580,1584,1588,1592,1596,1600,1604,1614,1624,1628],{"nctId":840,"briefTitle":841,"status":130,"phases":1544,"primaryCompletion":205,"completion":205,"start":843,"enrollment":693,"conditions":1545,"interventions":1546},[87],[845],[784,847,848,849,850,851],{"nctId":1548,"briefTitle":1549,"status":203,"phases":1550,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":795,"conditions":1553,"interventions":1554},"NCT06287944","225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome",[87],"2028-05-19","2025-07-01",[35,18,21],[1555,1556,847,1557,849,1149,851],"Actinium Ac 225-DOTA-Daratumumab","Daratumumab","Indium In 111-DOTA-Daratumumab",{"nctId":853,"briefTitle":854,"status":130,"phases":1559,"primaryCompletion":856,"completion":856,"start":857,"enrollment":36,"conditions":1560,"interventions":1561},[87],[859],[861,784,847],{"nctId":1563,"briefTitle":1564,"status":107,"phases":1565,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":36,"conditions":1569,"interventions":1570},"NCT02917096","Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis",[87],"2020-04-16","2023-08-31","2016-11-13",[1488,845],[847,823,849,1571,1165,1149,851],"Ruxolitinib",{"nctId":996,"briefTitle":997,"status":294,"phases":1573,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1574,"interventions":1575},[87],[1003,818],[784,847,1005],{"nctId":1007,"briefTitle":1008,"status":203,"phases":1577,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":36,"conditions":1578,"interventions":1579},[87],[1013,1014,1015],[784,847,1017],{"nctId":1019,"briefTitle":1020,"status":203,"phases":1581,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":919,"conditions":1582,"interventions":1583},[87],[1026],[1028,784,847],{"nctId":1030,"briefTitle":1031,"status":479,"phases":1585,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":99,"conditions":1586,"interventions":1587},[87],[1036,1037,1038,1039,1040,1041,1042,323,326,1043,1044,1045,1046,1047,302,1048,1049,1050,303,1051,1052,1053,470,1054,1055,1056,1057],[1059,784,847,1060],{"nctId":1062,"briefTitle":1063,"status":130,"phases":1589,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":251,"conditions":1590,"interventions":1591},[87],[1069,1070,1071,1072,1073],[1075,784,847,823],{"nctId":1077,"briefTitle":1078,"status":203,"phases":1593,"primaryCompletion":1080,"completion":1080,"start":1081,"enrollment":404,"conditions":1594,"interventions":1595},[87],[1083],[1085,784,847],{"nctId":1096,"briefTitle":1097,"status":203,"phases":1597,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":298,"conditions":1598,"interventions":1599},[87],[1102,1103],[784,847],{"nctId":1167,"briefTitle":1168,"status":203,"phases":1601,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":30,"conditions":1602,"interventions":1603},[87],[1173,1174],[1176,1177,784,847],{"nctId":1605,"briefTitle":1606,"status":907,"phases":1607,"primaryCompletion":1608,"completion":1608,"start":1609,"enrollment":1610,"conditions":1611,"interventions":1613},"NCT03494569","Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome",[87],"2026-06-11","2018-07-06",36,[35,1612,18,1194,1185,817,21,813],"Acute Lymphoblastic Leukemia in Remission",[847,849],{"nctId":1615,"briefTitle":1616,"status":203,"phases":1617,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":919,"conditions":1620,"interventions":1621},"NCT06195891","Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome",[87],"2030-03-22","2024-05-24",[35,18,21],[847,849,1622,851,1623],"Partially Engineered T-regulatory Cell Donor Graft TRGFT-201","Thiotepa",{"nctId":1202,"briefTitle":1203,"status":479,"phases":1625,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":99,"conditions":1626,"interventions":1627},[87],[1003,1208,818,1209],[1211,784,1212,847],{"nctId":1225,"briefTitle":1226,"status":203,"phases":1629,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":795,"conditions":1630,"interventions":1631},[87],[18,1231,21],[1233,784,1234,847,849,850,851],12,{"trials":1634,"activeCount":283,"soonestReadout":402},[1635,1639,1643,1655],{"nctId":1268,"briefTitle":1269,"status":203,"phases":1636,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":1273,"conditions":1637,"interventions":1638},[88],[35,18,1275,1231,21,1276],[784,847,849,851,1278],{"nctId":1434,"briefTitle":1435,"status":130,"phases":1640,"primaryCompletion":402,"completion":402,"start":1437,"enrollment":919,"conditions":1641,"interventions":1642},[88],[35,18,1439,21],[784,847,823,1441,850,851],{"nctId":1644,"briefTitle":1645,"status":107,"phases":1646,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":1650,"conditions":1651,"interventions":1653},"NCT04339101","Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation",[88],"2023-05-22","2025-10-09","2020-11-11",59,[1407,1652,21,1488,845],"Hematologic and Lymphocytic Disorder",[847,1654,849,1149,851],"Itacitinib Adipate",{"nctId":1447,"briefTitle":1448,"status":203,"phases":1656,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":404,"conditions":1657,"interventions":1658},[88],[1453,1454,1455],[784,847,1457,1458,838],{"trials":1660,"activeCount":99},[],{"trials":1662,"activeCount":99},[],{"trials":1664,"activeCount":99},[],{"intervention":851,"totalTrials":1666,"cells":1667},23,{"EARLY_PHASE1":1668,"PHASE1":1670,"PHASE2":1734,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1669,"activeCount":99},[],{"trials":1671,"activeCount":498,"soonestReadout":205},[1672,1676,1680,1684,1688,1701,1705,1709,1713,1717,1726,1730],{"nctId":840,"briefTitle":841,"status":130,"phases":1673,"primaryCompletion":205,"completion":205,"start":843,"enrollment":693,"conditions":1674,"interventions":1675},[87],[845],[784,847,848,849,850,851],{"nctId":1548,"briefTitle":1549,"status":203,"phases":1677,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":795,"conditions":1678,"interventions":1679},[87],[35,18,21],[1555,1556,847,1557,849,1149,851],{"nctId":905,"briefTitle":906,"status":907,"phases":1681,"primaryCompletion":909,"completion":909,"start":910,"enrollment":911,"conditions":1682,"interventions":1683},[87],[18],[784,66,851],{"nctId":1563,"briefTitle":1564,"status":107,"phases":1685,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":36,"conditions":1686,"interventions":1687},[87],[1488,845],[847,823,849,1571,1165,1149,851],{"nctId":1689,"briefTitle":1690,"status":107,"phases":1691,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":36,"conditions":1695,"interventions":1699},"NCT01163357","Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",[87],"2019-07-20","2024-05-20","2011-01-28",[1696,1697,1698,1102,1103],"Autologous Hematopoietic Stem Cell Transplant Recipient","Loss of Chromosome 17p","Plasma Cell Leukemia",[1700,61,1306,1305],"bortezomib",{"nctId":1106,"briefTitle":1107,"status":130,"phases":1702,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":283,"conditions":1703,"interventions":1704},[87],[1112,1113,1114,1115,1116],[784,1118,1119,851,1120,1121],{"nctId":1137,"briefTitle":1138,"status":907,"phases":1706,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":1707,"interventions":1708},[87],[1144,1145],[784,940,1147,1148,1149,851],{"nctId":1179,"briefTitle":1180,"status":479,"phases":1710,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":99,"conditions":1711,"interventions":1712},[87],[1145,1185],[784,940,1147,1148,1149,851],{"nctId":1188,"briefTitle":1189,"status":107,"phases":1714,"primaryCompletion":453,"completion":453,"start":1191,"enrollment":177,"conditions":1715,"interventions":1716},[87],[1193,1194,1195,1196,812,1197,1198,1199],[784,823,850,851],{"nctId":1718,"briefTitle":1719,"status":479,"phases":1720,"primaryCompletion":1721,"start":1722,"enrollment":99,"conditions":1723,"interventions":1725},"NCT02528877","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",[87],"2016-09","2015-11",[1194,1488,1724,813,845],"Primary Myelofibrosis, Prefibrotic Stage",[823,849,1165,1149,851],{"nctId":1615,"briefTitle":1616,"status":203,"phases":1727,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":919,"conditions":1728,"interventions":1729},[87],[35,18,21],[847,849,1622,851,1623],{"nctId":1225,"briefTitle":1226,"status":203,"phases":1731,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":795,"conditions":1732,"interventions":1733},[87],[18,1231,21],[1233,784,1234,847,849,850,851],{"trials":1735,"activeCount":486,"soonestReadout":41},[1736,1740,1744,1758,1762,1766,1776,1784,1788,1792,1805],{"nctId":1268,"briefTitle":1269,"status":203,"phases":1737,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":1273,"conditions":1738,"interventions":1739},[88],[35,18,1275,1231,21,1276],[784,847,849,851,1278],{"nctId":1290,"briefTitle":1291,"status":107,"phases":1741,"primaryCompletion":433,"completion":433,"start":1293,"enrollment":111,"conditions":1742,"interventions":1743},[88],[1295,1231,1296,32,27,1297,1298,1299,1300,845,1301],[1303,75,894,61,115,1304,1305,1306],{"nctId":1745,"briefTitle":1746,"status":294,"phases":1747,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":1273,"conditions":1750,"interventions":1757},"NCT07582172","Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome",[88],"2029-04-05","2027-04-05",[1751,1752,21,1003,1753,1208,1754,818,1755,1209,1756],"Acute Myeloid Leukemia With Complex Karyotype","Myelodysplastic Chronic Myelomonocytic Leukemia","Recurrent Myelodysplastic Chronic Myelomonocytic Leukemia","Recurrent Secondary Acute Myeloid Leukemia","Refractory Myelodysplastic Chronic Myelomonocytic Leukemia","Refractory Secondary Acute Myeloid Leukemia",[823,849,1148,1149,851],{"nctId":39,"briefTitle":40,"status":130,"phases":1759,"primaryCompletion":41,"completion":1367,"start":1368,"enrollment":1369,"conditions":1760,"interventions":1761},[88],[1295,1231,32,27,1297,1298,1371,1372],[42,75,1374,894,61,115,1304,1375,1305,1306],{"nctId":1399,"briefTitle":1400,"status":107,"phases":1763,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":1764,"interventions":1765},[88],[1407,1408,1409,1410,1411,1231,1412,1413,1414,21,1276,1415,1102,1103,1416],[1233,784,823,1418,850,851],{"nctId":1767,"briefTitle":1768,"status":107,"phases":1769,"primaryCompletion":1770,"completion":1771,"start":1772,"enrollment":16,"conditions":1773,"interventions":1774},"NCT00577278","A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan",[88],"2019-05-30","2023-12-14","2007-10-03",[1231,32,27],[1775,61,115,1305,1306],"rituximab",{"nctId":1777,"briefTitle":1778,"status":203,"phases":1779,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":188,"conditions":1782,"interventions":1783},"NCT06128070","Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",[88],"2030-11-22","2024-07-16",[35,18,21],[1134,1165,851],{"nctId":1434,"briefTitle":1435,"status":130,"phases":1785,"primaryCompletion":402,"completion":402,"start":1437,"enrollment":919,"conditions":1786,"interventions":1787},[88],[35,18,1439,21],[784,847,823,1441,850,851],{"nctId":1644,"briefTitle":1645,"status":107,"phases":1789,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":1650,"conditions":1790,"interventions":1791},[88],[1407,1652,21,1488,845],[847,1654,849,1149,851],{"nctId":1793,"briefTitle":1794,"status":130,"phases":1795,"primaryCompletion":1796,"completion":1797,"start":1798,"enrollment":1509,"conditions":1799,"interventions":1803},"NCT01885689","Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia",[88],"2019-12-27","2026-09-21","2014-02-10",[1800,1801,808,21,1416,1275,1802],"Adult Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Therapy-Related Myelodysplastic Syndrome",[1804,115,1306,1305],"clofarabine",{"nctId":1482,"briefTitle":1483,"status":130,"phases":1806,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":404,"conditions":1807,"interventions":1808},[88],[35,18,1275,21,1276,1488,845],[784,1490,851],{"trials":1810,"activeCount":99},[],{"trials":1812,"activeCount":99},[],{"trials":1814,"activeCount":99},[],{"intervention":1480,"totalTrials":1001,"cells":1816},{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1896,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":1818,"activeCount":99},[],{"trials":1820,"activeCount":195,"soonestReadout":1873},[1821,1830,1838,1861,1869],{"nctId":1822,"briefTitle":1823,"status":294,"phases":1824,"primaryCompletion":1825,"completion":1825,"start":1826,"enrollment":434,"conditions":1827,"interventions":1829},"NCT07619599","A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab",[87],"2028-12-22","2026-09-14",[501,211,1828,507],"Oligoprogressive Lung Non-Small Cell Carcinoma",[1480],{"nctId":1831,"briefTitle":1832,"status":203,"phases":1833,"primaryCompletion":1834,"completion":1834,"start":1835,"enrollment":1264,"conditions":1836,"interventions":1837},"NCT03969446","Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory",[87],"2027-07-04","2020-05-04",[18,21,1003,1208,818,1209],[1212,1480,956],{"nctId":1839,"briefTitle":1840,"status":130,"phases":1841,"primaryCompletion":1842,"completion":467,"start":1843,"enrollment":1383,"conditions":1844,"interventions":1859},"NCT03150329","Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.",[87],"2023-06-23","2017-07-18",[1845,1846,1847,972,973,1848,1849,1850,1851,1852,1853,1854,1855,1856,1857,1858],"Grade 3b Follicular Lymphoma","Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL","Recurrent Classic Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3a Follicular Lymphoma","Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Recurrent Transformed Non-Hodgkin Lymphoma","Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL","Refractory Classic Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Follicular Lymphoma","Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Refractory Transformed Non-Hodgkin Lymphoma",[1480,1860],"Vorinostat",{"nctId":1862,"briefTitle":1863,"status":479,"phases":1864,"primaryCompletion":1865,"completion":1865,"start":1866,"enrollment":99,"conditions":1867,"interventions":1868},"NCT04605614","64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression",[87],"2024-10-30","2022-08-15",[1145,29],[1480],{"nctId":1870,"briefTitle":1871,"status":130,"phases":1872,"primaryCompletion":1873,"completion":1874,"start":1875,"enrollment":264,"conditions":1876,"interventions":1894},"NCT02432963","Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy",[87],"2017-12-04","2026-10-02","2016-06-14",[1877,1878,1879,1880,1881,1882,1883,1884,1885,1886,1887,1888,1889,1890,1891,1892,1893],"Adult Solid Neoplasm","Bladder Carcinoma","Colon Carcinoma","Estrogen Receptor Negative","Head and Neck Squamous Cell Carcinoma","Hepatocellular Carcinoma","HER2\u002FNeu Negative","Melanoma","Non-Small Cell Lung Carcinoma","Pancreatic Carcinoma","Progesterone Receptor Negative","Rectal Carcinoma","Renal Cell Carcinoma","Soft Tissue Sarcoma","Triple-Negative Breast Carcinoma","TP53 Gene Mutation","Unresectable Solid Neoplasm",[1895,1480],"Modified Vaccinia Virus Ankara Vaccine Expressing p53",{"trials":1897,"activeCount":9,"soonestReadout":1942},[1898,1910,1938,1951,1964,1976,1990,2002,2012,2022,2044,2057,2061,2070],{"nctId":1899,"briefTitle":1900,"status":479,"phases":1901,"primaryCompletion":1902,"completion":1902,"start":1903,"enrollment":99,"conditions":1904,"interventions":1908},"NCT03592407","Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer",[88],"2020-04","2018-07-01",[1905,1906,1907],"Esophageal Squamous Cell Carcinoma","Esophageal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[1909,1480],"Epacadostat",{"nctId":1911,"briefTitle":1912,"status":130,"phases":1913,"primaryCompletion":403,"completion":1914,"start":1915,"enrollment":1916,"conditions":1917,"interventions":1936},"NCT03598998","Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas",[87,88],"2027-02-18","2019-02-04",13,[1918,1919,1920,1921,1922,973,1923,1924,1925,1926,1927,1928,1929,1930,1856,1931,1932,1933,1934,1935],"Anaplastic Large Cell Lymphoma","Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","Recurrent Anaplastic Large Cell Lymphoma","Recurrent Angioimmunoblastic T-Cell Lymphoma","Recurrent Enteropathy-Associated T-Cell Lymphoma","Recurrent Hepatosplenic T-Cell Lymphoma","Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma","Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma","Recurrent Mycosis Fungoides","Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified","Refractory Anaplastic Large Cell Lymphoma","Refractory Angioimmunoblastic T-Cell Lymphoma","Refractory Enteropathy-Associated T-Cell Lymphoma","Refractory Hepatosplenic T-Cell Lymphoma","Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Refractory Mycosis Fungoides","Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified","Subcutaneous Panniculitis-Like T-Cell Lymphoma",[1480,1937],"Pralatrexate",{"nctId":1939,"briefTitle":1940,"status":130,"phases":1941,"primaryCompletion":1942,"completion":1943,"start":1944,"enrollment":1945,"conditions":1946,"interventions":1950},"NCT03113487","P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[88],"2022-08-26","2026-05-04","2018-02-01",29,[1947,1948,1949],"Recurrent Platinum-Resistant Fallopian Tube Carcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma","Recurrent Platinum-Resistant Primary Peritoneal Carcinoma",[1895,1480],{"nctId":1952,"briefTitle":1953,"status":107,"phases":1954,"primaryCompletion":1955,"completion":1956,"start":1957,"enrollment":36,"conditions":1958,"interventions":1962},"NCT02971761","Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer",[88],"2020-10-28","2022-08-16","2017-06-01",[1959,1880,1883,1960,1887,1961],"Androgen Receptor Positive","Metastatic Triple-Negative Breast Carcinoma","Stage IV Breast Cancer AJCC v6 and v7",[1963,1480],"Enobosarm",{"nctId":1965,"briefTitle":1966,"status":294,"phases":1967,"primaryCompletion":1968,"completion":1968,"start":1943,"enrollment":1969,"conditions":1970,"interventions":1974},"NCT07037004","Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery",[88],"2028-10-24",62,[1971,1972,1973,1049,1052],"Clear Cell Renal Cell Carcinoma","Sarcomatoid Renal Cell Carcinoma","Stage II Renal Cell Cancer AJCC v8",[1975,1480],"Clostridium butyricum CBM588 Strain",{"nctId":1977,"briefTitle":1978,"status":107,"phases":1979,"primaryCompletion":1980,"completion":1981,"start":1982,"enrollment":251,"conditions":1983,"interventions":1989},"NCT02830594","Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer",[88],"2022-01-20","2024-01-16","2016-10-05",[1984,1985,1907,1986,1987,1988],"Gastric Adenocarcinoma","Gastric Squamous Cell Carcinoma","Metastatic Malignant Neoplasm in the Stomach","Stage IV Esophageal Adenocarcinoma AJCC v7","Stage IV Esophageal Squamous Cell Carcinoma AJCC v7",[1480],{"nctId":1991,"briefTitle":1992,"status":130,"phases":1993,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":19,"conditions":1996,"interventions":2000},"NCT04887805","Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer",[88],"2026-11-05","2021-07-21",[1997,1046,1998,1999,1048,1051,1056],"Advanced Pancreatic Ductal Adenocarcinoma","Stage IIA Pancreatic Cancer AJCC v8","Stage IIB Pancreatic Cancer AJCC v8",[2001,1480],"Lenvatinib Mesylate",{"nctId":2003,"briefTitle":2004,"status":130,"phases":2005,"primaryCompletion":2006,"completion":2006,"start":2007,"enrollment":1610,"conditions":2008,"interventions":2011},"NCT03512405","Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia",[87,88],"2025-11-11","2019-08-02",[2009,2010,1173,1174],"CD19 Positive","Philadelphia Chromosome Positive",[955,1480],{"nctId":2013,"briefTitle":2014,"status":203,"phases":2015,"primaryCompletion":2016,"completion":2016,"start":467,"enrollment":1666,"conditions":2017,"interventions":2019},"NCT07275216","Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment",[88],"2029-10-20",[2018],"Classic Hodgkin Lymphoma",[1256,2020,2021,1480],"Dacarbazine","Gemcitabine",{"nctId":2023,"briefTitle":2024,"status":130,"phases":2025,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":283,"conditions":2028,"interventions":2043},"NCT04929392","Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal\u002FGastroesophageal Junction Cancer",[88],"2027-04-25","2022-01-25",[2029,2030,2031,2032,2033,1467,1906,1905,2034,2035,2036,2037,2038,2039,2040,2041,2042,1471,1472],"Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8",[169,2001,170,1480],{"nctId":2045,"briefTitle":2046,"status":130,"phases":2047,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":2052,"interventions":2053},"NCT02778685","Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer",[88],"2025-10-31","2026-03-30","2016-09-30",47,[210,1961],[2054,2055,2056,1480],"Fulvestrant","Letrozole","Palbociclib",{"nctId":1460,"briefTitle":1461,"status":107,"phases":2058,"primaryCompletion":1463,"completion":1463,"start":1464,"enrollment":95,"conditions":2059,"interventions":2060},[87,88],[318,1466,319,1467,320,1468,1469,1470,328,1471,1472,1473,330,1474,1475,1476,1477,1478],[784,837,1480],{"nctId":2062,"briefTitle":2063,"status":479,"phases":2064,"primaryCompletion":2065,"completion":2065,"start":2066,"enrollment":99,"conditions":2067,"interventions":2069},"NCT03402880","ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer",[88],"2018-10-03","2018-10",[2068],"Extensive Stage Small Cell Lung Carcinoma",[1480,1909],{"nctId":2071,"briefTitle":2072,"status":107,"phases":2073,"primaryCompletion":2074,"completion":2075,"start":2076,"enrollment":298,"conditions":2077,"interventions":2080},"NCT02648477","Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer",[88],"2022-04-01","2023-12-30","2016-03-28",[1880,2078,1883,1887,2079,144,1891],"Estrogen Receptor Positive","Progesterone Receptor Positive",[2081,941,2082,2055,1480],"Anastrozole","Exemestane",{"trials":2084,"activeCount":99},[],{"trials":2086,"activeCount":99},[],{"trials":2088,"activeCount":99},[],{"intervention":838,"totalTrials":251,"cells":2090},{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2198,"PHASE3":2258,"PHASE4":2260,"NA":2262},{"trials":2092,"activeCount":99},[],{"trials":2094,"activeCount":486,"soonestReadout":2148},[2095,2107,2116,2140,2144,2155,2165,2177,2186],{"nctId":2096,"briefTitle":2097,"status":130,"phases":2098,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":22,"conditions":2101,"interventions":2105},"NCT03884998","Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma",[87],"2026-11-04","2019-02-26",[2102,1410,1411,2103,2104,1414,1455],"Chronic Lymphocytic Leukemia","Indolent Non-Hodgkin Lymphoma","Lymphoplasmacytic Lymphoma",[2106,838],"Copanlisib",{"nctId":2108,"briefTitle":2109,"status":130,"phases":2110,"primaryCompletion":402,"completion":402,"start":2111,"enrollment":177,"conditions":2112,"interventions":2113},"NCT06049576","Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma",[87],"2023-10-06",[1971,1972,1049,1052],[2114,2115,838],"Ipilimumab","Myrciaria dubia Prebiotic Supplement",{"nctId":2117,"briefTitle":2118,"status":107,"phases":2119,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":2122,"conditions":2123,"interventions":2138},"NCT04362839","Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer",[87],"2025-12-11","2020-05-27",39,[2124,406,407,323,408,2125,457,2126,2127,2128,2129,2130,2131,409,303,410,2132,335,2133,2134,339,2135,2136,343,2137],"Advanced Colon Adenocarcinoma","Stage III Colon Cancer AJCC v8","Stage IIIA Colon Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Colon Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Colon Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8","Stage IVA Colon Cancer AJCC v8","Stage IVA Rectal Cancer AJCC v8","Stage IVB Colon Cancer AJCC v8","Stage IVB Rectal Cancer AJCC v8","Stage IVC Colon Cancer AJCC v8","Stage IVC Rectal Cancer AJCC v8",[2114,838,2139],"Regorafenib",{"nctId":825,"briefTitle":826,"status":130,"phases":2141,"primaryCompletion":828,"completion":828,"start":829,"enrollment":9,"conditions":2142,"interventions":2143},[87],[831,832,833,834,835],[784,837,838],{"nctId":2145,"briefTitle":2146,"status":130,"phases":2147,"primaryCompletion":2148,"completion":2149,"start":2150,"enrollment":404,"conditions":2151,"interventions":2153},"NCT04003649","IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM",[87],"2024-12-18","2026-09-26","2019-12-02",[707,2152],"Refractory Glioblastoma",[2154,2114,838],"IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR\u002FTruncated CD19-expressing Autologous TN\u002FMEM Cells",{"nctId":2156,"briefTitle":2157,"status":107,"phases":2158,"primaryCompletion":2159,"completion":2159,"start":2160,"enrollment":298,"conditions":2161,"interventions":2163},"NCT03829111","CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer",[87],"2023-12-13","2019-05-14",[2162,1971,1045,1049,1052,1057],"Advanced Renal Cell Carcinoma",[2164,2114,838],"Clostridium butyricum CBM 588 Probiotic Strain",{"nctId":2166,"briefTitle":2167,"status":203,"phases":2168,"primaryCompletion":2169,"completion":2169,"start":2170,"enrollment":919,"conditions":2171,"interventions":2176},"NCT07128680","Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer",[87],"2028-08-25","2026-03-23",[2172,2173,2174,2175,1049,1052],"Advanced Clear Cell Renal Cell Carcinoma","Advanced Sarcomatoid Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Metastatic Sarcomatoid Renal Cell Carcinoma",[2114,838],{"nctId":2178,"briefTitle":2179,"status":130,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":919,"conditions":2183,"interventions":2184},"NCT05162976","CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed",[87],"2026-05-12","2022-01-03",[1847,1854],[838,2185],"Oral Azacitidine",{"nctId":2187,"briefTitle":2188,"status":130,"phases":2189,"primaryCompletion":2190,"completion":2190,"start":2191,"enrollment":177,"conditions":2192,"interventions":2196},"NCT05122546","CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer",[87],"2027-01-12","2021-11-01",[2172,2193,2162,2173,2174,2194,1045,2175,1049,1052,2195,1057],"Advanced Papillary Renal Cell Carcinoma","Metastatic Papillary Renal Cell Carcinoma","Unresectable Clear Cell Renal Cell Carcinoma",[2197,2164,838],"Cabozantinib S-malate",{"trials":2199,"activeCount":498,"soonestReadout":2249},[2200,2208,2232,2245,2254],{"nctId":2201,"briefTitle":2202,"status":203,"phases":2203,"primaryCompletion":1874,"completion":1874,"start":2204,"enrollment":177,"conditions":2205,"interventions":2207},"NCT04561206","Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed\u002FRefractory Classical Hodgkin Lymphoma",[88],"2021-11-12",[2206],"Relapsed Classic Hodgkin Lymphoma",[1256,838],{"nctId":2209,"briefTitle":2210,"status":130,"phases":2211,"primaryCompletion":2212,"completion":2212,"start":2213,"enrollment":2214,"conditions":2215,"interventions":2229},"NCT03712202","Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma",[88],"2024-12-23","2018-11-28",155,[2216,2217,2218,2219,2220,2221,2222,2223,2018,2224,2225,2226,2227,2228],"Ann Arbor Stage I Hodgkin Lymphoma","Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma","Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma","Ann Arbor Stage IA Hodgkin Lymphoma","Ann Arbor Stage IB Hodgkin Lymphoma","Ann Arbor Stage II Hodgkin Lymphoma","Ann Arbor Stage IIA Hodgkin Lymphoma","Ann Arbor Stage IIB Hodgkin Lymphoma","Lymphocyte-Rich Classic Hodgkin Lymphoma","Ann Arbor Stage I Lymphocyte-Depleted Classic HL","Ann Arbor Stage II Lymphocyte-Depleted Classic HL","Ann Arbor Stage II Mixed Cellularity Classic HL","Ann Arbor Stage II Nodular Sclerosis Classic HL",[2230,1256,2020,346,838,2231],"Bleomycin","Vinblastine",{"nctId":2233,"briefTitle":2234,"status":130,"phases":2235,"primaryCompletion":2236,"completion":2237,"start":2238,"enrollment":2239,"conditions":2240,"interventions":2243},"NCT03016871","Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL",[88],"2024-01-30","2026-06-30","2017-04-24",78,[2241,2242],"Recurrent Hodgkin Lymphoma","Refractory Hodgkin Lymphoma",[169,940,2244,838],"Ifosfamide",{"nctId":2246,"briefTitle":2247,"status":130,"phases":2248,"primaryCompletion":2249,"completion":2250,"start":2251,"enrollment":1969,"conditions":2252,"interventions":2253},"NCT03057795","Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma",[88],"2021-01-30","2027-02-25","2017-04-03",[2018,2241,2242],[1256,838],{"nctId":1447,"briefTitle":1448,"status":203,"phases":2255,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":404,"conditions":2256,"interventions":2257},[88],[1453,1454,1455],[784,847,1457,1458,838],{"trials":2259,"activeCount":99},[],{"trials":2261,"activeCount":99},[],{"trials":2263,"activeCount":99},[],{"intervention":115,"totalTrials":1273,"cells":2265},{"EARLY_PHASE1":2266,"PHASE1":2268,"PHASE2":2393,"PHASE3":2485,"PHASE4":2495,"NA":2497},{"trials":2267,"activeCount":99},[],{"trials":2269,"activeCount":498,"soonestReadout":205},[2270,2274,2278,2282,2286,2300,2337,2346,2350,2354,2358,2366,2370,2380],{"nctId":840,"briefTitle":841,"status":130,"phases":2271,"primaryCompletion":205,"completion":205,"start":843,"enrollment":693,"conditions":2272,"interventions":2273},[87],[845],[784,847,848,849,850,851],{"nctId":1548,"briefTitle":1549,"status":203,"phases":2275,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":795,"conditions":2276,"interventions":2277},[87],[35,18,21],[1555,1556,847,1557,849,1149,851],{"nctId":873,"briefTitle":874,"status":107,"phases":2279,"primaryCompletion":109,"completion":109,"start":876,"enrollment":9,"conditions":2280,"interventions":2281},[87],[878,879,880],[738,385,75,115,871,882,883,274],{"nctId":1563,"briefTitle":1564,"status":107,"phases":2283,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":36,"conditions":2284,"interventions":2285},[87],[1488,845],[847,823,849,1571,1165,1149,851],{"nctId":2287,"briefTitle":2288,"status":107,"phases":2289,"primaryCompletion":2290,"completion":2291,"start":2292,"enrollment":404,"conditions":2293,"interventions":2297},"NCT02342782","Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma",[87],"2020-09-18","2024-11-18","2020-06-08",[1161,2294,1932,2295,2296],"Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma","Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma",[2298,2299,940,1131,849],"Yttrium Y 90 Basiliximab","Carmustine",{"nctId":2301,"briefTitle":2302,"status":107,"phases":2303,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":890,"conditions":2307,"interventions":2336},"NCT00638898","Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor",[87],"2013-01-19","2024-12-10","2007-02-26",[2308,2309,2310,2311,2312,2313,2314,2315,2316,583,2317,2318,2319,2320,2321,2322,2323,2324,2325,2326,2327,2328,2329,2330,2331,2332,2333,2334,24,2335],"Solid Tumor","Adult Central Nervous System Germ Cell Tumor","Adult Rhabdomyosarcoma","Childhood Central Nervous System Germ Cell Tumor","Childhood Soft Tissue Sarcoma","Ewing Sarcoma","Metastatic Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor","Ovarian Mixed Germ Cell Tumor","Previously Untreated Childhood Rhabdomyosarcoma","Recurrent Adult Soft Tissue Sarcoma","Recurrent Childhood Brain Stem Glioma","Recurrent Childhood Cerebellar Astrocytoma","Recurrent Childhood Cerebral Astrocytoma","Recurrent Childhood Ependymoma","Recurrent Childhood Malignant Germ Cell Tumor","Recurrent Childhood Medulloblastoma","Recurrent Childhood Pineoblastoma","Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor","Recurrent Childhood Visual Pathway and Hypothalamic Glioma","Recurrent Childhood Visual Pathway Glioma","Recurrent Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor","Recurrent Extragonadal Germ Cell Tumor","Recurrent Extragonadal Non-seminomatous Germ Cell Tumor","Recurrent Malignant Testicular Germ Cell Tumor","Recurrent Neuroblastoma","Recurrent Ovarian Germ Cell Tumor","Recurrent Wilms Tumor and Other Childhood Kidney Tumors","Unspecified Childhood Solid Tumor, Protocol Specific",[42,115,882,738],{"nctId":2338,"briefTitle":2339,"status":107,"phases":2340,"primaryCompletion":2341,"completion":2341,"start":2342,"enrollment":404,"conditions":2343,"interventions":2344},"NCT00641030","Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes",[87],"2011-01","2007-07",[32,1298],[1804,115,274,2345],"reverse transcriptase-polymerase chain reaction",{"nctId":1718,"briefTitle":1719,"status":479,"phases":2347,"primaryCompletion":1721,"start":1722,"enrollment":99,"conditions":2348,"interventions":2349},[87],[1194,1488,1724,813,845],[823,849,1165,1149,851],{"nctId":1605,"briefTitle":1606,"status":907,"phases":2351,"primaryCompletion":1608,"completion":1608,"start":1609,"enrollment":1610,"conditions":2352,"interventions":2353},[87],[35,1612,18,1194,1185,817,21,813],[847,849],{"nctId":1615,"briefTitle":1616,"status":203,"phases":2355,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":919,"conditions":2356,"interventions":2357},[87],[35,18,21],[847,849,1622,851,1623],{"nctId":2359,"briefTitle":2360,"status":369,"phases":2361,"primaryCompletion":2362,"completion":2362,"start":2363,"enrollment":434,"conditions":2364,"interventions":2365},"NCT00800150","Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment",[87],"2010-10","2008-11",[1295,32,27,1297,1298,1299],[61,115],{"nctId":1225,"briefTitle":1226,"status":203,"phases":2367,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":795,"conditions":2368,"interventions":2369},[87],[18,1231,21],[1233,784,1234,847,849,850,851],{"nctId":2371,"briefTitle":2372,"status":130,"phases":2373,"primaryCompletion":2374,"completion":2374,"start":2375,"enrollment":486,"conditions":2376,"interventions":2377},"NCT05139004","90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome",[87],"2027-06-13","2022-07-19",[35,18,21,813],[2378,823,2379,849,1148,2298],"Basiliximab","Indium In 111-DOTA-Basiliximab",{"nctId":2381,"briefTitle":2382,"status":107,"phases":2383,"primaryCompletion":2384,"completion":2385,"start":2386,"enrollment":890,"conditions":2387,"interventions":2389},"NCT01476839","Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma",[87],"2021-07-24","2024-05-31","2012-11-09",[2388],"Recurrent Adult Hodgkin Lymphoma",[2390,893,894,2391,115,2392],"basiliximab","cytarabine","yttrium Y 90-labeled basiliximab",{"trials":2394,"activeCount":434,"soonestReadout":41},[2395,2404,2408,2412,2416,2420,2424,2428,2432,2436,2444,2451,2455,2459,2463,2470,2474],{"nctId":2396,"briefTitle":2397,"status":107,"phases":2398,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":2401,"conditions":2402,"interventions":2403},"NCT00695409","Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma",[88],"2017-03-27","2008-03-18",122,[27],[1775,893,2391,894,115],{"nctId":1268,"briefTitle":1269,"status":203,"phases":2405,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":1273,"conditions":2406,"interventions":2407},[88],[35,18,1275,1231,21,1276],[784,847,849,851,1278],{"nctId":1290,"briefTitle":1291,"status":107,"phases":2409,"primaryCompletion":433,"completion":433,"start":1293,"enrollment":111,"conditions":2410,"interventions":2411},[88],[1295,1231,1296,32,27,1297,1298,1299,1300,845,1301],[1303,75,894,61,115,1304,1305,1306],{"nctId":105,"briefTitle":106,"status":107,"phases":2413,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":2414,"interventions":2415},[88],[15],[94,114,75,115,116],{"nctId":1745,"briefTitle":1746,"status":294,"phases":2417,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":1273,"conditions":2418,"interventions":2419},[88],[1751,1752,21,1003,1753,1208,1754,818,1755,1209,1756],[823,849,1148,1149,851],{"nctId":1312,"briefTitle":1313,"status":479,"phases":2421,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":99,"conditions":2422,"interventions":2423},[87,88],[1318,1319],[784,66,1321,849,1148],{"nctId":1323,"briefTitle":1324,"status":107,"phases":2425,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1264,"conditions":2426,"interventions":2427},[87,88],[989,1329,990,991,992],[115,738,1331,1332,75,1333],{"nctId":1335,"briefTitle":1336,"status":107,"phases":2429,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":16,"conditions":2430,"interventions":2431},[88],[15],[738,385,75,168,115,923,871,1343],{"nctId":39,"briefTitle":40,"status":130,"phases":2433,"primaryCompletion":41,"completion":1367,"start":1368,"enrollment":1369,"conditions":2434,"interventions":2435},[88],[1295,1231,32,27,1297,1298,1371,1372],[42,75,1374,894,61,115,1304,1375,1305,1306],{"nctId":2437,"briefTitle":2438,"status":130,"phases":2439,"primaryCompletion":467,"completion":467,"start":2440,"enrollment":177,"conditions":2441,"interventions":2443},"NCT03346135","Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma",[88],"2019-07-17",[1319,2442],"Secondary Amyloidosis",[1556,849],{"nctId":58,"briefTitle":59,"status":130,"phases":2445,"primaryCompletion":60,"completion":2446,"start":2447,"enrollment":2448,"conditions":2449,"interventions":2450},[87,88],"2026-12-02","2006-07-31",75,[32,1298],[61,115],{"nctId":1767,"briefTitle":1768,"status":107,"phases":2452,"primaryCompletion":1770,"completion":1771,"start":1772,"enrollment":16,"conditions":2453,"interventions":2454},[88],[1231,32,27],[1775,61,115,1305,1306],{"nctId":1644,"briefTitle":1645,"status":107,"phases":2456,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":1650,"conditions":2457,"interventions":2458},[88],[1407,1652,21,1488,845],[847,1654,849,1149,851],{"nctId":1793,"briefTitle":1794,"status":130,"phases":2460,"primaryCompletion":1796,"completion":1797,"start":1798,"enrollment":1509,"conditions":2461,"interventions":2462},[88],[1800,1801,808,21,1416,1275,1802],[1804,115,1306,1305],{"nctId":2464,"briefTitle":2465,"status":107,"phases":2466,"primaryCompletion":2467,"completion":2467,"start":393,"enrollment":1916,"conditions":2468,"interventions":2469},"NCT00002601","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma",[88],"2014-09",[664],[738,385,168,740,115],{"nctId":1492,"briefTitle":1493,"status":107,"phases":2471,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":2472,"interventions":2473},[88],[1297],[738,1500,42,75,115,1501,1502],{"nctId":2475,"briefTitle":2476,"status":107,"phases":2477,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":2481,"interventions":2483},"NCT00792142","Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma",[88],"2014-04-21","2008-01-16",45,[1297,2482],"Neurotoxicity",[1700,2484,115,1502,1332,1331],"dexamethasone",{"trials":2486,"activeCount":99},[2487],{"nctId":2488,"briefTitle":2489,"status":369,"phases":2490,"primaryCompletion":2491,"completion":2491,"start":2492,"enrollment":283,"conditions":2493,"interventions":2494},"NCT02366663","BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)\u002FBEAM With ASCT for Relapsed DLBCL",[89],"2016-10","2015-01",[972,1855],[2299,940,1131,849,939],{"trials":2496,"activeCount":99},[],{"trials":2498,"activeCount":99},[2499,2503,2515],{"nctId":1519,"briefTitle":1520,"status":107,"phases":2500,"primaryCompletion":1522,"completion":1522,"start":1523,"enrollment":298,"conditions":2501,"interventions":2502},[91],[27],[738,893,75,894,115],{"nctId":2504,"briefTitle":2505,"status":479,"phases":2506,"primaryCompletion":2507,"start":2508,"enrollment":99,"conditions":2509,"interventions":2514},"NCT01795430","Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma",[91],"2018-03","2013-07",[2510,2511,2512,2314,2325,2328,2513],"Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)","Ewing Sarcoma of Bone","Extraosseous Ewing Sarcoma","Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor",[894,740,882,42,115],{"nctId":1527,"briefTitle":1528,"status":107,"phases":2516,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":207,"conditions":2517,"interventions":2518},[91],[32,27,1298],[738,1233,784,1535,1536,849,850],{"intervention":956,"totalTrials":251,"cells":2520},{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2587,"PHASE3":2650,"PHASE4":2652,"NA":2654},{"trials":2522,"activeCount":99},[],{"trials":2524,"activeCount":498,"soonestReadout":2551},[2525,2538,2547,2557,2561,2565,2574,2578],{"nctId":2526,"briefTitle":2527,"status":479,"phases":2528,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":99,"conditions":2531,"interventions":2532},"NCT04655391","Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation",[87],"2023-12-15","2022-06-25",[1003],[2533,1212,2534,2535,2536,2537,956],"Bosutinib Monohydrate","Enasidenib Mesylate","Gilteritinib Fumarate","Glasdegib Maleate","Ivosidenib",{"nctId":2539,"briefTitle":2540,"status":130,"phases":2541,"primaryCompletion":828,"completion":828,"start":2542,"enrollment":2543,"conditions":2544,"interventions":2545},"NCT05222984","Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax",[87],"2022-07-29",17,[1003,818],[1212,2546,956],"Navitoclax",{"nctId":2548,"briefTitle":2549,"status":203,"phases":2550,"primaryCompletion":2551,"completion":2551,"start":2552,"enrollment":1632,"conditions":2553,"interventions":2554},"NCT06763341","A Phase 1 Study of AOH1996 in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[87],"2027-01-16","2025-07-30",[1003,818],[2555,2556,956],"Azacitidine","PCNA Inhibitor AOH1996",{"nctId":945,"briefTitle":946,"status":203,"phases":2558,"primaryCompletion":948,"completion":948,"start":949,"enrollment":25,"conditions":2559,"interventions":2560},[87],[951,952],[954,955,784,956,957],{"nctId":1831,"briefTitle":1832,"status":203,"phases":2562,"primaryCompletion":1834,"completion":1834,"start":1835,"enrollment":1264,"conditions":2563,"interventions":2564},[87],[18,21,1003,1208,818,1209],[1212,1480,956],{"nctId":2566,"briefTitle":2567,"status":907,"phases":2568,"primaryCompletion":2569,"completion":2569,"start":2570,"enrollment":298,"conditions":2571,"interventions":2572},"NCT05263284","8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[87],"2029-01-25","2022-12-15",[18,1003,818],[2573,956],"8-Chloroadenosine",{"nctId":1123,"briefTitle":1124,"status":130,"phases":2575,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":30,"conditions":2576,"interventions":2577},[87],[859,1129],[784,1131,1132,1133,1134,1135,938,956,942],{"nctId":2579,"briefTitle":2580,"status":907,"phases":2581,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":404,"conditions":2584,"interventions":2586},"NCT06454409","Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia",[87],"2030-09-06","2025-05-21",[2585,1003,1208,818,1209],"Myelodysplastic Syndrome\u002FAcute Myeloid Leukemia",[2555,2139,956],{"trials":2588,"activeCount":498,"soonestReadout":2623},[2589,2597,2608,2619,2632,2642],{"nctId":2590,"briefTitle":2591,"status":203,"phases":2592,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":19,"conditions":2595,"interventions":2596},"NCT03523975","Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma",[87,88],"2027-06-24","2018-12-24",[1413],[956,1321,939],{"nctId":2598,"briefTitle":2599,"status":294,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":1273,"conditions":2603,"interventions":2605},"NCT07582159","Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[88],"2029-04-14","2026-12-19",[2102,1408,2604],"Small Lymphocytic Lymphoma",[2606,2607,956],"Acalabrutinib","Tafasitamab",{"nctId":2609,"briefTitle":2610,"status":107,"phases":2611,"primaryCompletion":2612,"completion":2613,"start":2614,"enrollment":1632,"conditions":2615,"interventions":2617},"NCT03534180","Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma",[88],"2021-04-21","2023-07-26","2018-08-21",[1918,2616,1932],"Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",[2618,956],"Romidepsin",{"nctId":2620,"briefTitle":2621,"status":203,"phases":2622,"primaryCompletion":2623,"completion":2623,"start":2624,"enrollment":2625,"conditions":2626,"interventions":2629},"NCT05861050","Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma",[87,88],"2027-02-01","2023-08-10",50,[2627,1413,2628],"Blastoid Variant Mantle Cell Lymphoma","Pleomorphic Variant Mantle Cell Lymphoma",[2630,1321,2631,956],"Glofitamab","Obinutuzumab",{"nctId":2633,"briefTitle":2634,"status":130,"phases":2635,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":9,"conditions":2638,"interventions":2640},"NCT04939272","Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",[87,88],"2027-02-12","2022-06-29",[976,2639],"Refractory Mantle Cell Lymphoma",[2641,956],"Copanlisib Hydrochloride",{"nctId":2643,"briefTitle":2644,"status":203,"phases":2645,"primaryCompletion":2646,"completion":2646,"start":1284,"enrollment":919,"conditions":2647,"interventions":2648},"NCT07218510","Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial",[88],"2029-06-08",[2102,2604],[2649,2631,956],"Epcoritamab",{"trials":2651,"activeCount":99},[],{"trials":2653,"activeCount":99},[],{"trials":2655,"activeCount":99},[],{"intervention":894,"totalTrials":1945,"cells":2657},{"EARLY_PHASE1":2658,"PHASE1":2660,"PHASE2":2716,"PHASE3":2819,"PHASE4":2825,"NA":2827},{"trials":2659,"activeCount":99},[],{"trials":2661,"activeCount":283,"soonestReadout":962},[2662,2669,2673,2677,2681,2685,2689,2693,2697,2701,2712],{"nctId":2663,"briefTitle":2664,"status":107,"phases":2665,"primaryCompletion":433,"completion":433,"start":2666,"enrollment":785,"conditions":2667,"interventions":2668},"NCT00551005","Etoposide and Celecoxib in Patients With Advanced Cancer",[87],"2001-12",[24],[903,894],{"nctId":885,"briefTitle":886,"status":107,"phases":2670,"primaryCompletion":888,"completion":888,"start":889,"enrollment":890,"conditions":2671,"interventions":2672},[87],[27],[893,75,894],{"nctId":915,"briefTitle":916,"status":107,"phases":2674,"primaryCompletion":175,"completion":175,"start":918,"enrollment":919,"conditions":2675,"interventions":2676},[87],[921],[738,114,385,75,894,740,923,871],{"nctId":2287,"briefTitle":2288,"status":107,"phases":2678,"primaryCompletion":2290,"completion":2291,"start":2292,"enrollment":404,"conditions":2679,"interventions":2680},[87],[1161,2294,1932,2295,2296],[2298,2299,940,1131,849],{"nctId":925,"briefTitle":926,"status":130,"phases":2682,"primaryCompletion":928,"completion":928,"start":929,"enrollment":207,"conditions":2683,"interventions":2684},[87],[931,932,933,934,935,936],[938,939,940,941,942,784,66,943],{"nctId":959,"briefTitle":960,"status":130,"phases":2686,"primaryCompletion":962,"completion":962,"start":963,"enrollment":964,"conditions":2687,"interventions":2688},[87],[966,967,968,969,970,971,972,973,974,975,976,977,978],[980,981,784,940,823],{"nctId":1087,"briefTitle":1088,"status":107,"phases":2690,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":498,"conditions":2691,"interventions":2692},[87],[27],[1094,893,75,894],{"nctId":1137,"briefTitle":1138,"status":907,"phases":2694,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":2695,"interventions":2696},[87],[1144,1145],[784,940,1147,1148,1149,851],{"nctId":1179,"briefTitle":1180,"status":479,"phases":2698,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":99,"conditions":2699,"interventions":2700},[87],[1145,1185],[784,940,1147,1148,1149,851],{"nctId":2702,"briefTitle":2703,"status":130,"phases":2704,"primaryCompletion":2705,"completion":2705,"start":2706,"enrollment":283,"conditions":2707,"interventions":2709},"NCT04560972","LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer",[87],"2027-01-27","2021-05-28",[2708],"Extensive Stage Lung Small Cell Carcinoma",[2710,169,940,2711],"Atezolizumab","Protein Phosphatase 2A Inhibitor LB-100",{"nctId":2381,"briefTitle":2382,"status":107,"phases":2713,"primaryCompletion":2384,"completion":2385,"start":2386,"enrollment":890,"conditions":2714,"interventions":2715},[87],[2388],[2390,893,894,2391,115,2392],{"trials":2717,"activeCount":486,"soonestReadout":41},[2718,2722,2726,2730,2734,2738,2749,2753,2765,2780,2791,2795,2799,2809,2813],{"nctId":1238,"briefTitle":1239,"status":130,"phases":2719,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":1244,"conditions":2720,"interventions":2721},[88],[1246,1247,1248,1249,1250,1251,1252,1253,1254,1161,1162],[1256,784,346,941,940,1257,938],{"nctId":1259,"briefTitle":1260,"status":107,"phases":2723,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":1264,"conditions":2724,"interventions":2725},[87,88],[27],[738,75,894],{"nctId":2396,"briefTitle":2397,"status":107,"phases":2727,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":2401,"conditions":2728,"interventions":2729},[88],[27],[1775,893,2391,894,115],{"nctId":1280,"briefTitle":1281,"status":107,"phases":2731,"primaryCompletion":1283,"completion":1284,"start":1285,"enrollment":1286,"conditions":2732,"interventions":2733},[87,88],[32],[75,894],{"nctId":1290,"briefTitle":1291,"status":107,"phases":2735,"primaryCompletion":433,"completion":433,"start":1293,"enrollment":111,"conditions":2736,"interventions":2737},[88],[1295,1231,1296,32,27,1297,1298,1299,1300,845,1301],[1303,75,894,61,115,1304,1305,1306],{"nctId":2739,"briefTitle":2740,"status":107,"phases":2741,"primaryCompletion":371,"completion":371,"start":2742,"enrollment":1244,"conditions":2743,"interventions":2748},"NCT00002931","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer",[88],"1997-02",[2744,2745,879,2746,2747],"Brain and Central Nervous System Tumors","Extragonadal Germ Cell Tumor","Teratoma","Testicular Germ Cell Tumor",[738,114,894,740,871],{"nctId":1356,"briefTitle":1357,"status":107,"phases":2750,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":2751,"interventions":2752},[88],[27],[893,75,894,1364],{"nctId":2754,"briefTitle":2755,"status":130,"phases":2756,"primaryCompletion":2757,"completion":467,"start":2758,"enrollment":16,"conditions":2759,"interventions":2763},"NCT04665765","Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[88],"2022-07-26","2021-01-18",[2760,972,1851,2761,1855,1857,2762],"Diffuse Large B-Cell Lymphoma Unclassifiable","Recurrent Transformed B-Cell Non-Hodgkin Lymphoma","Refractory Transformed B-Cell Non-Hodgkin Lymphoma",[169,940,2244,2764,939],"Polatuzumab Vedotin",{"nctId":2766,"briefTitle":2767,"status":369,"phases":2768,"primaryCompletion":2769,"completion":2770,"start":2771,"enrollment":890,"conditions":2772,"interventions":2779},"NCT00540995","Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer",[87,88],"2011-05-17","2011-08-09","2007-06-11",[808,1426,1427,1428,1429,1430,1431,2773,2774,2775,2776,2777,812,1198,2778],"Blastic Phase Chronic Myelogenous Leukemia","Childhood Acute Myeloid Leukemia in Remission","Childhood Chronic Myelogenous Leukemia","Childhood Myelodysplastic Syndromes","Previously Treated Myelodysplastic Syndromes","Refractory Anemia With Excess Blasts",[42,894],{"nctId":2781,"briefTitle":2782,"status":107,"phases":2783,"primaryCompletion":2784,"completion":2785,"start":2786,"enrollment":1361,"conditions":2787,"interventions":2788},"NCT00534469","Auto BMT for Non-M3 AML in 1st Remission in Pts \u003C\u002F=60y of Age Using Busulfan\u002FFTBI & VP16 as a Prep R",[88],"2022-12-31","2025-07-16","2000-02-08",[32],[2789,738,42,2391,894,2790],"aldesleukin","idarubicin",{"nctId":39,"briefTitle":40,"status":130,"phases":2792,"primaryCompletion":41,"completion":1367,"start":1368,"enrollment":1369,"conditions":2793,"interventions":2794},[88],[1295,1231,32,27,1297,1298,1371,1372],[42,75,1374,894,61,115,1304,1375,1305,1306],{"nctId":1420,"briefTitle":1421,"status":130,"phases":2796,"primaryCompletion":205,"completion":205,"start":1423,"enrollment":1424,"conditions":2797,"interventions":2798},[88],[1426,1427,1428,1429,1430,1431,1196,812,1197,1198],[894,75],{"nctId":2800,"briefTitle":2801,"status":203,"phases":2802,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":919,"conditions":2805,"interventions":2806},"NCT04871607","Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma",[88],"2029-10-02","2021-11-02",[2241,2242],[2378,2299,1131,940,2807,2808,2298],"Genetically Engineered Hematopoietic Stem Progenitor Cells","Recombinant Granulocyte Colony-Stimulating Factor",{"nctId":2233,"briefTitle":2234,"status":130,"phases":2810,"primaryCompletion":2236,"completion":2237,"start":2238,"enrollment":2239,"conditions":2811,"interventions":2812},[88],[2241,2242],[169,940,2244,838],{"nctId":44,"briefTitle":45,"status":130,"phases":2814,"primaryCompletion":46,"completion":2815,"start":2816,"enrollment":298,"conditions":2817,"interventions":2818},[88],"2026-03-18","2000-02-29",[32,1298],[42,1374,894,1375],{"trials":2820,"activeCount":99},[2821],{"nctId":2488,"briefTitle":2489,"status":369,"phases":2822,"primaryCompletion":2491,"completion":2491,"start":2492,"enrollment":283,"conditions":2823,"interventions":2824},[89],[972,1855],[2299,940,1131,849,939],{"trials":2826,"activeCount":99},[],{"trials":2828,"activeCount":99},[2829,2833],{"nctId":1519,"briefTitle":1520,"status":107,"phases":2830,"primaryCompletion":1522,"completion":1522,"start":1523,"enrollment":298,"conditions":2831,"interventions":2832},[91],[27],[738,893,75,894,115],{"nctId":2504,"briefTitle":2505,"status":479,"phases":2834,"primaryCompletion":2507,"start":2508,"enrollment":99,"conditions":2835,"interventions":2836},[91],[2510,2511,2512,2314,2325,2328,2513],[894,740,882,42,115],{"intervention":939,"totalTrials":36,"cells":2838},{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2885,"PHASE3":2994,"PHASE4":3000,"NA":3002},{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":214,"soonestReadout":928},[2843,2854,2863,2867],{"nctId":2844,"briefTitle":2845,"status":107,"phases":2846,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":576,"conditions":2849,"interventions":2851},"NCT03440567","Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma",[87],"2024-06-26","2018-04-02",[972,976,1855,2639,2850],"Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",[2852,169,1257,1457,2244,939,2853],"Avelumab","Utomilumab",{"nctId":2855,"briefTitle":2856,"status":107,"phases":2857,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":498,"conditions":2860,"interventions":2861},"NCT00182650","Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma",[87],"2008-03","2004-06",[27],[2789,1775,2862,61],"therapeutic autologous lymphocytes",{"nctId":925,"briefTitle":926,"status":130,"phases":2864,"primaryCompletion":928,"completion":928,"start":929,"enrollment":207,"conditions":2865,"interventions":2866},[87],[931,932,933,934,935,936],[938,939,940,941,942,784,66,943],{"nctId":2868,"briefTitle":2869,"status":107,"phases":2870,"primaryCompletion":481,"completion":481,"start":2871,"enrollment":95,"conditions":2872,"interventions":2883},"NCT00720135","Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",[87],"2008-01",[1918,2873,2874,2875,2876,2877,2878,1848,1849,977,2879,2880,2881,2882],"Cutaneous B-cell Non-Hodgkin Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","Testicular Lymphoma","Waldenstrom Macroglobulinemia",[2884,1775,2345],"DI-Leu16-IL2 immunocytokine",{"trials":2886,"activeCount":9,"soonestReadout":65},[2887,2891,2900,2904,2908,2925,2929,2938,2947,2960,2964,2977,2985],{"nctId":2396,"briefTitle":2397,"status":107,"phases":2888,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":2401,"conditions":2889,"interventions":2890},[88],[27],[1775,893,2391,894,115],{"nctId":63,"briefTitle":64,"status":130,"phases":2892,"primaryCompletion":65,"completion":1010,"start":2893,"enrollment":9,"conditions":2894,"interventions":2897},[87,88],"2011-09-19",[1848,1849,2895,976,2896],"Recurrent Grade 3 Follicular Lymphoma","Recurrent Non-Hodgkin Lymphoma",[66,2898,2899,939],"Genetically Engineered Lymphocyte Therapy","Plerixafor",{"nctId":2590,"briefTitle":2591,"status":203,"phases":2901,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":19,"conditions":2902,"interventions":2903},[87,88],[1413],[956,1321,939],{"nctId":1345,"briefTitle":1346,"status":203,"phases":2905,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1142,"conditions":2906,"interventions":2907},[88],[1351,1352],[954,784,1131,1131,1132,1354,1133,1134,939,942],{"nctId":2909,"briefTitle":2910,"status":203,"phases":2911,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":2914,"conditions":2915,"interventions":2924},"NCT07365306","Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[88],"2029-10-15","2026-04-15",43,[2916,2917,2918,2919,2920,2921,2922,2923],"Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory Primary Mediastinal Large B-Cell Lymphoma","Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",[2649,2021,349,939],{"nctId":2754,"briefTitle":2755,"status":130,"phases":2926,"primaryCompletion":2757,"completion":467,"start":2758,"enrollment":16,"conditions":2927,"interventions":2928},[88],[2760,972,1851,2761,1855,1857,2762],[169,940,2244,2764,939],{"nctId":2930,"briefTitle":2931,"status":107,"phases":2932,"primaryCompletion":2933,"completion":2934,"start":2935,"enrollment":919,"conditions":2936,"interventions":2937},"NCT00863369","Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma",[87,88],"2016-08-25","2023-06-20","2005-06-29",[27],[1775,1700,386],{"nctId":2939,"briefTitle":2940,"status":107,"phases":2941,"primaryCompletion":2942,"completion":2942,"start":2943,"enrollment":298,"conditions":2944,"interventions":2945},"NCT00720876","Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma",[88],"2017-06-08","2008-07-23",[27],[1775,2946],"vorinostat",{"nctId":2948,"briefTitle":2949,"status":107,"phases":2950,"primaryCompletion":2951,"completion":2951,"start":2952,"enrollment":1666,"conditions":2953,"interventions":2959},"NCT01267812","Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation",[88],"2020-11-02","2011-10-03",[2954,2955,976,2956,2957,2958],"Contiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Stage I Mantle Cell Lymphoma","Stage III Mantle Cell Lymphoma","Stage IV Mantle Cell Lymphoma",[1700,1775,273,274,71],{"nctId":1767,"briefTitle":1768,"status":107,"phases":2961,"primaryCompletion":1770,"completion":1771,"start":1772,"enrollment":16,"conditions":2962,"interventions":2963},[88],[1231,32,27],[1775,61,115,1305,1306],{"nctId":2965,"briefTitle":2966,"status":294,"phases":2967,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":1273,"conditions":2970,"interventions":2975},"NCT07583810","Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma",[88],"2028-05-02","2026-12-16",[2971,2972,1414,2973,2880,27,2974],"Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma","Gastric Mucosa-Associated Lymphoid Tissue Lymphoma","Nodal Marginal Zone Lymphoma","Extranodal Marginal Zone Lymphoma",[2976,939],"Nemtabrutinib",{"nctId":2978,"briefTitle":2979,"status":203,"phases":2980,"primaryCompletion":2981,"completion":2981,"start":2982,"enrollment":22,"conditions":2983,"interventions":2984},"NCT06572618","Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma",[88],"2027-01-08","2025-01-22",[1413],[2976,939],{"nctId":2986,"briefTitle":2987,"status":294,"phases":2988,"primaryCompletion":2989,"completion":2989,"start":2990,"enrollment":785,"conditions":2991,"interventions":2992},"NCT07578077","Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma",[87,88],"2030-04-21","2026-12-21",[976,2639],[2993,939],"Golcadomide",{"trials":2995,"activeCount":99},[2996],{"nctId":2488,"briefTitle":2489,"status":369,"phases":2997,"primaryCompletion":2491,"completion":2491,"start":2492,"enrollment":283,"conditions":2998,"interventions":2999},[89],[972,1855],[2299,940,1131,849,939],{"trials":3001,"activeCount":99},[],{"trials":3003,"activeCount":99},[],{"intervention":3005,"totalTrials":95,"cells":3006},"Multi-peptide CMV-Modified Vaccinia Ankara Vaccine",{"EARLY_PHASE1":3007,"PHASE1":3018,"PHASE2":3074,"PHASE3":3122,"PHASE4":3124,"NA":3126},{"trials":3008,"activeCount":214,"soonestReadout":3013},[3009],{"nctId":3010,"briefTitle":3011,"status":203,"phases":3012,"primaryCompletion":3013,"completion":3013,"start":3014,"enrollment":795,"conditions":3015,"interventions":3016},"NCT06735690","Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia",[86],"2029-03-07","2025-12-30",[35],[3017,3005],"Anti-CD19-CAR CMV-specific T-lymphocytes",{"trials":3019,"activeCount":195,"soonestReadout":3024},[3020,3038,3051,3064],{"nctId":3021,"briefTitle":3022,"status":130,"phases":3023,"primaryCompletion":3024,"completion":3025,"start":3026,"enrollment":3027,"conditions":3028,"interventions":3037},"NCT03560752","CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant",[87],"2022-01-22","2026-07-29","2018-08-20",34,[3029,1612,1194,2102,3030,3031,3032,3033,1412,21,3034,3035,3036,1145],"Accelerated Phase CML, BCR-ABL1 Positive","Chronic Phase CML, BCR-ABL1 Positive","Cytomegalovirus Positive","Donor","Hematopoietic Cell Transplant Recipient","Myelodysplastic\u002FMyeloproliferative Neoplasm","Non-Hodgkin Lymphoma","Myelofibrosis",[3005],{"nctId":3039,"briefTitle":3040,"status":203,"phases":3041,"primaryCompletion":3042,"completion":3042,"start":3043,"enrollment":3044,"conditions":3045,"interventions":3049},"NCT07020533","A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant",[87],"2030-02-14","2026-05-08",46,[3046,35,18,2102,3047,3048,1412,1352,21,3036,1276,3035],"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Hematopoietic and Lymphatic System Neoplasm",[3050,3005,2808],"Letermovir",{"nctId":3052,"briefTitle":3053,"status":203,"phases":3054,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":795,"conditions":3058,"interventions":3063},"NCT05801913","Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma",[87],"2028-03-30","2028-12-30","2023-09-29",[3059,3060,3061,3062],"High Grade B-Cell Non-Hodgkin's Lymphoma","Intermediate Grade B-Cell Non-Hodgkin's Lymphoma","Recurrent B-Cell Non-Hodgkin Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma",[3017,3005],{"nctId":3065,"briefTitle":3066,"status":203,"phases":3067,"primaryCompletion":3068,"completion":3056,"start":3069,"enrollment":795,"conditions":3070,"interventions":3073},"NCT05432635","Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma",[87],"2028-03-07","2023-08-01",[3071,1410,1413,3061,972,976,1852,3072],"B-Cell Non-Hodgkin Lymphoma","Transformed Non-Hodgkin Lymphoma",[3017,3005],{"trials":3075,"activeCount":195,"soonestReadout":3080},[3076,3090,3104,3113],{"nctId":3077,"briefTitle":3078,"status":130,"phases":3079,"primaryCompletion":3080,"completion":3081,"start":3082,"enrollment":3083,"conditions":3084,"interventions":3089},"NCT02506933","Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant",[88],"2018-01-25","2026-06-09","2015-12-21",102,[3085,1612,1194,2102,3086,3087,1412,3088,1352,21,3036,1276,3035],"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Cytomegaloviral Infection","Lymphadenopathy",[3005],{"nctId":3091,"briefTitle":3092,"status":203,"phases":3093,"primaryCompletion":3094,"completion":3095,"start":3096,"enrollment":3097,"conditions":3098,"interventions":3101},"NCT06059391","CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant",[88],"2028-01-01","2029-01-01","2024-07-12",216,[35,18,2102,3099,3100,1412,21,3036,1276,3035],"Chronic Myeloid Leukemia, BCR-ABL1 Positive","Hematopoietic and Lymphoid System Neoplasm",[1441,3102,3005,3103],"Hematopoietic Cell Transplantation Conditioning Regimen","Stem Cell Mobilization Therapy",{"nctId":3105,"briefTitle":3106,"status":203,"phases":3107,"primaryCompletion":3108,"completion":3108,"start":3109,"enrollment":3110,"conditions":3111,"interventions":3112},"NCT03354728","Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant",[87,88],"2026-12-11","2018-05-11",80,[3087,3033],[3005],{"nctId":3114,"briefTitle":3115,"status":130,"phases":3116,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":486,"conditions":3120,"interventions":3121},"NCT04060277","Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation",[88],"2023-06-06","2030-04-07","2019-11-27",[3085,35,18,2102,3086,1145,1412,1352,21,3036,1276,3035],[3050,3005],{"trials":3123,"activeCount":99},[],{"trials":3125,"activeCount":99},[],{"trials":3127,"activeCount":99},[],{"intervention":823,"totalTrials":36,"cells":3129},{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3174,"PHASE3":3204,"PHASE4":3206,"NA":3208},{"trials":3131,"activeCount":99},[],{"trials":3133,"activeCount":195,"soonestReadout":1065},[3134,3138,3142,3146,3150,3154,3158,3162,3166,3170],{"nctId":802,"briefTitle":803,"status":130,"phases":3135,"primaryCompletion":805,"completion":805,"start":806,"enrollment":177,"conditions":3136,"interventions":3137},[87],[808,809,810,811,812,813,814,18,815,816,817,818,819],[75,821,822,823],{"nctId":1563,"briefTitle":1564,"status":107,"phases":3139,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":36,"conditions":3140,"interventions":3141},[87],[1488,845],[847,823,849,1571,1165,1149,851],{"nctId":2855,"briefTitle":2856,"status":107,"phases":3143,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":498,"conditions":3144,"interventions":3145},[87],[27],[2789,1775,2862,61],{"nctId":1689,"briefTitle":1690,"status":107,"phases":3147,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":36,"conditions":3148,"interventions":3149},[87],[1696,1697,1698,1102,1103],[1700,61,1306,1305],{"nctId":959,"briefTitle":960,"status":130,"phases":3151,"primaryCompletion":962,"completion":962,"start":963,"enrollment":964,"conditions":3152,"interventions":3153},[87],[966,967,968,969,970,971,972,973,974,975,976,977,978],[980,981,784,940,823],{"nctId":1062,"briefTitle":1063,"status":130,"phases":3155,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":251,"conditions":3156,"interventions":3157},[87],[1069,1070,1071,1072,1073],[1075,784,847,823],{"nctId":1188,"briefTitle":1189,"status":107,"phases":3159,"primaryCompletion":453,"completion":453,"start":1191,"enrollment":177,"conditions":3160,"interventions":3161},[87],[1193,1194,1195,1196,812,1197,1198,1199],[784,823,850,851],{"nctId":1718,"briefTitle":1719,"status":479,"phases":3163,"primaryCompletion":1721,"start":1722,"enrollment":99,"conditions":3164,"interventions":3165},[87],[1194,1488,1724,813,845],[823,849,1165,1149,851],{"nctId":2359,"briefTitle":2360,"status":369,"phases":3167,"primaryCompletion":2362,"completion":2362,"start":2363,"enrollment":434,"conditions":3168,"interventions":3169},[87],[1295,32,27,1297,1298,1299],[61,115],{"nctId":2371,"briefTitle":2372,"status":130,"phases":3171,"primaryCompletion":2374,"completion":2374,"start":2375,"enrollment":486,"conditions":3172,"interventions":3173},[87],[35,18,21,813],[2378,823,2379,849,1148,2298],{"trials":3175,"activeCount":195,"soonestReadout":41},[3176,3180,3184,3188,3192,3196,3200],{"nctId":1290,"briefTitle":1291,"status":107,"phases":3177,"primaryCompletion":433,"completion":433,"start":1293,"enrollment":111,"conditions":3178,"interventions":3179},[88],[1295,1231,1296,32,27,1297,1298,1299,1300,845,1301],[1303,75,894,61,115,1304,1305,1306],{"nctId":1745,"briefTitle":1746,"status":294,"phases":3181,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":1273,"conditions":3182,"interventions":3183},[88],[1751,1752,21,1003,1753,1208,1754,818,1755,1209,1756],[823,849,1148,1149,851],{"nctId":39,"briefTitle":40,"status":130,"phases":3185,"primaryCompletion":41,"completion":1367,"start":1368,"enrollment":1369,"conditions":3186,"interventions":3187},[88],[1295,1231,32,27,1297,1298,1371,1372],[42,75,1374,894,61,115,1304,1375,1305,1306],{"nctId":1399,"briefTitle":1400,"status":107,"phases":3189,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":3190,"interventions":3191},[88],[1407,1408,1409,1410,1411,1231,1412,1413,1414,21,1276,1415,1102,1103,1416],[1233,784,823,1418,850,851],{"nctId":58,"briefTitle":59,"status":130,"phases":3193,"primaryCompletion":60,"completion":2446,"start":2447,"enrollment":2448,"conditions":3194,"interventions":3195},[87,88],[32,1298],[61,115],{"nctId":1767,"briefTitle":1768,"status":107,"phases":3197,"primaryCompletion":1770,"completion":1771,"start":1772,"enrollment":16,"conditions":3198,"interventions":3199},[88],[1231,32,27],[1775,61,115,1305,1306],{"nctId":1434,"briefTitle":1435,"status":130,"phases":3201,"primaryCompletion":402,"completion":402,"start":1437,"enrollment":919,"conditions":3202,"interventions":3203},[88],[35,18,1439,21],[784,847,823,1441,850,851],{"trials":3205,"activeCount":99},[],{"trials":3207,"activeCount":99},[],{"trials":3209,"activeCount":99},[3210],{"nctId":1527,"briefTitle":1528,"status":107,"phases":3211,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":207,"conditions":3212,"interventions":3213},[91],[32,27,1298],[738,1233,784,1535,1536,849,850],{"intervention":114,"totalTrials":2543,"cells":3215},{"EARLY_PHASE1":3216,"PHASE1":3218,"PHASE2":3290,"PHASE3":3366,"PHASE4":3368,"NA":3370},{"trials":3217,"activeCount":99},[],{"trials":3219,"activeCount":363,"soonestReadout":3234},[3220,3230,3268,3278,3282,3286],{"nctId":3221,"briefTitle":3222,"status":107,"phases":3223,"primaryCompletion":3224,"completion":3224,"start":3225,"enrollment":3226,"conditions":3227,"interventions":3228},"NCT00005078","Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors",[87],"2012-07","2000-03",44,[24],[114,871,3229],"tirapazamine",{"nctId":3231,"briefTitle":3232,"status":130,"phases":3233,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":188,"conditions":3236,"interventions":3265},"NCT01970722","Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer",[87],"2027-01-05","2014-05-19",[3237,3238,1026,3239,3240,3241,3242,3243,3244,3245,3246,3247,3248,3249,3250,3251,3252,3253,3254,3255,3256,3257,3258,3259,3260,3261,3262,3263,3264],"FIGO Stage IVA Ovarian Cancer","FIGO Stage IVB Ovarian Cancer","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Uterine Corpus Carcinoma","Stage III Fallopian Tube Cancer AJCC v7","Stage III Ovarian Cancer AJCC v6 and v7","Stage III Primary Peritoneal Cancer AJCC v7","Stage III Uterine Corpus Cancer AJCC v7","Stage IIIA Fallopian Tube Cancer AJCC v7","Stage IIIA Ovarian Cancer AJCC v6 and v7","Stage IIIA Primary Peritoneal Cancer AJCC v7","Stage IIIA Uterine Corpus Cancer AJCC v7","Stage IIIB Fallopian Tube Cancer AJCC v7","Stage IIIB Ovarian Cancer AJCC v6 and v7","Stage IIIB Primary Peritoneal Cancer AJCC v7","Stage IIIB Uterine Corpus Cancer AJCC v7","Stage IIIC Fallopian Tube Cancer AJCC v7","Stage IIIC Ovarian Cancer AJCC v6 and v7","Stage IIIC Primary Peritoneal Cancer AJCC v7","Stage IIIC Uterine Corpus Cancer AJCC v7","Stage IV Fallopian Tube Cancer AJCC v6 and v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Primary Peritoneal Cancer AJCC v7","Stage IV Uterine Corpus Cancer AJCC v7","Stage IVA Uterine Corpus Cancer AJCC v7","Stage IVB Uterine Corpus Cancer AJCC v7",[169,345,3266,170,3267],"Gemcitabine Hydrochloride","Pegylated Liposomal Doxorubicin Hydrochloride",{"nctId":3269,"briefTitle":3270,"status":107,"phases":3271,"primaryCompletion":1721,"completion":1721,"start":2508,"enrollment":95,"conditions":3272,"interventions":3275},"NCT01723800","PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer",[87],[3273,3274],"Recurrent Non-small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer",[3276,3277,114],"PI3K inhibitor BKM120","pemetrexed disodium",{"nctId":2844,"briefTitle":2845,"status":107,"phases":3279,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":576,"conditions":3280,"interventions":3281},[87],[972,976,1855,2639,2850],[2852,169,1257,1457,2244,939,2853],{"nctId":915,"briefTitle":916,"status":107,"phases":3283,"primaryCompletion":175,"completion":175,"start":918,"enrollment":919,"conditions":3284,"interventions":3285},[87],[921],[738,114,385,75,894,740,923,871],{"nctId":2702,"briefTitle":2703,"status":130,"phases":3287,"primaryCompletion":2705,"completion":2705,"start":2706,"enrollment":283,"conditions":3288,"interventions":3289},[87],[2708],[2710,169,940,2711],{"trials":3291,"activeCount":498,"soonestReadout":70},[3292,3296,3300,3304,3319,3331,3335,3339,3343,3354,3362],{"nctId":105,"briefTitle":106,"status":107,"phases":3293,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":3294,"interventions":3295},[88],[15],[94,114,75,115,116],{"nctId":2739,"briefTitle":2740,"status":107,"phases":3297,"primaryCompletion":371,"completion":371,"start":2742,"enrollment":1244,"conditions":3298,"interventions":3299},[88],[2744,2745,879,2746,2747],[738,114,894,740,871],{"nctId":2754,"briefTitle":2755,"status":130,"phases":3301,"primaryCompletion":2757,"completion":467,"start":2758,"enrollment":16,"conditions":3302,"interventions":3303},[88],[2760,972,1851,2761,1855,1857,2762],[169,940,2244,2764,939],{"nctId":3305,"briefTitle":3306,"status":369,"phases":3307,"primaryCompletion":3308,"completion":3309,"start":3310,"enrollment":486,"conditions":3311,"interventions":3316},"NCT00788125","Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors",[87,88],"2010-04-30","2022-07-30","2008-09-03",[2744,3312,2745,3313,3314,27,3315,879,664,2747,2335],"Childhood Germ Cell Tumor","Kidney Cancer","Liver Cancer","Neuroblastoma",[114,3317,3318,740,447,276],"dasatinib","etoposide phosphate",{"nctId":3320,"briefTitle":3321,"status":130,"phases":3322,"primaryCompletion":3323,"completion":3324,"start":3325,"enrollment":3326,"conditions":3327,"interventions":3330},"NCT01525966","Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer",[88],"2019-01-11","2026-11-11","2012-02-15",67,[3328,139,141,142,143,3329,140,1880,1887,1883],"Inflammatory Breast Cancer","Triple-negative Breast Cancer",[114,56],{"nctId":2233,"briefTitle":2234,"status":130,"phases":3332,"primaryCompletion":2236,"completion":2237,"start":2238,"enrollment":2239,"conditions":3333,"interventions":3334},[88],[2241,2242],[169,940,2244,838],{"nctId":73,"briefTitle":74,"status":130,"phases":3336,"primaryCompletion":70,"completion":163,"start":164,"enrollment":165,"conditions":3337,"interventions":3338},[88],[15],[75,126,168,160,169,170],{"nctId":2023,"briefTitle":2024,"status":130,"phases":3340,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":283,"conditions":3341,"interventions":3342},[88],[2029,2030,2031,2032,2033,1467,1906,1905,2034,2035,2036,2037,2038,2039,2040,2041,2042,1471,1472],[169,2001,170,1480],{"nctId":3344,"briefTitle":3345,"status":107,"phases":3346,"primaryCompletion":3347,"completion":3348,"start":3349,"enrollment":19,"conditions":3350,"interventions":3352},"NCT03853707","Ipatasertib in Combination With Carboplatin, Carboplatin\u002FPaclitaxel, or Capecitabine\u002FAtezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer",[87,88],"2023-01-21","2023-09-19","2019-03-04",[209,1960,3351],"Prognostic Stage IV Breast Cancer AJCC v8",[2710,459,169,3353,170],"Ipatasertib",{"nctId":3355,"briefTitle":3356,"status":107,"phases":3357,"primaryCompletion":3358,"completion":3358,"start":3359,"enrollment":2625,"conditions":3360,"interventions":3361},"NCT00541138","Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors",[88],"2007-10","2003-05",[2744,395,24],[114,1343,882],{"nctId":1504,"briefTitle":1505,"status":107,"phases":3363,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":3364,"interventions":3365},[88],[15],[738,114,75,168,871,116],{"trials":3367,"activeCount":99},[],{"trials":3369,"activeCount":99},[],{"trials":3371,"activeCount":99},[],{"intervention":3373,"totalTrials":207,"cells":3374},"Leflunomide",{"EARLY_PHASE1":3375,"PHASE1":3386,"PHASE2":3417,"PHASE3":3472,"PHASE4":3474,"NA":3476},{"trials":3376,"activeCount":214,"soonestReadout":3381},[3377],{"nctId":3378,"briefTitle":3379,"status":130,"phases":3380,"primaryCompletion":3381,"completion":3381,"start":3382,"enrollment":214,"conditions":3383,"interventions":3385},"NCT04370483","Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma",[86],"2026-11-10","2020-10-08",[3384],"Smoldering Plasma Cell Myeloma",[3373],{"trials":3387,"activeCount":283,"soonestReadout":3402},[3388,3398,3408],{"nctId":3389,"briefTitle":3390,"status":203,"phases":3391,"primaryCompletion":3234,"completion":3234,"start":3392,"enrollment":36,"conditions":3393,"interventions":3395},"NCT05443425","Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies",[87],"2023-06-16",[3394,3100],"Acute Graft Versus Host Disease",[3396,3373,3397],"Cholestyramine","Steroid Therapy",{"nctId":3399,"briefTitle":3400,"status":130,"phases":3401,"primaryCompletion":3402,"completion":3402,"start":3403,"enrollment":36,"conditions":3404,"interventions":3407},"NCT04212416","Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease",[87],"2026-06-22","2020-05-12",[3405,3406],"Chronic Graft Versus Host Disease","Steroid Refractory Graft Versus Host Disease",[3373],{"nctId":3409,"briefTitle":3410,"status":203,"phases":3411,"primaryCompletion":3412,"completion":3412,"start":3413,"enrollment":1001,"conditions":3414,"interventions":3416},"NCT06454383","Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer",[87],"2026-11-13","2024-05-13",[3415,1048,1051,1056],"Advanced Pancreatic Adenocarcinoma",[3396,2021,3373],{"trials":3418,"activeCount":363,"soonestReadout":2551},[3419,3427,3434,3444,3454,3463],{"nctId":3420,"briefTitle":3421,"status":479,"phases":3422,"primaryCompletion":3423,"completion":3423,"start":3424,"enrollment":99,"conditions":3425,"interventions":3426},"NCT03952832","Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma",[88],"2021-06-11","2019-12-11",[3384],[3373],{"nctId":3428,"briefTitle":3429,"status":130,"phases":3430,"primaryCompletion":2551,"completion":2551,"start":3431,"enrollment":22,"conditions":3432,"interventions":3433},"NCT05014646","Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients",[88],"2022-03-07",[3384],[3396,3373],{"nctId":3435,"briefTitle":3436,"status":107,"phases":3437,"primaryCompletion":3438,"completion":3438,"start":3439,"enrollment":214,"conditions":3440,"interventions":3443},"NCT04463615","Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders",[88],"2021-07-28","2021-05-05",[3441,3442],"Recurrent Lymphoproliferative Disorder","Refractory Lymphoproliferative Disorder",[3373],{"nctId":3445,"briefTitle":3446,"status":107,"phases":3447,"primaryCompletion":3448,"completion":3449,"start":3450,"enrollment":363,"conditions":3451,"interventions":3453},"NCT04532372","Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy",[87,88],"2021-08-26","2021-10-27","2021-01-07",[1145,29,3452],"Symptomatic COVID-19 Infection Laboratory-Confirmed",[3373],{"nctId":3455,"briefTitle":3456,"status":203,"phases":3457,"primaryCompletion":3458,"completion":3458,"start":3459,"enrollment":1945,"conditions":3460,"interventions":3461},"NCT04508790","Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma",[88],"2027-02-14","2020-11-24",[1102,1103],[1354,3373,3462],"Pomalidomide",{"nctId":3464,"briefTitle":3465,"status":107,"phases":3466,"primaryCompletion":3467,"completion":3468,"start":3469,"enrollment":1632,"conditions":3470,"interventions":3471},"NCT02509052","Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma",[87,88],"2018-09-18","2022-06-09","2015-12-02",[1102,1103],[3373],{"trials":3473,"activeCount":99},[],{"trials":3475,"activeCount":99},[],{"trials":3477,"activeCount":99},[],{"intervention":850,"totalTrials":95,"cells":3479},{"EARLY_PHASE1":3480,"PHASE1":3482,"PHASE2":3500,"PHASE3":3518,"PHASE4":3520,"NA":3522},{"trials":3481,"activeCount":99},[],{"trials":3483,"activeCount":283,"soonestReadout":205},[3484,3488,3492,3496],{"nctId":840,"briefTitle":841,"status":130,"phases":3485,"primaryCompletion":205,"completion":205,"start":843,"enrollment":693,"conditions":3486,"interventions":3487},[87],[845],[784,847,848,849,850,851],{"nctId":1106,"briefTitle":1107,"status":130,"phases":3489,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":283,"conditions":3490,"interventions":3491},[87],[1112,1113,1114,1115,1116],[784,1118,1119,851,1120,1121],{"nctId":1188,"briefTitle":1189,"status":107,"phases":3493,"primaryCompletion":453,"completion":453,"start":1191,"enrollment":177,"conditions":3494,"interventions":3495},[87],[1193,1194,1195,1196,812,1197,1198,1199],[784,823,850,851],{"nctId":1225,"briefTitle":1226,"status":203,"phases":3497,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":795,"conditions":3498,"interventions":3499},[87],[18,1231,21],[1233,784,1234,847,849,850,851],{"trials":3501,"activeCount":283,"soonestReadout":41},[3502,3506,3510,3514],{"nctId":39,"briefTitle":40,"status":130,"phases":3503,"primaryCompletion":41,"completion":1367,"start":1368,"enrollment":1369,"conditions":3504,"interventions":3505},[88],[1295,1231,32,27,1297,1298,1371,1372],[42,75,1374,894,61,115,1304,1375,1305,1306],{"nctId":1399,"briefTitle":1400,"status":107,"phases":3507,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":3508,"interventions":3509},[88],[1407,1408,1409,1410,1411,1231,1412,1413,1414,21,1276,1415,1102,1103,1416],[1233,784,823,1418,850,851],{"nctId":1434,"briefTitle":1435,"status":130,"phases":3511,"primaryCompletion":402,"completion":402,"start":1437,"enrollment":919,"conditions":3512,"interventions":3513},[88],[35,18,1439,21],[784,847,823,1441,850,851],{"nctId":44,"briefTitle":45,"status":130,"phases":3515,"primaryCompletion":46,"completion":2815,"start":2816,"enrollment":298,"conditions":3516,"interventions":3517},[88],[32,1298],[42,1374,894,1375],{"trials":3519,"activeCount":99},[],{"trials":3521,"activeCount":99},[],{"trials":3523,"activeCount":99},[3524],{"nctId":1527,"briefTitle":1528,"status":107,"phases":3525,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":207,"conditions":3526,"interventions":3527},[91],[32,27,1298],[738,1233,784,1535,1536,849,850],{"intervention":1149,"totalTrials":1916,"cells":3529},{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3567,"PHASE3":3593,"PHASE4":3595,"NA":3597},{"trials":3531,"activeCount":99},[],{"trials":3533,"activeCount":363,"soonestReadout":3550},[3534,3538,3542,3546,3555,3559,3563],{"nctId":1548,"briefTitle":1549,"status":203,"phases":3535,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":795,"conditions":3536,"interventions":3537},[87],[35,18,21],[1555,1556,847,1557,849,1149,851],{"nctId":1563,"briefTitle":1564,"status":107,"phases":3539,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":36,"conditions":3540,"interventions":3541},[87],[1488,845],[847,823,849,1571,1165,1149,851],{"nctId":1689,"briefTitle":1690,"status":107,"phases":3543,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":36,"conditions":3544,"interventions":3545},[87],[1696,1697,1698,1102,1103],[1700,61,1306,1305],{"nctId":3547,"briefTitle":3548,"status":130,"phases":3549,"primaryCompletion":3550,"completion":3550,"start":3551,"enrollment":363,"conditions":3552,"interventions":3553},"NCT05384756","TMLI and Alemtuzumab for Treatment of Sickle Cell Disease",[87],"2026-12-01","2022-07-13",[1112],[3554,1149],"Alemtuzumab",{"nctId":1137,"briefTitle":1138,"status":907,"phases":3556,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":3557,"interventions":3558},[87],[1144,1145],[784,940,1147,1148,1149,851],{"nctId":1179,"briefTitle":1180,"status":479,"phases":3560,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":99,"conditions":3561,"interventions":3562},[87],[1145,1185],[784,940,1147,1148,1149,851],{"nctId":1718,"briefTitle":1719,"status":479,"phases":3564,"primaryCompletion":1721,"start":1722,"enrollment":99,"conditions":3565,"interventions":3566},[87],[1194,1488,1724,813,845],[823,849,1165,1149,851],{"trials":3568,"activeCount":283,"soonestReadout":41},[3569,3573,3577,3581,3585,3589],{"nctId":1290,"briefTitle":1291,"status":107,"phases":3570,"primaryCompletion":433,"completion":433,"start":1293,"enrollment":111,"conditions":3571,"interventions":3572},[88],[1295,1231,1296,32,27,1297,1298,1299,1300,845,1301],[1303,75,894,61,115,1304,1305,1306],{"nctId":1745,"briefTitle":1746,"status":294,"phases":3574,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":1273,"conditions":3575,"interventions":3576},[88],[1751,1752,21,1003,1753,1208,1754,818,1755,1209,1756],[823,849,1148,1149,851],{"nctId":39,"briefTitle":40,"status":130,"phases":3578,"primaryCompletion":41,"completion":1367,"start":1368,"enrollment":1369,"conditions":3579,"interventions":3580},[88],[1295,1231,32,27,1297,1298,1371,1372],[42,75,1374,894,61,115,1304,1375,1305,1306],{"nctId":1767,"briefTitle":1768,"status":107,"phases":3582,"primaryCompletion":1770,"completion":1771,"start":1772,"enrollment":16,"conditions":3583,"interventions":3584},[88],[1231,32,27],[1775,61,115,1305,1306],{"nctId":1644,"briefTitle":1645,"status":107,"phases":3586,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":1650,"conditions":3587,"interventions":3588},[88],[1407,1652,21,1488,845],[847,1654,849,1149,851],{"nctId":1793,"briefTitle":1794,"status":130,"phases":3590,"primaryCompletion":1796,"completion":1797,"start":1798,"enrollment":1509,"conditions":3591,"interventions":3592},[88],[1800,1801,808,21,1416,1275,1802],[1804,115,1306,1305],{"trials":3594,"activeCount":99},[],{"trials":3596,"activeCount":99},[],{"trials":3598,"activeCount":99},[],{"intervention":1256,"totalTrials":95,"cells":3600},{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3628,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3602,"activeCount":99},[],{"trials":3604,"activeCount":99},[3605,3615],{"nctId":3606,"briefTitle":3607,"status":107,"phases":3608,"primaryCompletion":3609,"completion":3609,"start":3610,"enrollment":1945,"conditions":3611,"interventions":3612},"NCT03013933","Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma",[87],"2022-05-24","2017-05-03",[2241,2242],[1256,1535,3613,3614],"Verapamil","Verapamil Hydrochloride",{"nctId":3616,"briefTitle":3617,"status":479,"phases":3618,"primaryCompletion":3619,"completion":3619,"start":3620,"enrollment":99,"conditions":3621,"interventions":3627},"NCT03373305","Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas",[87],"2019-04-26","2019-03",[3622,3623,1926,3624,1933,3625,3626],"CD30-Positive Neoplastic Cells Present","Folliculotropic Mycosis Fungoides","Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Sezary Syndrome",[1256,1321],{"trials":3629,"activeCount":498,"soonestReadout":2249},[3630,3634,3638,3642,3651,3655,3659],{"nctId":1238,"briefTitle":1239,"status":130,"phases":3631,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":1244,"conditions":3632,"interventions":3633},[88],[1246,1247,1248,1249,1250,1251,1252,1253,1254,1161,1162],[1256,784,346,941,940,1257,938],{"nctId":2201,"briefTitle":2202,"status":203,"phases":3635,"primaryCompletion":1874,"completion":1874,"start":2204,"enrollment":177,"conditions":3636,"interventions":3637},[88],[2206],[1256,838],{"nctId":2209,"briefTitle":2210,"status":130,"phases":3639,"primaryCompletion":2212,"completion":2212,"start":2213,"enrollment":2214,"conditions":3640,"interventions":3641},[88],[2216,2217,2218,2219,2220,2221,2222,2223,2018,2224,2225,2226,2227,2228],[2230,1256,2020,346,838,2231],{"nctId":3643,"briefTitle":3644,"status":107,"phases":3645,"primaryCompletion":3646,"completion":3646,"start":3647,"enrollment":900,"conditions":3648,"interventions":3649},"NCT01393717","Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma",[88],"2017-02-01","2011-10-20",[2241,2242],[3650],"brentuximab vedotin",{"nctId":2013,"briefTitle":2014,"status":203,"phases":3652,"primaryCompletion":2016,"completion":2016,"start":467,"enrollment":1666,"conditions":3653,"interventions":3654},[88],[2018],[1256,2020,2021,1480],{"nctId":2246,"briefTitle":2247,"status":130,"phases":3656,"primaryCompletion":2249,"completion":2250,"start":2251,"enrollment":1969,"conditions":3657,"interventions":3658},[88],[2018,2241,2242],[1256,838],{"nctId":3660,"briefTitle":3661,"status":107,"phases":3662,"primaryCompletion":3663,"completion":3664,"start":3665,"enrollment":2122,"conditions":3666,"interventions":3667},"NCT02744612","Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma",[88],"2021-03-03","2024-07-30","2016-06-20",[2241,2242],[1256,1457],{"trials":3669,"activeCount":99},[],{"trials":3671,"activeCount":99},[],{"trials":3673,"activeCount":99},[],{"intervention":2021,"totalTrials":434,"cells":3675},{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3719,"PHASE3":3729,"PHASE4":3731,"NA":3733},{"trials":3677,"activeCount":99},[],{"trials":3679,"activeCount":283,"soonestReadout":3412},[3680,3695,3705,3715],{"nctId":3681,"briefTitle":3682,"status":203,"phases":3683,"primaryCompletion":3684,"completion":3684,"start":3685,"enrollment":1632,"conditions":3686,"interventions":3694},"NCT05285358","Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases",[87],"2028-10-11","2022-09-19",[3687,3688,3689,325,3690,3691,3692,3693],"Distal Bile Duct Adenocarcinoma","Gallbladder Carcinoma","Intrahepatic Cholangiocarcinoma","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Intrahepatic Bile Duct Cancer AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Stage IVB Gallbladder Cancer AJCC v8",[345,2021,84],{"nctId":3696,"briefTitle":3697,"status":107,"phases":3698,"primaryCompletion":3699,"completion":3699,"start":3700,"enrollment":3226,"conditions":3701,"interventions":3703},"NCT02996825","Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",[87],"2024-02-09","2017-03-22",[3702,3239,3240,3241,3242,1891],"Recurrent Breast Carcinoma",[2021,3266,3704],"Mirvetuximab Soravtansine",{"nctId":3706,"briefTitle":3707,"status":203,"phases":3708,"primaryCompletion":3709,"completion":3709,"start":3710,"enrollment":33,"conditions":3711,"interventions":3713},"NCT04158635","Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer",[87],"2027-03-09","2021-09-01",[1048,1051,3712],"Unresectable Pancreatic Carcinoma",[3714,2021,84],"Bosentan",{"nctId":3409,"briefTitle":3410,"status":203,"phases":3716,"primaryCompletion":3412,"completion":3412,"start":3413,"enrollment":1001,"conditions":3717,"interventions":3718},[87],[3415,1048,1051,1056],[3396,2021,3373],{"trials":3720,"activeCount":363,"soonestReadout":2912},[3721,3725],{"nctId":2909,"briefTitle":2910,"status":203,"phases":3722,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":2914,"conditions":3723,"interventions":3724},[88],[2916,2917,2918,2919,2920,2921,2922,2923],[2649,2021,349,939],{"nctId":2013,"briefTitle":2014,"status":203,"phases":3726,"primaryCompletion":2016,"completion":2016,"start":467,"enrollment":1666,"conditions":3727,"interventions":3728},[88],[2018],[1256,2020,2021,1480],{"trials":3730,"activeCount":99},[],{"trials":3732,"activeCount":99},[],{"trials":3734,"activeCount":99},[],{"intervention":938,"totalTrials":498,"cells":3736},{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3753,"PHASE3":3775,"PHASE4":3777,"NA":3779},{"trials":3738,"activeCount":99},[],{"trials":3740,"activeCount":283,"soonestReadout":928},[3741,3745,3749],{"nctId":925,"briefTitle":926,"status":130,"phases":3742,"primaryCompletion":928,"completion":928,"start":929,"enrollment":207,"conditions":3743,"interventions":3744},[87],[931,932,933,934,935,936],[938,939,940,941,942,784,66,943],{"nctId":1123,"briefTitle":1124,"status":130,"phases":3746,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":30,"conditions":3747,"interventions":3748},[87],[859,1129],[784,1131,1132,1133,1134,1135,938,956,942],{"nctId":1151,"briefTitle":1152,"status":294,"phases":3750,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":404,"conditions":3751,"interventions":3752},[87],[1157,1158,1159,1160,1161,1162],[784,346,66,1164,938,1165,957],{"trials":3754,"activeCount":363,"soonestReadout":1241},[3755,3759],{"nctId":1238,"briefTitle":1239,"status":130,"phases":3756,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":1244,"conditions":3757,"interventions":3758},[88],[1246,1247,1248,1249,1250,1251,1252,1253,1254,1161,1162],[1256,784,346,941,940,1257,938],{"nctId":3760,"briefTitle":3761,"status":203,"phases":3762,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":3766,"interventions":3769},"NCT04734730","Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer",[88],"2027-08-23","2021-05-04",70,[3767,3768,1071,1072,1073],"Castration-Sensitive Prostate Carcinoma","Metastatic Prostate Adenocarcinoma",[3770,51,3771,3772,3773,938,3774],"Abiraterone Acetate","Degarelix","Goserelin Acetate","Leuprolide Acetate","Talazoparib",{"trials":3776,"activeCount":99},[],{"trials":3778,"activeCount":99},[],{"trials":3780,"activeCount":99},[],{"intervention":2606,"totalTrials":498,"cells":3782},{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3830,"PHASE4":3832,"NA":3834},{"trials":3784,"activeCount":99},[],{"trials":3786,"activeCount":99},[],{"trials":3788,"activeCount":498,"soonestReadout":3808},[3789,3793,3804,3815,3823],{"nctId":2598,"briefTitle":2599,"status":294,"phases":3790,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":1273,"conditions":3791,"interventions":3792},[88],[2102,1408,2604],[2606,2607,956],{"nctId":3794,"briefTitle":3795,"status":130,"phases":3796,"primaryCompletion":3797,"completion":3798,"start":3799,"enrollment":195,"conditions":3800,"interventions":3803},"NCT04657094","Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia",[88],"2023-04-01","2027-02-08","2021-03-16",[3801,2102,1408,3802],"Autoimmune Hemolytic Anemia","Warm Antibody Autoimmune Hemolytic Anemia",[2606],{"nctId":3805,"briefTitle":3806,"status":130,"phases":3807,"primaryCompletion":3808,"completion":3809,"start":3810,"enrollment":1632,"conditions":3811,"interventions":3812},"NCT04783415","Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",[88],"2022-07-31","2025-09-20","2021-03-26",[1413],[2606,3813,3814],"Ublituximab","Umbralisib",{"nctId":3816,"briefTitle":3817,"status":203,"phases":3818,"primaryCompletion":3819,"completion":3819,"start":3820,"enrollment":188,"conditions":3821,"interventions":3822},"NCT06054776","Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",[88],"2026-10-16","2024-12-02",[1413],[2606,2630,2631],{"nctId":3824,"briefTitle":3825,"status":203,"phases":3826,"primaryCompletion":962,"completion":962,"start":3827,"enrollment":1610,"conditions":3828,"interventions":3829},"NCT04484012","Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",[88],"2020-12-31",[976,2639],[2606,1176],{"trials":3831,"activeCount":99},[],{"trials":3833,"activeCount":99},[],{"trials":3835,"activeCount":99},[],{"intervention":871,"totalTrials":576,"cells":3837},{"EARLY_PHASE1":3838,"PHASE1":3840,"PHASE2":3879,"PHASE3":3914,"PHASE4":3916,"NA":3918},{"trials":3839,"activeCount":99},[],{"trials":3841,"activeCount":363,"soonestReadout":3234},[3842,3846,3850,3854,3858,3862,3871],{"nctId":3221,"briefTitle":3222,"status":107,"phases":3843,"primaryCompletion":3224,"completion":3224,"start":3225,"enrollment":3226,"conditions":3844,"interventions":3845},[87],[24],[114,871,3229],{"nctId":863,"briefTitle":864,"status":107,"phases":3847,"primaryCompletion":866,"completion":866,"start":867,"enrollment":795,"conditions":3848,"interventions":3849},[87],[15],[738,870,75,168,871],{"nctId":3231,"briefTitle":3232,"status":130,"phases":3851,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":188,"conditions":3852,"interventions":3853},[87],[3237,3238,1026,3239,3240,3241,3242,3243,3244,3245,3246,3247,3248,3249,3250,3251,3252,3253,3254,3255,3256,3257,3258,3259,3260,3261,3262,3263,3264],[169,345,3266,170,3267],{"nctId":873,"briefTitle":874,"status":107,"phases":3855,"primaryCompletion":109,"completion":109,"start":876,"enrollment":9,"conditions":3856,"interventions":3857},[87],[878,879,880],[738,385,75,115,871,882,883,274],{"nctId":915,"briefTitle":916,"status":107,"phases":3859,"primaryCompletion":175,"completion":175,"start":918,"enrollment":919,"conditions":3860,"interventions":3861},[87],[921],[738,114,385,75,894,740,923,871],{"nctId":3863,"briefTitle":3864,"status":203,"phases":3865,"primaryCompletion":3866,"completion":3866,"start":3867,"enrollment":298,"conditions":3868,"interventions":3869},"NCT06675136","Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases",[87],"2029-01-14","2025-10-29",[320,1469,325],[84,170,3870],"Ramucirumab",{"nctId":3872,"briefTitle":3873,"status":107,"phases":3874,"start":3875,"conditions":3876,"interventions":3877},"NCT00006257","SU5416 and Paclitaxel in Treating Patients With Advanced Cancer",[87],"2000-11",[24],[871,3878],"semaxanib",{"trials":3880,"activeCount":363,"soonestReadout":70},[3881,3885,3889,3893,3897,3901,3910],{"nctId":2739,"briefTitle":2740,"status":107,"phases":3882,"primaryCompletion":371,"completion":371,"start":2742,"enrollment":1244,"conditions":3883,"interventions":3884},[88],[2744,2745,879,2746,2747],[738,114,894,740,871],{"nctId":1335,"briefTitle":1336,"status":107,"phases":3886,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":16,"conditions":3887,"interventions":3888},[88],[15],[738,385,75,168,115,923,871,1343],{"nctId":73,"briefTitle":74,"status":130,"phases":3890,"primaryCompletion":70,"completion":163,"start":164,"enrollment":165,"conditions":3891,"interventions":3892},[88],[15],[75,126,168,160,169,170],{"nctId":2023,"briefTitle":2024,"status":130,"phases":3894,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":283,"conditions":3895,"interventions":3896},[88],[2029,2030,2031,2032,2033,1467,1906,1905,2034,2035,2036,2037,2038,2039,2040,2041,2042,1471,1472],[169,2001,170,1480],{"nctId":3344,"briefTitle":3345,"status":107,"phases":3898,"primaryCompletion":3347,"completion":3348,"start":3349,"enrollment":19,"conditions":3899,"interventions":3900},[87,88],[209,1960,3351],[2710,459,169,3353,170],{"nctId":3902,"briefTitle":3903,"status":107,"phases":3904,"primaryCompletion":3905,"completion":3905,"start":3906,"enrollment":3765,"conditions":3907,"interventions":3908},"NCT00002937","Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer",[88],"2005-11","1996-06",[15],[871,3909],"valspodar",{"nctId":1504,"briefTitle":1505,"status":107,"phases":3911,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":3912,"interventions":3913},[88],[15],[738,114,75,168,871,116],{"trials":3915,"activeCount":99},[],{"trials":3917,"activeCount":99},[],{"trials":3919,"activeCount":214,"soonestReadout":3924},[3920,3931],{"nctId":3921,"briefTitle":3922,"status":203,"phases":3923,"primaryCompletion":3924,"completion":3924,"start":3925,"enrollment":3926,"conditions":3927,"interventions":3930},"NCT06490159","Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer",[],"2026-06-18","2018-10-01",150,[3928,3929,170,3870],"Gastric Cancer","Chemotherapy-induced Peripheral Neuropathy",[170],{"nctId":3932,"briefTitle":3933,"status":107,"phases":3934,"primaryCompletion":3935,"completion":1552,"start":3925,"enrollment":3936,"conditions":3937,"interventions":3939},"NCT06490055","Predicting the Efficacy in Advanced Gastric Cancer.",[],"2025-02-18",162,[3928,3938,170,3870],"Chemotherapy Effect",[170],{"intervention":271,"totalTrials":1916,"cells":3941},{"EARLY_PHASE1":3942,"PHASE1":3944,"PHASE2":3984,"PHASE3":4014,"PHASE4":4016,"NA":4018},{"trials":3943,"activeCount":99},[],{"trials":3945,"activeCount":214,"soonestReadout":314},[3946,3950,3956,3963,3970,3976,3980],{"nctId":258,"briefTitle":259,"status":107,"phases":3947,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":3948,"interventions":3949},[87],[266],[268,269,250,270,271,272,273,274,275,276],{"nctId":3951,"briefTitle":3952,"status":107,"phases":3953,"start":3225,"conditions":3954,"interventions":3955},"NCT00004243","Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor",[87],[24],[126,271],{"nctId":3957,"briefTitle":3958,"status":107,"phases":3959,"start":3960,"conditions":3961,"interventions":3962},"NCT00004220","Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer",[87],"1999-10",[24],[386,271],{"nctId":3964,"briefTitle":3965,"status":107,"phases":3966,"start":3967,"conditions":3968,"interventions":3969},"NCT00005077","Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction",[87],"2000-02",[24],[271],{"nctId":3971,"briefTitle":3972,"status":107,"phases":3973,"primaryCompletion":2859,"completion":2859,"start":122,"conditions":3974,"interventions":3975},"NCT00005839","Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor",[87],[24],[696,271],{"nctId":311,"briefTitle":312,"status":203,"phases":3977,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":3978,"interventions":3979},[87],[318,319,320,321,322,323,324,325,326,327,328,329,330,331,303,332,333,334,335,336,337,338,339,340,341,342,343],[345,346,305,306,347,348,349],{"nctId":351,"briefTitle":352,"status":107,"phases":3981,"primaryCompletion":354,"completion":354,"start":355,"enrollment":25,"conditions":3982,"interventions":3983},[87],[285,286,357,358,359,360],[362,270,250,271],{"trials":3985,"activeCount":283,"soonestReadout":402},[3986,3990,3994,4002,4006,4010],{"nctId":367,"briefTitle":368,"status":369,"phases":3987,"primaryCompletion":371,"completion":371,"start":372,"enrollment":214,"conditions":3988,"interventions":3989},[88],[226,285,286,357,358,359,360],[271,270,250,268,290],{"nctId":2909,"briefTitle":2910,"status":203,"phases":3991,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":2914,"conditions":3992,"interventions":3993},[88],[2916,2917,2918,2919,2920,2921,2922,2923],[2649,2021,349,939],{"nctId":3995,"briefTitle":3996,"status":369,"phases":3997,"primaryCompletion":109,"completion":109,"start":3998,"enrollment":195,"conditions":3999,"interventions":4001},"NCT03026803","A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer",[88],"2006-11",[3314,4000],"Hepatocellular Cancer",[349,459],{"nctId":399,"briefTitle":400,"status":130,"phases":4003,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":4004,"interventions":4005},[87,88],[406,407,301,408,409,303,410],[412,413,414,305,308,349],{"nctId":429,"briefTitle":430,"status":107,"phases":4007,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":4008,"interventions":4009},[87,88],[436,437,438,439,440,441,442,443,444],[250,270,271,446,447],{"nctId":449,"briefTitle":450,"status":203,"phases":4011,"primaryCompletion":452,"completion":452,"start":453,"enrollment":25,"conditions":4012,"interventions":4013},[88],[455,456,457],[412,414,459,305,308,349],{"trials":4015,"activeCount":99},[],{"trials":4017,"activeCount":99},[],{"trials":4019,"activeCount":99},[],{"intervention":1321,"totalTrials":95,"cells":4021},{"EARLY_PHASE1":4022,"PHASE1":4024,"PHASE2":4060,"PHASE3":4094,"PHASE4":4096,"NA":4098},{"trials":4023,"activeCount":99},[],{"trials":4025,"activeCount":99},[4026,4035,4056],{"nctId":4027,"briefTitle":4028,"status":479,"phases":4029,"primaryCompletion":4030,"completion":4030,"start":4031,"enrollment":99,"conditions":4032,"interventions":4033},"NCT03591744","Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia",[87],"2019-10-25","2018-10-25",[1698],[4034,1556,1354,1321,3267],"Bortezomib",{"nctId":4036,"briefTitle":4037,"status":369,"phases":4038,"primaryCompletion":4039,"completion":4040,"start":4041,"enrollment":298,"conditions":4042,"interventions":4055},"NCT01116154","Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma",[87],"2010-07","2010-08","2010-05",[4043,1918,4044,2873,2874,4045,2875,2876,4046,4047,970,4048,4049,2877,2878,2388,4050,4051,4052,4053,1848,1849,2895,976,977,4054,978,2879,2880,2881,2882],"Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Hepatosplenic T-cell Lymphoma","Peripheral T-Cell Lymphoma","Post-transplant Lymphoproliferative Disorder","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome",[1333,2946],{"nctId":3616,"briefTitle":3617,"status":479,"phases":4057,"primaryCompletion":3619,"completion":3619,"start":3620,"enrollment":99,"conditions":4058,"interventions":4059},[87],[3622,3623,1926,3624,1933,3625,3626],[1256,1321],{"trials":4061,"activeCount":195,"soonestReadout":402},[4062,4066,4070,4074,4082,4086],{"nctId":2590,"briefTitle":2591,"status":203,"phases":4063,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":19,"conditions":4064,"interventions":4065},[87,88],[1413],[956,1321,939],{"nctId":1312,"briefTitle":1313,"status":479,"phases":4067,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":99,"conditions":4068,"interventions":4069},[87,88],[1318,1319],[784,66,1321,849,1148],{"nctId":1323,"briefTitle":1324,"status":107,"phases":4071,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1264,"conditions":4072,"interventions":4073},[87,88],[989,1329,990,991,992],[115,738,1331,1332,75,1333],{"nctId":4075,"briefTitle":4076,"status":130,"phases":4077,"primaryCompletion":4078,"completion":4078,"start":4079,"enrollment":1945,"conditions":4080,"interventions":4081},"NCT06112847","Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma",[88],"2026-07-17","2024-01-24",[1411],[2649,1321],{"nctId":2620,"briefTitle":2621,"status":203,"phases":4083,"primaryCompletion":2623,"completion":2623,"start":2624,"enrollment":2625,"conditions":4084,"interventions":4085},[87,88],[2627,1413,2628],[2630,1321,2631,956],{"nctId":4087,"briefTitle":4088,"status":130,"phases":4089,"primaryCompletion":402,"completion":4090,"start":4091,"enrollment":1405,"conditions":4092,"interventions":4093},"NCT03011814","Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma",[87,88],"2026-08-30","2017-03-08",[3623,2295,1926,2296,1933,1934,3626,2294],[544,1321],{"trials":4095,"activeCount":99},[],{"trials":4097,"activeCount":99},[],{"trials":4099,"activeCount":99},[],{"intervention":56,"totalTrials":498,"cells":4101},{"EARLY_PHASE1":4102,"PHASE1":4104,"PHASE2":4128,"PHASE3":4144,"PHASE4":4146,"NA":4148},{"trials":4103,"activeCount":99},[],{"trials":4105,"activeCount":214,"soonestReadout":4110},[4106,4120],{"nctId":4107,"briefTitle":4108,"status":130,"phases":4109,"primaryCompletion":4110,"completion":4111,"start":4112,"enrollment":33,"conditions":4113,"interventions":4117},"NCT02336087","Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery",[87],"2020-10-04","2026-12-09","2016-01-14",[4114,3712,4115,4116],"Pancreatic Adenocarcinoma","Stage III Pancreatic Cancer AJCC v6 and v7","Stage IV Pancreatic Cancer AJCC v6 and v7",[3266,4118,4119],"Paclitaxel Albumin-Stabilized Nanoparticle Formulation","Metformin Hydrochloride",{"nctId":4121,"briefTitle":4122,"status":107,"phases":4123,"primaryCompletion":4124,"completion":4124,"start":4125,"enrollment":22,"conditions":4126,"interventions":4127},"NCT00825201","Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity",[87],"2018-01-16","2009-01",[879,880,24],[56],{"trials":4129,"activeCount":283,"soonestReadout":55},[4130,4136,4140],{"nctId":53,"briefTitle":54,"status":130,"phases":4131,"primaryCompletion":55,"completion":4132,"start":4133,"enrollment":188,"conditions":4134,"interventions":4135},[88],"2026-04-24","2008-02-11",[15],[56],{"nctId":128,"briefTitle":129,"status":130,"phases":4137,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":4138,"interventions":4139},[88],[137,138,139,140,141,142,143,144,145,146],[148,94,56],{"nctId":3320,"briefTitle":3321,"status":130,"phases":4141,"primaryCompletion":3323,"completion":3324,"start":3325,"enrollment":3326,"conditions":4142,"interventions":4143},[88],[3328,139,141,142,143,3329,140,1880,1887,1883],[114,56],{"trials":4145,"activeCount":99},[],{"trials":4147,"activeCount":99},[],{"trials":4149,"activeCount":99},[],{"intervention":412,"totalTrials":498,"cells":4151},{"EARLY_PHASE1":4152,"PHASE1":4154,"PHASE2":4156,"PHASE3":4198,"PHASE4":4200,"NA":4202},{"trials":4153,"activeCount":99},[],{"trials":4155,"activeCount":99},[],{"trials":4157,"activeCount":195,"soonestReadout":4193},[4158,4168,4181,4185,4189],{"nctId":4159,"briefTitle":4160,"status":479,"phases":4161,"primaryCompletion":4162,"completion":4162,"start":4163,"enrollment":99,"conditions":4164,"interventions":4167},"NCT06575725","Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer",[88],"2027-01-28","2024-11-01",[2124,4165,4166,406,407,408,2125,302,457,409,303,410],"Advanced Colorectal Adenocarcinoma","Advanced Rectal Adenocarcinoma",[412,414,2139],{"nctId":4169,"briefTitle":4170,"status":294,"phases":4171,"primaryCompletion":4172,"completion":4172,"start":4173,"enrollment":4174,"conditions":4175,"interventions":4180},"NCT07595874","Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3",[88],"2027-05-27","2026-12-27",100,[2124,4165,4166,4176,4177,4178,4179,2126,2127,2128,2129,2130,2131],"Stage IIB Colon Cancer AJCC v8","Stage IIB Rectal Cancer AJCC v8","Stage IIC Colon Cancer AJCC v8","Stage IIC Rectal Cancer AJCC v8",[412,414],{"nctId":399,"briefTitle":400,"status":130,"phases":4182,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":4183,"interventions":4184},[87,88],[406,407,301,408,409,303,410],[412,413,414,305,308,349],{"nctId":449,"briefTitle":450,"status":203,"phases":4186,"primaryCompletion":452,"completion":452,"start":453,"enrollment":25,"conditions":4187,"interventions":4188},[88],[455,456,457],[412,414,459,305,308,349],{"nctId":4190,"briefTitle":4191,"status":130,"phases":4192,"primaryCompletion":4193,"completion":4194,"start":4195,"enrollment":19,"conditions":4196,"interventions":4197},"NCT05672316","Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy",[87,88],"2025-05-10","2026-08-25","2023-05-11",[4165,300,407,301,302,303],[412,414,2139],{"trials":4199,"activeCount":99},[],{"trials":4201,"activeCount":99},[],{"trials":4203,"activeCount":99},[],{"intervention":414,"totalTrials":498,"cells":4205},{"EARLY_PHASE1":4206,"PHASE1":4208,"PHASE2":4210,"PHASE3":4232,"PHASE4":4234,"NA":4236},{"trials":4207,"activeCount":99},[],{"trials":4209,"activeCount":99},[],{"trials":4211,"activeCount":195,"soonestReadout":4193},[4212,4216,4220,4224,4228],{"nctId":4159,"briefTitle":4160,"status":479,"phases":4213,"primaryCompletion":4162,"completion":4162,"start":4163,"enrollment":99,"conditions":4214,"interventions":4215},[88],[2124,4165,4166,406,407,408,2125,302,457,409,303,410],[412,414,2139],{"nctId":4169,"briefTitle":4170,"status":294,"phases":4217,"primaryCompletion":4172,"completion":4172,"start":4173,"enrollment":4174,"conditions":4218,"interventions":4219},[88],[2124,4165,4166,4176,4177,4178,4179,2126,2127,2128,2129,2130,2131],[412,414],{"nctId":399,"briefTitle":400,"status":130,"phases":4221,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":4222,"interventions":4223},[87,88],[406,407,301,408,409,303,410],[412,413,414,305,308,349],{"nctId":449,"briefTitle":450,"status":203,"phases":4225,"primaryCompletion":452,"completion":452,"start":453,"enrollment":25,"conditions":4226,"interventions":4227},[88],[455,456,457],[412,414,459,305,308,349],{"nctId":4190,"briefTitle":4191,"status":130,"phases":4229,"primaryCompletion":4193,"completion":4194,"start":4195,"enrollment":19,"conditions":4230,"interventions":4231},[87,88],[4165,300,407,301,302,303],[412,414,2139],{"trials":4233,"activeCount":99},[],{"trials":4235,"activeCount":99},[],{"trials":4237,"activeCount":99},[],{"intervention":84,"totalTrials":195,"cells":4239},{"EARLY_PHASE1":4240,"PHASE1":4242,"PHASE2":4256,"PHASE3":4269,"PHASE4":4271,"NA":4273},{"trials":4241,"activeCount":99},[],{"trials":4243,"activeCount":283,"soonestReadout":3709},[4244,4248,4252],{"nctId":3681,"briefTitle":3682,"status":203,"phases":4245,"primaryCompletion":3684,"completion":3684,"start":3685,"enrollment":1632,"conditions":4246,"interventions":4247},[87],[3687,3688,3689,325,3690,3691,3692,3693],[345,2021,84],{"nctId":3706,"briefTitle":3707,"status":203,"phases":4249,"primaryCompletion":3709,"completion":3709,"start":3710,"enrollment":33,"conditions":4250,"interventions":4251},[87],[1048,1051,3712],[3714,2021,84],{"nctId":3863,"briefTitle":3864,"status":203,"phases":4253,"primaryCompletion":3866,"completion":3866,"start":3867,"enrollment":298,"conditions":4254,"interventions":4255},[87],[320,1469,325],[84,170,3870],{"trials":4257,"activeCount":214,"soonestReadout":83},[4258],{"nctId":81,"briefTitle":82,"status":130,"phases":4259,"primaryCompletion":83,"completion":4260,"start":4261,"enrollment":188,"conditions":4262,"interventions":4268},[88],"2026-05-18","2012-06-19",[4263,210,3702,4264,4265,4266,4267,1961],"Locally Advanced Breast Carcinoma","Stage III Breast Cancer AJCC v7","Stage IIIA Breast Cancer AJCC v7","Stage IIIB Breast Cancer AJCC v7","Stage IIIC Breast Cancer AJCC v7",[84],{"trials":4270,"activeCount":99},[],{"trials":4272,"activeCount":99},[],{"trials":4274,"activeCount":99},[],{"intervention":346,"totalTrials":195,"cells":4276},{"EARLY_PHASE1":4277,"PHASE1":4279,"PHASE2":4289,"PHASE3":4299,"PHASE4":4301,"NA":4303},{"trials":4278,"activeCount":99},[],{"trials":4280,"activeCount":363,"soonestReadout":1154},[4281,4285],{"nctId":1151,"briefTitle":1152,"status":294,"phases":4282,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":404,"conditions":4283,"interventions":4284},[87],[1157,1158,1159,1160,1161,1162],[784,346,66,1164,938,1165,957],{"nctId":311,"briefTitle":312,"status":203,"phases":4286,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":4287,"interventions":4288},[87],[318,319,320,321,322,323,324,325,326,327,328,329,330,331,303,332,333,334,335,336,337,338,339,340,341,342,343],[345,346,305,306,347,348,349],{"trials":4290,"activeCount":363,"soonestReadout":1241},[4291,4295],{"nctId":1238,"briefTitle":1239,"status":130,"phases":4292,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":1244,"conditions":4293,"interventions":4294},[88],[1246,1247,1248,1249,1250,1251,1252,1253,1254,1161,1162],[1256,784,346,941,940,1257,938],{"nctId":2209,"briefTitle":2210,"status":130,"phases":4296,"primaryCompletion":2212,"completion":2212,"start":2213,"enrollment":2214,"conditions":4297,"interventions":4298},[88],[2216,2217,2218,2219,2220,2221,2222,2223,2018,2224,2225,2226,2227,2228],[2230,1256,2020,346,838,2231],{"trials":4300,"activeCount":99},[],{"trials":4302,"activeCount":99},[],{"trials":4304,"activeCount":99},[],{"intervention":2631,"totalTrials":195,"cells":4306},{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4320,"PHASE3":4334,"PHASE4":4336,"NA":4338},{"trials":4308,"activeCount":99},[],{"trials":4310,"activeCount":214,"soonestReadout":4315},[4311],{"nctId":4312,"briefTitle":4313,"status":203,"phases":4314,"primaryCompletion":4315,"completion":4315,"start":2552,"enrollment":404,"conditions":4316,"interventions":4319},"NCT06922604","Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma",[87],"2029-01-02",[4317,4318],"Primary Central Nervous System Lymphoma","Secondary Central Nervous System Lymphoma",[2630,2631],{"trials":4321,"activeCount":283,"soonestReadout":3819},[4322,4326,4330],{"nctId":2620,"briefTitle":2621,"status":203,"phases":4323,"primaryCompletion":2623,"completion":2623,"start":2624,"enrollment":2625,"conditions":4324,"interventions":4325},[87,88],[2627,1413,2628],[2630,1321,2631,956],{"nctId":2643,"briefTitle":2644,"status":203,"phases":4327,"primaryCompletion":2646,"completion":2646,"start":1284,"enrollment":919,"conditions":4328,"interventions":4329},[88],[2102,2604],[2649,2631,956],{"nctId":3816,"briefTitle":3817,"status":203,"phases":4331,"primaryCompletion":3819,"completion":3819,"start":3820,"enrollment":188,"conditions":4332,"interventions":4333},[88],[1413],[2606,2630,2631],{"trials":4335,"activeCount":99},[],{"trials":4337,"activeCount":99},[],{"trials":4339,"activeCount":99},[],{"intervention":42,"totalTrials":264,"cells":4341},{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4365,"PHASE3":4391,"PHASE4":4393,"NA":4395},{"trials":4343,"activeCount":99},[],{"trials":4345,"activeCount":363,"soonestReadout":4350},[4346,4357,4361],{"nctId":4347,"briefTitle":4348,"status":130,"phases":4349,"primaryCompletion":4350,"completion":4350,"start":4351,"enrollment":283,"conditions":4352,"interventions":4356},"NCT01961063","Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma",[87],"2026-08-05","2015-12-31",[4353,4354,4355,935],"AIDS-related Non-Hodgkin Lymphoma","AIDS-related Plasmablastic Lymphoma","AIDS-related Primary Effusion Lymphoma",[42,1094],{"nctId":2301,"briefTitle":2302,"status":107,"phases":4358,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":890,"conditions":4359,"interventions":4360},[87],[2308,2309,2310,2311,2312,2313,2314,2315,2316,583,2317,2318,2319,2320,2321,2322,2323,2324,2325,2326,2327,2328,2329,2330,2331,2332,2333,2334,24,2335],[42,115,882,738],{"nctId":1225,"briefTitle":1226,"status":203,"phases":4362,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":795,"conditions":4363,"interventions":4364},[87],[18,1231,21],[1233,784,1234,847,849,850,851],{"trials":4366,"activeCount":363,"soonestReadout":41},[4367,4371,4375,4379,4383,4387],{"nctId":2766,"briefTitle":2767,"status":369,"phases":4368,"primaryCompletion":2769,"completion":2770,"start":2771,"enrollment":890,"conditions":4369,"interventions":4370},[87,88],[808,1426,1427,1428,1429,1430,1431,2773,2774,2775,2776,2777,812,1198,2778],[42,894],{"nctId":2781,"briefTitle":2782,"status":107,"phases":4372,"primaryCompletion":2784,"completion":2785,"start":2786,"enrollment":1361,"conditions":4373,"interventions":4374},[88],[32],[2789,738,42,2391,894,2790],{"nctId":39,"briefTitle":40,"status":130,"phases":4376,"primaryCompletion":41,"completion":1367,"start":1368,"enrollment":1369,"conditions":4377,"interventions":4378},[88],[1295,1231,32,27,1297,1298,1371,1372],[42,75,1374,894,61,115,1304,1375,1305,1306],{"nctId":1399,"briefTitle":1400,"status":107,"phases":4380,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":4381,"interventions":4382},[88],[1407,1408,1409,1410,1411,1231,1412,1413,1414,21,1276,1415,1102,1103,1416],[1233,784,823,1418,850,851],{"nctId":44,"briefTitle":45,"status":130,"phases":4384,"primaryCompletion":46,"completion":2815,"start":2816,"enrollment":298,"conditions":4385,"interventions":4386},[88],[32,1298],[42,1374,894,1375],{"nctId":1492,"briefTitle":1493,"status":107,"phases":4388,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":4389,"interventions":4390},[88],[1297],[738,1500,42,75,115,1501,1502],{"trials":4392,"activeCount":99},[],{"trials":4394,"activeCount":99},[],{"trials":4396,"activeCount":99},[4397,4401],{"nctId":2504,"briefTitle":2505,"status":479,"phases":4398,"primaryCompletion":2507,"start":2508,"enrollment":99,"conditions":4399,"interventions":4400},[91],[2510,2511,2512,2314,2325,2328,2513],[894,740,882,42,115],{"nctId":1527,"briefTitle":1528,"status":107,"phases":4402,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":207,"conditions":4403,"interventions":4404},[91],[32,27,1298],[738,1233,784,1535,1536,849,850],{"intervention":1304,"totalTrials":434,"cells":4406},{"EARLY_PHASE1":4407,"PHASE1":4409,"PHASE2":4415,"PHASE3":4433,"PHASE4":4435,"NA":4437},{"trials":4408,"activeCount":99},[],{"trials":4410,"activeCount":214,"soonestReadout":1126},[4411],{"nctId":1123,"briefTitle":1124,"status":130,"phases":4412,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":30,"conditions":4413,"interventions":4414},[87],[859,1129],[784,1131,1132,1133,1134,1135,938,956,942],{"trials":4416,"activeCount":283,"soonestReadout":41},[4417,4421,4425,4429],{"nctId":1290,"briefTitle":1291,"status":107,"phases":4418,"primaryCompletion":433,"completion":433,"start":1293,"enrollment":111,"conditions":4419,"interventions":4420},[88],[1295,1231,1296,32,27,1297,1298,1299,1300,845,1301],[1303,75,894,61,115,1304,1305,1306],{"nctId":1345,"briefTitle":1346,"status":203,"phases":4422,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1142,"conditions":4423,"interventions":4424},[88],[1351,1352],[954,784,1131,1131,1132,1354,1133,1134,939,942],{"nctId":39,"briefTitle":40,"status":130,"phases":4426,"primaryCompletion":41,"completion":1367,"start":1368,"enrollment":1369,"conditions":4427,"interventions":4428},[88],[1295,1231,32,27,1297,1298,1371,1372],[42,75,1374,894,61,115,1304,1375,1305,1306],{"nctId":1777,"briefTitle":1778,"status":203,"phases":4430,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":188,"conditions":4431,"interventions":4432},[88],[35,18,21],[1134,1165,851],{"trials":4434,"activeCount":99},[],{"trials":4436,"activeCount":99},[],{"trials":4438,"activeCount":99},[4439],{"nctId":4440,"briefTitle":4441,"status":479,"phases":4442,"primaryCompletion":4443,"start":4444,"enrollment":99,"conditions":4445,"interventions":4447},"NCT01438021","Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease",[91],"2013-11","2012-09",[4446],"Leptomeningeal Metastases",[1304],{"intervention":2391,"totalTrials":207,"cells":4449},{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4466,"PHASE3":4500,"PHASE4":4506,"NA":4508},{"trials":4451,"activeCount":99},[],{"trials":4453,"activeCount":214,"soonestReadout":1126},[4454,4458,4462],{"nctId":2287,"briefTitle":2288,"status":107,"phases":4455,"primaryCompletion":2290,"completion":2291,"start":2292,"enrollment":404,"conditions":4456,"interventions":4457},[87],[1161,2294,1932,2295,2296],[2298,2299,940,1131,849],{"nctId":1123,"briefTitle":1124,"status":130,"phases":4459,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":30,"conditions":4460,"interventions":4461},[87],[859,1129],[784,1131,1132,1133,1134,1135,938,956,942],{"nctId":2381,"briefTitle":2382,"status":107,"phases":4463,"primaryCompletion":2384,"completion":2385,"start":2386,"enrollment":890,"conditions":4464,"interventions":4465},[87],[2388],[2390,893,894,2391,115,2392],{"trials":4467,"activeCount":363,"soonestReadout":1348},[4468,4472,4480,4484,4488,4492],{"nctId":2396,"briefTitle":2397,"status":107,"phases":4469,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":2401,"conditions":4470,"interventions":4471},[88],[27],[1775,893,2391,894,115],{"nctId":4473,"briefTitle":4474,"status":107,"phases":4475,"primaryCompletion":4476,"completion":4476,"start":393,"enrollment":4477,"conditions":4478,"interventions":4479},"NCT00528398","Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia",[88],"2015-12",111,[32],[2391,2790],{"nctId":1345,"briefTitle":1346,"status":203,"phases":4481,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1142,"conditions":4482,"interventions":4483},[88],[1351,1352],[954,784,1131,1131,1132,1354,1133,1134,939,942],{"nctId":2781,"briefTitle":2782,"status":107,"phases":4485,"primaryCompletion":2784,"completion":2785,"start":2786,"enrollment":1361,"conditions":4486,"interventions":4487},[88],[32],[2789,738,42,2391,894,2790],{"nctId":2800,"briefTitle":2801,"status":203,"phases":4489,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":919,"conditions":4490,"interventions":4491},[88],[2241,2242],[2378,2299,1131,940,2807,2808,2298],{"nctId":4493,"briefTitle":4494,"status":369,"phases":4495,"primaryCompletion":4496,"completion":4496,"start":4497,"enrollment":404,"conditions":4498,"interventions":4499},"NCT01876953","Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia",[87,88],"2018-04-25","2013-09-13",[1426,1427,1428,1429,1430,1431,812,813,819],[2391,2790,3317],{"trials":4501,"activeCount":99},[4502],{"nctId":2488,"briefTitle":2489,"status":369,"phases":4503,"primaryCompletion":2491,"completion":2491,"start":2492,"enrollment":283,"conditions":4504,"interventions":4505},[89],[972,1855],[2299,940,1131,849,939],{"trials":4507,"activeCount":99},[],{"trials":4509,"activeCount":99},[],{"intervention":168,"totalTrials":95,"cells":4511},{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4524,"PHASE3":4554,"PHASE4":4556,"NA":4558},{"trials":4513,"activeCount":99},[],{"trials":4515,"activeCount":214,"soonestReadout":928},[4516,4520],{"nctId":863,"briefTitle":864,"status":107,"phases":4517,"primaryCompletion":866,"completion":866,"start":867,"enrollment":795,"conditions":4518,"interventions":4519},[87],[15],[738,870,75,168,871],{"nctId":925,"briefTitle":926,"status":130,"phases":4521,"primaryCompletion":928,"completion":928,"start":929,"enrollment":207,"conditions":4522,"interventions":4523},[87],[931,932,933,934,935,936],[938,939,940,941,942,784,66,943],{"trials":4525,"activeCount":363,"soonestReadout":70},[4526,4530,4534,4538,4542,4546,4550],{"nctId":1238,"briefTitle":1239,"status":130,"phases":4527,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":1244,"conditions":4528,"interventions":4529},[88],[1246,1247,1248,1249,1250,1251,1252,1253,1254,1161,1162],[1256,784,346,941,940,1257,938],{"nctId":1335,"briefTitle":1336,"status":107,"phases":4531,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":16,"conditions":4532,"interventions":4533},[88],[15],[738,385,75,168,115,923,871,1343],{"nctId":73,"briefTitle":74,"status":130,"phases":4535,"primaryCompletion":70,"completion":163,"start":164,"enrollment":165,"conditions":4536,"interventions":4537},[88],[15],[75,126,168,160,169,170],{"nctId":2464,"briefTitle":2465,"status":107,"phases":4539,"primaryCompletion":2467,"completion":2467,"start":393,"enrollment":1916,"conditions":4540,"interventions":4541},[88],[664],[738,385,168,740,115],{"nctId":2071,"briefTitle":2072,"status":107,"phases":4543,"primaryCompletion":2074,"completion":2075,"start":2076,"enrollment":298,"conditions":4544,"interventions":4545},[88],[1880,2078,1883,1887,2079,144,1891],[2081,941,2082,2055,1480],{"nctId":731,"briefTitle":732,"status":369,"phases":4547,"primaryCompletion":734,"start":735,"enrollment":486,"conditions":4548,"interventions":4549},[88],[664],[738,739,168,740,290,387],{"nctId":1504,"briefTitle":1505,"status":107,"phases":4551,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":4552,"interventions":4553},[88],[15],[738,114,75,168,871,116],{"trials":4555,"activeCount":99},[],{"trials":4557,"activeCount":99},[],{"trials":4559,"activeCount":99},[],{"intervention":1354,"totalTrials":9,"cells":4561},{"EARLY_PHASE1":4562,"PHASE1":4564,"PHASE2":4605,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4563,"activeCount":99},[],{"trials":4565,"activeCount":99},[4566,4591,4595],{"nctId":4567,"briefTitle":4568,"status":107,"phases":4569,"primaryCompletion":4570,"completion":4570,"start":4571,"enrollment":1916,"conditions":4572,"interventions":4585},"NCT04681105","Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies",[87],"2025-08-05","2020-11-18",[4573,951,4574,4575,974,4576,2241,4577,4578,952,4579,4580,4581,4582,2242,4583,4584],"Recurrent Acute Leukemia","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Hematologic Malignancy","Recurrent T Acute Lymphoblastic Leukemia","Refractory Acute Leukemia","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Hairy Cell Leukemia","Refractory Hematologic Malignancy","Refractory T Acute Lymphoblastic Leukemia","Systemic Mastocytosis",[4586,1354,4587,4588,4589,4590],"Acetaminophen","Diphenhydramine","Flotetuzumab","Ibuprofen","Ranitidine",{"nctId":4027,"briefTitle":4028,"status":479,"phases":4592,"primaryCompletion":4030,"completion":4030,"start":4031,"enrollment":99,"conditions":4593,"interventions":4594},[87],[1698],[4034,1556,1354,1321,3267],{"nctId":4596,"briefTitle":4597,"status":479,"phases":4598,"primaryCompletion":4599,"completion":4599,"start":1218,"enrollment":99,"conditions":4600,"interventions":4603},"NCT05773664","Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma",[87],"2024-11-29",[4601,4602],"Glioblastoma","Malignant Glioma",[4604,1354],"Azeliragon",{"trials":4606,"activeCount":283,"soonestReadout":4611},[4607,4615,4619,4630,4634],{"nctId":4608,"briefTitle":4609,"status":130,"phases":4610,"primaryCompletion":4611,"completion":4611,"start":4612,"enrollment":25,"conditions":4613,"interventions":4614},"NCT05139043","Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors",[88],"2025-09-03","2022-04-09",[1013,211,1014],[1354],{"nctId":1345,"briefTitle":1346,"status":203,"phases":4616,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1142,"conditions":4617,"interventions":4618},[88],[1351,1352],[954,784,1131,1131,1132,1354,1133,1134,939,942],{"nctId":4620,"briefTitle":4621,"status":107,"phases":4622,"primaryCompletion":4623,"completion":4624,"start":4625,"enrollment":111,"conditions":4626,"interventions":4627},"NCT02119468","Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed\u002FRefractory Multiple Myeloma",[87,88],"2016-05-18","2022-12-01","2014-06-30",[1103,1102],[4628,2484,4629],"ixazomib citrate","pomalidomide",{"nctId":3455,"briefTitle":3456,"status":203,"phases":4631,"primaryCompletion":3458,"completion":3458,"start":3459,"enrollment":1945,"conditions":4632,"interventions":4633},[88],[1102,1103],[1354,3373,3462],{"nctId":2475,"briefTitle":2476,"status":107,"phases":4635,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":4636,"interventions":4637},[88],[1297,2482],[1700,2484,115,1502,1332,1331],{"trials":4639,"activeCount":99},[],{"trials":4641,"activeCount":99},[],{"trials":4643,"activeCount":99},[],{"intervention":1556,"totalTrials":498,"cells":4645},{"EARLY_PHASE1":4646,"PHASE1":4648,"PHASE2":4676,"PHASE3":4682,"PHASE4":4684,"NA":4686},{"trials":4647,"activeCount":99},[],{"trials":4649,"activeCount":363,"soonestReadout":4672},[4650,4654,4658,4668],{"nctId":1548,"briefTitle":1549,"status":203,"phases":4651,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":795,"conditions":4652,"interventions":4653},[87],[35,18,21],[1555,1556,847,1557,849,1149,851],{"nctId":4027,"briefTitle":4028,"status":479,"phases":4655,"primaryCompletion":4030,"completion":4030,"start":4031,"enrollment":99,"conditions":4656,"interventions":4657},[87],[1698],[4034,1556,1354,1321,3267],{"nctId":4659,"briefTitle":4660,"status":107,"phases":4661,"primaryCompletion":4662,"completion":4663,"start":4664,"enrollment":1632,"conditions":4665,"interventions":4666},"NCT03311828","Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma",[87],"2020-01-22","2023-06-05","2018-02-21",[1102,1319,2442],[1556,4667],"Imaging Agent",{"nctId":4669,"briefTitle":4670,"status":203,"phases":4671,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":795,"conditions":4674,"interventions":4675},"NCT05363111","Radioimmunotherapy (111Indium\u002F225Actinium-DOTA-daratumumab) for the Treatment of Relapsed\u002FRefractory Multiple Myeloma",[87],"2027-03-23","2022-11-22",[1102,1103],[1555,1556,1557],{"trials":4677,"activeCount":214,"soonestReadout":467},[4678],{"nctId":2437,"briefTitle":2438,"status":130,"phases":4679,"primaryCompletion":467,"completion":467,"start":2440,"enrollment":177,"conditions":4680,"interventions":4681},[88],[1319,2442],[1556,849],{"trials":4683,"activeCount":99},[],{"trials":4685,"activeCount":99},[],{"trials":4687,"activeCount":99},[],{"intervention":2649,"totalTrials":195,"cells":4689},{"EARLY_PHASE1":4690,"PHASE1":4692,"PHASE2":4694,"PHASE3":4720,"PHASE4":4722,"NA":4724},{"trials":4691,"activeCount":99},[],{"trials":4693,"activeCount":99},[],{"trials":4695,"activeCount":283,"soonestReadout":4078},[4696,4700,4704,4708],{"nctId":2909,"briefTitle":2910,"status":203,"phases":4697,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":2914,"conditions":4698,"interventions":4699},[88],[2916,2917,2918,2919,2920,2921,2922,2923],[2649,2021,349,939],{"nctId":4075,"briefTitle":4076,"status":130,"phases":4701,"primaryCompletion":4078,"completion":4078,"start":4079,"enrollment":1945,"conditions":4702,"interventions":4703},[88],[1411],[2649,1321],{"nctId":2643,"briefTitle":2644,"status":203,"phases":4705,"primaryCompletion":2646,"completion":2646,"start":1284,"enrollment":919,"conditions":4706,"interventions":4707},[88],[2102,2604],[2649,2631,956],{"nctId":4709,"briefTitle":4710,"status":907,"phases":4711,"primaryCompletion":4712,"completion":4712,"start":4713,"enrollment":919,"conditions":4714,"interventions":4718},"NCT06575686","Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",[88],"2028-07-16","2025-03-11",[1848,1849,1850,4715,4716,4717],"Refractory Grade 1 Follicular Lymphoma","Refractory Grade 2 Follicular Lymphoma","Refractory Grade 3a Follicular Lymphoma",[2649,4719],"Tazemetostat",{"trials":4721,"activeCount":99},[],{"trials":4723,"activeCount":99},[],{"trials":4725,"activeCount":99},[],{"intervention":544,"totalTrials":195,"cells":4727},{"EARLY_PHASE1":4728,"PHASE1":4730,"PHASE2":4759,"PHASE3":4769,"PHASE4":4771,"NA":4773},{"trials":4729,"activeCount":99},[],{"trials":4731,"activeCount":214,"soonestReadout":1099},[4732,4745],{"nctId":4733,"briefTitle":4734,"status":107,"phases":4735,"primaryCompletion":4736,"completion":4736,"start":4737,"enrollment":95,"conditions":4738,"interventions":4744},"NCT03005002","Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver",[87],"2019-11-26","2017-06-28",[4739,4740,4741,4742,4743,423,424],"Metastatic Carcinoma in the Liver","MLH1 Gene Mutation","MSH6 Gene Mutation","PMS2 Gene Mutation","Stage IV Colorectal Cancer",[544,545],{"nctId":4746,"briefTitle":4747,"status":130,"phases":4748,"primaryCompletion":1099,"completion":1099,"start":4749,"enrollment":890,"conditions":4750,"interventions":4758},"NCT04605731","Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer",[87],"2021-08-03",[4751,4752,4753,4754,4755,4756,833,834,835,4757],"BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Locally Advanced Hepatocellular Carcinoma","Stage III Hepatocellular Carcinoma AJCC v8","Stage IIIA Hepatocellular Carcinoma AJCC v8","Stage IIIB Hepatocellular Carcinoma AJCC v8","Unresectable Hepatocellular Carcinoma",[544,545],{"trials":4760,"activeCount":363,"soonestReadout":402},[4761,4765],{"nctId":531,"briefTitle":532,"status":203,"phases":4762,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":4763,"interventions":4764},[88],[538,505,507],[540,541,542,413,543,544,545],{"nctId":4087,"briefTitle":4088,"status":130,"phases":4766,"primaryCompletion":402,"completion":4090,"start":4091,"enrollment":1405,"conditions":4767,"interventions":4768},[87,88],[3623,2295,1926,2296,1933,1934,3626,2294],[544,1321],{"trials":4770,"activeCount":99},[],{"trials":4772,"activeCount":99},[],{"trials":4774,"activeCount":99},[],{"intervention":3396,"totalTrials":283,"cells":4776},{"EARLY_PHASE1":4777,"PHASE1":4779,"PHASE2":4789,"PHASE3":4795,"PHASE4":4797,"NA":4799},{"trials":4778,"activeCount":99},[],{"trials":4780,"activeCount":363,"soonestReadout":3412},[4781,4785],{"nctId":3389,"briefTitle":3390,"status":203,"phases":4782,"primaryCompletion":3234,"completion":3234,"start":3392,"enrollment":36,"conditions":4783,"interventions":4784},[87],[3394,3100],[3396,3373,3397],{"nctId":3409,"briefTitle":3410,"status":203,"phases":4786,"primaryCompletion":3412,"completion":3412,"start":3413,"enrollment":1001,"conditions":4787,"interventions":4788},[87],[3415,1048,1051,1056],[3396,2021,3373],{"trials":4790,"activeCount":214,"soonestReadout":2551},[4791],{"nctId":3428,"briefTitle":3429,"status":130,"phases":4792,"primaryCompletion":2551,"completion":2551,"start":3431,"enrollment":22,"conditions":4793,"interventions":4794},[88],[3384],[3396,3373],{"trials":4796,"activeCount":99},[],{"trials":4798,"activeCount":99},[],{"trials":4800,"activeCount":99},[],{"intervention":3772,"totalTrials":283,"cells":4802},{"EARLY_PHASE1":4803,"PHASE1":4805,"PHASE2":4807,"PHASE3":4831,"PHASE4":4833,"NA":4835},{"trials":4804,"activeCount":99},[],{"trials":4806,"activeCount":99},[],{"trials":4808,"activeCount":283,"soonestReadout":50},[4809,4817,4827],{"nctId":48,"briefTitle":49,"status":130,"phases":4810,"primaryCompletion":50,"completion":4811,"start":4812,"enrollment":1945,"conditions":4813,"interventions":4816},[88],"2027-02-15","2006-07-18",[4814,4815],"PSA Level Greater Than Two","Stage IV Prostate Adenocarcinoma AJCC v7",[51,3772,3773],{"nctId":4818,"briefTitle":4819,"status":130,"phases":4820,"primaryCompletion":4821,"completion":4822,"start":4823,"enrollment":890,"conditions":4824,"interventions":4826},"NCT03361735","Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer",[88],"2024-03-21","2027-01-06","2018-08-29",[4825],"Prostate Adenocarcinoma",[3773,3772,3771],{"nctId":3760,"briefTitle":3761,"status":203,"phases":4828,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":4829,"interventions":4830},[88],[3767,3768,1071,1072,1073],[3770,51,3771,3772,3773,938,3774],{"trials":4832,"activeCount":99},[],{"trials":4834,"activeCount":99},[],{"trials":4836,"activeCount":99},[],{"intervention":3773,"totalTrials":283,"cells":4838},{"EARLY_PHASE1":4839,"PHASE1":4841,"PHASE2":4843,"PHASE3":4857,"PHASE4":4859,"NA":4861},{"trials":4840,"activeCount":99},[],{"trials":4842,"activeCount":99},[],{"trials":4844,"activeCount":283,"soonestReadout":50},[4845,4849,4853],{"nctId":48,"briefTitle":49,"status":130,"phases":4846,"primaryCompletion":50,"completion":4811,"start":4812,"enrollment":1945,"conditions":4847,"interventions":4848},[88],[4814,4815],[51,3772,3773],{"nctId":4818,"briefTitle":4819,"status":130,"phases":4850,"primaryCompletion":4821,"completion":4822,"start":4823,"enrollment":890,"conditions":4851,"interventions":4852},[88],[4825],[3773,3772,3771],{"nctId":3760,"briefTitle":3761,"status":203,"phases":4854,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":4855,"interventions":4856},[88],[3767,3768,1071,1072,1073],[3770,51,3771,3772,3773,938,3774],{"trials":4858,"activeCount":99},[],{"trials":4860,"activeCount":99},[],{"trials":4862,"activeCount":99},[],{"intervention":942,"totalTrials":283,"cells":4864},{"EARLY_PHASE1":4865,"PHASE1":4867,"PHASE2":4877,"PHASE3":4883,"PHASE4":4885,"NA":4887},{"trials":4866,"activeCount":99},[],{"trials":4868,"activeCount":363,"soonestReadout":928},[4869,4873],{"nctId":925,"briefTitle":926,"status":130,"phases":4870,"primaryCompletion":928,"completion":928,"start":929,"enrollment":207,"conditions":4871,"interventions":4872},[87],[931,932,933,934,935,936],[938,939,940,941,942,784,66,943],{"nctId":1123,"briefTitle":1124,"status":130,"phases":4874,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":30,"conditions":4875,"interventions":4876},[87],[859,1129],[784,1131,1132,1133,1134,1135,938,956,942],{"trials":4878,"activeCount":214,"soonestReadout":1348},[4879],{"nctId":1345,"briefTitle":1346,"status":203,"phases":4880,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1142,"conditions":4881,"interventions":4882},[88],[1351,1352],[954,784,1131,1131,1132,1354,1133,1134,939,942],{"trials":4884,"activeCount":99},[],{"trials":4886,"activeCount":99},[],{"trials":4888,"activeCount":99},[],{"intervention":4890,"totalTrials":283,"cells":4891},"Zanubrutinib",{"EARLY_PHASE1":4892,"PHASE1":4894,"PHASE2":4923,"PHASE3":4932,"PHASE4":4934,"NA":4936},{"trials":4893,"activeCount":99},[],{"trials":4895,"activeCount":363,"soonestReadout":4917},[4896,4913],{"nctId":4897,"briefTitle":4898,"status":203,"phases":4899,"primaryCompletion":4900,"completion":4900,"start":4901,"enrollment":964,"conditions":4902,"interventions":4911},"NCT06859008","Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",[87],"2029-01-31","2025-08-25",[1408,4903,972,4904,1848,1849,1850,976,4905,4906,4907,1855,4908,4715,4716,4717,2639,4909,4910],"Recurrent Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Recurrent Nodal Marginal Zone Lymphoma","Recurrent Splenic Marginal Zone Lymphoma","Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Refractory Nodal Marginal Zone Lymphoma","Refractory Splenic Marginal Zone Lymphoma",[4912,4890],"Sonrotoclax",{"nctId":4914,"briefTitle":4915,"status":203,"phases":4916,"primaryCompletion":4917,"completion":4917,"start":4918,"enrollment":1666,"conditions":4919,"interventions":4921},"NCT06735664","Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation",[87],"2027-12-13","2025-08-14",[1453,1454,1455,4920],"Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma",[4922,4890],"Odronextamab",{"trials":4924,"activeCount":214,"soonestReadout":928},[4925],{"nctId":4926,"briefTitle":4927,"status":130,"phases":4928,"primaryCompletion":928,"completion":928,"start":4929,"enrollment":25,"conditions":4930,"interventions":4931},"NCT05718869","Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study",[88],"2023-05-18",[2102,2604],[2607,4890],{"trials":4933,"activeCount":99},[],{"trials":4935,"activeCount":99},[],{"trials":4937,"activeCount":99},[],{"intervention":2630,"totalTrials":283,"cells":4939},{"EARLY_PHASE1":4940,"PHASE1":4942,"PHASE2":4948,"PHASE3":4958,"PHASE4":4960,"NA":4962},{"trials":4941,"activeCount":99},[],{"trials":4943,"activeCount":214,"soonestReadout":4315},[4944],{"nctId":4312,"briefTitle":4313,"status":203,"phases":4945,"primaryCompletion":4315,"completion":4315,"start":2552,"enrollment":404,"conditions":4946,"interventions":4947},[87],[4317,4318],[2630,2631],{"trials":4949,"activeCount":363,"soonestReadout":3819},[4950,4954],{"nctId":2620,"briefTitle":2621,"status":203,"phases":4951,"primaryCompletion":2623,"completion":2623,"start":2624,"enrollment":2625,"conditions":4952,"interventions":4953},[87,88],[2627,1413,2628],[2630,1321,2631,956],{"nctId":3816,"briefTitle":3817,"status":203,"phases":4955,"primaryCompletion":3819,"completion":3819,"start":3820,"enrollment":188,"conditions":4956,"interventions":4957},[88],[1413],[2606,2630,2631],{"trials":4959,"activeCount":99},[],{"trials":4961,"activeCount":99},[],{"trials":4963,"activeCount":99},[],{"intervention":1176,"totalTrials":283,"cells":4965},{"EARLY_PHASE1":4966,"PHASE1":4968,"PHASE2":4984,"PHASE3":4990,"PHASE4":4992,"NA":4994},{"trials":4967,"activeCount":99},[],{"trials":4969,"activeCount":363,"soonestReadout":4974},[4970,4980],{"nctId":4971,"briefTitle":4972,"status":130,"phases":4973,"primaryCompletion":4974,"completion":4974,"start":4975,"enrollment":4976,"conditions":4977,"interventions":4978},"NCT02146924","Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia",[87],"2026-07-15","2014-10-16",71,[859,1173,1174],[4979,1176],"CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes",{"nctId":1167,"briefTitle":1168,"status":203,"phases":4981,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":30,"conditions":4982,"interventions":4983},[87],[1173,1174],[1176,1177,784,847],{"trials":4985,"activeCount":214,"soonestReadout":962},[4986],{"nctId":3824,"briefTitle":3825,"status":203,"phases":4987,"primaryCompletion":962,"completion":962,"start":3827,"enrollment":1610,"conditions":4988,"interventions":4989},[88],[976,2639],[2606,1176],{"trials":4991,"activeCount":99},[],{"trials":4993,"activeCount":99},[],{"trials":4995,"activeCount":99},[],{"intervention":738,"totalTrials":33,"cells":4997},{"EARLY_PHASE1":4998,"PHASE1":5000,"PHASE2":5034,"PHASE3":5080,"PHASE4":5082,"NA":5084},{"trials":4999,"activeCount":99},[],{"trials":5001,"activeCount":363,"soonestReadout":928},[5002,5006,5010,5014,5018,5022,5026,5030],{"nctId":863,"briefTitle":864,"status":107,"phases":5003,"primaryCompletion":866,"completion":866,"start":867,"enrollment":795,"conditions":5004,"interventions":5005},[87],[15],[738,870,75,168,871],{"nctId":873,"briefTitle":874,"status":107,"phases":5007,"primaryCompletion":109,"completion":109,"start":876,"enrollment":9,"conditions":5008,"interventions":5009},[87],[878,879,880],[738,385,75,115,871,882,883,274],{"nctId":905,"briefTitle":906,"status":907,"phases":5011,"primaryCompletion":909,"completion":909,"start":910,"enrollment":911,"conditions":5012,"interventions":5013},[87],[18],[784,66,851],{"nctId":915,"briefTitle":916,"status":107,"phases":5015,"primaryCompletion":175,"completion":175,"start":918,"enrollment":919,"conditions":5016,"interventions":5017},[87],[921],[738,114,385,75,894,740,923,871],{"nctId":925,"briefTitle":926,"status":130,"phases":5019,"primaryCompletion":928,"completion":928,"start":929,"enrollment":207,"conditions":5020,"interventions":5021},[87],[931,932,933,934,935,936],[938,939,940,941,942,784,66,943],{"nctId":983,"briefTitle":984,"status":107,"phases":5023,"primaryCompletion":986,"completion":986,"start":987,"enrollment":36,"conditions":5024,"interventions":5025},[87],[989,990,991,992],[994,738,75],{"nctId":2301,"briefTitle":2302,"status":107,"phases":5027,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":890,"conditions":5028,"interventions":5029},[87],[2308,2309,2310,2311,2312,2313,2314,2315,2316,583,2317,2318,2319,2320,2321,2322,2323,2324,2325,2326,2327,2328,2329,2330,2331,2332,2333,2334,24,2335],[42,115,882,738],{"nctId":1151,"briefTitle":1152,"status":294,"phases":5031,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":404,"conditions":5032,"interventions":5033},[87],[1157,1158,1159,1160,1161,1162],[784,346,66,1164,938,1165,957],{"trials":5035,"activeCount":214,"soonestReadout":65},[5036,5040,5044,5048,5052,5056,5060,5064,5068,5072,5076],{"nctId":1259,"briefTitle":1260,"status":107,"phases":5037,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":1264,"conditions":5038,"interventions":5039},[87,88],[27],[738,75,894],{"nctId":63,"briefTitle":64,"status":130,"phases":5041,"primaryCompletion":65,"completion":1010,"start":2893,"enrollment":9,"conditions":5042,"interventions":5043},[87,88],[1848,1849,2895,976,2896],[66,2898,2899,939],{"nctId":2739,"briefTitle":2740,"status":107,"phases":5045,"primaryCompletion":371,"completion":371,"start":2742,"enrollment":1244,"conditions":5046,"interventions":5047},[88],[2744,2745,879,2746,2747],[738,114,894,740,871],{"nctId":1312,"briefTitle":1313,"status":479,"phases":5049,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":99,"conditions":5050,"interventions":5051},[87,88],[1318,1319],[784,66,1321,849,1148],{"nctId":1323,"briefTitle":1324,"status":107,"phases":5053,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1264,"conditions":5054,"interventions":5055},[87,88],[989,1329,990,991,992],[115,738,1331,1332,75,1333],{"nctId":1335,"briefTitle":1336,"status":107,"phases":5057,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":16,"conditions":5058,"interventions":5059},[88],[15],[738,385,75,168,115,923,871,1343],{"nctId":2781,"briefTitle":2782,"status":107,"phases":5061,"primaryCompletion":2784,"completion":2785,"start":2786,"enrollment":1361,"conditions":5062,"interventions":5063},[88],[32],[2789,738,42,2391,894,2790],{"nctId":2464,"briefTitle":2465,"status":107,"phases":5065,"primaryCompletion":2467,"completion":2467,"start":393,"enrollment":1916,"conditions":5066,"interventions":5067},[88],[664],[738,385,168,740,115],{"nctId":731,"briefTitle":732,"status":369,"phases":5069,"primaryCompletion":734,"start":735,"enrollment":486,"conditions":5070,"interventions":5071},[88],[664],[738,739,168,740,290,387],{"nctId":1492,"briefTitle":1493,"status":107,"phases":5073,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":5074,"interventions":5075},[88],[1297],[738,1500,42,75,115,1501,1502],{"nctId":1504,"briefTitle":1505,"status":107,"phases":5077,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":5078,"interventions":5079},[88],[15],[738,114,75,168,871,116],{"trials":5081,"activeCount":99},[],{"trials":5083,"activeCount":99},[],{"trials":5085,"activeCount":99},[5086,5090],{"nctId":1519,"briefTitle":1520,"status":107,"phases":5087,"primaryCompletion":1522,"completion":1522,"start":1523,"enrollment":298,"conditions":5088,"interventions":5089},[91],[27],[738,893,75,894,115],{"nctId":1527,"briefTitle":1528,"status":107,"phases":5091,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":207,"conditions":5092,"interventions":5093},[91],[32,27,1298],[738,1233,784,1535,1536,849,850],{"intervention":126,"totalTrials":486,"cells":5095},{"EARLY_PHASE1":5096,"PHASE1":5098,"PHASE2":5112,"PHASE3":5134,"PHASE4":5136,"NA":5138},{"trials":5097,"activeCount":99},[],{"trials":5099,"activeCount":99},[5100,5104],{"nctId":3951,"briefTitle":3952,"status":107,"phases":5101,"start":3225,"conditions":5102,"interventions":5103},[87],[24],[126,271],{"nctId":5105,"briefTitle":5106,"status":107,"phases":5107,"start":5108,"conditions":5109,"interventions":5111},"NCT00002901","Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function",[87],"1996-12",[15,383,5110,879,24],"Lung Cancer",[126],{"trials":5113,"activeCount":363,"soonestReadout":70},[5114,5118,5122,5126,5130],{"nctId":118,"briefTitle":119,"status":107,"phases":5115,"primaryCompletion":121,"completion":121,"start":122,"conditions":5116,"interventions":5117},[88],[124],[94,126],{"nctId":1388,"briefTitle":1389,"status":203,"phases":5119,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":5120,"interventions":5121},[88],[774,775,776,1395],[784,1397],{"nctId":376,"briefTitle":377,"status":107,"phases":5123,"primaryCompletion":379,"completion":380,"start":381,"enrollment":177,"conditions":5124,"interventions":5125},[88],[383],[385,126,250,386,270,274,387],{"nctId":73,"briefTitle":74,"status":130,"phases":5127,"primaryCompletion":70,"completion":163,"start":164,"enrollment":165,"conditions":5128,"interventions":5129},[88],[15],[75,126,168,160,169,170],{"nctId":172,"briefTitle":173,"status":107,"phases":5131,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":5132,"interventions":5133},[87,88],[15],[94,126,180],{"trials":5135,"activeCount":99},[],{"trials":5137,"activeCount":99},[],{"trials":5139,"activeCount":99},[],{"intervention":1148,"totalTrials":498,"cells":5141},{"EARLY_PHASE1":5142,"PHASE1":5144,"PHASE2":5158,"PHASE3":5168,"PHASE4":5170,"NA":5172},{"trials":5143,"activeCount":99},[],{"trials":5145,"activeCount":214,"soonestReadout":2374},[5146,5150,5154],{"nctId":1137,"briefTitle":1138,"status":907,"phases":5147,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":5148,"interventions":5149},[87],[1144,1145],[784,940,1147,1148,1149,851],{"nctId":1179,"briefTitle":1180,"status":479,"phases":5151,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":99,"conditions":5152,"interventions":5153},[87],[1145,1185],[784,940,1147,1148,1149,851],{"nctId":2371,"briefTitle":2372,"status":130,"phases":5155,"primaryCompletion":2374,"completion":2374,"start":2375,"enrollment":486,"conditions":5156,"interventions":5157},[87],[35,18,21,813],[2378,823,2379,849,1148,2298],{"trials":5159,"activeCount":214,"soonestReadout":1748},[5160,5164],{"nctId":1745,"briefTitle":1746,"status":294,"phases":5161,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":1273,"conditions":5162,"interventions":5163},[88],[1751,1752,21,1003,1753,1208,1754,818,1755,1209,1756],[823,849,1148,1149,851],{"nctId":1312,"briefTitle":1313,"status":479,"phases":5165,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":99,"conditions":5166,"interventions":5167},[87,88],[1318,1319],[784,66,1321,849,1148],{"trials":5169,"activeCount":99},[],{"trials":5171,"activeCount":99},[],{"trials":5173,"activeCount":99},[],{"intervention":1895,"totalTrials":195,"cells":5175},{"EARLY_PHASE1":5176,"PHASE1":5178,"PHASE2":5206,"PHASE3":5212,"PHASE4":5214,"NA":5216},{"trials":5177,"activeCount":99},[],{"trials":5179,"activeCount":214,"soonestReadout":1873},[5180,5188,5192],{"nctId":5181,"briefTitle":5182,"status":107,"phases":5183,"primaryCompletion":5184,"completion":5184,"start":2492,"enrollment":1632,"conditions":5185,"interventions":5186},"NCT02275039","p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer",[87],"2018-04-23",[1385,3239,3241],[5187,386],"modified vaccinia virus ankara vaccine expressing p53",{"nctId":1870,"briefTitle":1871,"status":130,"phases":5189,"primaryCompletion":1873,"completion":1874,"start":1875,"enrollment":264,"conditions":5190,"interventions":5191},[87],[1877,1878,1879,1880,1881,1882,1883,1884,1885,1886,1887,1888,1889,1890,1891,1892,1893],[1895,1480],{"nctId":5193,"briefTitle":5194,"status":107,"phases":5195,"primaryCompletion":5196,"completion":5196,"start":5197,"enrollment":1632,"conditions":5198,"interventions":5205},"NCT01191684","Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer",[87],"2013-08","2011-10",[285,442,5199,286,5200,5201,5202,5203,287,444,5204,288],"Recurrent Pancreatic Cancer","Stage III Colon Cancer","Stage III Gastric Cancer","Stage III Pancreatic Cancer","Stage III Rectal Cancer","Stage IV Pancreatic Cancer",[5187],{"trials":5207,"activeCount":214,"soonestReadout":1942},[5208],{"nctId":1939,"briefTitle":1940,"status":130,"phases":5209,"primaryCompletion":1942,"completion":1943,"start":1944,"enrollment":1945,"conditions":5210,"interventions":5211},[88],[1947,1948,1949],[1895,1480],{"trials":5213,"activeCount":99},[],{"trials":5215,"activeCount":99},[],{"trials":5217,"activeCount":99},[],{"intervention":1457,"totalTrials":195,"cells":5219},{"EARLY_PHASE1":5220,"PHASE1":5222,"PHASE2":5241,"PHASE3":5251,"PHASE4":5253,"NA":5255},{"trials":5221,"activeCount":99},[],{"trials":5223,"activeCount":214,"soonestReadout":1994},[5224,5228],{"nctId":2844,"briefTitle":2845,"status":107,"phases":5225,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":576,"conditions":5226,"interventions":5227},[87],[972,976,1855,2639,2850],[2852,169,1257,1457,2244,939,2853],{"nctId":5229,"briefTitle":5230,"status":130,"phases":5231,"primaryCompletion":1994,"completion":1994,"start":5232,"enrollment":36,"conditions":5233,"interventions":5239},"NCT03479268","Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma",[87],"2018-04-27",[967,971,972,973,975,976,977,2896,978,5234,1855,1856,5235,2639,5236,5237,5238,1455],"Refractory Chronic Lymphocytic Leukemia","Refractory Lymphoplasmacytic Lymphoma","Refractory Marginal Zone Lymphoma","Refractory Non-Hodgkin Lymphoma","Refractory Small Lymphocytic Lymphoma",[1457,5240],"Pevonedistat",{"trials":5242,"activeCount":214,"soonestReadout":1450},[5243,5247],{"nctId":1447,"briefTitle":1448,"status":203,"phases":5244,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":404,"conditions":5245,"interventions":5246},[88],[1453,1454,1455],[784,847,1457,1458,838],{"nctId":3660,"briefTitle":3661,"status":107,"phases":5248,"primaryCompletion":3663,"completion":3664,"start":3665,"enrollment":2122,"conditions":5249,"interventions":5250},[88],[2241,2242],[1256,1457],{"trials":5252,"activeCount":99},[],{"trials":5254,"activeCount":99},[],{"trials":5256,"activeCount":99},[],{"intervention":1165,"totalTrials":195,"cells":5258},{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5275,"PHASE3":5281,"PHASE4":5283,"NA":5285},{"trials":5260,"activeCount":99},[],{"trials":5262,"activeCount":214,"soonestReadout":1154},[5263,5267,5271],{"nctId":1563,"briefTitle":1564,"status":107,"phases":5264,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":36,"conditions":5265,"interventions":5266},[87],[1488,845],[847,823,849,1571,1165,1149,851],{"nctId":1151,"briefTitle":1152,"status":294,"phases":5268,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":404,"conditions":5269,"interventions":5270},[87],[1157,1158,1159,1160,1161,1162],[784,346,66,1164,938,1165,957],{"nctId":1718,"briefTitle":1719,"status":479,"phases":5272,"primaryCompletion":1721,"start":1722,"enrollment":99,"conditions":5273,"interventions":5274},[87],[1194,1488,1724,813,845],[823,849,1165,1149,851],{"trials":5276,"activeCount":214,"soonestReadout":1780},[5277],{"nctId":1777,"briefTitle":1778,"status":203,"phases":5278,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":188,"conditions":5279,"interventions":5280},[88],[35,18,21],[1134,1165,851],{"trials":5282,"activeCount":99},[],{"trials":5284,"activeCount":99},[],{"trials":5286,"activeCount":99},[],{"intervention":2899,"totalTrials":283,"cells":5288},{"EARLY_PHASE1":5289,"PHASE1":5291,"PHASE2":5305,"PHASE3":5311,"PHASE4":5313,"NA":5315},{"trials":5290,"activeCount":99},[],{"trials":5292,"activeCount":214,"soonestReadout":5301},[5293,5297],{"nctId":983,"briefTitle":984,"status":107,"phases":5294,"primaryCompletion":986,"completion":986,"start":987,"enrollment":36,"conditions":5295,"interventions":5296},[87],[989,990,991,992],[994,738,75],{"nctId":5298,"briefTitle":5299,"status":130,"phases":5300,"primaryCompletion":5301,"completion":5301,"start":5302,"enrollment":498,"conditions":5303,"interventions":5304},"NCT03664830","Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease",[87],"2026-08-03","2018-09-19",[1112],[2899],{"trials":5306,"activeCount":214,"soonestReadout":65},[5307],{"nctId":63,"briefTitle":64,"status":130,"phases":5308,"primaryCompletion":65,"completion":1010,"start":2893,"enrollment":9,"conditions":5309,"interventions":5310},[87,88],[1848,1849,2895,976,2896],[66,2898,2899,939],{"trials":5312,"activeCount":99},[],{"trials":5314,"activeCount":99},[],{"trials":5316,"activeCount":99},[],{"intervention":1303,"totalTrials":283,"cells":5318},{"EARLY_PHASE1":5319,"PHASE1":5321,"PHASE2":5327,"PHASE3":5348,"PHASE4":5350,"NA":5352},{"trials":5320,"activeCount":99},[],{"trials":5322,"activeCount":214,"soonestReadout":1217},[5323],{"nctId":1214,"briefTitle":1215,"status":203,"phases":5324,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":434,"conditions":5325,"interventions":5326},[87],[1220,1221],[1223,784,1118],{"trials":5328,"activeCount":214,"soonestReadout":5337},[5329,5333],{"nctId":1290,"briefTitle":1291,"status":107,"phases":5330,"primaryCompletion":433,"completion":433,"start":1293,"enrollment":111,"conditions":5331,"interventions":5332},[88],[1295,1231,1296,32,27,1297,1298,1299,1300,845,1301],[1303,75,894,61,115,1304,1305,1306],{"nctId":5334,"briefTitle":5335,"status":203,"phases":5336,"primaryCompletion":5337,"completion":5338,"start":5339,"enrollment":5340,"conditions":5341,"interventions":5344},"NCT07061574","A Randomized Phase 1\u002F2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes",[87,88],"2030-04-15","2031-04-15","2026-03-10",120,[5342,5343],"Type 1 Diabetes","New Onset",[5345,5346,5347],"Anti-thymocyte globulin","verapamil extended-release","Adalimumab",{"trials":5349,"activeCount":99},[],{"trials":5351,"activeCount":99},[],{"trials":5353,"activeCount":99},[],{"intervention":2607,"totalTrials":283,"cells":5355},{"EARLY_PHASE1":5356,"PHASE1":5358,"PHASE2":5369,"PHASE3":5379,"PHASE4":5381,"NA":5383},{"trials":5357,"activeCount":99},[],{"trials":5359,"activeCount":99},[5360],{"nctId":5361,"briefTitle":5362,"status":907,"phases":5363,"primaryCompletion":5364,"completion":5364,"start":5365,"enrollment":22,"conditions":5366,"interventions":5367},"NCT05993611","Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation",[87],"2028-05-21","2024-02-19",[3405,1652,3406],[5368,2607],"Chimeric Antigen Receptor T-Cell Therapy",{"trials":5370,"activeCount":363,"soonestReadout":928},[5371,5375],{"nctId":2598,"briefTitle":2599,"status":294,"phases":5372,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":1273,"conditions":5373,"interventions":5374},[88],[2102,1408,2604],[2606,2607,956],{"nctId":4926,"briefTitle":4927,"status":130,"phases":5376,"primaryCompletion":928,"completion":928,"start":4929,"enrollment":25,"conditions":5377,"interventions":5378},[88],[2102,2604],[2607,4890],{"trials":5380,"activeCount":99},[],{"trials":5382,"activeCount":99},[],{"trials":5384,"activeCount":99},[],{"intervention":545,"totalTrials":283,"cells":5386},{"EARLY_PHASE1":5387,"PHASE1":5389,"PHASE2":5399,"PHASE3":5405,"PHASE4":5407,"NA":5409},{"trials":5388,"activeCount":99},[],{"trials":5390,"activeCount":214,"soonestReadout":1099},[5391,5395],{"nctId":4733,"briefTitle":4734,"status":107,"phases":5392,"primaryCompletion":4736,"completion":4736,"start":4737,"enrollment":95,"conditions":5393,"interventions":5394},[87],[4739,4740,4741,4742,4743,423,424],[544,545],{"nctId":4746,"briefTitle":4747,"status":130,"phases":5396,"primaryCompletion":1099,"completion":1099,"start":4749,"enrollment":890,"conditions":5397,"interventions":5398},[87],[4751,4752,4753,4754,4755,4756,833,834,835,4757],[544,545],{"trials":5400,"activeCount":214,"soonestReadout":534},[5401],{"nctId":531,"briefTitle":532,"status":203,"phases":5402,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":5403,"interventions":5404},[88],[538,505,507],[540,541,542,413,543,544,545],{"trials":5406,"activeCount":99},[],{"trials":5408,"activeCount":99},[],{"trials":5410,"activeCount":99},[],{"intervention":2298,"totalTrials":283,"cells":5412},{"EARLY_PHASE1":5413,"PHASE1":5415,"PHASE2":5425,"PHASE3":5431,"PHASE4":5433,"NA":5435},{"trials":5414,"activeCount":99},[],{"trials":5416,"activeCount":214,"soonestReadout":2374},[5417,5421],{"nctId":2287,"briefTitle":2288,"status":107,"phases":5418,"primaryCompletion":2290,"completion":2291,"start":2292,"enrollment":404,"conditions":5419,"interventions":5420},[87],[1161,2294,1932,2295,2296],[2298,2299,940,1131,849],{"nctId":2371,"briefTitle":2372,"status":130,"phases":5422,"primaryCompletion":2374,"completion":2374,"start":2375,"enrollment":486,"conditions":5423,"interventions":5424},[87],[35,18,21,813],[2378,823,2379,849,1148,2298],{"trials":5426,"activeCount":214,"soonestReadout":2803},[5427],{"nctId":2800,"briefTitle":2801,"status":203,"phases":5428,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":919,"conditions":5429,"interventions":5430},[88],[2241,2242],[2378,2299,1131,940,2807,2808,2298],{"trials":5432,"activeCount":99},[],{"trials":5434,"activeCount":99},[],{"trials":5436,"activeCount":99},[],{"intervention":2378,"totalTrials":283,"cells":5438},{"EARLY_PHASE1":5439,"PHASE1":5441,"PHASE2":5451,"PHASE3":5457,"PHASE4":5459,"NA":5461},{"trials":5440,"activeCount":99},[],{"trials":5442,"activeCount":214,"soonestReadout":2374},[5443,5447],{"nctId":2371,"briefTitle":2372,"status":130,"phases":5444,"primaryCompletion":2374,"completion":2374,"start":2375,"enrollment":486,"conditions":5445,"interventions":5446},[87],[35,18,21,813],[2378,823,2379,849,1148,2298],{"nctId":2381,"briefTitle":2382,"status":107,"phases":5448,"primaryCompletion":2384,"completion":2385,"start":2386,"enrollment":890,"conditions":5449,"interventions":5450},[87],[2388],[2390,893,894,2391,115,2392],{"trials":5452,"activeCount":214,"soonestReadout":2803},[5453],{"nctId":2800,"briefTitle":2801,"status":203,"phases":5454,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":919,"conditions":5455,"interventions":5456},[88],[2241,2242],[2378,2299,1131,940,2807,2808,2298],{"trials":5458,"activeCount":99},[],{"trials":5460,"activeCount":99},[],{"trials":5462,"activeCount":99},[],{"intervention":5464,"totalTrials":363,"cells":5465},"Mosunetuzumab",{"EARLY_PHASE1":5466,"PHASE1":5468,"PHASE2":5470,"PHASE3":5494,"PHASE4":5496,"NA":5498},{"trials":5467,"activeCount":99},[],{"trials":5469,"activeCount":99},[],{"trials":5471,"activeCount":363,"soonestReadout":4672},[5472,5480],{"nctId":5473,"briefTitle":5474,"status":203,"phases":5475,"primaryCompletion":5476,"completion":5476,"start":5477,"enrollment":16,"conditions":5478,"interventions":5479},"NCT06453044","Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma",[88],"2028-03-14","2024-09-09",[1848,1849,1850,4715,4716,4717],[5464,2764],{"nctId":5481,"briefTitle":5482,"status":203,"phases":5483,"primaryCompletion":4672,"completion":4672,"start":5484,"enrollment":1610,"conditions":5485,"interventions":5492},"NCT05672251","Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[88],"2024-01-02",[972,5486,5487,5488,1453,2919,1855,5489,5490,5491,1454,2923],"Recurrent Grade 3b Follicular Lymphoma","Recurrent High Grade B-Cell Lymphoma","Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Refractory Grade 3b Follicular Lymphoma","Refractory High Grade B-Cell Lymphoma","Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma",[5493,5464],"Loncastuximab Tesirine",{"trials":5495,"activeCount":99},[],{"trials":5497,"activeCount":99},[],{"trials":5499,"activeCount":99},[],{"intervention":2764,"totalTrials":363,"cells":5501},{"EARLY_PHASE1":5502,"PHASE1":5504,"PHASE2":5506,"PHASE3":5516,"PHASE4":5518,"NA":5520},{"trials":5503,"activeCount":99},[],{"trials":5505,"activeCount":99},[],{"trials":5507,"activeCount":363,"soonestReadout":2757},[5508,5512],{"nctId":5473,"briefTitle":5474,"status":203,"phases":5509,"primaryCompletion":5476,"completion":5476,"start":5477,"enrollment":16,"conditions":5510,"interventions":5511},[88],[1848,1849,1850,4715,4716,4717],[5464,2764],{"nctId":2754,"briefTitle":2755,"status":130,"phases":5513,"primaryCompletion":2757,"completion":467,"start":2758,"enrollment":16,"conditions":5514,"interventions":5515},[88],[2760,972,1851,2761,1855,1857,2762],[169,940,2244,2764,939],{"trials":5517,"activeCount":99},[],{"trials":5519,"activeCount":99},[],{"trials":5521,"activeCount":99},[],{"intervention":5523,"totalTrials":363,"cells":5524},"Osimertinib",{"EARLY_PHASE1":5525,"PHASE1":5527,"PHASE2":5538,"PHASE3":5548,"PHASE4":5550,"NA":5552},{"trials":5526,"activeCount":99},[],{"trials":5528,"activeCount":214,"soonestReadout":656},[5529],{"nctId":5530,"briefTitle":5531,"status":130,"phases":5532,"primaryCompletion":656,"completion":656,"start":3431,"enrollment":9,"conditions":5533,"interventions":5536},"NCT05166616","Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer",[87],[5534,500,503,504,505,506,507,508,509,5535],"Advanced Lung Non-Small Cell Carcinoma","Unresectable Lung Non-Small Cell Carcinoma",[5523,5537],"Triptolide Analog",{"trials":5539,"activeCount":214,"soonestReadout":5544},[5540],{"nctId":5541,"briefTitle":5542,"status":203,"phases":5543,"primaryCompletion":5544,"completion":5544,"start":5545,"enrollment":111,"conditions":5546,"interventions":5547},"NCT06014827","Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma",[88],"2026-07-11","2024-10-09",[538,507],[5523],{"trials":5549,"activeCount":99},[],{"trials":5551,"activeCount":99},[],{"trials":5553,"activeCount":99},[],{"intervention":51,"totalTrials":363,"cells":5555},{"EARLY_PHASE1":5556,"PHASE1":5558,"PHASE2":5560,"PHASE3":5570,"PHASE4":5572,"NA":5574},{"trials":5557,"activeCount":99},[],{"trials":5559,"activeCount":99},[],{"trials":5561,"activeCount":363,"soonestReadout":50},[5562,5566],{"nctId":48,"briefTitle":49,"status":130,"phases":5563,"primaryCompletion":50,"completion":4811,"start":4812,"enrollment":1945,"conditions":5564,"interventions":5565},[88],[4814,4815],[51,3772,3773],{"nctId":3760,"briefTitle":3761,"status":203,"phases":5567,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":5568,"interventions":5569},[88],[3767,3768,1071,1072,1073],[3770,51,3771,3772,3773,938,3774],{"trials":5571,"activeCount":99},[],{"trials":5573,"activeCount":99},[],{"trials":5575,"activeCount":99},[],{"intervention":2020,"totalTrials":363,"cells":5577},{"EARLY_PHASE1":5578,"PHASE1":5580,"PHASE2":5582,"PHASE3":5592,"PHASE4":5594,"NA":5596},{"trials":5579,"activeCount":99},[],{"trials":5581,"activeCount":99},[],{"trials":5583,"activeCount":363,"soonestReadout":2212},[5584,5588],{"nctId":2209,"briefTitle":2210,"status":130,"phases":5585,"primaryCompletion":2212,"completion":2212,"start":2213,"enrollment":2214,"conditions":5586,"interventions":5587},[88],[2216,2217,2218,2219,2220,2221,2222,2223,2018,2224,2225,2226,2227,2228],[2230,1256,2020,346,838,2231],{"nctId":2013,"briefTitle":2014,"status":203,"phases":5589,"primaryCompletion":2016,"completion":2016,"start":467,"enrollment":1666,"conditions":5590,"interventions":5591},[88],[2018],[1256,2020,2021,1480],{"trials":5593,"activeCount":99},[],{"trials":5595,"activeCount":99},[],{"trials":5597,"activeCount":99},[],{"intervention":954,"totalTrials":363,"cells":5599},{"EARLY_PHASE1":5600,"PHASE1":5602,"PHASE2":5608,"PHASE3":5614,"PHASE4":5616,"NA":5618},{"trials":5601,"activeCount":99},[],{"trials":5603,"activeCount":214,"soonestReadout":948},[5604],{"nctId":945,"briefTitle":946,"status":203,"phases":5605,"primaryCompletion":948,"completion":948,"start":949,"enrollment":25,"conditions":5606,"interventions":5607},[87],[951,952],[954,955,784,956,957],{"trials":5609,"activeCount":214,"soonestReadout":1348},[5610],{"nctId":1345,"briefTitle":1346,"status":203,"phases":5611,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1142,"conditions":5612,"interventions":5613},[88],[1351,1352],[954,784,1131,1131,1132,1354,1133,1134,939,942],{"trials":5615,"activeCount":99},[],{"trials":5617,"activeCount":99},[],{"trials":5619,"activeCount":99},[],{"intervention":1132,"totalTrials":363,"cells":5621},{"EARLY_PHASE1":5622,"PHASE1":5624,"PHASE2":5630,"PHASE3":5636,"PHASE4":5638,"NA":5640},{"trials":5623,"activeCount":99},[],{"trials":5625,"activeCount":214,"soonestReadout":1126},[5626],{"nctId":1123,"briefTitle":1124,"status":130,"phases":5627,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":30,"conditions":5628,"interventions":5629},[87],[859,1129],[784,1131,1132,1133,1134,1135,938,956,942],{"trials":5631,"activeCount":214,"soonestReadout":1348},[5632],{"nctId":1345,"briefTitle":1346,"status":203,"phases":5633,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1142,"conditions":5634,"interventions":5635},[88],[1351,1352],[954,784,1131,1131,1132,1354,1133,1134,939,942],{"trials":5637,"activeCount":99},[],{"trials":5639,"activeCount":99},[],{"trials":5641,"activeCount":99},[],{"intervention":1133,"totalTrials":363,"cells":5643},{"EARLY_PHASE1":5644,"PHASE1":5646,"PHASE2":5652,"PHASE3":5658,"PHASE4":5660,"NA":5662},{"trials":5645,"activeCount":99},[],{"trials":5647,"activeCount":214,"soonestReadout":1126},[5648],{"nctId":1123,"briefTitle":1124,"status":130,"phases":5649,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":30,"conditions":5650,"interventions":5651},[87],[859,1129],[784,1131,1132,1133,1134,1135,938,956,942],{"trials":5653,"activeCount":214,"soonestReadout":1348},[5654],{"nctId":1345,"briefTitle":1346,"status":203,"phases":5655,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1142,"conditions":5656,"interventions":5657},[88],[1351,1352],[954,784,1131,1131,1132,1354,1133,1134,939,942],{"trials":5659,"activeCount":99},[],{"trials":5661,"activeCount":99},[],{"trials":5663,"activeCount":99},[],{"intervention":148,"totalTrials":363,"cells":5665},{"EARLY_PHASE1":5666,"PHASE1":5668,"PHASE2":5670,"PHASE3":5680,"PHASE4":5682,"NA":5684},{"trials":5667,"activeCount":99},[],{"trials":5669,"activeCount":99},[],{"trials":5671,"activeCount":363,"soonestReadout":153},[5672,5676],{"nctId":128,"briefTitle":129,"status":130,"phases":5673,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":5674,"interventions":5675},[88],[137,138,139,140,141,142,143,144,145,146],[148,94,56],{"nctId":150,"briefTitle":151,"status":130,"phases":5677,"primaryCompletion":153,"completion":154,"start":155,"enrollment":36,"conditions":5678,"interventions":5679},[88],[157,141,142,143],[159,160],{"trials":5681,"activeCount":99},[],{"trials":5683,"activeCount":99},[],{"trials":5685,"activeCount":99},[],{"intervention":543,"totalTrials":363,"cells":5687},{"EARLY_PHASE1":5688,"PHASE1":5690,"PHASE2":5692,"PHASE3":5711,"PHASE4":5713,"NA":5715},{"trials":5689,"activeCount":99},[],{"trials":5691,"activeCount":99},[],{"trials":5693,"activeCount":363,"soonestReadout":534},[5694,5707],{"nctId":5695,"briefTitle":5696,"status":203,"phases":5697,"primaryCompletion":5698,"completion":5698,"start":5699,"enrollment":911,"conditions":5700,"interventions":5705},"NCT07042438","Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells",[88],"2029-01-23","2026-02-11",[972,5701,5702,1855,5703,5704],"Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",[5706,543],"Axicabtagene Ciloleucel",{"nctId":531,"briefTitle":532,"status":203,"phases":5708,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":5709,"interventions":5710},[88],[538,505,507],[540,541,542,413,543,544,545],{"trials":5712,"activeCount":99},[],{"trials":5714,"activeCount":99},[],{"trials":5716,"activeCount":99},[],{"intervention":3050,"totalTrials":363,"cells":5718},{"EARLY_PHASE1":5719,"PHASE1":5721,"PHASE2":5727,"PHASE3":5733,"PHASE4":5735,"NA":5737},{"trials":5720,"activeCount":99},[],{"trials":5722,"activeCount":214,"soonestReadout":3042},[5723],{"nctId":3039,"briefTitle":3040,"status":203,"phases":5724,"primaryCompletion":3042,"completion":3042,"start":3043,"enrollment":3044,"conditions":5725,"interventions":5726},[87],[3046,35,18,2102,3047,3048,1412,1352,21,3036,1276,3035],[3050,3005,2808],{"trials":5728,"activeCount":214,"soonestReadout":3117},[5729],{"nctId":3114,"briefTitle":3115,"status":130,"phases":5730,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":486,"conditions":5731,"interventions":5732},[88],[3085,35,18,2102,3086,1145,1412,1352,21,3036,1276,3035],[3050,3005],{"trials":5734,"activeCount":99},[],{"trials":5736,"activeCount":99},[],{"trials":5738,"activeCount":99},[],{"intervention":2808,"totalTrials":363,"cells":5740},{"EARLY_PHASE1":5741,"PHASE1":5743,"PHASE2":5749,"PHASE3":5755,"PHASE4":5757,"NA":5759},{"trials":5742,"activeCount":99},[],{"trials":5744,"activeCount":214,"soonestReadout":3042},[5745],{"nctId":3039,"briefTitle":3040,"status":203,"phases":5746,"primaryCompletion":3042,"completion":3042,"start":3043,"enrollment":3044,"conditions":5747,"interventions":5748},[87],[3046,35,18,2102,3047,3048,1412,1352,21,3036,1276,3035],[3050,3005,2808],{"trials":5750,"activeCount":214,"soonestReadout":2803},[5751],{"nctId":2800,"briefTitle":2801,"status":203,"phases":5752,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":919,"conditions":5753,"interventions":5754},[88],[2241,2242],[2378,2299,1131,940,2807,2808,2298],{"trials":5756,"activeCount":99},[],{"trials":5758,"activeCount":99},[],{"trials":5760,"activeCount":99},[],{"intervention":5762,"totalTrials":363,"cells":5763},"Allogenic Human Islet Cells",{"EARLY_PHASE1":5764,"PHASE1":5766,"PHASE2":5768,"PHASE3":5790,"PHASE4":5792,"NA":5794},{"trials":5765,"activeCount":99},[],{"trials":5767,"activeCount":99},[],{"trials":5769,"activeCount":363,"soonestReadout":5774},[5770,5781],{"nctId":5771,"briefTitle":5772,"status":130,"phases":5773,"primaryCompletion":5774,"completion":5774,"start":5775,"enrollment":207,"conditions":5776,"interventions":5778},"NCT01909245","Islet Cell Transplant for Type 1 Diabetes",[88],"2026-09-22","2013-10-16",[5777],"Type 1 Diabetes Mellitus",[5762,5779,5780],"Immunosuppressive Agents","Gastrin 17",{"nctId":5782,"briefTitle":5783,"status":203,"phases":5784,"primaryCompletion":5785,"completion":5785,"start":5786,"enrollment":404,"conditions":5787,"interventions":5789},"NCT03746769","Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes",[87,88],"2028-08-01","2019-07-07",[5788],"Diabetes Mellitus, Type 1",[5762,5780],{"trials":5791,"activeCount":99},[],{"trials":5793,"activeCount":99},[],{"trials":5795,"activeCount":99},[],{"intervention":5780,"totalTrials":363,"cells":5797},{"EARLY_PHASE1":5798,"PHASE1":5800,"PHASE2":5802,"PHASE3":5812,"PHASE4":5814,"NA":5816},{"trials":5799,"activeCount":99},[],{"trials":5801,"activeCount":99},[],{"trials":5803,"activeCount":363,"soonestReadout":5774},[5804,5808],{"nctId":5771,"briefTitle":5772,"status":130,"phases":5805,"primaryCompletion":5774,"completion":5774,"start":5775,"enrollment":207,"conditions":5806,"interventions":5807},[88],[5777],[5762,5779,5780],{"nctId":5782,"briefTitle":5783,"status":203,"phases":5809,"primaryCompletion":5785,"completion":5785,"start":5786,"enrollment":404,"conditions":5810,"interventions":5811},[87,88],[5788],[5762,5780],{"trials":5813,"activeCount":99},[],{"trials":5815,"activeCount":99},[],{"trials":5817,"activeCount":99},[],{"intervention":1441,"totalTrials":363,"cells":5819},{"EARLY_PHASE1":5820,"PHASE1":5822,"PHASE2":5824,"PHASE3":5834,"PHASE4":5836,"NA":5838},{"trials":5821,"activeCount":99},[],{"trials":5823,"activeCount":99},[],{"trials":5825,"activeCount":363,"soonestReadout":402},[5826,5830],{"nctId":3091,"briefTitle":3092,"status":203,"phases":5827,"primaryCompletion":3094,"completion":3095,"start":3096,"enrollment":3097,"conditions":5828,"interventions":5829},[88],[35,18,2102,3099,3100,1412,21,3036,1276,3035],[1441,3102,3005,3103],{"nctId":1434,"briefTitle":1435,"status":130,"phases":5831,"primaryCompletion":402,"completion":402,"start":1437,"enrollment":919,"conditions":5832,"interventions":5833},[88],[35,18,1439,21],[784,847,823,1441,850,851],{"trials":5835,"activeCount":99},[],{"trials":5837,"activeCount":99},[],{"trials":5839,"activeCount":99},[],{"intervention":955,"totalTrials":363,"cells":5841},{"EARLY_PHASE1":5842,"PHASE1":5844,"PHASE2":5850,"PHASE3":5856,"PHASE4":5858,"NA":5860},{"trials":5843,"activeCount":99},[],{"trials":5845,"activeCount":214,"soonestReadout":948},[5846],{"nctId":945,"briefTitle":946,"status":203,"phases":5847,"primaryCompletion":948,"completion":948,"start":949,"enrollment":25,"conditions":5848,"interventions":5849},[87],[951,952],[954,955,784,956,957],{"trials":5851,"activeCount":214,"soonestReadout":2006},[5852],{"nctId":2003,"briefTitle":2004,"status":130,"phases":5853,"primaryCompletion":2006,"completion":2006,"start":2007,"enrollment":1610,"conditions":5854,"interventions":5855},[87,88],[2009,2010,1173,1174],[955,1480],{"trials":5857,"activeCount":99},[],{"trials":5859,"activeCount":99},[],{"trials":5861,"activeCount":99},[],{"intervention":3771,"totalTrials":363,"cells":5863},{"EARLY_PHASE1":5864,"PHASE1":5866,"PHASE2":5868,"PHASE3":5878,"PHASE4":5880,"NA":5882},{"trials":5865,"activeCount":99},[],{"trials":5867,"activeCount":99},[],{"trials":5869,"activeCount":363,"soonestReadout":4821},[5870,5874],{"nctId":4818,"briefTitle":4819,"status":130,"phases":5871,"primaryCompletion":4821,"completion":4822,"start":4823,"enrollment":890,"conditions":5872,"interventions":5873},[88],[4825],[3773,3772,3771],{"nctId":3760,"briefTitle":3761,"status":203,"phases":5875,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":5876,"interventions":5877},[88],[3767,3768,1071,1072,1073],[3770,51,3771,3772,3773,938,3774],{"trials":5879,"activeCount":99},[],{"trials":5881,"activeCount":99},[],{"trials":5883,"activeCount":99},[],{"intervention":307,"totalTrials":363,"cells":5885},{"EARLY_PHASE1":5886,"PHASE1":5888,"PHASE2":5894,"PHASE3":5906,"PHASE4":5908,"NA":5910},{"trials":5887,"activeCount":99},[],{"trials":5889,"activeCount":214,"soonestReadout":296},[5890],{"nctId":292,"briefTitle":293,"status":294,"phases":5891,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":5892,"interventions":5893},[87],[300,301,302,303],[305,306,307,308,309],{"trials":5895,"activeCount":214,"soonestReadout":5900},[5896],{"nctId":5897,"briefTitle":5898,"status":294,"phases":5899,"primaryCompletion":5900,"completion":5900,"start":5901,"enrollment":177,"conditions":5902,"interventions":5905},"NCT07226544","Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer",[88],"2027-09-08","2026-06-08",[5903,5904,1973,1049,1052],"Localized Clear Cell Renal Cell Carcinoma","Resectable Clear Cell Renal Cell Carcinoma",[307],{"trials":5907,"activeCount":99},[],{"trials":5909,"activeCount":99},[],{"trials":5911,"activeCount":99},[],{"intervention":5913,"totalTrials":363,"cells":5914},"Duvelisib",{"EARLY_PHASE1":5915,"PHASE1":5917,"PHASE2":5919,"PHASE3":5938,"PHASE4":5940,"NA":5942},{"trials":5916,"activeCount":99},[],{"trials":5918,"activeCount":99},[],{"trials":5920,"activeCount":363,"soonestReadout":5925},[5921,5930],{"nctId":5922,"briefTitle":5923,"status":130,"phases":5924,"primaryCompletion":5925,"completion":5926,"start":5927,"enrollment":795,"conditions":5928,"interventions":5929},"NCT03961672","Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[88],"2023-07-31","2026-10-26","2020-05-13",[971,978,5234,5238],[5913],{"nctId":5931,"briefTitle":5932,"status":203,"phases":5933,"primaryCompletion":5934,"completion":5934,"start":5935,"enrollment":890,"conditions":5936,"interventions":5937},"NCT07293403","Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas",[88],"2027-11-23","2026-06-07",[1157,1162],[5913],{"trials":5939,"activeCount":99},[],{"trials":5941,"activeCount":99},[],{"trials":5943,"activeCount":99},[],{"intervention":2001,"totalTrials":363,"cells":5945},{"EARLY_PHASE1":5946,"PHASE1":5948,"PHASE2":5950,"PHASE3":5960,"PHASE4":5962,"NA":5964},{"trials":5947,"activeCount":99},[],{"trials":5949,"activeCount":99},[],{"trials":5951,"activeCount":363,"soonestReadout":1994},[5952,5956],{"nctId":1991,"briefTitle":1992,"status":130,"phases":5953,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":19,"conditions":5954,"interventions":5955},[88],[1997,1046,1998,1999,1048,1051,1056],[2001,1480],{"nctId":2023,"briefTitle":2024,"status":130,"phases":5957,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":283,"conditions":5958,"interventions":5959},[88],[2029,2030,2031,2032,2033,1467,1906,1905,2034,2035,2036,2037,2038,2039,2040,2041,2042,1471,1472],[169,2001,170,1480],{"trials":5961,"activeCount":99},[],{"trials":5963,"activeCount":99},[],{"trials":5965,"activeCount":99},[],{"intervention":2976,"totalTrials":363,"cells":5967},{"EARLY_PHASE1":5968,"PHASE1":5970,"PHASE2":5972,"PHASE3":5982,"PHASE4":5984,"NA":5986},{"trials":5969,"activeCount":99},[],{"trials":5971,"activeCount":99},[],{"trials":5973,"activeCount":363,"soonestReadout":2981},[5974,5978],{"nctId":2965,"briefTitle":2966,"status":294,"phases":5975,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":1273,"conditions":5976,"interventions":5977},[88],[2971,2972,1414,2973,2880,27,2974],[2976,939],{"nctId":2978,"briefTitle":2979,"status":203,"phases":5979,"primaryCompletion":2981,"completion":2981,"start":2982,"enrollment":22,"conditions":5980,"interventions":5981},[88],[1413],[2976,939],{"trials":5983,"activeCount":99},[],{"trials":5985,"activeCount":99},[],{"trials":5987,"activeCount":99},[],{"intervention":740,"totalTrials":95,"cells":5989},{"EARLY_PHASE1":5990,"PHASE1":5992,"PHASE2":6002,"PHASE3":6028,"PHASE4":6030,"NA":6032},{"trials":5991,"activeCount":99},[],{"trials":5993,"activeCount":99},[5994,5998],{"nctId":2844,"briefTitle":2845,"status":107,"phases":5995,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":576,"conditions":5996,"interventions":5997},[87],[972,976,1855,2639,2850],[2852,169,1257,1457,2244,939,2853],{"nctId":915,"briefTitle":916,"status":107,"phases":5999,"primaryCompletion":175,"completion":175,"start":918,"enrollment":919,"conditions":6000,"interventions":6001},[87],[921],[738,114,385,75,894,740,923,871],{"trials":6003,"activeCount":363,"soonestReadout":2757},[6004,6008,6012,6016,6020,6024],{"nctId":2739,"briefTitle":2740,"status":107,"phases":6005,"primaryCompletion":371,"completion":371,"start":2742,"enrollment":1244,"conditions":6006,"interventions":6007},[88],[2744,2745,879,2746,2747],[738,114,894,740,871],{"nctId":2754,"briefTitle":2755,"status":130,"phases":6009,"primaryCompletion":2757,"completion":467,"start":2758,"enrollment":16,"conditions":6010,"interventions":6011},[88],[2760,972,1851,2761,1855,1857,2762],[169,940,2244,2764,939],{"nctId":3305,"briefTitle":3306,"status":369,"phases":6013,"primaryCompletion":3308,"completion":3309,"start":3310,"enrollment":486,"conditions":6014,"interventions":6015},[87,88],[2744,3312,2745,3313,3314,27,3315,879,664,2747,2335],[114,3317,3318,740,447,276],{"nctId":2233,"briefTitle":2234,"status":130,"phases":6017,"primaryCompletion":2236,"completion":2237,"start":2238,"enrollment":2239,"conditions":6018,"interventions":6019},[88],[2241,2242],[169,940,2244,838],{"nctId":2464,"briefTitle":2465,"status":107,"phases":6021,"primaryCompletion":2467,"completion":2467,"start":393,"enrollment":1916,"conditions":6022,"interventions":6023},[88],[664],[738,385,168,740,115],{"nctId":731,"briefTitle":732,"status":369,"phases":6025,"primaryCompletion":734,"start":735,"enrollment":486,"conditions":6026,"interventions":6027},[88],[664],[738,739,168,740,290,387],{"trials":6029,"activeCount":99},[],{"trials":6031,"activeCount":99},[],{"trials":6033,"activeCount":99},[6034],{"nctId":2504,"briefTitle":2505,"status":479,"phases":6035,"primaryCompletion":2507,"start":2508,"enrollment":99,"conditions":6036,"interventions":6037},[91],[2510,2511,2512,2314,2325,2328,2513],[894,740,882,42,115],{"intervention":6039,"totalTrials":195,"cells":6040},"White Button Mushroom Extract",{"EARLY_PHASE1":6041,"PHASE1":6043,"PHASE2":6063,"PHASE3":6083,"PHASE4":6085,"NA":6087},{"trials":6042,"activeCount":99},[],{"trials":6044,"activeCount":99},[6045,6055],{"nctId":6046,"briefTitle":6047,"status":107,"phases":6048,"primaryCompletion":6049,"completion":6049,"start":6050,"enrollment":576,"conditions":6051,"interventions":6053},"NCT00709020","White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors",[87],"2010-12","2008-06",[15,6052],"Cancer Survivor",[6054],"white button mushroom extract",{"nctId":6056,"briefTitle":6057,"status":107,"phases":6058,"primaryCompletion":6059,"completion":6059,"start":6060,"enrollment":1610,"conditions":6061,"interventions":6062},"NCT00779168","White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy",[87],"2021-06-10","2009-01-29",[124],[6054],{"trials":6064,"activeCount":214,"soonestReadout":6069},[6065],{"nctId":6066,"briefTitle":6067,"status":130,"phases":6068,"primaryCompletion":6069,"completion":6069,"start":6070,"enrollment":6071,"conditions":6072,"interventions":6082},"NCT04519879","White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA",[88],"2026-05-14","2021-05-10",133,[4825,6073,6074,6075,6076,6077,6078,6079,6080,6081],"PSA Failure","PSA Progression","Recurrent Prostate Carcinoma","Stage I Prostate Cancer AJCC v8","Stage IIA Prostate Cancer AJCC v8","Stage IIB Prostate Cancer AJCC v8","Stage IIC Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8",[6039],{"trials":6084,"activeCount":99},[],{"trials":6086,"activeCount":99},[],{"trials":6088,"activeCount":214,"soonestReadout":2190},[6089],{"nctId":6090,"briefTitle":6091,"status":203,"phases":6092,"primaryCompletion":2190,"completion":2190,"start":6093,"enrollment":25,"conditions":6094,"interventions":6096},"NCT04913064","Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer",[91],"2021-07-27",[6095],"Breast Carcinoma",[6039],{"intervention":1535,"totalTrials":195,"cells":6098},{"EARLY_PHASE1":6099,"PHASE1":6101,"PHASE2":6107,"PHASE3":6117,"PHASE4":6119,"NA":6121},{"trials":6100,"activeCount":99},[],{"trials":6102,"activeCount":99},[6103],{"nctId":3606,"briefTitle":3607,"status":107,"phases":6104,"primaryCompletion":3609,"completion":3609,"start":3610,"enrollment":1945,"conditions":6105,"interventions":6106},[87],[2241,2242],[1256,1535,3613,3614],{"trials":6108,"activeCount":363,"soonestReadout":41},[6109,6113],{"nctId":39,"briefTitle":40,"status":130,"phases":6110,"primaryCompletion":41,"completion":1367,"start":1368,"enrollment":1369,"conditions":6111,"interventions":6112},[88],[1295,1231,32,27,1297,1298,1371,1372],[42,75,1374,894,61,115,1304,1375,1305,1306],{"nctId":44,"briefTitle":45,"status":130,"phases":6114,"primaryCompletion":46,"completion":2815,"start":2816,"enrollment":298,"conditions":6115,"interventions":6116},[88],[32,1298],[42,1374,894,1375],{"trials":6118,"activeCount":99},[],{"trials":6120,"activeCount":99},[],{"trials":6122,"activeCount":99},[6123],{"nctId":1527,"briefTitle":1528,"status":107,"phases":6124,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":207,"conditions":6125,"interventions":6126},[91],[32,27,1298],[738,1233,784,1535,1536,849,850],{"intervention":459,"totalTrials":486,"cells":6128},{"EARLY_PHASE1":6129,"PHASE1":6131,"PHASE2":6153,"PHASE3":6177,"PHASE4":6179,"NA":6181},{"trials":6130,"activeCount":99},[],{"trials":6132,"activeCount":99},[6133,6137,6149],{"nctId":688,"briefTitle":689,"status":107,"phases":6134,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":6135,"interventions":6136},[87],[24],[696,290],{"nctId":6138,"briefTitle":6139,"status":479,"phases":6140,"primaryCompletion":6141,"start":6142,"enrollment":99,"conditions":6143,"interventions":6148},"NCT03117855","Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery",[87],"2019-06","2016-12",[6144,6145,6146,6147],"Bile Duct Adenocarcinoma","Stage III Intrahepatic Cholangiocarcinoma","Stage IVA Intrahepatic Cholangiocarcinoma","Stage IVB Intrahepatic Cholangiocarcinoma",[459],{"nctId":3971,"briefTitle":3972,"status":107,"phases":6150,"primaryCompletion":2859,"completion":2859,"start":122,"conditions":6151,"interventions":6152},[87],[24],[696,271],{"trials":6154,"activeCount":214,"soonestReadout":452},[6155,6159,6169,6173],{"nctId":3995,"briefTitle":3996,"status":369,"phases":6156,"primaryCompletion":109,"completion":109,"start":3998,"enrollment":195,"conditions":6157,"interventions":6158},[88],[3314,4000],[349,459],{"nctId":6160,"briefTitle":6161,"status":369,"phases":6162,"primaryCompletion":6163,"start":6164,"enrollment":1916,"conditions":6165,"interventions":6166},"NCT00538291","Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment",[88],"2009-02","2005-08",[266],[6167,696,274,447,6168,2345],"cetuximab","polymorphism analysis",{"nctId":3344,"briefTitle":3345,"status":107,"phases":6170,"primaryCompletion":3347,"completion":3348,"start":3349,"enrollment":19,"conditions":6171,"interventions":6172},[87,88],[209,1960,3351],[2710,459,169,3353,170],{"nctId":449,"briefTitle":450,"status":203,"phases":6174,"primaryCompletion":452,"completion":452,"start":453,"enrollment":25,"conditions":6175,"interventions":6176},[88],[455,456,457],[412,414,459,305,308,349],{"trials":6178,"activeCount":99},[],{"trials":6180,"activeCount":99},[],{"trials":6182,"activeCount":99},[],{"intervention":2139,"totalTrials":195,"cells":6184},{"EARLY_PHASE1":6185,"PHASE1":6187,"PHASE2":6197,"PHASE3":6207,"PHASE4":6209,"NA":6211},{"trials":6186,"activeCount":99},[],{"trials":6188,"activeCount":99},[6189,6193],{"nctId":2117,"briefTitle":2118,"status":107,"phases":6190,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":2122,"conditions":6191,"interventions":6192},[87],[2124,406,407,323,408,2125,457,2126,2127,2128,2129,2130,2131,409,303,410,2132,335,2133,2134,339,2135,2136,343,2137],[2114,838,2139],{"nctId":2579,"briefTitle":2580,"status":907,"phases":6194,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":404,"conditions":6195,"interventions":6196},[87],[2585,1003,1208,818,1209],[2555,2139,956],{"trials":6198,"activeCount":214,"soonestReadout":4193},[6199,6203],{"nctId":4159,"briefTitle":4160,"status":479,"phases":6200,"primaryCompletion":4162,"completion":4162,"start":4163,"enrollment":99,"conditions":6201,"interventions":6202},[88],[2124,4165,4166,406,407,408,2125,302,457,409,303,410],[412,414,2139],{"nctId":4190,"briefTitle":4191,"status":130,"phases":6204,"primaryCompletion":4193,"completion":4194,"start":4195,"enrollment":19,"conditions":6205,"interventions":6206},[87,88],[4165,300,407,301,302,303],[412,414,2139],{"trials":6208,"activeCount":99},[],{"trials":6210,"activeCount":99},[],{"trials":6212,"activeCount":99},[],{"intervention":6214,"totalTrials":195,"cells":6215},"temozolomide",{"EARLY_PHASE1":6216,"PHASE1":6218,"PHASE2":6245,"PHASE3":6269,"PHASE4":6271,"NA":6273},{"trials":6217,"activeCount":99},[],{"trials":6219,"activeCount":99},[6220,6228,6236],{"nctId":6221,"briefTitle":6222,"status":107,"phases":6223,"primaryCompletion":6163,"completion":6163,"start":6224,"enrollment":36,"conditions":6225,"interventions":6226},"NCT00720564","Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma",[87],"2008-04",[2744],[6227,6214],"arsenic trioxide",{"nctId":6229,"briefTitle":6230,"status":107,"phases":6231,"primaryCompletion":6232,"completion":6232,"start":6233,"enrollment":890,"conditions":6234,"interventions":6235},"NCT00544284","Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment",[87],"2012-01","2005-01",[2744,27,395,24],[1700,6214],{"nctId":6237,"briefTitle":6238,"status":107,"phases":6239,"primaryCompletion":6240,"completion":6241,"start":6242,"enrollment":1632,"conditions":6243,"interventions":6244},"NCT00547131","Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors",[87],"2008-05","2009-05","2006-01",[2744,395],[6214],{"trials":6246,"activeCount":214,"soonestReadout":6251},[6247],{"nctId":6248,"briefTitle":6249,"status":130,"phases":6250,"primaryCompletion":6251,"completion":1450,"start":6252,"enrollment":6253,"conditions":6254,"interventions":6266},"NCT04200443","Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma",[88],"2025-04-04","2020-01-14",96,[6255,6256,6257,6258,6259,6260,6261,6262,6263,6264,6265],"Metastatic Leiomyosarcoma","Metastatic Soft Tissue Sarcoma","Stage III Uterine Corpus Leiomyosarcoma AJCC v8","Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8","Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8","Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8","Stage IV Uterine Corpus Leiomyosarcoma AJCC v8","Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8","Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8","Unresectable Leiomyosarcoma","Unresectable Soft Tissue Sarcoma",[6267,6268],"Cabozantinib","Temozolomide",{"trials":6270,"activeCount":99},[],{"trials":6272,"activeCount":99},[],{"trials":6274,"activeCount":99},[],{"intervention":1257,"totalTrials":283,"cells":6276},{"EARLY_PHASE1":6277,"PHASE1":6279,"PHASE2":6285,"PHASE3":6295,"PHASE4":6297,"NA":6299},{"trials":6278,"activeCount":99},[],{"trials":6280,"activeCount":99},[6281],{"nctId":2844,"briefTitle":2845,"status":107,"phases":6282,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":576,"conditions":6283,"interventions":6284},[87],[972,976,1855,2639,2850],[2852,169,1257,1457,2244,939,2853],{"trials":6286,"activeCount":214,"soonestReadout":1241},[6287,6291],{"nctId":1238,"briefTitle":1239,"status":130,"phases":6288,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":1244,"conditions":6289,"interventions":6290},[88],[1246,1247,1248,1249,1250,1251,1252,1253,1254,1161,1162],[1256,784,346,941,940,1257,938],{"nctId":3305,"briefTitle":3306,"status":369,"phases":6292,"primaryCompletion":3308,"completion":3309,"start":3310,"enrollment":486,"conditions":6293,"interventions":6294},[87,88],[2744,3312,2745,3313,3314,27,3315,879,664,2747,2335],[114,3317,3318,740,447,276],{"trials":6296,"activeCount":99},[],{"trials":6298,"activeCount":99},[],{"trials":6300,"activeCount":99},[],{"intervention":2534,"totalTrials":283,"cells":6302},{"EARLY_PHASE1":6303,"PHASE1":6305,"PHASE2":6320,"PHASE3":6330,"PHASE4":6332,"NA":6334},{"trials":6304,"activeCount":99},[],{"trials":6306,"activeCount":99},[6307,6316],{"nctId":6308,"briefTitle":6309,"status":107,"phases":6310,"primaryCompletion":6311,"completion":6311,"start":6312,"enrollment":283,"conditions":6313,"interventions":6314},"NCT05441514","Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",[87],"2026-03-19","2023-04-28",[1003,818],[6315,2534],"Cobimetinib",{"nctId":2526,"briefTitle":2527,"status":479,"phases":6317,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":99,"conditions":6318,"interventions":6319},[87],[1003],[2533,1212,2534,2535,2536,2537,956],{"trials":6321,"activeCount":214,"soonestReadout":6326},[6322],{"nctId":6323,"briefTitle":6324,"status":203,"phases":6325,"primaryCompletion":6326,"completion":6326,"start":6327,"enrollment":1273,"conditions":6328,"interventions":6329},"NCT03728335","Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation",[88],"2027-01-11","2019-07-11",[18],[2534],{"trials":6331,"activeCount":99},[],{"trials":6333,"activeCount":99},[],{"trials":6335,"activeCount":99},[],{"intervention":6315,"totalTrials":363,"cells":6337},{"EARLY_PHASE1":6338,"PHASE1":6340,"PHASE2":6346,"PHASE3":6361,"PHASE4":6363,"NA":6365},{"trials":6339,"activeCount":99},[],{"trials":6341,"activeCount":99},[6342],{"nctId":6308,"briefTitle":6309,"status":107,"phases":6343,"primaryCompletion":6311,"completion":6311,"start":6312,"enrollment":283,"conditions":6344,"interventions":6345},[87],[1003,818],[6315,2534],{"trials":6347,"activeCount":214,"soonestReadout":6352},[6348],{"nctId":6349,"briefTitle":6350,"status":203,"phases":6351,"primaryCompletion":6352,"completion":6352,"start":6353,"enrollment":33,"conditions":6354,"interventions":6358},"NCT06440850","Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation",[88],"2026-11-22","2024-07-15",[6355,6356,6357],"Thyroid Gland Follicular Carcinoma","Thyroid Gland Oncocytic Carcinoma","Thyroid Gland Papillary Carcinoma",[6315,6359,6360],"Recombinant Thyrotropin Alfa","Vemurafenib",{"trials":6362,"activeCount":99},[],{"trials":6364,"activeCount":99},[],{"trials":6366,"activeCount":99},[],{"intervention":6368,"totalTrials":363,"cells":6369},"Cannabidiol",{"EARLY_PHASE1":6370,"PHASE1":6381,"PHASE2":6383,"PHASE3":6394,"PHASE4":6396,"NA":6398},{"trials":6371,"activeCount":99},[6372],{"nctId":6373,"briefTitle":6374,"status":479,"phases":6375,"primaryCompletion":2048,"completion":2048,"start":6376,"enrollment":99,"conditions":6377,"interventions":6379},"NCT05672342","Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors",[86],"2024-07-06",[6095,6378,1879],"Chemotherapy-Induced Peripheral Neuropathy",[6368,6380],"Delta-8-Tetrahydrocannabinol",{"trials":6382,"activeCount":99},[],{"trials":6384,"activeCount":214,"soonestReadout":6389},[6385],{"nctId":6386,"briefTitle":6387,"status":203,"phases":6388,"primaryCompletion":6389,"completion":6389,"start":6390,"enrollment":5340,"conditions":6391,"interventions":6392},"NCT06731894","Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors",[88],"2028-01-07","2025-10-03",[6095,6378,1879],[6368,6393],"Dronabinol",{"trials":6395,"activeCount":99},[],{"trials":6397,"activeCount":99},[],{"trials":6399,"activeCount":99},[],{"intervention":6401,"totalTrials":363,"cells":6402},"Cemiplimab",{"EARLY_PHASE1":6403,"PHASE1":6405,"PHASE2":6407,"PHASE3":6425,"PHASE4":6427,"NA":6429},{"trials":6404,"activeCount":99},[],{"trials":6406,"activeCount":99},[],{"trials":6408,"activeCount":214,"soonestReadout":6413},[6409,6417],{"nctId":6410,"briefTitle":6411,"status":203,"phases":6412,"primaryCompletion":6413,"completion":6413,"start":6414,"enrollment":264,"conditions":6415,"interventions":6416},"NCT06860815","Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer",[88],"2027-01-30","2026-01-30",[209,210,4739],[6401],{"nctId":6418,"briefTitle":6419,"status":479,"phases":6420,"primaryCompletion":6421,"completion":6421,"start":6422,"enrollment":99,"conditions":6423,"interventions":6424},"NCT05840770","Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer",[88],"2029-10-30","2025-04-15",[501,211,507],[6401],{"trials":6426,"activeCount":99},[],{"trials":6428,"activeCount":99},[],{"trials":6430,"activeCount":99},[],{"intervention":4629,"totalTrials":363,"cells":6432},{"EARLY_PHASE1":6433,"PHASE1":6435,"PHASE2":6437,"PHASE3":6447,"PHASE4":6449,"NA":6451},{"trials":6434,"activeCount":99},[],{"trials":6436,"activeCount":99},[],{"trials":6438,"activeCount":214,"soonestReadout":3458},[6439,6443],{"nctId":4620,"briefTitle":4621,"status":107,"phases":6440,"primaryCompletion":4623,"completion":4624,"start":4625,"enrollment":111,"conditions":6441,"interventions":6442},[87,88],[1103,1102],[4628,2484,4629],{"nctId":3455,"briefTitle":3456,"status":203,"phases":6444,"primaryCompletion":3458,"completion":3458,"start":3459,"enrollment":1945,"conditions":6445,"interventions":6446},[88],[1102,1103],[1354,3373,3462],{"trials":6448,"activeCount":99},[],{"trials":6450,"activeCount":99},[],{"trials":6452,"activeCount":99},[],{"intervention":1804,"totalTrials":363,"cells":6454},{"EARLY_PHASE1":6455,"PHASE1":6457,"PHASE2":6463,"PHASE3":6469,"PHASE4":6471,"NA":6473},{"trials":6456,"activeCount":99},[],{"trials":6458,"activeCount":99},[6459],{"nctId":2338,"briefTitle":2339,"status":107,"phases":6460,"primaryCompletion":2341,"completion":2341,"start":2342,"enrollment":404,"conditions":6461,"interventions":6462},[87],[32,1298],[1804,115,274,2345],{"trials":6464,"activeCount":214,"soonestReadout":1796},[6465],{"nctId":1793,"briefTitle":1794,"status":130,"phases":6466,"primaryCompletion":1796,"completion":1797,"start":1798,"enrollment":1509,"conditions":6467,"interventions":6468},[88],[1800,1801,808,21,1416,1275,1802],[1804,115,1306,1305],{"trials":6470,"activeCount":99},[],{"trials":6472,"activeCount":99},[],{"trials":6474,"activeCount":99},[],{"intervention":3813,"totalTrials":363,"cells":6476},{"EARLY_PHASE1":6477,"PHASE1":6479,"PHASE2":6481,"PHASE3":6495,"PHASE4":6497,"NA":6499},{"trials":6478,"activeCount":99},[],{"trials":6480,"activeCount":99},[],{"trials":6482,"activeCount":214,"soonestReadout":3808},[6483,6487],{"nctId":3805,"briefTitle":3806,"status":130,"phases":6484,"primaryCompletion":3808,"completion":3809,"start":3810,"enrollment":1632,"conditions":6485,"interventions":6486},[88],[1413],[2606,3813,3814],{"nctId":6488,"briefTitle":6489,"status":479,"phases":6490,"primaryCompletion":6491,"completion":6491,"start":6492,"enrollment":99,"conditions":6493,"interventions":6494},"NCT05152459","Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma",[87,88],"2024-12-15","2023-05-01",[973,1856],[4719,3813,3814],{"trials":6496,"activeCount":99},[],{"trials":6498,"activeCount":99},[],{"trials":6500,"activeCount":99},[],{"intervention":3814,"totalTrials":363,"cells":6502},{"EARLY_PHASE1":6503,"PHASE1":6505,"PHASE2":6507,"PHASE3":6517,"PHASE4":6519,"NA":6521},{"trials":6504,"activeCount":99},[],{"trials":6506,"activeCount":99},[],{"trials":6508,"activeCount":214,"soonestReadout":3808},[6509,6513],{"nctId":3805,"briefTitle":3806,"status":130,"phases":6510,"primaryCompletion":3808,"completion":3809,"start":3810,"enrollment":1632,"conditions":6511,"interventions":6512},[88],[1413],[2606,3813,3814],{"nctId":6488,"briefTitle":6489,"status":479,"phases":6514,"primaryCompletion":6491,"completion":6491,"start":6492,"enrollment":99,"conditions":6515,"interventions":6516},[87,88],[973,1856],[4719,3813,3814],{"trials":6518,"activeCount":99},[],{"trials":6520,"activeCount":99},[],{"trials":6522,"activeCount":99},[],{"intervention":1278,"totalTrials":214,"cells":6524},{"EARLY_PHASE1":6525,"PHASE1":6527,"PHASE2":6529,"PHASE3":6535,"PHASE4":6537,"NA":6539},{"trials":6526,"activeCount":99},[],{"trials":6528,"activeCount":99},[],{"trials":6530,"activeCount":214,"soonestReadout":1271},[6531],{"nctId":1268,"briefTitle":1269,"status":203,"phases":6532,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":1273,"conditions":6533,"interventions":6534},[88],[35,18,1275,1231,21,1276],[784,847,849,851,1278],{"trials":6536,"activeCount":99},[],{"trials":6538,"activeCount":99},[],{"trials":6540,"activeCount":99},[],{"intervention":2898,"totalTrials":214,"cells":6542},{"EARLY_PHASE1":6543,"PHASE1":6545,"PHASE2":6547,"PHASE3":6553,"PHASE4":6555,"NA":6557},{"trials":6544,"activeCount":99},[],{"trials":6546,"activeCount":99},[],{"trials":6548,"activeCount":214,"soonestReadout":65},[6549],{"nctId":63,"briefTitle":64,"status":130,"phases":6550,"primaryCompletion":65,"completion":1010,"start":2893,"enrollment":9,"conditions":6551,"interventions":6552},[87,88],[1848,1849,2895,976,2896],[66,2898,2899,939],{"trials":6554,"activeCount":99},[],{"trials":6556,"activeCount":99},[],{"trials":6558,"activeCount":99},[],{"intervention":1937,"totalTrials":214,"cells":6560},{"EARLY_PHASE1":6561,"PHASE1":6563,"PHASE2":6565,"PHASE3":6571,"PHASE4":6573,"NA":6575},{"trials":6562,"activeCount":99},[],{"trials":6564,"activeCount":99},[],{"trials":6566,"activeCount":214,"soonestReadout":403},[6567],{"nctId":1911,"briefTitle":1912,"status":130,"phases":6568,"primaryCompletion":403,"completion":1914,"start":1915,"enrollment":1916,"conditions":6569,"interventions":6570},[87,88],[1918,1919,1920,1921,1922,973,1923,1924,1925,1926,1927,1928,1929,1930,1856,1931,1932,1933,1934,1935],[1480,1937],{"trials":6572,"activeCount":99},[],{"trials":6574,"activeCount":99},[],{"trials":6576,"activeCount":99},[],{"intervention":6578,"totalTrials":214,"cells":6579},"Abemaciclib",{"EARLY_PHASE1":6580,"PHASE1":6582,"PHASE2":6584,"PHASE3":6595,"PHASE4":6597,"NA":6599},{"trials":6581,"activeCount":99},[],{"trials":6583,"activeCount":99},[],{"trials":6585,"activeCount":214,"soonestReadout":6590},[6586],{"nctId":6587,"briefTitle":6588,"status":203,"phases":6589,"primaryCompletion":6590,"completion":6590,"start":6591,"enrollment":2914,"conditions":6592,"interventions":6594},"NCT04305834","Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.",[88],"2026-08-21","2020-03-25",[209,6593,210,3351],"Hormone Receptor Positive Breast Carcinoma",[6578],{"trials":6596,"activeCount":99},[],{"trials":6598,"activeCount":99},[],{"trials":6600,"activeCount":99},[],{"intervention":6602,"totalTrials":214,"cells":6603},"ADT",{"EARLY_PHASE1":6604,"PHASE1":6606,"PHASE2":6608,"PHASE3":6619,"PHASE4":6621,"NA":6623},{"trials":6605,"activeCount":99},[],{"trials":6607,"activeCount":99},[],{"trials":6609,"activeCount":214,"soonestReadout":6614},[6610],{"nctId":6611,"briefTitle":6612,"status":203,"phases":6613,"primaryCompletion":6614,"completion":6614,"start":6615,"enrollment":2625,"conditions":6616,"interventions":6617},"NCT07210086","Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic\u002FProgressive-directed Treatment With Radiotherapy (PROMPT-R)",[88],"2028-05-13","2025-11-26",[124],[6602,6618],"ARSI",{"trials":6620,"activeCount":99},[],{"trials":6622,"activeCount":99},[],{"trials":6624,"activeCount":99},[],{"intervention":6618,"totalTrials":214,"cells":6626},{"EARLY_PHASE1":6627,"PHASE1":6629,"PHASE2":6631,"PHASE3":6637,"PHASE4":6639,"NA":6641},{"trials":6628,"activeCount":99},[],{"trials":6630,"activeCount":99},[],{"trials":6632,"activeCount":214,"soonestReadout":6614},[6633],{"nctId":6611,"briefTitle":6612,"status":203,"phases":6634,"primaryCompletion":6614,"completion":6614,"start":6615,"enrollment":2625,"conditions":6635,"interventions":6636},[88],[124],[6602,6618],{"trials":6638,"activeCount":99},[],{"trials":6640,"activeCount":99},[],{"trials":6642,"activeCount":99},[],{"intervention":6644,"totalTrials":214,"cells":6645},"Megestrol Acetate",{"EARLY_PHASE1":6646,"PHASE1":6648,"PHASE2":6650,"PHASE3":6663,"PHASE4":6665,"NA":6667},{"trials":6647,"activeCount":99},[],{"trials":6649,"activeCount":99},[],{"trials":6651,"activeCount":214,"soonestReadout":6656},[6652],{"nctId":6653,"briefTitle":6654,"status":130,"phases":6655,"primaryCompletion":6656,"completion":2049,"start":6657,"enrollment":3226,"conditions":6658,"interventions":6661},"NCT03671811","Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy",[88],"2022-12-12","2019-01-21",[6659,6660],"Atypical Endometrial Hyperplasia","Endometrial Carcinoma",[6644,6662],"Pterostilbene",{"trials":6664,"activeCount":99},[],{"trials":6666,"activeCount":99},[],{"trials":6668,"activeCount":99},[],{"intervention":6662,"totalTrials":214,"cells":6670},{"EARLY_PHASE1":6671,"PHASE1":6673,"PHASE2":6675,"PHASE3":6681,"PHASE4":6683,"NA":6685},{"trials":6672,"activeCount":99},[],{"trials":6674,"activeCount":99},[],{"trials":6676,"activeCount":214,"soonestReadout":6656},[6677],{"nctId":6653,"briefTitle":6654,"status":130,"phases":6678,"primaryCompletion":6656,"completion":2049,"start":6657,"enrollment":3226,"conditions":6679,"interventions":6680},[88],[6659,6660],[6644,6662],{"trials":6682,"activeCount":99},[],{"trials":6684,"activeCount":99},[],{"trials":6686,"activeCount":99},[],{"intervention":6688,"totalTrials":214,"cells":6689},"Combination Drug Therapy",{"EARLY_PHASE1":6690,"PHASE1":6692,"PHASE2":6694,"PHASE3":6708,"PHASE4":6710,"NA":6712},{"trials":6691,"activeCount":99},[],{"trials":6693,"activeCount":99},[],{"trials":6695,"activeCount":214,"soonestReadout":6700},[6696],{"nctId":6697,"briefTitle":6698,"status":203,"phases":6699,"primaryCompletion":6700,"completion":6700,"start":6701,"enrollment":6702,"conditions":6703,"interventions":6707},"NCT05869682","Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy",[88],"2028-11-30","2024-07-09",210,[6704,1070,6705,6706,1071],"Advanced Prostate Carcinoma","Prostate Carcinoma","Stage III Prostate Cancer AJCC v8",[6688],{"trials":6709,"activeCount":99},[],{"trials":6711,"activeCount":99},[],{"trials":6713,"activeCount":99},[],{"intervention":2230,"totalTrials":214,"cells":6715},{"EARLY_PHASE1":6716,"PHASE1":6718,"PHASE2":6720,"PHASE3":6726,"PHASE4":6728,"NA":6730},{"trials":6717,"activeCount":99},[],{"trials":6719,"activeCount":99},[],{"trials":6721,"activeCount":214,"soonestReadout":2212},[6722],{"nctId":2209,"briefTitle":2210,"status":130,"phases":6723,"primaryCompletion":2212,"completion":2212,"start":2213,"enrollment":2214,"conditions":6724,"interventions":6725},[88],[2216,2217,2218,2219,2220,2221,2222,2223,2018,2224,2225,2226,2227,2228],[2230,1256,2020,346,838,2231],{"trials":6727,"activeCount":99},[],{"trials":6729,"activeCount":99},[],{"trials":6731,"activeCount":99},[],{"intervention":2231,"totalTrials":214,"cells":6733},{"EARLY_PHASE1":6734,"PHASE1":6736,"PHASE2":6738,"PHASE3":6744,"PHASE4":6746,"NA":6748},{"trials":6735,"activeCount":99},[],{"trials":6737,"activeCount":99},[],{"trials":6739,"activeCount":214,"soonestReadout":2212},[6740],{"nctId":2209,"briefTitle":2210,"status":130,"phases":6741,"primaryCompletion":2212,"completion":2212,"start":2213,"enrollment":2214,"conditions":6742,"interventions":6743},[88],[2216,2217,2218,2219,2220,2221,2222,2223,2018,2224,2225,2226,2227,2228],[2230,1256,2020,346,838,2231],{"trials":6745,"activeCount":99},[],{"trials":6747,"activeCount":99},[],{"trials":6749,"activeCount":99},[],{"intervention":6359,"totalTrials":214,"cells":6751},{"EARLY_PHASE1":6752,"PHASE1":6754,"PHASE2":6756,"PHASE3":6762,"PHASE4":6764,"NA":6766},{"trials":6753,"activeCount":99},[],{"trials":6755,"activeCount":99},[],{"trials":6757,"activeCount":214,"soonestReadout":6352},[6758],{"nctId":6349,"briefTitle":6350,"status":203,"phases":6759,"primaryCompletion":6352,"completion":6352,"start":6353,"enrollment":33,"conditions":6760,"interventions":6761},[88],[6355,6356,6357],[6315,6359,6360],{"trials":6763,"activeCount":99},[],{"trials":6765,"activeCount":99},[],{"trials":6767,"activeCount":99},[],{"intervention":6360,"totalTrials":214,"cells":6769},{"EARLY_PHASE1":6770,"PHASE1":6772,"PHASE2":6774,"PHASE3":6780,"PHASE4":6782,"NA":6784},{"trials":6771,"activeCount":99},[],{"trials":6773,"activeCount":99},[],{"trials":6775,"activeCount":214,"soonestReadout":6352},[6776],{"nctId":6349,"briefTitle":6350,"status":203,"phases":6777,"primaryCompletion":6352,"completion":6352,"start":6353,"enrollment":33,"conditions":6778,"interventions":6779},[88],[6355,6356,6357],[6315,6359,6360],{"trials":6781,"activeCount":99},[],{"trials":6783,"activeCount":99},[],{"trials":6785,"activeCount":99},[],{"intervention":1975,"totalTrials":214,"cells":6787},{"EARLY_PHASE1":6788,"PHASE1":6790,"PHASE2":6792,"PHASE3":6798,"PHASE4":6800,"NA":6802},{"trials":6789,"activeCount":99},[],{"trials":6791,"activeCount":99},[],{"trials":6793,"activeCount":214,"soonestReadout":1968},[6794],{"nctId":1965,"briefTitle":1966,"status":294,"phases":6795,"primaryCompletion":1968,"completion":1968,"start":1943,"enrollment":1969,"conditions":6796,"interventions":6797},[88],[1971,1972,1973,1049,1052],[1975,1480],{"trials":6799,"activeCount":99},[],{"trials":6801,"activeCount":99},[],{"trials":6803,"activeCount":99},[],{"intervention":6805,"totalTrials":214,"cells":6806},"Denosumab",{"EARLY_PHASE1":6807,"PHASE1":6809,"PHASE2":6811,"PHASE3":6821,"PHASE4":6823,"NA":6825},{"trials":6808,"activeCount":99},[],{"trials":6810,"activeCount":99},[],{"trials":6812,"activeCount":214,"soonestReadout":6817},[6813],{"nctId":6814,"briefTitle":6815,"status":203,"phases":6816,"primaryCompletion":6817,"completion":6817,"start":6818,"enrollment":2480,"conditions":6819,"interventions":6820},"NCT06524960","Denosumab for Type 1 Diabetes",[87,88],"2027-10-11","2024-09-03",[5342],[6805],{"trials":6822,"activeCount":99},[],{"trials":6824,"activeCount":99},[],{"trials":6826,"activeCount":99},[],{"intervention":6828,"totalTrials":214,"cells":6829},"BRC-001",{"EARLY_PHASE1":6830,"PHASE1":6832,"PHASE2":6834,"PHASE3":6849,"PHASE4":6851,"NA":6853},{"trials":6831,"activeCount":99},[],{"trials":6833,"activeCount":99},[],{"trials":6835,"activeCount":214,"soonestReadout":6840},[6836],{"nctId":6837,"briefTitle":6838,"status":203,"phases":6839,"primaryCompletion":6840,"completion":6840,"start":6841,"enrollment":1610,"conditions":6842,"interventions":6848},"NCT06538389","High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer",[88],"2027-01-24","2024-08-26",[6843,774,775,6844,145,6845,6846,6847],"Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Breast Ductal Carcinoma In Situ","Estrogen Receptor-Positive Breast Carcinoma","Progesterone Receptor-Positive Breast Carcinoma",[6828],{"trials":6850,"activeCount":99},[],{"trials":6852,"activeCount":99},[],{"trials":6854,"activeCount":99},[],{"intervention":5706,"totalTrials":214,"cells":6856},{"EARLY_PHASE1":6857,"PHASE1":6859,"PHASE2":6861,"PHASE3":6867,"PHASE4":6869,"NA":6871},{"trials":6858,"activeCount":99},[],{"trials":6860,"activeCount":99},[],{"trials":6862,"activeCount":214,"soonestReadout":5698},[6863],{"nctId":5695,"briefTitle":5696,"status":203,"phases":6864,"primaryCompletion":5698,"completion":5698,"start":5699,"enrollment":911,"conditions":6865,"interventions":6866},[88],[972,5701,5702,1855,5703,5704],[5706,543],{"trials":6868,"activeCount":99},[],{"trials":6870,"activeCount":99},[],{"trials":6872,"activeCount":99},[],{"intervention":6874,"totalTrials":214,"cells":6875},"C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03",{"EARLY_PHASE1":6876,"PHASE1":6878,"PHASE2":6880,"PHASE3":6891,"PHASE4":6893,"NA":6895},{"trials":6877,"activeCount":99},[],{"trials":6879,"activeCount":99},[],{"trials":6881,"activeCount":214,"soonestReadout":6886},[6882],{"nctId":6883,"briefTitle":6884,"status":294,"phases":6885,"primaryCompletion":6886,"completion":6886,"start":6887,"enrollment":3027,"conditions":6888,"interventions":6889},"NCT07578025","Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy",[88],"2028-06-24","2026-11-28",[2174,1052],[6874,6890],"Zanzalintinib",{"trials":6892,"activeCount":99},[],{"trials":6894,"activeCount":99},[],{"trials":6896,"activeCount":99},[],{"intervention":6890,"totalTrials":214,"cells":6898},{"EARLY_PHASE1":6899,"PHASE1":6901,"PHASE2":6903,"PHASE3":6909,"PHASE4":6911,"NA":6913},{"trials":6900,"activeCount":99},[],{"trials":6902,"activeCount":99},[],{"trials":6904,"activeCount":214,"soonestReadout":6886},[6905],{"nctId":6883,"briefTitle":6884,"status":294,"phases":6906,"primaryCompletion":6886,"completion":6886,"start":6887,"enrollment":3027,"conditions":6907,"interventions":6908},[88],[2174,1052],[6874,6890],{"trials":6910,"activeCount":99},[],{"trials":6912,"activeCount":99},[],{"trials":6914,"activeCount":99},[],{"intervention":6267,"totalTrials":214,"cells":6916},{"EARLY_PHASE1":6917,"PHASE1":6919,"PHASE2":6921,"PHASE3":6927,"PHASE4":6929,"NA":6931},{"trials":6918,"activeCount":99},[],{"trials":6920,"activeCount":99},[],{"trials":6922,"activeCount":214,"soonestReadout":6251},[6923],{"nctId":6248,"briefTitle":6249,"status":130,"phases":6924,"primaryCompletion":6251,"completion":1450,"start":6252,"enrollment":6253,"conditions":6925,"interventions":6926},[88],[6255,6256,6257,6258,6259,6260,6261,6262,6263,6264,6265],[6267,6268],{"trials":6928,"activeCount":99},[],{"trials":6930,"activeCount":99},[],{"trials":6932,"activeCount":99},[],{"intervention":5779,"totalTrials":214,"cells":6934},{"EARLY_PHASE1":6935,"PHASE1":6937,"PHASE2":6939,"PHASE3":6945,"PHASE4":6947,"NA":6949},{"trials":6936,"activeCount":99},[],{"trials":6938,"activeCount":99},[],{"trials":6940,"activeCount":214,"soonestReadout":5774},[6941],{"nctId":5771,"briefTitle":5772,"status":130,"phases":6942,"primaryCompletion":5774,"completion":5774,"start":5775,"enrollment":207,"conditions":6943,"interventions":6944},[88],[5777],[5762,5779,5780],{"trials":6946,"activeCount":99},[],{"trials":6948,"activeCount":99},[],{"trials":6950,"activeCount":99},[],{"intervention":6952,"totalTrials":214,"cells":6953},"Talquetamab",{"EARLY_PHASE1":6954,"PHASE1":6956,"PHASE2":6958,"PHASE3":6970,"PHASE4":6972,"NA":6974},{"trials":6955,"activeCount":99},[],{"trials":6957,"activeCount":99},[],{"trials":6959,"activeCount":214,"soonestReadout":6964},[6960],{"nctId":6961,"briefTitle":6962,"status":203,"phases":6963,"primaryCompletion":6964,"completion":6964,"start":6965,"enrollment":404,"conditions":6966,"interventions":6969},"NCT06572605","External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease",[87,88],"2030-01-18","2025-08-29",[6967,6968],"Extramedullary Disease in Multiple Myeloma","Multiple Myeloma",[6952],{"trials":6971,"activeCount":99},[],{"trials":6973,"activeCount":99},[],{"trials":6975,"activeCount":99},[],{"intervention":3102,"totalTrials":214,"cells":6977},{"EARLY_PHASE1":6978,"PHASE1":6980,"PHASE2":6982,"PHASE3":6988,"PHASE4":6990,"NA":6992},{"trials":6979,"activeCount":99},[],{"trials":6981,"activeCount":99},[],{"trials":6983,"activeCount":214,"soonestReadout":3094},[6984],{"nctId":3091,"briefTitle":3092,"status":203,"phases":6985,"primaryCompletion":3094,"completion":3095,"start":3096,"enrollment":3097,"conditions":6986,"interventions":6987},[88],[35,18,2102,3099,3100,1412,21,3036,1276,3035],[1441,3102,3005,3103],{"trials":6989,"activeCount":99},[],{"trials":6991,"activeCount":99},[],{"trials":6993,"activeCount":99},[],{"intervention":3103,"totalTrials":214,"cells":6995},{"EARLY_PHASE1":6996,"PHASE1":6998,"PHASE2":7000,"PHASE3":7006,"PHASE4":7008,"NA":7010},{"trials":6997,"activeCount":99},[],{"trials":6999,"activeCount":99},[],{"trials":7001,"activeCount":214,"soonestReadout":3094},[7002],{"nctId":3091,"briefTitle":3092,"status":203,"phases":7003,"primaryCompletion":3094,"completion":3095,"start":3096,"enrollment":3097,"conditions":7004,"interventions":7005},[88],[35,18,2102,3099,3100,1412,21,3036,1276,3035],[1441,3102,3005,3103],{"trials":7007,"activeCount":99},[],{"trials":7009,"activeCount":99},[],{"trials":7011,"activeCount":99},[],{"intervention":5346,"totalTrials":214,"cells":7013},{"EARLY_PHASE1":7014,"PHASE1":7016,"PHASE2":7018,"PHASE3":7024,"PHASE4":7026,"NA":7028},{"trials":7015,"activeCount":99},[],{"trials":7017,"activeCount":99},[],{"trials":7019,"activeCount":214,"soonestReadout":5337},[7020],{"nctId":5334,"briefTitle":5335,"status":203,"phases":7021,"primaryCompletion":5337,"completion":5338,"start":5339,"enrollment":5340,"conditions":7022,"interventions":7023},[87,88],[5342,5343],[5345,5346,5347],{"trials":7025,"activeCount":99},[],{"trials":7027,"activeCount":99},[],{"trials":7029,"activeCount":99},[],{"intervention":5347,"totalTrials":214,"cells":7031},{"EARLY_PHASE1":7032,"PHASE1":7034,"PHASE2":7036,"PHASE3":7042,"PHASE4":7044,"NA":7046},{"trials":7033,"activeCount":99},[],{"trials":7035,"activeCount":99},[],{"trials":7037,"activeCount":214,"soonestReadout":5337},[7038],{"nctId":5334,"briefTitle":5335,"status":203,"phases":7039,"primaryCompletion":5337,"completion":5338,"start":5339,"enrollment":5340,"conditions":7040,"interventions":7041},[87,88],[5342,5343],[5345,5346,5347],{"trials":7043,"activeCount":99},[],{"trials":7045,"activeCount":99},[],{"trials":7047,"activeCount":99},[],{"intervention":6393,"totalTrials":214,"cells":7049},{"EARLY_PHASE1":7050,"PHASE1":7052,"PHASE2":7054,"PHASE3":7060,"PHASE4":7062,"NA":7064},{"trials":7051,"activeCount":99},[],{"trials":7053,"activeCount":99},[],{"trials":7055,"activeCount":214,"soonestReadout":6389},[7056],{"nctId":6386,"briefTitle":6387,"status":203,"phases":7057,"primaryCompletion":6389,"completion":6389,"start":6390,"enrollment":5340,"conditions":7058,"interventions":7059},[88],[6095,6378,1879],[6368,6393],{"trials":7061,"activeCount":99},[],{"trials":7063,"activeCount":99},[],{"trials":7065,"activeCount":99},[],{"intervention":7067,"totalTrials":214,"cells":7068},"Mogamulizumab",{"EARLY_PHASE1":7069,"PHASE1":7071,"PHASE2":7073,"PHASE3":7089,"PHASE4":7091,"NA":7093},{"trials":7070,"activeCount":99},[],{"trials":7072,"activeCount":99},[],{"trials":7074,"activeCount":214,"soonestReadout":7079},[7075],{"nctId":7076,"briefTitle":7077,"status":203,"phases":7078,"primaryCompletion":7079,"completion":7079,"start":7080,"enrollment":3027,"conditions":7081,"interventions":7088},"NCT04930653","Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma",[88],"2028-06-15","2022-10-19",[3623,7082,3626,7083,7084,7085,7086,7087],"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8","Transformed Mycosis Fungoides",[7067],{"trials":7090,"activeCount":99},[],{"trials":7092,"activeCount":99},[],{"trials":7094,"activeCount":99},[],{"intervention":666,"totalTrials":214,"cells":7096},{"EARLY_PHASE1":7097,"PHASE1":7099,"PHASE2":7101,"PHASE3":7107,"PHASE4":7109,"NA":7111},{"trials":7098,"activeCount":99},[],{"trials":7100,"activeCount":99},[],{"trials":7102,"activeCount":214,"soonestReadout":656},[7103],{"nctId":653,"briefTitle":654,"status":203,"phases":7104,"primaryCompletion":656,"completion":656,"start":657,"enrollment":298,"conditions":7105,"interventions":7106},[88],[538,659,660,661,662,663,664],[666,348],{"trials":7108,"activeCount":99},[],{"trials":7110,"activeCount":99},[],{"trials":7112,"activeCount":99},[],{"intervention":2641,"totalTrials":214,"cells":7114},{"EARLY_PHASE1":7115,"PHASE1":7117,"PHASE2":7119,"PHASE3":7125,"PHASE4":7127,"NA":7129},{"trials":7116,"activeCount":99},[],{"trials":7118,"activeCount":99},[],{"trials":7120,"activeCount":214,"soonestReadout":2636},[7121],{"nctId":2633,"briefTitle":2634,"status":130,"phases":7122,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":9,"conditions":7123,"interventions":7124},[87,88],[976,2639],[2641,956],{"trials":7126,"activeCount":99},[],{"trials":7128,"activeCount":99},[],{"trials":7130,"activeCount":99},[],{"intervention":3770,"totalTrials":214,"cells":7132},{"EARLY_PHASE1":7133,"PHASE1":7135,"PHASE2":7137,"PHASE3":7143,"PHASE4":7145,"NA":7147},{"trials":7134,"activeCount":99},[],{"trials":7136,"activeCount":99},[],{"trials":7138,"activeCount":214,"soonestReadout":3763},[7139],{"nctId":3760,"briefTitle":3761,"status":203,"phases":7140,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":7141,"interventions":7142},[88],[3767,3768,1071,1072,1073],[3770,51,3771,3772,3773,938,3774],{"trials":7144,"activeCount":99},[],{"trials":7146,"activeCount":99},[],{"trials":7148,"activeCount":99},[],{"intervention":3774,"totalTrials":214,"cells":7150},{"EARLY_PHASE1":7151,"PHASE1":7153,"PHASE2":7155,"PHASE3":7161,"PHASE4":7163,"NA":7165},{"trials":7152,"activeCount":99},[],{"trials":7154,"activeCount":99},[],{"trials":7156,"activeCount":214,"soonestReadout":3763},[7157],{"nctId":3760,"briefTitle":3761,"status":203,"phases":7158,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":7159,"interventions":7160},[88],[3767,3768,1071,1072,1073],[3770,51,3771,3772,3773,938,3774],{"trials":7162,"activeCount":99},[],{"trials":7164,"activeCount":99},[],{"trials":7166,"activeCount":99},[],{"intervention":540,"totalTrials":214,"cells":7168},{"EARLY_PHASE1":7169,"PHASE1":7171,"PHASE2":7173,"PHASE3":7179,"PHASE4":7181,"NA":7183},{"trials":7170,"activeCount":99},[],{"trials":7172,"activeCount":99},[],{"trials":7174,"activeCount":214,"soonestReadout":534},[7175],{"nctId":531,"briefTitle":532,"status":203,"phases":7176,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":7177,"interventions":7178},[88],[538,505,507],[540,541,542,413,543,544,545],{"trials":7180,"activeCount":99},[],{"trials":7182,"activeCount":99},[],{"trials":7184,"activeCount":99},[],{"intervention":541,"totalTrials":214,"cells":7186},{"EARLY_PHASE1":7187,"PHASE1":7189,"PHASE2":7191,"PHASE3":7197,"PHASE4":7199,"NA":7201},{"trials":7188,"activeCount":99},[],{"trials":7190,"activeCount":99},[],{"trials":7192,"activeCount":214,"soonestReadout":534},[7193],{"nctId":531,"briefTitle":532,"status":203,"phases":7194,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":7195,"interventions":7196},[88],[538,505,507],[540,541,542,413,543,544,545],{"trials":7198,"activeCount":99},[],{"trials":7200,"activeCount":99},[],{"trials":7202,"activeCount":99},[],{"intervention":542,"totalTrials":214,"cells":7204},{"EARLY_PHASE1":7205,"PHASE1":7207,"PHASE2":7209,"PHASE3":7215,"PHASE4":7217,"NA":7219},{"trials":7206,"activeCount":99},[],{"trials":7208,"activeCount":99},[],{"trials":7210,"activeCount":214,"soonestReadout":534},[7211],{"nctId":531,"briefTitle":532,"status":203,"phases":7212,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":7213,"interventions":7214},[88],[538,505,507],[540,541,542,413,543,544,545],{"trials":7216,"activeCount":99},[],{"trials":7218,"activeCount":99},[],{"trials":7220,"activeCount":99},[],{"intervention":7222,"totalTrials":214,"cells":7223},"F-18 16 Alpha-Fluoroestradiol",{"EARLY_PHASE1":7224,"PHASE1":7226,"PHASE2":7228,"PHASE3":7238,"PHASE4":7240,"NA":7242},{"trials":7225,"activeCount":99},[],{"trials":7227,"activeCount":99},[],{"trials":7229,"activeCount":214,"soonestReadout":7234},[7230],{"nctId":7231,"briefTitle":7232,"status":203,"phases":7233,"primaryCompletion":7234,"completion":7234,"start":7235,"enrollment":36,"conditions":7236,"interventions":7237},"NCT06260033","Stereotactic Body Radiation Therapy and FES PET\u002FCT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer",[88],"2026-10-29","2024-07-23",[209,6846,210],[7222],{"trials":7239,"activeCount":99},[],{"trials":7241,"activeCount":99},[],{"trials":7243,"activeCount":99},[],{"intervention":2807,"totalTrials":214,"cells":7245},{"EARLY_PHASE1":7246,"PHASE1":7248,"PHASE2":7250,"PHASE3":7256,"PHASE4":7258,"NA":7260},{"trials":7247,"activeCount":99},[],{"trials":7249,"activeCount":99},[],{"trials":7251,"activeCount":214,"soonestReadout":2803},[7252],{"nctId":2800,"briefTitle":2801,"status":203,"phases":7253,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":919,"conditions":7254,"interventions":7255},[88],[2241,2242],[2378,2299,1131,940,2807,2808,2298],{"trials":7257,"activeCount":99},[],{"trials":7259,"activeCount":99},[],{"trials":7261,"activeCount":99},[],{"intervention":2054,"totalTrials":214,"cells":7263},{"EARLY_PHASE1":7264,"PHASE1":7266,"PHASE2":7268,"PHASE3":7274,"PHASE4":7276,"NA":7278},{"trials":7265,"activeCount":99},[],{"trials":7267,"activeCount":99},[],{"trials":7269,"activeCount":214,"soonestReadout":2048},[7270],{"nctId":2045,"briefTitle":2046,"status":130,"phases":7271,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":7272,"interventions":7273},[88],[210,1961],[2054,2055,2056,1480],{"trials":7275,"activeCount":99},[],{"trials":7277,"activeCount":99},[],{"trials":7279,"activeCount":99},[],{"intervention":2056,"totalTrials":214,"cells":7281},{"EARLY_PHASE1":7282,"PHASE1":7284,"PHASE2":7286,"PHASE3":7292,"PHASE4":7294,"NA":7296},{"trials":7283,"activeCount":99},[],{"trials":7285,"activeCount":99},[],{"trials":7287,"activeCount":214,"soonestReadout":2048},[7288],{"nctId":2045,"briefTitle":2046,"status":130,"phases":7289,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":7290,"interventions":7291},[88],[210,1961],[2054,2055,2056,1480],{"trials":7293,"activeCount":99},[],{"trials":7295,"activeCount":99},[],{"trials":7297,"activeCount":99},[],{"intervention":1458,"totalTrials":214,"cells":7299},{"EARLY_PHASE1":7300,"PHASE1":7302,"PHASE2":7304,"PHASE3":7310,"PHASE4":7312,"NA":7314},{"trials":7301,"activeCount":99},[],{"trials":7303,"activeCount":99},[],{"trials":7305,"activeCount":214,"soonestReadout":1450},[7306],{"nctId":1447,"briefTitle":1448,"status":203,"phases":7307,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":404,"conditions":7308,"interventions":7309},[88],[1453,1454,1455],[784,847,1457,1458,838],{"trials":7311,"activeCount":99},[],{"trials":7313,"activeCount":99},[],{"trials":7315,"activeCount":99},[],{"intervention":5493,"totalTrials":214,"cells":7317},{"EARLY_PHASE1":7318,"PHASE1":7320,"PHASE2":7322,"PHASE3":7328,"PHASE4":7330,"NA":7332},{"trials":7319,"activeCount":99},[],{"trials":7321,"activeCount":99},[],{"trials":7323,"activeCount":214,"soonestReadout":4672},[7324],{"nctId":5481,"briefTitle":5482,"status":203,"phases":7325,"primaryCompletion":4672,"completion":4672,"start":5484,"enrollment":1610,"conditions":7326,"interventions":7327},[88],[972,5486,5487,5488,1453,2919,1855,5489,5490,5491,1454,2923],[5493,5464],{"trials":7329,"activeCount":99},[],{"trials":7331,"activeCount":99},[],{"trials":7333,"activeCount":99},[],{"intervention":7335,"totalTrials":214,"cells":7336},"Antiandrogen Therapy",{"EARLY_PHASE1":7337,"PHASE1":7339,"PHASE2":7341,"PHASE3":7353,"PHASE4":7355,"NA":7357},{"trials":7338,"activeCount":99},[],{"trials":7340,"activeCount":99},[],{"trials":7342,"activeCount":214,"soonestReadout":7347},[7343],{"nctId":7344,"briefTitle":7345,"status":203,"phases":7346,"primaryCompletion":7347,"completion":7347,"start":7348,"enrollment":1361,"conditions":7349,"interventions":7350},"NCT07202247","Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial",[88],"2028-04-09","2026-01-23",[6705,6075],[7335,7351,7352],"Semaglutide","Tirzepatide",{"trials":7354,"activeCount":99},[],{"trials":7356,"activeCount":99},[],{"trials":7358,"activeCount":99},[],{"intervention":7351,"totalTrials":214,"cells":7360},{"EARLY_PHASE1":7361,"PHASE1":7363,"PHASE2":7365,"PHASE3":7371,"PHASE4":7373,"NA":7375},{"trials":7362,"activeCount":99},[],{"trials":7364,"activeCount":99},[],{"trials":7366,"activeCount":214,"soonestReadout":7347},[7367],{"nctId":7344,"briefTitle":7345,"status":203,"phases":7368,"primaryCompletion":7347,"completion":7347,"start":7348,"enrollment":1361,"conditions":7369,"interventions":7370},[88],[6705,6075],[7335,7351,7352],{"trials":7372,"activeCount":99},[],{"trials":7374,"activeCount":99},[],{"trials":7376,"activeCount":99},[],{"intervention":7352,"totalTrials":214,"cells":7378},{"EARLY_PHASE1":7379,"PHASE1":7381,"PHASE2":7383,"PHASE3":7389,"PHASE4":7391,"NA":7393},{"trials":7380,"activeCount":99},[],{"trials":7382,"activeCount":99},[],{"trials":7384,"activeCount":214,"soonestReadout":7347},[7385],{"nctId":7344,"briefTitle":7345,"status":203,"phases":7386,"primaryCompletion":7347,"completion":7347,"start":7348,"enrollment":1361,"conditions":7387,"interventions":7388},[88],[6705,6075],[7335,7351,7352],{"trials":7390,"activeCount":99},[],{"trials":7392,"activeCount":99},[],{"trials":7394,"activeCount":99},[],{"intervention":1490,"totalTrials":214,"cells":7396},{"EARLY_PHASE1":7397,"PHASE1":7399,"PHASE2":7401,"PHASE3":7407,"PHASE4":7409,"NA":7411},{"trials":7398,"activeCount":99},[],{"trials":7400,"activeCount":99},[],{"trials":7402,"activeCount":214,"soonestReadout":1485},[7403],{"nctId":1482,"briefTitle":1483,"status":130,"phases":7404,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":404,"conditions":7405,"interventions":7406},[88],[35,18,1275,21,1276,1488,845],[784,1490,851],{"trials":7408,"activeCount":99},[],{"trials":7410,"activeCount":99},[],{"trials":7412,"activeCount":99},[],{"intervention":194,"totalTrials":214,"cells":7414},{"EARLY_PHASE1":7415,"PHASE1":7417,"PHASE2":7419,"PHASE3":7425,"PHASE4":7427,"NA":7429},{"trials":7416,"activeCount":99},[],{"trials":7418,"activeCount":99},[],{"trials":7420,"activeCount":214,"soonestReadout":185},[7421],{"nctId":182,"briefTitle":183,"status":130,"phases":7422,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":7423,"interventions":7424},[88],[190,191,192],[194,160],{"trials":7426,"activeCount":99},[],{"trials":7428,"activeCount":99},[],{"trials":7430,"activeCount":99},[],{"intervention":2993,"totalTrials":214,"cells":7432},{"EARLY_PHASE1":7433,"PHASE1":7435,"PHASE2":7437,"PHASE3":7443,"PHASE4":7445,"NA":7447},{"trials":7434,"activeCount":99},[],{"trials":7436,"activeCount":99},[],{"trials":7438,"activeCount":214,"soonestReadout":2989},[7439],{"nctId":2986,"briefTitle":2987,"status":294,"phases":7440,"primaryCompletion":2989,"completion":2989,"start":2990,"enrollment":785,"conditions":7441,"interventions":7442},[87,88],[976,2639],[2993,939],{"trials":7444,"activeCount":99},[],{"trials":7446,"activeCount":99},[],{"trials":7448,"activeCount":99},[],{"intervention":7450,"totalTrials":214,"cells":7451},"Sturlimogene Erparepvec",{"EARLY_PHASE1":7452,"PHASE1":7454,"PHASE2":7456,"PHASE3":7467,"PHASE4":7469,"NA":7471},{"trials":7453,"activeCount":99},[],{"trials":7455,"activeCount":99},[],{"trials":7457,"activeCount":214,"soonestReadout":7462},[7458],{"nctId":7459,"briefTitle":7460,"status":294,"phases":7461,"primaryCompletion":7462,"completion":7462,"start":163,"enrollment":1273,"conditions":7463,"interventions":7465},"NCT07218692","RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy",[88],"2027-08-11",[2172,2162,2173,2174,1045,2175,7464,1049,1052],"Recurrent Renal Cell Carcinoma",[7450,7466],"Tivozanib",{"trials":7468,"activeCount":99},[],{"trials":7470,"activeCount":99},[],{"trials":7472,"activeCount":99},[],{"intervention":7466,"totalTrials":214,"cells":7474},{"EARLY_PHASE1":7475,"PHASE1":7477,"PHASE2":7479,"PHASE3":7485,"PHASE4":7487,"NA":7489},{"trials":7476,"activeCount":99},[],{"trials":7478,"activeCount":99},[],{"trials":7480,"activeCount":214,"soonestReadout":7462},[7481],{"nctId":7459,"briefTitle":7460,"status":294,"phases":7482,"primaryCompletion":7462,"completion":7462,"start":163,"enrollment":1273,"conditions":7483,"interventions":7484},[88],[2172,2162,2173,2174,1045,2175,7464,1049,1052],[7450,7466],{"trials":7486,"activeCount":99},[],{"trials":7488,"activeCount":99},[],{"trials":7490,"activeCount":99},[],{"intervention":7492,"totalTrials":214,"cells":7493},"therapeutic estradiol",{"EARLY_PHASE1":7494,"PHASE1":7496,"PHASE2":7498,"PHASE3":7513,"PHASE4":7515,"NA":7517},{"trials":7495,"activeCount":99},[],{"trials":7497,"activeCount":99},[],{"trials":7499,"activeCount":214,"soonestReadout":7504},[7500],{"nctId":7501,"briefTitle":7502,"status":130,"phases":7503,"primaryCompletion":7504,"completion":7505,"start":7506,"enrollment":264,"conditions":7507,"interventions":7510},"NCT00080756","Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease",[88],"2024-09-15","2024-10-15","2004-03-11",[7508,7509,15],"brca1 Mutation Carrier","brca2 Mutation Carrier",[7492,7511,7512],"deslorelin","therapeutic testosterone",{"trials":7514,"activeCount":99},[],{"trials":7516,"activeCount":99},[],{"trials":7518,"activeCount":99},[],{"intervention":7511,"totalTrials":214,"cells":7520},{"EARLY_PHASE1":7521,"PHASE1":7523,"PHASE2":7525,"PHASE3":7531,"PHASE4":7533,"NA":7535},{"trials":7522,"activeCount":99},[],{"trials":7524,"activeCount":99},[],{"trials":7526,"activeCount":214,"soonestReadout":7504},[7527],{"nctId":7501,"briefTitle":7502,"status":130,"phases":7528,"primaryCompletion":7504,"completion":7505,"start":7506,"enrollment":264,"conditions":7529,"interventions":7530},[88],[7508,7509,15],[7492,7511,7512],{"trials":7532,"activeCount":99},[],{"trials":7534,"activeCount":99},[],{"trials":7536,"activeCount":99},[],{"intervention":7512,"totalTrials":214,"cells":7538},{"EARLY_PHASE1":7539,"PHASE1":7541,"PHASE2":7543,"PHASE3":7549,"PHASE4":7551,"NA":7553},{"trials":7540,"activeCount":99},[],{"trials":7542,"activeCount":99},[],{"trials":7544,"activeCount":214,"soonestReadout":7504},[7545],{"nctId":7501,"briefTitle":7502,"status":130,"phases":7546,"primaryCompletion":7504,"completion":7505,"start":7506,"enrollment":264,"conditions":7547,"interventions":7548},[88],[7508,7509,15],[7492,7511,7512],{"trials":7550,"activeCount":99},[],{"trials":7552,"activeCount":99},[],{"trials":7554,"activeCount":99},[],{"intervention":893,"totalTrials":95,"cells":7556},{"EARLY_PHASE1":7557,"PHASE1":7559,"PHASE2":7577,"PHASE3":7591,"PHASE4":7597,"NA":7599},{"trials":7558,"activeCount":99},[],{"trials":7560,"activeCount":99},[7561,7565,7569,7573],{"nctId":885,"briefTitle":886,"status":107,"phases":7562,"primaryCompletion":888,"completion":888,"start":889,"enrollment":890,"conditions":7563,"interventions":7564},[87],[27],[893,75,894],{"nctId":2287,"briefTitle":2288,"status":107,"phases":7566,"primaryCompletion":2290,"completion":2291,"start":2292,"enrollment":404,"conditions":7567,"interventions":7568},[87],[1161,2294,1932,2295,2296],[2298,2299,940,1131,849],{"nctId":1087,"briefTitle":1088,"status":107,"phases":7570,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":498,"conditions":7571,"interventions":7572},[87],[27],[1094,893,75,894],{"nctId":2381,"briefTitle":2382,"status":107,"phases":7574,"primaryCompletion":2384,"completion":2385,"start":2386,"enrollment":890,"conditions":7575,"interventions":7576},[87],[2388],[2390,893,894,2391,115,2392],{"trials":7578,"activeCount":214,"soonestReadout":2803},[7579,7583,7587],{"nctId":2396,"briefTitle":2397,"status":107,"phases":7580,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":2401,"conditions":7581,"interventions":7582},[88],[27],[1775,893,2391,894,115],{"nctId":1356,"briefTitle":1357,"status":107,"phases":7584,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":7585,"interventions":7586},[88],[27],[893,75,894,1364],{"nctId":2800,"briefTitle":2801,"status":203,"phases":7588,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":919,"conditions":7589,"interventions":7590},[88],[2241,2242],[2378,2299,1131,940,2807,2808,2298],{"trials":7592,"activeCount":99},[7593],{"nctId":2488,"briefTitle":2489,"status":369,"phases":7594,"primaryCompletion":2491,"completion":2491,"start":2492,"enrollment":283,"conditions":7595,"interventions":7596},[89],[972,1855],[2299,940,1131,849,939],{"trials":7598,"activeCount":99},[],{"trials":7600,"activeCount":99},[7601],{"nctId":1519,"briefTitle":1520,"status":107,"phases":7602,"primaryCompletion":1522,"completion":1522,"start":1523,"enrollment":298,"conditions":7603,"interventions":7604},[91],[27],[738,893,75,894,115],{"intervention":2055,"totalTrials":283,"cells":7606},{"EARLY_PHASE1":7607,"PHASE1":7609,"PHASE2":7611,"PHASE3":7621,"PHASE4":7623,"NA":7625},{"trials":7608,"activeCount":99},[],{"trials":7610,"activeCount":99},[],{"trials":7612,"activeCount":214,"soonestReadout":2048},[7613,7617],{"nctId":2045,"briefTitle":2046,"status":130,"phases":7614,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":7615,"interventions":7616},[88],[210,1961],[2054,2055,2056,1480],{"nctId":2071,"briefTitle":2072,"status":107,"phases":7618,"primaryCompletion":2074,"completion":2075,"start":2076,"enrollment":298,"conditions":7619,"interventions":7620},[88],[1880,2078,1883,1887,2079,144,1891],[2081,941,2082,2055,1480],{"trials":7622,"activeCount":99},[],{"trials":7624,"activeCount":99},[],{"trials":7626,"activeCount":99},[7627],{"nctId":7628,"briefTitle":7629,"status":107,"phases":7630,"primaryCompletion":2341,"completion":2341,"start":3358,"enrollment":1509,"conditions":7631,"interventions":7632},"NCT00681928","Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy",[],[15],[7633,7634],"anastrozole","letrozole",{"intervention":385,"totalTrials":1632,"cells":7636},{"EARLY_PHASE1":7637,"PHASE1":7639,"PHASE2":7692,"PHASE3":7714,"PHASE4":7716,"NA":7718},{"trials":7638,"activeCount":99},[],{"trials":7640,"activeCount":195,"soonestReadout":3234},[7641,7645,7649,7653,7660,7664,7680,7688],{"nctId":3681,"briefTitle":3682,"status":203,"phases":7642,"primaryCompletion":3684,"completion":3684,"start":3685,"enrollment":1632,"conditions":7643,"interventions":7644},[87],[3687,3688,3689,325,3690,3691,3692,3693],[345,2021,84],{"nctId":3231,"briefTitle":3232,"status":130,"phases":7646,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":188,"conditions":7647,"interventions":7648},[87],[3237,3238,1026,3239,3240,3241,3242,3243,3244,3245,3246,3247,3248,3249,3250,3251,3252,3253,3254,3255,3256,3257,3258,3259,3260,3261,3262,3263,3264],[169,345,3266,170,3267],{"nctId":873,"briefTitle":874,"status":107,"phases":7650,"primaryCompletion":109,"completion":109,"start":876,"enrollment":9,"conditions":7651,"interventions":7652},[87],[878,879,880],[738,385,75,115,871,882,883,274],{"nctId":7654,"briefTitle":7655,"status":107,"phases":7656,"primaryCompletion":2342,"completion":2342,"start":7657,"enrollment":890,"conditions":7658,"interventions":7659},"NCT00550901","Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors",[87],"2001-02",[24],[385,739],{"nctId":915,"briefTitle":916,"status":107,"phases":7661,"primaryCompletion":175,"completion":175,"start":918,"enrollment":919,"conditions":7662,"interventions":7663},[87],[921],[738,114,385,75,894,740,923,871],{"nctId":7665,"briefTitle":7666,"status":203,"phases":7667,"primaryCompletion":7668,"completion":7668,"start":7669,"enrollment":3226,"conditions":7670,"interventions":7678},"NCT07218913","Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors",[87],"2031-01-22","2026-02-19",[7671,7672,7673,7674,7675,7676,7677],"Hearing Loss","Metastatic Malignant Germ Cell Tumor","Metastatic Malignant Nongerminomatous Germ Cell Tumor","Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor","Metastatic Testicular Seminoma","Stage II Testicular Cancer AJCC v8","Stage III Testicular Cancer AJCC v8",[345,7679],"Sodium Thiosulfate Anhydrous",{"nctId":7681,"briefTitle":7682,"status":107,"phases":7683,"primaryCompletion":6233,"completion":6050,"start":7684,"conditions":7685,"interventions":7686},"NCT00006464","UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors",[87],"2001-03",[24],[7687,385],"7-hydroxystaurosporine",{"nctId":311,"briefTitle":312,"status":203,"phases":7689,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":7690,"interventions":7691},[87],[318,319,320,321,322,323,324,325,326,327,328,329,330,331,303,332,333,334,335,336,337,338,339,340,341,342,343],[345,346,305,306,347,348,349],{"trials":7693,"activeCount":99},[7694,7698,7702,7706],{"nctId":1335,"briefTitle":1336,"status":107,"phases":7695,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":16,"conditions":7696,"interventions":7697},[88],[15],[738,385,75,168,115,923,871,1343],{"nctId":376,"briefTitle":377,"status":107,"phases":7699,"primaryCompletion":379,"completion":380,"start":381,"enrollment":177,"conditions":7700,"interventions":7701},[88],[383],[385,126,250,386,270,274,387],{"nctId":2464,"briefTitle":2465,"status":107,"phases":7703,"primaryCompletion":2467,"completion":2467,"start":393,"enrollment":1916,"conditions":7704,"interventions":7705},[88],[664],[738,385,168,740,115],{"nctId":7707,"briefTitle":7708,"status":369,"phases":7709,"primaryCompletion":7710,"completion":7710,"start":7711,"enrollment":283,"conditions":7712,"interventions":7713},"NCT00530634","Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer",[88],"2013-06","1999-08",[5110],[385,386,274,2345],{"trials":7715,"activeCount":99},[],{"trials":7717,"activeCount":99},[],{"trials":7719,"activeCount":99},[],{"intervention":2114,"totalTrials":498,"cells":7721},{"EARLY_PHASE1":7722,"PHASE1":7724,"PHASE2":7746,"PHASE3":7748,"PHASE4":7750,"NA":7752},{"trials":7723,"activeCount":99},[],{"trials":7725,"activeCount":283,"soonestReadout":2148},[7726,7730,7734,7738,7742],{"nctId":2108,"briefTitle":2109,"status":130,"phases":7727,"primaryCompletion":402,"completion":402,"start":2111,"enrollment":177,"conditions":7728,"interventions":7729},[87],[1971,1972,1049,1052],[2114,2115,838],{"nctId":2117,"briefTitle":2118,"status":107,"phases":7731,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":2122,"conditions":7732,"interventions":7733},[87],[2124,406,407,323,408,2125,457,2126,2127,2128,2129,2130,2131,409,303,410,2132,335,2133,2134,339,2135,2136,343,2137],[2114,838,2139],{"nctId":2145,"briefTitle":2146,"status":130,"phases":7735,"primaryCompletion":2148,"completion":2149,"start":2150,"enrollment":404,"conditions":7736,"interventions":7737},[87],[707,2152],[2154,2114,838],{"nctId":2156,"briefTitle":2157,"status":107,"phases":7739,"primaryCompletion":2159,"completion":2159,"start":2160,"enrollment":298,"conditions":7740,"interventions":7741},[87],[2162,1971,1045,1049,1052,1057],[2164,2114,838],{"nctId":2166,"briefTitle":2167,"status":203,"phases":7743,"primaryCompletion":2169,"completion":2169,"start":2170,"enrollment":919,"conditions":7744,"interventions":7745},[87],[2172,2173,2174,2175,1049,1052],[2114,838],{"trials":7747,"activeCount":99},[],{"trials":7749,"activeCount":99},[],{"trials":7751,"activeCount":99},[],{"trials":7753,"activeCount":99},[],{"intervention":5368,"totalTrials":195,"cells":7755},{"EARLY_PHASE1":7756,"PHASE1":7766,"PHASE2":7791,"PHASE3":7793,"PHASE4":7795,"NA":7797},{"trials":7757,"activeCount":214,"soonestReadout":7762},[7758],{"nctId":7759,"briefTitle":7760,"status":203,"phases":7761,"primaryCompletion":7762,"completion":7762,"start":7763,"enrollment":95,"conditions":7764,"interventions":7765},"NCT05800405","Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma",[86],"2027-01-04","2023-07-20",[972,1855],[5368],{"trials":7767,"activeCount":363,"soonestReadout":6840},[7768,7778,7782],{"nctId":7769,"briefTitle":7770,"status":203,"phases":7771,"primaryCompletion":7772,"completion":7772,"start":7773,"enrollment":22,"conditions":7774,"interventions":7777},"NCT06815029","Intracranial Genetically Modified Immune Cells (TGFβR2KO\u002FIL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma",[87],"2030-10-11","2025-06-17",[7775,7776,707],"Recurrent Astrocytoma, IDH-Mutant, Grade 3","Recurrent Astrocytoma, IDH-Mutant, Grade 4",[5368],{"nctId":5361,"briefTitle":5362,"status":907,"phases":7779,"primaryCompletion":5364,"completion":5364,"start":5365,"enrollment":22,"conditions":7780,"interventions":7781},[87],[3405,1652,3406],[5368,2607],{"nctId":7783,"briefTitle":7784,"status":130,"phases":7785,"primaryCompletion":6840,"completion":6840,"start":7786,"enrollment":30,"conditions":7787,"interventions":7790},"NCT03696030","HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases",[87],"2018-08-31",[7788,211,7789,15,137],"Malignant Neoplasm","Metastatic Malignant Neoplasm in the Leptomeninges",[5368],{"trials":7792,"activeCount":99},[],{"trials":7794,"activeCount":99},[],{"trials":7796,"activeCount":99},[],{"trials":7798,"activeCount":99},[],{"intervention":3017,"totalTrials":283,"cells":7800},{"EARLY_PHASE1":7801,"PHASE1":7807,"PHASE2":7817,"PHASE3":7819,"PHASE4":7821,"NA":7823},{"trials":7802,"activeCount":214,"soonestReadout":3013},[7803],{"nctId":3010,"briefTitle":3011,"status":203,"phases":7804,"primaryCompletion":3013,"completion":3013,"start":3014,"enrollment":795,"conditions":7805,"interventions":7806},[86],[35],[3017,3005],{"trials":7808,"activeCount":363,"soonestReadout":3068},[7809,7813],{"nctId":3052,"briefTitle":3053,"status":203,"phases":7810,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":795,"conditions":7811,"interventions":7812},[87],[3059,3060,3061,3062],[3017,3005],{"nctId":3065,"briefTitle":3066,"status":203,"phases":7814,"primaryCompletion":3068,"completion":3056,"start":3069,"enrollment":795,"conditions":7815,"interventions":7816},[87],[3071,1410,1413,3061,972,976,1852,3072],[3017,3005],{"trials":7818,"activeCount":99},[],{"trials":7820,"activeCount":99},[],{"trials":7822,"activeCount":99},[],{"trials":7824,"activeCount":99},[],{"intervention":306,"totalTrials":283,"cells":7826},{"EARLY_PHASE1":7827,"PHASE1":7829,"PHASE2":7843,"PHASE3":7845,"PHASE4":7847,"NA":7849},{"trials":7828,"activeCount":99},[],{"trials":7830,"activeCount":283,"soonestReadout":701},[7831,7835,7839],{"nctId":292,"briefTitle":293,"status":294,"phases":7832,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":7833,"interventions":7834},[87],[300,301,302,303],[305,306,307,308,309],{"nctId":698,"briefTitle":699,"status":130,"phases":7836,"primaryCompletion":701,"completion":154,"start":702,"enrollment":36,"conditions":7837,"interventions":7838},[87],[704,705,706,707,708,709,710],[712,306,426],{"nctId":311,"briefTitle":312,"status":203,"phases":7840,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":7841,"interventions":7842},[87],[318,319,320,321,322,323,324,325,326,327,328,329,330,331,303,332,333,334,335,336,337,338,339,340,341,342,343],[345,346,305,306,347,348,349],{"trials":7844,"activeCount":99},[],{"trials":7846,"activeCount":99},[],{"trials":7848,"activeCount":99},[],{"trials":7850,"activeCount":99},[],{"intervention":386,"totalTrials":207,"cells":7852},{"EARLY_PHASE1":7853,"PHASE1":7855,"PHASE2":7887,"PHASE3":7910,"PHASE4":7912,"NA":7914},{"trials":7854,"activeCount":99},[],{"trials":7856,"activeCount":363,"soonestReadout":4110},[7857,7867,7871,7875,7879,7883],{"nctId":7858,"briefTitle":7859,"status":107,"phases":7860,"primaryCompletion":691,"completion":691,"start":7861,"enrollment":576,"conditions":7862,"interventions":7866},"NCT00544193","Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer",[87],"1997-12",[7863,7864,3928,7865,1301],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Pancreatic Cancer",[386,275],{"nctId":3231,"briefTitle":3232,"status":130,"phases":7868,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":188,"conditions":7869,"interventions":7870},[87],[3237,3238,1026,3239,3240,3241,3242,3243,3244,3245,3246,3247,3248,3249,3250,3251,3252,3253,3254,3255,3256,3257,3258,3259,3260,3261,3262,3263,3264],[169,345,3266,170,3267],{"nctId":4107,"briefTitle":4108,"status":130,"phases":7872,"primaryCompletion":4110,"completion":4111,"start":4112,"enrollment":33,"conditions":7873,"interventions":7874},[87],[4114,3712,4115,4116],[3266,4118,4119],{"nctId":5181,"briefTitle":5182,"status":107,"phases":7876,"primaryCompletion":5184,"completion":5184,"start":2492,"enrollment":1632,"conditions":7877,"interventions":7878},[87],[1385,3239,3241],[5187,386],{"nctId":3696,"briefTitle":3697,"status":107,"phases":7880,"primaryCompletion":3699,"completion":3699,"start":3700,"enrollment":3226,"conditions":7881,"interventions":7882},[87],[3702,3239,3240,3241,3242,1891],[2021,3266,3704],{"nctId":3957,"briefTitle":3958,"status":107,"phases":7884,"start":3960,"conditions":7885,"interventions":7886},[87],[24],[386,271],{"trials":7888,"activeCount":99},[7889,7898,7902,7906],{"nctId":7890,"briefTitle":7891,"status":107,"phases":7892,"primaryCompletion":7893,"completion":7893,"start":7894,"enrollment":576,"conditions":7895,"interventions":7896},"NCT00645710","Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery",[87,88],"2018-02-07","2005-02-11",[226,285,286,287,288],[386,397,7897],"proteomic profiling",{"nctId":2930,"briefTitle":2931,"status":107,"phases":7899,"primaryCompletion":2933,"completion":2934,"start":2935,"enrollment":919,"conditions":7900,"interventions":7901},[87,88],[27],[1775,1700,386],{"nctId":376,"briefTitle":377,"status":107,"phases":7903,"primaryCompletion":379,"completion":380,"start":381,"enrollment":177,"conditions":7904,"interventions":7905},[88],[383],[385,126,250,386,270,274,387],{"nctId":7707,"briefTitle":7708,"status":369,"phases":7907,"primaryCompletion":7710,"completion":7710,"start":7711,"enrollment":283,"conditions":7908,"interventions":7909},[88],[5110],[385,386,274,2345],{"trials":7911,"activeCount":99},[],{"trials":7913,"activeCount":99},[],{"trials":7915,"activeCount":99},[],{"intervention":2710,"totalTrials":283,"cells":7917},{"EARLY_PHASE1":7918,"PHASE1":7920,"PHASE2":7937,"PHASE3":7943,"PHASE4":7945,"NA":7947},{"trials":7919,"activeCount":99},[],{"trials":7921,"activeCount":363,"soonestReadout":2705},[7922,7933],{"nctId":7923,"briefTitle":7924,"status":203,"phases":7925,"primaryCompletion":7926,"completion":7926,"start":7927,"enrollment":1632,"conditions":7928,"interventions":7932},"NCT05085496","Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC",[87],"2027-09-10","2022-04-19",[7929,7930,7931],"Locally Advanced Skin Squamous Cell Carcinoma","Resectable Skin Squamous Cell Carcinoma","Unresectable Skin Squamous Cell Carcinoma",[2710],{"nctId":2702,"briefTitle":2703,"status":130,"phases":7934,"primaryCompletion":2705,"completion":2705,"start":2706,"enrollment":283,"conditions":7935,"interventions":7936},[87],[2708],[2710,169,940,2711],{"trials":7938,"activeCount":99},[7939],{"nctId":3344,"briefTitle":3345,"status":107,"phases":7940,"primaryCompletion":3347,"completion":3348,"start":3349,"enrollment":19,"conditions":7941,"interventions":7942},[87,88],[209,1960,3351],[2710,459,169,3353,170],{"trials":7944,"activeCount":99},[],{"trials":7946,"activeCount":99},[],{"trials":7948,"activeCount":99},[],{"intervention":1212,"totalTrials":498,"cells":7950},{"EARLY_PHASE1":7951,"PHASE1":7953,"PHASE2":7979,"PHASE3":7981,"PHASE4":7983,"NA":7985},{"trials":7952,"activeCount":99},[],{"trials":7954,"activeCount":363,"soonestReadout":828},[7955,7963,7967,7971,7975],{"nctId":7956,"briefTitle":7957,"status":107,"phases":7958,"primaryCompletion":6311,"completion":6311,"start":7959,"enrollment":1632,"conditions":7960,"interventions":7962},"NCT03009240","Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia",[87],"2017-08-21",[18,1003,818,813,7961,819],"Therapy-Related Acute Myeloid Leukemia",[1212,5240],{"nctId":2526,"briefTitle":2527,"status":479,"phases":7964,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":99,"conditions":7965,"interventions":7966},[87],[1003],[2533,1212,2534,2535,2536,2537,956],{"nctId":2539,"briefTitle":2540,"status":130,"phases":7968,"primaryCompletion":828,"completion":828,"start":2542,"enrollment":2543,"conditions":7969,"interventions":7970},[87],[1003,818],[1212,2546,956],{"nctId":1831,"briefTitle":1832,"status":203,"phases":7972,"primaryCompletion":1834,"completion":1834,"start":1835,"enrollment":1264,"conditions":7973,"interventions":7974},[87],[18,21,1003,1208,818,1209],[1212,1480,956],{"nctId":1202,"briefTitle":1203,"status":479,"phases":7976,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":99,"conditions":7977,"interventions":7978},[87],[1003,1208,818,1209],[1211,784,1212,847],{"trials":7980,"activeCount":99},[],{"trials":7982,"activeCount":99},[],{"trials":7984,"activeCount":99},[],{"trials":7986,"activeCount":99},[],{"intervention":2555,"totalTrials":195,"cells":7988},{"EARLY_PHASE1":7989,"PHASE1":7991,"PHASE2":8017,"PHASE3":8019,"PHASE4":8021,"NA":8023},{"trials":7990,"activeCount":99},[],{"trials":7992,"activeCount":363,"soonestReadout":2551},[7993,8001,8009,8013],{"nctId":7994,"briefTitle":7995,"status":203,"phases":7996,"primaryCompletion":2026,"completion":2026,"start":7997,"enrollment":2914,"conditions":7998,"interventions":7999},"NCT06498973","Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant",[87],"2025-01-28",[18,21],[2555,8000],"Tagraxofusp-erzs",{"nctId":8002,"briefTitle":8003,"status":479,"phases":8004,"primaryCompletion":8005,"completion":8005,"start":5545,"enrollment":99,"conditions":8006,"interventions":8007},"NCT05823480","Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS",[87],"2026-02-14",[18,21],[2555,8008],"Magrolimab",{"nctId":2548,"briefTitle":2549,"status":203,"phases":8010,"primaryCompletion":2551,"completion":2551,"start":2552,"enrollment":1632,"conditions":8011,"interventions":8012},[87],[1003,818],[2555,2556,956],{"nctId":2579,"briefTitle":2580,"status":907,"phases":8014,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":404,"conditions":8015,"interventions":8016},[87],[2585,1003,1208,818,1209],[2555,2139,956],{"trials":8018,"activeCount":99},[],{"trials":8020,"activeCount":99},[],{"trials":8022,"activeCount":99},[],{"trials":8024,"activeCount":99},[],{"intervention":2164,"totalTrials":283,"cells":8026},{"EARLY_PHASE1":8027,"PHASE1":8029,"PHASE2":8047,"PHASE3":8049,"PHASE4":8051,"NA":8053},{"trials":8028,"activeCount":99},[],{"trials":8030,"activeCount":363,"soonestReadout":2190},[8031,8035,8039],{"nctId":2156,"briefTitle":2157,"status":107,"phases":8032,"primaryCompletion":2159,"completion":2159,"start":2160,"enrollment":298,"conditions":8033,"interventions":8034},[87],[2162,1971,1045,1049,1052,1057],[2164,2114,838],{"nctId":2187,"briefTitle":2188,"status":130,"phases":8036,"primaryCompletion":2190,"completion":2190,"start":2191,"enrollment":177,"conditions":8037,"interventions":8038},[87],[2172,2193,2162,2173,2174,2194,1045,2175,1049,1052,2195,1057],[2197,2164,838],{"nctId":8040,"briefTitle":8041,"status":130,"phases":8042,"primaryCompletion":8043,"completion":8043,"start":8044,"enrollment":1610,"conditions":8045,"interventions":8046},"NCT03922035","CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant",[87],"2027-02-05","2019-04-18",[1145],[2164],{"trials":8048,"activeCount":99},[],{"trials":8050,"activeCount":99},[],{"trials":8052,"activeCount":99},[],{"trials":8054,"activeCount":99},[],{"intervention":1555,"totalTrials":363,"cells":8056},{"EARLY_PHASE1":8057,"PHASE1":8059,"PHASE2":8069,"PHASE3":8071,"PHASE4":8073,"NA":8075},{"trials":8058,"activeCount":99},[],{"trials":8060,"activeCount":363,"soonestReadout":4672},[8061,8065],{"nctId":1548,"briefTitle":1549,"status":203,"phases":8062,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":795,"conditions":8063,"interventions":8064},[87],[35,18,21],[1555,1556,847,1557,849,1149,851],{"nctId":4669,"briefTitle":4670,"status":203,"phases":8066,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":795,"conditions":8067,"interventions":8068},[87],[1102,1103],[1555,1556,1557],{"trials":8070,"activeCount":99},[],{"trials":8072,"activeCount":99},[],{"trials":8074,"activeCount":99},[],{"trials":8076,"activeCount":99},[],{"intervention":1557,"totalTrials":363,"cells":8078},{"EARLY_PHASE1":8079,"PHASE1":8081,"PHASE2":8091,"PHASE3":8093,"PHASE4":8095,"NA":8097},{"trials":8080,"activeCount":99},[],{"trials":8082,"activeCount":363,"soonestReadout":4672},[8083,8087],{"nctId":1548,"briefTitle":1549,"status":203,"phases":8084,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":795,"conditions":8085,"interventions":8086},[87],[35,18,21],[1555,1556,847,1557,849,1149,851],{"nctId":4669,"briefTitle":4670,"status":203,"phases":8088,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":795,"conditions":8089,"interventions":8090},[87],[1102,1103],[1555,1556,1557],{"trials":8092,"activeCount":99},[],{"trials":8094,"activeCount":99},[],{"trials":8096,"activeCount":99},[],{"trials":8098,"activeCount":99},[],{"intervention":1075,"totalTrials":363,"cells":8100},{"EARLY_PHASE1":8101,"PHASE1":8103,"PHASE2":8117,"PHASE3":8119,"PHASE4":8121,"NA":8123},{"trials":8102,"activeCount":99},[],{"trials":8104,"activeCount":363,"soonestReadout":1065},[8105,8113],{"nctId":8106,"briefTitle":8107,"status":203,"phases":8108,"primaryCompletion":8109,"completion":8109,"start":8110,"enrollment":33,"conditions":8111,"interventions":8112},"NCT05805371","PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer",[87],"2028-11-11","2024-07-19",[1069,1070,1073],[1075],{"nctId":1062,"briefTitle":1063,"status":130,"phases":8114,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":251,"conditions":8115,"interventions":8116},[87],[1069,1070,1071,1072,1073],[1075,784,847,823],{"trials":8118,"activeCount":99},[],{"trials":8120,"activeCount":99},[],{"trials":8122,"activeCount":99},[],{"trials":8124,"activeCount":99},[],{"intervention":1017,"totalTrials":363,"cells":8126},{"EARLY_PHASE1":8127,"PHASE1":8129,"PHASE2":8145,"PHASE3":8147,"PHASE4":8149,"NA":8151},{"trials":8128,"activeCount":99},[],{"trials":8130,"activeCount":363,"soonestReadout":2190},[8131,8141],{"nctId":8132,"briefTitle":8133,"status":130,"phases":8134,"primaryCompletion":2190,"completion":2190,"start":8135,"enrollment":207,"conditions":8136,"interventions":8140},"NCT04661384","Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma",[87],"2021-03-05",[8137,4601,8138,8139],"Ependymoma","Medulloblastoma","Recurrent Metastatic Malignant Neoplasm in the Leptomeninges",[1017],{"nctId":1007,"briefTitle":1008,"status":203,"phases":8142,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":36,"conditions":8143,"interventions":8144},[87],[1013,1014,1015],[784,847,1017],{"trials":8146,"activeCount":99},[],{"trials":8148,"activeCount":99},[],{"trials":8150,"activeCount":99},[],{"trials":8152,"activeCount":99},[],{"intervention":8154,"totalTrials":363,"cells":8155},"autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells",{"EARLY_PHASE1":8156,"PHASE1":8158,"PHASE2":8178,"PHASE3":8180,"PHASE4":8182,"NA":8184},{"trials":8157,"activeCount":99},[],{"trials":8159,"activeCount":363,"soonestReadout":1495},[8160,8169],{"nctId":8161,"briefTitle":8162,"status":130,"phases":8163,"primaryCompletion":1495,"completion":949,"start":8164,"enrollment":298,"conditions":8165,"interventions":8168},"NCT01815749","Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma",[87],"2013-10-08",[8166,2873,2874,2875,2876,4047,970,4048,4049,2877,2878,4050,4051,1848,1849,2895,976,977,978,4581,2879,2880,2881,8167],"Adult Grade III Lymphomatoid Granulomatosis","Waldenström Macroglobulinemia",[8154],{"nctId":8170,"briefTitle":8171,"status":130,"phases":8172,"primaryCompletion":828,"completion":828,"start":8173,"enrollment":1286,"conditions":8174,"interventions":8176},"NCT02051257","Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma",[87],"2014-06-19",[972,976,1855,2639,8175],"Transformed Recurrent Non-Hodgkin Lymphoma",[8177,980],"Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells",{"trials":8179,"activeCount":99},[],{"trials":8181,"activeCount":99},[],{"trials":8183,"activeCount":99},[],{"trials":8185,"activeCount":99},[],{"intervention":2556,"totalTrials":363,"cells":8187},{"EARLY_PHASE1":8188,"PHASE1":8190,"PHASE2":8210,"PHASE3":8212,"PHASE4":8214,"NA":8216},{"trials":8189,"activeCount":99},[],{"trials":8191,"activeCount":363,"soonestReadout":2551},[8192,8196],{"nctId":2548,"briefTitle":2549,"status":203,"phases":8193,"primaryCompletion":2551,"completion":2551,"start":2552,"enrollment":1632,"conditions":8194,"interventions":8195},[87],[1003,818],[2555,2556,956],{"nctId":8197,"briefTitle":8198,"status":203,"phases":8199,"primaryCompletion":8200,"completion":8200,"start":8201,"enrollment":8202,"conditions":8203,"interventions":8209},"NCT05227326","AOH1996 for the Treatment of Refractory Solid Tumors",[87],"2029-09-13","2022-08-12",92,[8204,8205,8206,8207,879,8208,7865],"Refractory Malignant Solid Neoplasm","Osteosarcoma","Leiomyosarcomas","Synovial Sarcomas","Non-Small Cell Lung Cancer",[2556],{"trials":8211,"activeCount":99},[],{"trials":8213,"activeCount":99},[],{"trials":8215,"activeCount":99},[],{"trials":8217,"activeCount":99},[],{"intervention":957,"totalTrials":363,"cells":8219},{"EARLY_PHASE1":8220,"PHASE1":8222,"PHASE2":8232,"PHASE3":8234,"PHASE4":8236,"NA":8238},{"trials":8221,"activeCount":99},[],{"trials":8223,"activeCount":363,"soonestReadout":1154},[8224,8228],{"nctId":945,"briefTitle":946,"status":203,"phases":8225,"primaryCompletion":948,"completion":948,"start":949,"enrollment":25,"conditions":8226,"interventions":8227},[87],[951,952],[954,955,784,956,957],{"nctId":1151,"briefTitle":1152,"status":294,"phases":8229,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":404,"conditions":8230,"interventions":8231},[87],[1157,1158,1159,1160,1161,1162],[784,346,66,1164,938,1165,957],{"trials":8233,"activeCount":99},[],{"trials":8235,"activeCount":99},[],{"trials":8237,"activeCount":99},[],{"trials":8239,"activeCount":99},[],{"intervention":980,"totalTrials":363,"cells":8241},{"EARLY_PHASE1":8242,"PHASE1":8244,"PHASE2":8254,"PHASE3":8256,"PHASE4":8258,"NA":8260},{"trials":8243,"activeCount":99},[],{"trials":8245,"activeCount":363,"soonestReadout":962},[8246,8250],{"nctId":959,"briefTitle":960,"status":130,"phases":8247,"primaryCompletion":962,"completion":962,"start":963,"enrollment":964,"conditions":8248,"interventions":8249},[87],[966,967,968,969,970,971,972,973,974,975,976,977,978],[980,981,784,940,823],{"nctId":8170,"briefTitle":8171,"status":130,"phases":8251,"primaryCompletion":828,"completion":828,"start":8173,"enrollment":1286,"conditions":8252,"interventions":8253},[87],[972,976,1855,2639,8175],[8177,980],{"trials":8255,"activeCount":99},[],{"trials":8257,"activeCount":99},[],{"trials":8259,"activeCount":99},[],{"trials":8261,"activeCount":99},[],{"intervention":1118,"totalTrials":363,"cells":8263},{"EARLY_PHASE1":8264,"PHASE1":8266,"PHASE2":8276,"PHASE3":8278,"PHASE4":8280,"NA":8282},{"trials":8265,"activeCount":99},[],{"trials":8267,"activeCount":363,"soonestReadout":1109},[8268,8272],{"nctId":1106,"briefTitle":1107,"status":130,"phases":8269,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":283,"conditions":8270,"interventions":8271},[87],[1112,1113,1114,1115,1116],[784,1118,1119,851,1120,1121],{"nctId":1214,"briefTitle":1215,"status":203,"phases":8273,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":434,"conditions":8274,"interventions":8275},[87],[1220,1221],[1223,784,1118],{"trials":8277,"activeCount":99},[],{"trials":8279,"activeCount":99},[],{"trials":8281,"activeCount":99},[],{"trials":8283,"activeCount":99},[],{"intervention":275,"totalTrials":486,"cells":8285},{"EARLY_PHASE1":8286,"PHASE1":8288,"PHASE2":8316,"PHASE3":8325,"PHASE4":8327,"NA":8329},{"trials":8287,"activeCount":99},[],{"trials":8289,"activeCount":214,"soonestReadout":79},[8290,8294,8304,8308],{"nctId":7858,"briefTitle":7859,"status":107,"phases":8291,"primaryCompletion":691,"completion":691,"start":7861,"enrollment":576,"conditions":8292,"interventions":8293},[87],[7863,7864,3928,7865,1301],[386,275],{"nctId":8295,"briefTitle":8296,"status":107,"phases":8297,"primaryCompletion":8298,"completion":8299,"start":6240,"enrollment":95,"conditions":8300,"interventions":8301},"NCT00686218","Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia",[87],"2013-03","2014-08",[32],[8302,8303,275,387,276],"imatinib mesylate","panobinostat",{"nctId":258,"briefTitle":259,"status":107,"phases":8305,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":8306,"interventions":8307},[87],[266],[268,269,250,270,271,272,273,274,275,276],{"nctId":77,"briefTitle":78,"status":130,"phases":8309,"primaryCompletion":79,"completion":8310,"start":8311,"enrollment":8312,"conditions":8313,"interventions":8314},[87],"2026-07-08","2007-11-26",1045,[124],[71,8315,273,274,275],"DNA methylation analysis",{"trials":8317,"activeCount":99},[8318],{"nctId":8319,"briefTitle":8320,"status":369,"phases":8321,"primaryCompletion":987,"completion":987,"start":8322,"enrollment":214,"conditions":8323,"interventions":8324},"NCT00740597","Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma",[88],"2008-07",[664],[274,275,276],{"trials":8326,"activeCount":99},[],{"trials":8328,"activeCount":99},[],{"trials":8330,"activeCount":214,"soonestReadout":70},[8331,8438],{"nctId":68,"briefTitle":69,"status":130,"phases":8332,"primaryCompletion":70,"completion":3550,"start":6049,"enrollment":8333,"conditions":8334,"interventions":8434},[],153,[8335,8336,8337,1800,808,1426,1427,1428,1429,1430,1431,8166,4043,1918,4044,8338,8339,2773,8340,1275,8341,8342,8343,8344,8345,8346,8347,8348,8349,8350,8351,2954,8352,8353,2873,8354,8355,8356,8357,2874,2875,8358,8359,8360,8361,2876,8362,8363,8364,8365,8366,8367,8368,8369,8370,2955,8371,8372,8373,4047,2777,1488,8374,8375,8376,1196,812,970,4048,4049,2877,2878,2388,4050,4051,4052,4053,1848,1849,2895,976,977,4054,978,5234,4581,989,8377,813,8378,845,2880,8379,8380,8381,8382,8383,8384,8385,8386,8387,8388,8389,8390,8391,8392,2956,8393,990,8394,8395,8396,8397,8398,8399,991,8400,8401,8402,8403,8404,8405,8406,8407,8408,8409,8410,8411,8412,8413,2957,8414,992,8415,8416,8417,8418,8419,8420,8421,8422,8423,8424,8425,8426,8427,8428,8429,2958,8430,8431,8432,8433,2882],"Hematopoietic\u002FLymphoid Cancer","Accelerated Phase Chronic Myelogenous Leukemia","Acute Undifferentiated Leukemia","Aplastic Anemia","Atypical Chronic Myeloid Leukemia, BCR-ABL Negative","Chronic Eosinophilic Leukemia","Chronic Neutrophilic Leukemia","Chronic Phase Chronic Myelogenous Leukemia","Contiguous Stage II Adult Burkitt Lymphoma","Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Contiguous Stage II Adult Lymphoblastic Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","Cytomegalovirus Infection","de Novo Myelodysplastic Syndromes","Essential Thrombocythemia","Extramedullary Plasmacytoma","Isolated Plasmacytoma of Bone","Mast Cell Leukemia","Meningeal Chronic Myelogenous Leukemia","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable","Noncontiguous Stage II Adult Burkitt Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Adult Lymphoblastic Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Polycythemia Vera","Primary Systemic Amyloidosis","Progressive Hairy Cell Leukemia, Initial Treatment","Prolymphocytic Leukemia","Relapsing Chronic Myelogenous Leukemia","Secondary Myelodysplastic Syndromes","Stage 0 Chronic Lymphocytic Leukemia","Stage I Adult Burkitt Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Mixed Cell Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Adult Hodgkin Lymphoma","Stage I Adult Immunoblastic Large Cell Lymphoma","Stage I Adult Lymphoblastic Lymphoma","Stage I Adult T-cell Leukemia\u002FLymphoma","Stage I Chronic Lymphocytic Leukemia","Stage I Cutaneous T-cell Non-Hodgkin Lymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Mycosis Fungoides\u002FSezary Syndrome","Stage I Small Lymphocytic Lymphoma","Stage II Adult Hodgkin Lymphoma","Stage II Adult T-cell Leukemia\u002FLymphoma","Stage II Chronic Lymphocytic Leukemia","Stage II Cutaneous T-cell Non-Hodgkin Lymphoma","Stage II Mycosis Fungoides\u002FSezary Syndrome","Stage III Adult Burkitt Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Mixed Cell Lymphoma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Hodgkin Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Adult Lymphoblastic Lymphoma","Stage III Adult T-cell Leukemia\u002FLymphoma","Stage III Chronic Lymphocytic Leukemia","Stage III Cutaneous T-cell Non-Hodgkin Lymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Marginal Zone Lymphoma","Stage III Mycosis Fungoides\u002FSezary Syndrome","Stage III Small Lymphocytic Lymphoma","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Mixed Cell Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Hodgkin Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Adult Lymphoblastic Lymphoma","Stage IV Adult T-cell Leukemia\u002FLymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IV Mycosis Fungoides\u002FSezary Syndrome","Stage IV Small Lymphocytic Lymphoma","T-cell Large Granular Lymphocyte Leukemia",[71,273,8435,8436,8437,275,387],"ganciclovir","valganciclovir","foscarnet sodium",{"nctId":8439,"briefTitle":8440,"status":107,"phases":8441,"primaryCompletion":2342,"completion":2342,"start":8442,"enrollment":4174,"conditions":8443,"interventions":8445},"NCT00716911","Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant",[91],"2000-01",[1295,32,27,1297,1298,1299,8444],"Nonneoplastic Condition",[8435,275],{"intervention":273,"totalTrials":195,"cells":8447},{"EARLY_PHASE1":8448,"PHASE1":8450,"PHASE2":8460,"PHASE3":8466,"PHASE4":8468,"NA":8470},{"trials":8449,"activeCount":99},[],{"trials":8451,"activeCount":214,"soonestReadout":79},[8452,8456],{"nctId":258,"briefTitle":259,"status":107,"phases":8453,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":8454,"interventions":8455},[87],[266],[268,269,250,270,271,272,273,274,275,276],{"nctId":77,"briefTitle":78,"status":130,"phases":8457,"primaryCompletion":79,"completion":8310,"start":8311,"enrollment":8312,"conditions":8458,"interventions":8459},[87],[124],[71,8315,273,274,275],{"trials":8461,"activeCount":99},[8462],{"nctId":2948,"briefTitle":2949,"status":107,"phases":8463,"primaryCompletion":2951,"completion":2951,"start":2952,"enrollment":1666,"conditions":8464,"interventions":8465},[88],[2954,2955,976,2956,2957,2958],[1700,1775,273,274,71],{"trials":8467,"activeCount":99},[],{"trials":8469,"activeCount":99},[],{"trials":8471,"activeCount":214,"soonestReadout":70},[8472],{"nctId":68,"briefTitle":69,"status":130,"phases":8473,"primaryCompletion":70,"completion":3550,"start":6049,"enrollment":8333,"conditions":8474,"interventions":8475},[],[8335,8336,8337,1800,808,1426,1427,1428,1429,1430,1431,8166,4043,1918,4044,8338,8339,2773,8340,1275,8341,8342,8343,8344,8345,8346,8347,8348,8349,8350,8351,2954,8352,8353,2873,8354,8355,8356,8357,2874,2875,8358,8359,8360,8361,2876,8362,8363,8364,8365,8366,8367,8368,8369,8370,2955,8371,8372,8373,4047,2777,1488,8374,8375,8376,1196,812,970,4048,4049,2877,2878,2388,4050,4051,4052,4053,1848,1849,2895,976,977,4054,978,5234,4581,989,8377,813,8378,845,2880,8379,8380,8381,8382,8383,8384,8385,8386,8387,8388,8389,8390,8391,8392,2956,8393,990,8394,8395,8396,8397,8398,8399,991,8400,8401,8402,8403,8404,8405,8406,8407,8408,8409,8410,8411,8412,8413,2957,8414,992,8415,8416,8417,8418,8419,8420,8421,8422,8423,8424,8425,8426,8427,8428,8429,2958,8430,8431,8432,8433,2882],[71,273,8435,8436,8437,275,387],{"intervention":71,"totalTrials":283,"cells":8477},{"EARLY_PHASE1":8478,"PHASE1":8480,"PHASE2":8486,"PHASE3":8492,"PHASE4":8494,"NA":8496},{"trials":8479,"activeCount":99},[],{"trials":8481,"activeCount":214,"soonestReadout":79},[8482],{"nctId":77,"briefTitle":78,"status":130,"phases":8483,"primaryCompletion":79,"completion":8310,"start":8311,"enrollment":8312,"conditions":8484,"interventions":8485},[87],[124],[71,8315,273,274,275],{"trials":8487,"activeCount":99},[8488],{"nctId":2948,"briefTitle":2949,"status":107,"phases":8489,"primaryCompletion":2951,"completion":2951,"start":2952,"enrollment":1666,"conditions":8490,"interventions":8491},[88],[2954,2955,976,2956,2957,2958],[1700,1775,273,274,71],{"trials":8493,"activeCount":99},[],{"trials":8495,"activeCount":99},[],{"trials":8497,"activeCount":214,"soonestReadout":70},[8498],{"nctId":68,"briefTitle":69,"status":130,"phases":8499,"primaryCompletion":70,"completion":3550,"start":6049,"enrollment":8333,"conditions":8500,"interventions":8501},[],[8335,8336,8337,1800,808,1426,1427,1428,1429,1430,1431,8166,4043,1918,4044,8338,8339,2773,8340,1275,8341,8342,8343,8344,8345,8346,8347,8348,8349,8350,8351,2954,8352,8353,2873,8354,8355,8356,8357,2874,2875,8358,8359,8360,8361,2876,8362,8363,8364,8365,8366,8367,8368,8369,8370,2955,8371,8372,8373,4047,2777,1488,8374,8375,8376,1196,812,970,4048,4049,2877,2878,2388,4050,4051,4052,4053,1848,1849,2895,976,977,4054,978,5234,4581,989,8377,813,8378,845,2880,8379,8380,8381,8382,8383,8384,8385,8386,8387,8388,8389,8390,8391,8392,2956,8393,990,8394,8395,8396,8397,8398,8399,991,8400,8401,8402,8403,8404,8405,8406,8407,8408,8409,8410,8411,8412,8413,2957,8414,992,8415,8416,8417,8418,8419,8420,8421,8422,8423,8424,8425,8426,8427,8428,8429,2958,8430,8431,8432,8433,2882],[71,273,8435,8436,8437,275,387],{"intervention":2946,"totalTrials":498,"cells":8503},{"EARLY_PHASE1":8504,"PHASE1":8506,"PHASE2":8536,"PHASE3":8542,"PHASE4":8544,"NA":8546},{"trials":8505,"activeCount":99},[],{"trials":8507,"activeCount":214,"soonestReadout":1842},[8508,8517,8528,8532],{"nctId":8509,"briefTitle":8510,"status":107,"phases":8511,"primaryCompletion":8512,"completion":8512,"start":8513,"enrollment":498,"conditions":8514,"interventions":8515},"NCT00816283","Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",[87],"2011-06","2008-09",[32],[3317,2946,1332,274,8516,2345],"mutation analysis",{"nctId":8518,"briefTitle":8519,"status":107,"phases":8520,"primaryCompletion":8521,"completion":8522,"start":8523,"enrollment":911,"conditions":8524,"interventions":8526},"NCT01084057","Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer",[87],"2012-11-12","2019-09-27","2010-05-17",[8525,138,144],"Male Breast Cancer",[2946,8527],"ixabepilone",{"nctId":1839,"briefTitle":1840,"status":130,"phases":8529,"primaryCompletion":1842,"completion":467,"start":1843,"enrollment":1383,"conditions":8530,"interventions":8531},[87],[1845,1846,1847,972,973,1848,1849,1850,1851,1852,1853,1854,1855,1856,1857,1858],[1480,1860],{"nctId":4036,"briefTitle":4037,"status":369,"phases":8533,"primaryCompletion":4039,"completion":4040,"start":4041,"enrollment":298,"conditions":8534,"interventions":8535},[87],[4043,1918,4044,2873,2874,4045,2875,2876,4046,4047,970,4048,4049,2877,2878,2388,4050,4051,4052,4053,1848,1849,2895,976,977,4054,978,2879,2880,2881,2882],[1333,2946],{"trials":8537,"activeCount":99},[8538],{"nctId":2939,"briefTitle":2940,"status":107,"phases":8539,"primaryCompletion":2942,"completion":2942,"start":2943,"enrollment":298,"conditions":8540,"interventions":8541},[88],[27],[1775,2946],{"trials":8543,"activeCount":99},[],{"trials":8545,"activeCount":99},[],{"trials":8547,"activeCount":99},[],{"intervention":116,"totalTrials":283,"cells":8549},{"EARLY_PHASE1":8550,"PHASE1":8552,"PHASE2":8558,"PHASE3":8568,"PHASE4":8570,"NA":8572},{"trials":8551,"activeCount":99},[],{"trials":8553,"activeCount":214,"soonestReadout":1618},[8554],{"nctId":1615,"briefTitle":1616,"status":203,"phases":8555,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":919,"conditions":8556,"interventions":8557},[87],[35,18,21],[847,849,1622,851,1623],{"trials":8559,"activeCount":99},[8560,8564],{"nctId":105,"briefTitle":106,"status":107,"phases":8561,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":8562,"interventions":8563},[88],[15],[94,114,75,115,116],{"nctId":1504,"briefTitle":1505,"status":107,"phases":8565,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":8566,"interventions":8567},[88],[15],[738,114,75,168,871,116],{"trials":8569,"activeCount":99},[],{"trials":8571,"activeCount":99},[],{"trials":8573,"activeCount":99},[],{"intervention":837,"totalTrials":363,"cells":8575},{"EARLY_PHASE1":8576,"PHASE1":8578,"PHASE2":8584,"PHASE3":8590,"PHASE4":8592,"NA":8594},{"trials":8577,"activeCount":99},[],{"trials":8579,"activeCount":214,"soonestReadout":828},[8580],{"nctId":825,"briefTitle":826,"status":130,"phases":8581,"primaryCompletion":828,"completion":828,"start":829,"enrollment":9,"conditions":8582,"interventions":8583},[87],[831,832,833,834,835],[784,837,838],{"trials":8585,"activeCount":99},[8586],{"nctId":1460,"briefTitle":1461,"status":107,"phases":8587,"primaryCompletion":1463,"completion":1463,"start":1464,"enrollment":95,"conditions":8588,"interventions":8589},[87,88],[318,1466,319,1467,320,1468,1469,1470,328,1471,1472,1473,330,1474,1475,1476,1477,1478],[784,837,1480],{"trials":8591,"activeCount":99},[],{"trials":8593,"activeCount":99},[],{"trials":8595,"activeCount":99},[],{"intervention":6167,"totalTrials":363,"cells":8597},{"EARLY_PHASE1":8598,"PHASE1":8600,"PHASE2":8606,"PHASE3":8612,"PHASE4":8614,"NA":8616},{"trials":8599,"activeCount":99},[],{"trials":8601,"activeCount":214,"soonestReadout":1170},[8602],{"nctId":1167,"briefTitle":1168,"status":203,"phases":8603,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":30,"conditions":8604,"interventions":8605},[87],[1173,1174],[1176,1177,784,847],{"trials":8607,"activeCount":99},[8608],{"nctId":6160,"briefTitle":6161,"status":369,"phases":8609,"primaryCompletion":6163,"start":6164,"enrollment":1916,"conditions":8610,"interventions":8611},[88],[266],[6167,696,274,447,6168,2345],{"trials":8613,"activeCount":99},[],{"trials":8615,"activeCount":99},[],{"trials":8617,"activeCount":99},[],{"intervention":8619,"totalTrials":363,"cells":8620},"sipuleucel-T",{"EARLY_PHASE1":8621,"PHASE1":8623,"PHASE2":8636,"PHASE3":8651,"PHASE4":8653,"NA":8655},{"trials":8622,"activeCount":99},[],{"trials":8624,"activeCount":214,"soonestReadout":8629},[8625],{"nctId":8626,"briefTitle":8627,"status":203,"phases":8628,"primaryCompletion":8629,"completion":8629,"start":8630,"enrollment":298,"conditions":8631,"interventions":8633},"NCT07219147","177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer",[87],"2028-07-26","2026-03-06",[8632,1073],"Metastatic Castration-Resistant Prostate Adenocarcinoma",[8634,8635],"Lutetium Lu 177 Vipivotide Tetraxetan","Sipuleucel-T",{"trials":8637,"activeCount":99},[8638],{"nctId":8639,"briefTitle":8640,"status":107,"phases":8641,"primaryCompletion":8642,"completion":8643,"start":8644,"enrollment":1286,"conditions":8645,"interventions":8650},"NCT01807065","Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer",[88],"2018-12-31","2019-12-31","2013-06-07",[8646,225,8647,8648,228,8649],"Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer","Stage IV Prostate Cancer",[8619],{"trials":8652,"activeCount":99},[],{"trials":8654,"activeCount":99},[],{"trials":8656,"activeCount":99},[],{"intervention":8658,"totalTrials":363,"cells":8659},"Trametinib",{"EARLY_PHASE1":8660,"PHASE1":8662,"PHASE2":8709,"PHASE3":8711,"PHASE4":8713,"NA":8715},{"trials":8661,"activeCount":99},[],{"trials":8663,"activeCount":214,"soonestReadout":8701},[8664,8697],{"nctId":8665,"briefTitle":8666,"status":107,"phases":8667,"primaryCompletion":8668,"completion":8668,"start":8669,"enrollment":25,"conditions":8670,"interventions":8695},"NCT03317119","Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery",[87],"2023-07-14","2018-04-11",[8671,323,8672,8673,8674,8675,8676,8677,8678,8679,8680,8681,8682,8683,8684,8685,8686,8687,8688,8689,8690,8691,8692,8693,8694],"Metastatic Colon Carcinoma","Metastatic Rectal Carcinoma","RAS Family Gene Mutation","Stage III Colon Cancer AJCC v7","Stage III Colorectal Cancer AJCC v7","Stage III Rectal Cancer AJCC v7","Stage IIIA Colon Cancer AJCC v7","Stage IIIA Colorectal Cancer AJCC v7","Stage IIIA Rectal Cancer AJCC v7","Stage IIIB Colon Cancer AJCC v7","Stage IIIB Colorectal Cancer AJCC v7","Stage IIIB Rectal Cancer AJCC v7","Stage IIIC Colon Cancer AJCC v7","Stage IIIC Colorectal Cancer AJCC v7","Stage IIIC Rectal Cancer AJCC v7","Stage IV Colon Cancer AJCC v7","Stage IV Colorectal Cancer AJCC v7","Stage IV Rectal Cancer AJCC v7","Stage IVA Colon Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVA Rectal Cancer AJCC v7","Stage IVB Colon Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7","Stage IVB Rectal Cancer AJCC v7",[8658,8696],"Trifluridine and Tipiracil Hydrochloride",{"nctId":8698,"briefTitle":8699,"status":203,"phases":8700,"primaryCompletion":8701,"completion":8701,"start":8702,"enrollment":434,"conditions":8703,"interventions":8707},"NCT03975231","Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer",[87],"2027-10-05","2020-09-14",[8704,8705,8706],"BRAF NP_004324.2:p.V600E","BRAF V600K Mutation Present","Thyroid Gland Anaplastic Carcinoma",[8708,8658],"Dabrafenib",{"trials":8710,"activeCount":99},[],{"trials":8712,"activeCount":99},[],{"trials":8714,"activeCount":99},[],{"trials":8716,"activeCount":99},[],{"intervention":8718,"totalTrials":363,"cells":8719},"Islet cell transplantation",{"EARLY_PHASE1":8720,"PHASE1":8722,"PHASE2":8740,"PHASE3":8742,"PHASE4":8744,"NA":8746},{"trials":8721,"activeCount":99},[],{"trials":8723,"activeCount":214,"soonestReadout":8736},[8724,8732],{"nctId":8725,"briefTitle":8726,"status":107,"phases":8727,"primaryCompletion":355,"completion":355,"start":8728,"enrollment":283,"conditions":8729,"interventions":8731},"NCT00708604","Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes",[87],"2008-10-18",[8730],"Diabetes Mellitus",[8718],{"nctId":8733,"briefTitle":8734,"status":130,"phases":8735,"primaryCompletion":8736,"completion":8736,"start":8737,"enrollment":2543,"conditions":8738,"interventions":8739},"NCT00706420","Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen",[87],"2026-10-12","2004-04-07",[8730],[8718],{"trials":8741,"activeCount":99},[],{"trials":8743,"activeCount":99},[],{"trials":8745,"activeCount":99},[],{"trials":8747,"activeCount":99},[],{"intervention":1571,"totalTrials":363,"cells":8749},{"EARLY_PHASE1":8750,"PHASE1":8752,"PHASE2":8766,"PHASE3":8768,"PHASE4":8770,"NA":8772},{"trials":8751,"activeCount":99},[],{"trials":8753,"activeCount":214,"soonestReadout":8758},[8754,8762],{"nctId":8755,"briefTitle":8756,"status":203,"phases":8757,"primaryCompletion":8758,"completion":8758,"start":949,"enrollment":8759,"conditions":8760,"interventions":8761},"NCT07025538","Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation",[87],"2028-06-22",42,[3048],[1571],{"nctId":1563,"briefTitle":1564,"status":107,"phases":8763,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":36,"conditions":8764,"interventions":8765},[87],[1488,845],[847,823,849,1571,1165,1149,851],{"trials":8767,"activeCount":99},[],{"trials":8769,"activeCount":99},[],{"trials":8771,"activeCount":99},[],{"trials":8773,"activeCount":99},[],{"intervention":3267,"totalTrials":363,"cells":8775},{"EARLY_PHASE1":8776,"PHASE1":8778,"PHASE2":8788,"PHASE3":8790,"PHASE4":8792,"NA":8794},{"trials":8777,"activeCount":99},[],{"trials":8779,"activeCount":214,"soonestReadout":3234},[8780,8784],{"nctId":3231,"briefTitle":3232,"status":130,"phases":8781,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":188,"conditions":8782,"interventions":8783},[87],[3237,3238,1026,3239,3240,3241,3242,3243,3244,3245,3246,3247,3248,3249,3250,3251,3252,3253,3254,3255,3256,3257,3258,3259,3260,3261,3262,3263,3264],[169,345,3266,170,3267],{"nctId":4027,"briefTitle":4028,"status":479,"phases":8785,"primaryCompletion":4030,"completion":4030,"start":4031,"enrollment":99,"conditions":8786,"interventions":8787},[87],[1698],[4034,1556,1354,1321,3267],{"trials":8789,"activeCount":99},[],{"trials":8791,"activeCount":99},[],{"trials":8793,"activeCount":99},[],{"trials":8795,"activeCount":99},[],{"intervention":5240,"totalTrials":363,"cells":8797},{"EARLY_PHASE1":8798,"PHASE1":8800,"PHASE2":8810,"PHASE3":8812,"PHASE4":8814,"NA":8816},{"trials":8799,"activeCount":99},[],{"trials":8801,"activeCount":214,"soonestReadout":1994},[8802,8806],{"nctId":7956,"briefTitle":7957,"status":107,"phases":8803,"primaryCompletion":6311,"completion":6311,"start":7959,"enrollment":1632,"conditions":8804,"interventions":8805},[87],[18,1003,818,813,7961,819],[1212,5240],{"nctId":5229,"briefTitle":5230,"status":130,"phases":8807,"primaryCompletion":1994,"completion":1994,"start":5232,"enrollment":36,"conditions":8808,"interventions":8809},[87],[967,971,972,973,975,976,977,2896,978,5234,1855,1856,5235,2639,5236,5237,5238,1455],[1457,5240],{"trials":8811,"activeCount":99},[],{"trials":8813,"activeCount":99},[],{"trials":8815,"activeCount":99},[],{"trials":8817,"activeCount":99},[],{"intervention":4119,"totalTrials":363,"cells":8819},{"EARLY_PHASE1":8820,"PHASE1":8822,"PHASE2":8845,"PHASE3":8847,"PHASE4":8849,"NA":8851},{"trials":8821,"activeCount":99},[],{"trials":8823,"activeCount":214,"soonestReadout":4110},[8824,8828],{"nctId":4107,"briefTitle":4108,"status":130,"phases":8825,"primaryCompletion":4110,"completion":4111,"start":4112,"enrollment":33,"conditions":8826,"interventions":8827},[87],[4114,3712,4115,4116],[3266,4118,4119],{"nctId":8829,"briefTitle":8830,"status":107,"phases":8831,"primaryCompletion":8832,"completion":8832,"start":8833,"enrollment":283,"conditions":8834,"interventions":8843},"NCT02948283","Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia",[87],"2017-12-01","2017-09-05",[8835,8836,8837,3088,8838,8839,971,1102,5234,1103,8840,8841,8842],"Anemia","Fatigue","Fever","Lymphocytosis","Night Sweats","Splenomegaly","Thrombocytopenia","Weight Loss",[4119,8844],"Ritonavir",{"trials":8846,"activeCount":99},[],{"trials":8848,"activeCount":99},[],{"trials":8850,"activeCount":99},[],{"trials":8852,"activeCount":99},[],{"intervention":1094,"totalTrials":363,"cells":8854},{"EARLY_PHASE1":8855,"PHASE1":8857,"PHASE2":8867,"PHASE3":8869,"PHASE4":8871,"NA":8873},{"trials":8856,"activeCount":99},[],{"trials":8858,"activeCount":214,"soonestReadout":4350},[8859,8863],{"nctId":4347,"briefTitle":4348,"status":130,"phases":8860,"primaryCompletion":4350,"completion":4350,"start":4351,"enrollment":283,"conditions":8861,"interventions":8862},[87],[4353,4354,4355,935],[42,1094],{"nctId":1087,"briefTitle":1088,"status":107,"phases":8864,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":498,"conditions":8865,"interventions":8866},[87],[27],[1094,893,75,894],{"trials":8868,"activeCount":99},[],{"trials":8870,"activeCount":99},[],{"trials":8872,"activeCount":99},[],{"trials":8874,"activeCount":99},[],{"intervention":8315,"totalTrials":363,"cells":8876},{"EARLY_PHASE1":8877,"PHASE1":8879,"PHASE2":8896,"PHASE3":8898,"PHASE4":8900,"NA":8902},{"trials":8878,"activeCount":99},[],{"trials":8880,"activeCount":214,"soonestReadout":79},[8881,8892],{"nctId":8882,"briefTitle":8883,"status":107,"phases":8884,"primaryCompletion":8885,"completion":8885,"start":8886,"enrollment":890,"conditions":8887,"interventions":8889},"NCT01041443","5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes",[87],"2013-10","2009-12",[8888,8355,2777,812,813,8378,819],"Adult Acute Myeloid Leukemia",[8890,8891,2345,8315],"5-fluoro-2-deoxycytidine","tetrahydrouridine",{"nctId":77,"briefTitle":78,"status":130,"phases":8893,"primaryCompletion":79,"completion":8310,"start":8311,"enrollment":8312,"conditions":8894,"interventions":8895},[87],[124],[71,8315,273,274,275],{"trials":8897,"activeCount":99},[],{"trials":8899,"activeCount":99},[],{"trials":8901,"activeCount":99},[],{"trials":8903,"activeCount":99},[],{"intervention":712,"totalTrials":363,"cells":8905},{"EARLY_PHASE1":8906,"PHASE1":8908,"PHASE2":8918,"PHASE3":8920,"PHASE4":8922,"NA":8924},{"trials":8907,"activeCount":99},[],{"trials":8909,"activeCount":214,"soonestReadout":701},[8910,8914],{"nctId":698,"briefTitle":699,"status":130,"phases":8911,"primaryCompletion":701,"completion":154,"start":702,"enrollment":36,"conditions":8912,"interventions":8913},[87],[704,705,706,707,708,709,710],[712,306,426],{"nctId":714,"briefTitle":715,"status":479,"phases":8915,"primaryCompletion":392,"enrollment":99,"conditions":8916,"interventions":8917},[87],[578,579,580,581,582,583],[719,290],{"trials":8919,"activeCount":99},[],{"trials":8921,"activeCount":99},[],{"trials":8923,"activeCount":99},[],{"trials":8925,"activeCount":99},[],{"intervention":3397,"totalTrials":214,"cells":8927},{"EARLY_PHASE1":8928,"PHASE1":8930,"PHASE2":8936,"PHASE3":8938,"PHASE4":8940,"NA":8942},{"trials":8929,"activeCount":99},[],{"trials":8931,"activeCount":214,"soonestReadout":3234},[8932],{"nctId":3389,"briefTitle":3390,"status":203,"phases":8933,"primaryCompletion":3234,"completion":3234,"start":3392,"enrollment":36,"conditions":8934,"interventions":8935},[87],[3394,3100],[3396,3373,3397],{"trials":8937,"activeCount":99},[],{"trials":8939,"activeCount":99},[],{"trials":8941,"activeCount":99},[],{"trials":8943,"activeCount":99},[],{"intervention":2106,"totalTrials":214,"cells":8945},{"EARLY_PHASE1":8946,"PHASE1":8948,"PHASE2":8954,"PHASE3":8956,"PHASE4":8958,"NA":8960},{"trials":8947,"activeCount":99},[],{"trials":8949,"activeCount":214,"soonestReadout":2099},[8950],{"nctId":2096,"briefTitle":2097,"status":130,"phases":8951,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":22,"conditions":8952,"interventions":8953},[87],[2102,1410,1411,2103,2104,1414,1455],[2106,838],{"trials":8955,"activeCount":99},[],{"trials":8957,"activeCount":99},[],{"trials":8959,"activeCount":99},[],{"trials":8961,"activeCount":99},[],{"intervention":8963,"totalTrials":214,"cells":8964},"miR-126 Inhibitor miRisten",{"EARLY_PHASE1":8965,"PHASE1":8967,"PHASE2":8977,"PHASE3":8979,"PHASE4":8981,"NA":8983},{"trials":8966,"activeCount":99},[],{"trials":8968,"activeCount":214,"soonestReadout":8973},[8969],{"nctId":8970,"briefTitle":8971,"status":203,"phases":8972,"primaryCompletion":8973,"completion":8973,"start":8974,"enrollment":1632,"conditions":8975,"interventions":8976},"NCT07025564","MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",[87],"2027-04-08","2025-10-24",[1003,818],[8963],{"trials":8978,"activeCount":99},[],{"trials":8980,"activeCount":99},[],{"trials":8982,"activeCount":99},[],{"trials":8984,"activeCount":99},[],{"intervention":2115,"totalTrials":214,"cells":8986},{"EARLY_PHASE1":8987,"PHASE1":8989,"PHASE2":8995,"PHASE3":8997,"PHASE4":8999,"NA":9001},{"trials":8988,"activeCount":99},[],{"trials":8990,"activeCount":214,"soonestReadout":402},[8991],{"nctId":2108,"briefTitle":2109,"status":130,"phases":8992,"primaryCompletion":402,"completion":402,"start":2111,"enrollment":177,"conditions":8993,"interventions":8994},[87],[1971,1972,1049,1052],[2114,2115,838],{"trials":8996,"activeCount":99},[],{"trials":8998,"activeCount":99},[],{"trials":9000,"activeCount":99},[],{"trials":9002,"activeCount":99},[],{"intervention":821,"totalTrials":214,"cells":9004},{"EARLY_PHASE1":9005,"PHASE1":9007,"PHASE2":9013,"PHASE3":9015,"PHASE4":9017,"NA":9019},{"trials":9006,"activeCount":99},[],{"trials":9008,"activeCount":214,"soonestReadout":805},[9009],{"nctId":802,"briefTitle":803,"status":130,"phases":9010,"primaryCompletion":805,"completion":805,"start":806,"enrollment":177,"conditions":9011,"interventions":9012},[87],[808,809,810,811,812,813,814,18,815,816,817,818,819],[75,821,822,823],{"trials":9014,"activeCount":99},[],{"trials":9016,"activeCount":99},[],{"trials":9018,"activeCount":99},[],{"trials":9020,"activeCount":99},[],{"intervention":822,"totalTrials":214,"cells":9022},{"EARLY_PHASE1":9023,"PHASE1":9025,"PHASE2":9031,"PHASE3":9033,"PHASE4":9035,"NA":9037},{"trials":9024,"activeCount":99},[],{"trials":9026,"activeCount":214,"soonestReadout":805},[9027],{"nctId":802,"briefTitle":803,"status":130,"phases":9028,"primaryCompletion":805,"completion":805,"start":806,"enrollment":177,"conditions":9029,"interventions":9030},[87],[808,809,810,811,812,813,814,18,815,816,817,818,819],[75,821,822,823],{"trials":9032,"activeCount":99},[],{"trials":9034,"activeCount":99},[],{"trials":9036,"activeCount":99},[],{"trials":9038,"activeCount":99},[],{"intervention":8000,"totalTrials":214,"cells":9040},{"EARLY_PHASE1":9041,"PHASE1":9043,"PHASE2":9049,"PHASE3":9051,"PHASE4":9053,"NA":9055},{"trials":9042,"activeCount":99},[],{"trials":9044,"activeCount":214,"soonestReadout":2026},[9045],{"nctId":7994,"briefTitle":7995,"status":203,"phases":9046,"primaryCompletion":2026,"completion":2026,"start":7997,"enrollment":2914,"conditions":9047,"interventions":9048},[87],[18,21],[2555,8000],{"trials":9050,"activeCount":99},[],{"trials":9052,"activeCount":99},[],{"trials":9054,"activeCount":99},[],{"trials":9056,"activeCount":99},[],{"intervention":848,"totalTrials":214,"cells":9058},{"EARLY_PHASE1":9059,"PHASE1":9061,"PHASE2":9067,"PHASE3":9069,"PHASE4":9071,"NA":9073},{"trials":9060,"activeCount":99},[],{"trials":9062,"activeCount":214,"soonestReadout":205},[9063],{"nctId":840,"briefTitle":841,"status":130,"phases":9064,"primaryCompletion":205,"completion":205,"start":843,"enrollment":693,"conditions":9065,"interventions":9066},[87],[845],[784,847,848,849,850,851],{"trials":9068,"activeCount":99},[],{"trials":9070,"activeCount":99},[],{"trials":9072,"activeCount":99},[],{"trials":9074,"activeCount":99},[],{"intervention":5537,"totalTrials":214,"cells":9076},{"EARLY_PHASE1":9077,"PHASE1":9079,"PHASE2":9085,"PHASE3":9087,"PHASE4":9089,"NA":9091},{"trials":9078,"activeCount":99},[],{"trials":9080,"activeCount":214,"soonestReadout":656},[9081],{"nctId":5530,"briefTitle":5531,"status":130,"phases":9082,"primaryCompletion":656,"completion":656,"start":3431,"enrollment":9,"conditions":9083,"interventions":9084},[87],[5534,500,503,504,505,506,507,508,509,5535],[5523,5537],{"trials":9086,"activeCount":99},[],{"trials":9088,"activeCount":99},[],{"trials":9090,"activeCount":99},[],{"trials":9092,"activeCount":99},[],{"intervention":861,"totalTrials":214,"cells":9094},{"EARLY_PHASE1":9095,"PHASE1":9097,"PHASE2":9103,"PHASE3":9105,"PHASE4":9107,"NA":9109},{"trials":9096,"activeCount":99},[],{"trials":9098,"activeCount":214,"soonestReadout":856},[9099],{"nctId":853,"briefTitle":854,"status":130,"phases":9100,"primaryCompletion":856,"completion":856,"start":857,"enrollment":36,"conditions":9101,"interventions":9102},[87],[859],[861,784,847],{"trials":9104,"activeCount":99},[],{"trials":9106,"activeCount":99},[],{"trials":9108,"activeCount":99},[],{"trials":9110,"activeCount":99},[],{"intervention":9112,"totalTrials":214,"cells":9113},"Arm 1: IL13Ra2-specific CAR Tcm cells",{"EARLY_PHASE1":9114,"PHASE1":9116,"PHASE2":9135,"PHASE3":9137,"PHASE4":9139,"NA":9141},{"trials":9115,"activeCount":99},[],{"trials":9117,"activeCount":214,"soonestReadout":9122},[9118],{"nctId":9119,"briefTitle":9120,"status":130,"phases":9121,"primaryCompletion":9122,"completion":5901,"start":9123,"enrollment":9124,"conditions":9125,"interventions":9130},"NCT02208362","Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma",[87],"2021-02-08","2015-05-18",65,[707,709,9126,710,2152,9127,9128,9129],"Recurrent WHO Grade II Glioma","Refractory Malignant Glioma","Refractory WHO Grade II Glioma","Refractory WHO Grade III Glioma",[9112,9131,9132,9133,9134],"Arm 2: IL13Ra2-specific CAR Tcm cells","Arm 3: IL13Ra2-specific CAR Tcm cells","Arm 4: IL13Ra2-specific CAR Tcm cells","Arm 5: IL13Ra2-specific CAR Tn\u002Fmem cells",{"trials":9136,"activeCount":99},[],{"trials":9138,"activeCount":99},[],{"trials":9140,"activeCount":99},[],{"trials":9142,"activeCount":99},[],{"intervention":9131,"totalTrials":214,"cells":9144},{"EARLY_PHASE1":9145,"PHASE1":9147,"PHASE2":9153,"PHASE3":9155,"PHASE4":9157,"NA":9159},{"trials":9146,"activeCount":99},[],{"trials":9148,"activeCount":214,"soonestReadout":9122},[9149],{"nctId":9119,"briefTitle":9120,"status":130,"phases":9150,"primaryCompletion":9122,"completion":5901,"start":9123,"enrollment":9124,"conditions":9151,"interventions":9152},[87],[707,709,9126,710,2152,9127,9128,9129],[9112,9131,9132,9133,9134],{"trials":9154,"activeCount":99},[],{"trials":9156,"activeCount":99},[],{"trials":9158,"activeCount":99},[],{"trials":9160,"activeCount":99},[],{"intervention":9132,"totalTrials":214,"cells":9162},{"EARLY_PHASE1":9163,"PHASE1":9165,"PHASE2":9171,"PHASE3":9173,"PHASE4":9175,"NA":9177},{"trials":9164,"activeCount":99},[],{"trials":9166,"activeCount":214,"soonestReadout":9122},[9167],{"nctId":9119,"briefTitle":9120,"status":130,"phases":9168,"primaryCompletion":9122,"completion":5901,"start":9123,"enrollment":9124,"conditions":9169,"interventions":9170},[87],[707,709,9126,710,2152,9127,9128,9129],[9112,9131,9132,9133,9134],{"trials":9172,"activeCount":99},[],{"trials":9174,"activeCount":99},[],{"trials":9176,"activeCount":99},[],{"trials":9178,"activeCount":99},[],{"intervention":9133,"totalTrials":214,"cells":9180},{"EARLY_PHASE1":9181,"PHASE1":9183,"PHASE2":9189,"PHASE3":9191,"PHASE4":9193,"NA":9195},{"trials":9182,"activeCount":99},[],{"trials":9184,"activeCount":214,"soonestReadout":9122},[9185],{"nctId":9119,"briefTitle":9120,"status":130,"phases":9186,"primaryCompletion":9122,"completion":5901,"start":9123,"enrollment":9124,"conditions":9187,"interventions":9188},[87],[707,709,9126,710,2152,9127,9128,9129],[9112,9131,9132,9133,9134],{"trials":9190,"activeCount":99},[],{"trials":9192,"activeCount":99},[],{"trials":9194,"activeCount":99},[],{"trials":9196,"activeCount":99},[],{"intervention":9134,"totalTrials":214,"cells":9198},{"EARLY_PHASE1":9199,"PHASE1":9201,"PHASE2":9207,"PHASE3":9209,"PHASE4":9211,"NA":9213},{"trials":9200,"activeCount":99},[],{"trials":9202,"activeCount":214,"soonestReadout":9122},[9203],{"nctId":9119,"briefTitle":9120,"status":130,"phases":9204,"primaryCompletion":9122,"completion":5901,"start":9123,"enrollment":9124,"conditions":9205,"interventions":9206},[87],[707,709,9126,710,2152,9127,9128,9129],[9112,9131,9132,9133,9134],{"trials":9208,"activeCount":99},[],{"trials":9210,"activeCount":99},[],{"trials":9212,"activeCount":99},[],{"trials":9214,"activeCount":99},[],{"intervention":511,"totalTrials":214,"cells":9216},{"EARLY_PHASE1":9217,"PHASE1":9219,"PHASE2":9225,"PHASE3":9227,"PHASE4":9229,"NA":9231},{"trials":9218,"activeCount":99},[],{"trials":9220,"activeCount":214,"soonestReadout":496},[9221],{"nctId":493,"briefTitle":494,"status":130,"phases":9222,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":9223,"interventions":9224},[87],[500,501,502,503,504,505,506,507,508,509],[413,511],{"trials":9226,"activeCount":99},[],{"trials":9228,"activeCount":99},[],{"trials":9230,"activeCount":99},[],{"trials":9232,"activeCount":99},[],{"intervention":9234,"totalTrials":214,"cells":9235},"Carfilzomib",{"EARLY_PHASE1":9236,"PHASE1":9238,"PHASE2":9249,"PHASE3":9251,"PHASE4":9253,"NA":9255},{"trials":9237,"activeCount":99},[],{"trials":9239,"activeCount":214,"soonestReadout":9244},[9240],{"nctId":9241,"briefTitle":9242,"status":203,"phases":9243,"primaryCompletion":9244,"completion":9244,"start":9245,"enrollment":795,"conditions":9246,"interventions":9247},"NCT06249282","Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer",[87],"2026-11-24","2024-04-24",[5534,501,503,507],[9234,9248],"Sotorasib",{"trials":9250,"activeCount":99},[],{"trials":9252,"activeCount":99},[],{"trials":9254,"activeCount":99},[],{"trials":9256,"activeCount":99},[],{"intervention":9248,"totalTrials":214,"cells":9258},{"EARLY_PHASE1":9259,"PHASE1":9261,"PHASE2":9267,"PHASE3":9269,"PHASE4":9271,"NA":9273},{"trials":9260,"activeCount":99},[],{"trials":9262,"activeCount":214,"soonestReadout":9244},[9263],{"nctId":9241,"briefTitle":9242,"status":203,"phases":9264,"primaryCompletion":9244,"completion":9244,"start":9245,"enrollment":795,"conditions":9265,"interventions":9266},[87],[5534,501,503,507],[9234,9248],{"trials":9268,"activeCount":99},[],{"trials":9270,"activeCount":99},[],{"trials":9272,"activeCount":99},[],{"trials":9274,"activeCount":99},[],{"intervention":4912,"totalTrials":214,"cells":9276},{"EARLY_PHASE1":9277,"PHASE1":9279,"PHASE2":9285,"PHASE3":9287,"PHASE4":9289,"NA":9291},{"trials":9278,"activeCount":99},[],{"trials":9280,"activeCount":214,"soonestReadout":4900},[9281],{"nctId":4897,"briefTitle":4898,"status":203,"phases":9282,"primaryCompletion":4900,"completion":4900,"start":4901,"enrollment":964,"conditions":9283,"interventions":9284},[87],[1408,4903,972,4904,1848,1849,1850,976,4905,4906,4907,1855,4908,4715,4716,4717,2639,4909,4910],[4912,4890],{"trials":9286,"activeCount":99},[],{"trials":9288,"activeCount":99},[],{"trials":9290,"activeCount":99},[],{"trials":9292,"activeCount":99},[],{"intervention":4922,"totalTrials":214,"cells":9294},{"EARLY_PHASE1":9295,"PHASE1":9297,"PHASE2":9303,"PHASE3":9305,"PHASE4":9307,"NA":9309},{"trials":9296,"activeCount":99},[],{"trials":9298,"activeCount":214,"soonestReadout":4917},[9299],{"nctId":4914,"briefTitle":4915,"status":203,"phases":9300,"primaryCompletion":4917,"completion":4917,"start":4918,"enrollment":1666,"conditions":9301,"interventions":9302},[87],[1453,1454,1455,4920],[4922,4890],{"trials":9304,"activeCount":99},[],{"trials":9306,"activeCount":99},[],{"trials":9308,"activeCount":99},[],{"trials":9310,"activeCount":99},[],{"intervention":9312,"totalTrials":214,"cells":9313},"SB-728mR-HSPC Infusion 3 days following busulfan conditioning",{"EARLY_PHASE1":9314,"PHASE1":9316,"PHASE2":9327,"PHASE3":9329,"PHASE4":9331,"NA":9333},{"trials":9315,"activeCount":99},[],{"trials":9317,"activeCount":214,"soonestReadout":9322},[9318],{"nctId":9319,"briefTitle":9320,"status":130,"phases":9321,"primaryCompletion":9322,"completion":9322,"start":9323,"enrollment":1632,"conditions":9324,"interventions":9326},"NCT02500849","Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem\u002FProgenitor Cells in HIV-1 Infected Patients",[87],"2026-08-24","2016-03-10",[9325],"HIV",[9312],{"trials":9328,"activeCount":99},[],{"trials":9330,"activeCount":99},[],{"trials":9332,"activeCount":99},[],{"trials":9334,"activeCount":99},[],{"intervention":9336,"totalTrials":214,"cells":9337},"Agent Affecting Integumentary System",{"EARLY_PHASE1":9338,"PHASE1":9340,"PHASE2":9351,"PHASE3":9353,"PHASE4":9355,"NA":9357},{"trials":9339,"activeCount":99},[],{"trials":9341,"activeCount":214,"soonestReadout":9346},[9342],{"nctId":9343,"briefTitle":9344,"status":130,"phases":9345,"primaryCompletion":9346,"completion":9346,"start":9347,"enrollment":9348,"conditions":9349,"interventions":9350},"NCT05340673","Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer",[87],"2026-12-15","2022-06-21",208,[6845,777],[9336],{"trials":9352,"activeCount":99},[],{"trials":9354,"activeCount":99},[],{"trials":9356,"activeCount":99},[],{"trials":9358,"activeCount":99},[],{"intervention":9360,"totalTrials":214,"cells":9361},"BTK Inhibitor",{"EARLY_PHASE1":9362,"PHASE1":9364,"PHASE2":9374,"PHASE3":9376,"PHASE4":9378,"NA":9380},{"trials":9363,"activeCount":99},[],{"trials":9365,"activeCount":214,"soonestReadout":9370},[9366],{"nctId":9367,"briefTitle":9368,"status":203,"phases":9369,"primaryCompletion":9370,"completion":9370,"start":949,"enrollment":207,"conditions":9371,"interventions":9372},"NCT06675123","Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma",[87],"2028-03-08",[976,2639],[9360,9373],"Pacritinib",{"trials":9375,"activeCount":99},[],{"trials":9377,"activeCount":99},[],{"trials":9379,"activeCount":99},[],{"trials":9381,"activeCount":99},[],{"intervention":9373,"totalTrials":214,"cells":9383},{"EARLY_PHASE1":9384,"PHASE1":9386,"PHASE2":9392,"PHASE3":9394,"PHASE4":9396,"NA":9398},{"trials":9385,"activeCount":99},[],{"trials":9387,"activeCount":214,"soonestReadout":9370},[9388],{"nctId":9367,"briefTitle":9368,"status":203,"phases":9389,"primaryCompletion":9370,"completion":9370,"start":949,"enrollment":207,"conditions":9390,"interventions":9391},[87],[976,2639],[9360,9373],{"trials":9393,"activeCount":99},[],{"trials":9395,"activeCount":99},[],{"trials":9397,"activeCount":99},[],{"trials":9399,"activeCount":99},[],{"intervention":9401,"totalTrials":214,"cells":9402},"Hematopoietic stem cell transplantation",{"EARLY_PHASE1":9403,"PHASE1":9405,"PHASE2":9414,"PHASE3":9416,"PHASE4":9418,"NA":9420},{"trials":9404,"activeCount":99},[],{"trials":9406,"activeCount":214,"soonestReadout":1109},[9407],{"nctId":9408,"briefTitle":9409,"status":203,"phases":9410,"primaryCompletion":1109,"completion":1109,"start":9411,"enrollment":264,"conditions":9412,"interventions":9413},"NCT03279094","Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease",[87],"2018-02-02",[1112],[9401],{"trials":9415,"activeCount":99},[],{"trials":9417,"activeCount":99},[],{"trials":9419,"activeCount":99},[],{"trials":9421,"activeCount":99},[],{"intervention":8708,"totalTrials":214,"cells":9423},{"EARLY_PHASE1":9424,"PHASE1":9426,"PHASE2":9432,"PHASE3":9434,"PHASE4":9436,"NA":9438},{"trials":9425,"activeCount":99},[],{"trials":9427,"activeCount":214,"soonestReadout":8701},[9428],{"nctId":8698,"briefTitle":8699,"status":203,"phases":9429,"primaryCompletion":8701,"completion":8701,"start":8702,"enrollment":434,"conditions":9430,"interventions":9431},[87],[8704,8705,8706],[8708,8658],{"trials":9433,"activeCount":99},[],{"trials":9435,"activeCount":99},[],{"trials":9437,"activeCount":99},[],{"trials":9439,"activeCount":99},[],{"intervention":3714,"totalTrials":214,"cells":9441},{"EARLY_PHASE1":9442,"PHASE1":9444,"PHASE2":9450,"PHASE3":9452,"PHASE4":9454,"NA":9456},{"trials":9443,"activeCount":99},[],{"trials":9445,"activeCount":214,"soonestReadout":3709},[9446],{"nctId":3706,"briefTitle":3707,"status":203,"phases":9447,"primaryCompletion":3709,"completion":3709,"start":3710,"enrollment":33,"conditions":9448,"interventions":9449},[87],[1048,1051,3712],[3714,2021,84],{"trials":9451,"activeCount":99},[],{"trials":9453,"activeCount":99},[],{"trials":9455,"activeCount":99},[],{"trials":9457,"activeCount":99},[],{"intervention":2154,"totalTrials":214,"cells":9459},{"EARLY_PHASE1":9460,"PHASE1":9462,"PHASE2":9468,"PHASE3":9470,"PHASE4":9472,"NA":9474},{"trials":9461,"activeCount":99},[],{"trials":9463,"activeCount":214,"soonestReadout":2148},[9464],{"nctId":2145,"briefTitle":2146,"status":130,"phases":9465,"primaryCompletion":2148,"completion":2149,"start":2150,"enrollment":404,"conditions":9466,"interventions":9467},[87],[707,2152],[2154,2114,838],{"trials":9469,"activeCount":99},[],{"trials":9471,"activeCount":99},[],{"trials":9473,"activeCount":99},[],{"trials":9475,"activeCount":99},[],{"intervention":9477,"totalTrials":214,"cells":9478},"Tolerogenic Dendritic Cell Vaccine",{"EARLY_PHASE1":9479,"PHASE1":9481,"PHASE2":9491,"PHASE3":9493,"PHASE4":9495,"NA":9497},{"trials":9480,"activeCount":99},[],{"trials":9482,"activeCount":214,"soonestReadout":9487},[9483],{"nctId":9484,"briefTitle":9485,"status":130,"phases":9486,"primaryCompletion":9487,"completion":9346,"start":9488,"enrollment":434,"conditions":9489,"interventions":9490},"NCT04590872","An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes",[87],"2024-06-03","2022-06-16",[5777],[9477],{"trials":9492,"activeCount":99},[],{"trials":9494,"activeCount":99},[],{"trials":9496,"activeCount":99},[],{"trials":9498,"activeCount":99},[],{"intervention":2546,"totalTrials":214,"cells":9500},{"EARLY_PHASE1":9501,"PHASE1":9503,"PHASE2":9509,"PHASE3":9511,"PHASE4":9513,"NA":9515},{"trials":9502,"activeCount":99},[],{"trials":9504,"activeCount":214,"soonestReadout":828},[9505],{"nctId":2539,"briefTitle":2540,"status":130,"phases":9506,"primaryCompletion":828,"completion":828,"start":2542,"enrollment":2543,"conditions":9507,"interventions":9508},[87],[1003,818],[1212,2546,956],{"trials":9510,"activeCount":99},[],{"trials":9512,"activeCount":99},[],{"trials":9514,"activeCount":99},[],{"trials":9516,"activeCount":99},[],{"intervention":9518,"totalTrials":214,"cells":9519},"Copper Cu 64-DOTA-A2DM",{"EARLY_PHASE1":9520,"PHASE1":9522,"PHASE2":9533,"PHASE3":9535,"PHASE4":9537,"NA":9539},{"trials":9521,"activeCount":99},[],{"trials":9523,"activeCount":214,"soonestReadout":9528},[9524],{"nctId":9525,"briefTitle":9526,"status":294,"phases":9527,"primaryCompletion":9528,"completion":9528,"start":2969,"enrollment":795,"conditions":9529,"interventions":9532},"NCT07608627","64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer",[87],"2028-07-14",[9530,9531,1048,1051],"Locally Advanced Pancreatic Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma",[9518],{"trials":9534,"activeCount":99},[],{"trials":9536,"activeCount":99},[],{"trials":9538,"activeCount":99},[],{"trials":9540,"activeCount":99},[],{"intervention":9542,"totalTrials":214,"cells":9543},"Consolidation Therapy",{"EARLY_PHASE1":9544,"PHASE1":9546,"PHASE2":9559,"PHASE3":9561,"PHASE4":9563,"NA":9565},{"trials":9545,"activeCount":99},[],{"trials":9547,"activeCount":214,"soonestReadout":9552},[9548],{"nctId":9549,"briefTitle":9550,"status":203,"phases":9551,"primaryCompletion":9552,"completion":9552,"start":9553,"enrollment":1610,"conditions":9554,"interventions":9557},"NCT06834126","Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial",[87],"2028-09-19","2025-04-07",[9555,9556,457],"Locally Advanced Rectal Adenocarcinoma","Stage II Rectal Cancer AJCC v8",[9542,9558],"Papaverine",{"trials":9560,"activeCount":99},[],{"trials":9562,"activeCount":99},[],{"trials":9564,"activeCount":99},[],{"trials":9566,"activeCount":99},[],{"intervention":9558,"totalTrials":214,"cells":9568},{"EARLY_PHASE1":9569,"PHASE1":9571,"PHASE2":9577,"PHASE3":9579,"PHASE4":9581,"NA":9583},{"trials":9570,"activeCount":99},[],{"trials":9572,"activeCount":214,"soonestReadout":9552},[9573],{"nctId":9549,"briefTitle":9550,"status":203,"phases":9574,"primaryCompletion":9552,"completion":9552,"start":9553,"enrollment":1610,"conditions":9575,"interventions":9576},[87],[9555,9556,457],[9542,9558],{"trials":9578,"activeCount":99},[],{"trials":9580,"activeCount":99},[],{"trials":9582,"activeCount":99},[],{"trials":9584,"activeCount":99},[],{"intervention":943,"totalTrials":214,"cells":9586},{"EARLY_PHASE1":9587,"PHASE1":9589,"PHASE2":9595,"PHASE3":9597,"PHASE4":9599,"NA":9601},{"trials":9588,"activeCount":99},[],{"trials":9590,"activeCount":214,"soonestReadout":928},[9591],{"nctId":925,"briefTitle":926,"status":130,"phases":9592,"primaryCompletion":928,"completion":928,"start":929,"enrollment":207,"conditions":9593,"interventions":9594},[87],[931,932,933,934,935,936],[938,939,940,941,942,784,66,943],{"trials":9596,"activeCount":99},[],{"trials":9598,"activeCount":99},[],{"trials":9600,"activeCount":99},[],{"trials":9602,"activeCount":99},[],{"intervention":981,"totalTrials":214,"cells":9604},{"EARLY_PHASE1":9605,"PHASE1":9607,"PHASE2":9613,"PHASE3":9615,"PHASE4":9617,"NA":9619},{"trials":9606,"activeCount":99},[],{"trials":9608,"activeCount":214,"soonestReadout":962},[9609],{"nctId":959,"briefTitle":960,"status":130,"phases":9610,"primaryCompletion":962,"completion":962,"start":963,"enrollment":964,"conditions":9611,"interventions":9612},[87],[966,967,968,969,970,971,972,973,974,975,976,977,978],[980,981,784,940,823],{"trials":9614,"activeCount":99},[],{"trials":9616,"activeCount":99},[],{"trials":9618,"activeCount":99},[],{"trials":9620,"activeCount":99},[],{"intervention":309,"totalTrials":214,"cells":9622},{"EARLY_PHASE1":9623,"PHASE1":9625,"PHASE2":9631,"PHASE3":9633,"PHASE4":9635,"NA":9637},{"trials":9624,"activeCount":99},[],{"trials":9626,"activeCount":214,"soonestReadout":296},[9627],{"nctId":292,"briefTitle":293,"status":294,"phases":9628,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":9629,"interventions":9630},[87],[300,301,302,303],[305,306,307,308,309],{"trials":9632,"activeCount":99},[],{"trials":9634,"activeCount":99},[],{"trials":9636,"activeCount":99},[],{"trials":9638,"activeCount":99},[],{"intervention":9640,"totalTrials":214,"cells":9641},"Revumenib",{"EARLY_PHASE1":9642,"PHASE1":9644,"PHASE2":9659,"PHASE3":9661,"PHASE4":9663,"NA":9665},{"trials":9643,"activeCount":99},[],{"trials":9645,"activeCount":214,"soonestReadout":9650},[9646],{"nctId":9647,"briefTitle":9648,"status":203,"phases":9649,"primaryCompletion":9650,"completion":9650,"start":9651,"enrollment":22,"conditions":9652,"interventions":9658},"NCT06575296","Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant",[87],"2028-04-29","2024-12-06",[1407,9653,35,18,9654,9655,9656,9657],"Acute Leukemia of Ambiguous Lineage","Childhood Acute Leukemia","Childhood Acute Leukemia of Ambiguous Lineage","Childhood Acute Lymphoblastic Leukemia","Childhood Acute Myeloid Leukemia",[9640],{"trials":9660,"activeCount":99},[],{"trials":9662,"activeCount":99},[],{"trials":9664,"activeCount":99},[],{"trials":9666,"activeCount":99},[],{"intervention":1005,"totalTrials":214,"cells":9668},{"EARLY_PHASE1":9669,"PHASE1":9671,"PHASE2":9677,"PHASE3":9679,"PHASE4":9681,"NA":9683},{"trials":9670,"activeCount":99},[],{"trials":9672,"activeCount":214,"soonestReadout":999},[9673],{"nctId":996,"briefTitle":997,"status":294,"phases":9674,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":9675,"interventions":9676},[87],[1003,818],[784,847,1005],{"trials":9678,"activeCount":99},[],{"trials":9680,"activeCount":99},[],{"trials":9682,"activeCount":99},[],{"trials":9684,"activeCount":99},[],{"intervention":7679,"totalTrials":214,"cells":9686},{"EARLY_PHASE1":9687,"PHASE1":9689,"PHASE2":9695,"PHASE3":9697,"PHASE4":9699,"NA":9701},{"trials":9688,"activeCount":99},[],{"trials":9690,"activeCount":214,"soonestReadout":7668},[9691],{"nctId":7665,"briefTitle":7666,"status":203,"phases":9692,"primaryCompletion":7668,"completion":7668,"start":7669,"enrollment":3226,"conditions":9693,"interventions":9694},[87],[7671,7672,7673,7674,7675,7676,7677],[345,7679],{"trials":9696,"activeCount":99},[],{"trials":9698,"activeCount":99},[],{"trials":9700,"activeCount":99},[],{"trials":9702,"activeCount":99},[],{"intervention":9704,"totalTrials":214,"cells":9705},"Microencapsulated Sodium Butyrate",{"EARLY_PHASE1":9706,"PHASE1":9708,"PHASE2":9719,"PHASE3":9721,"PHASE4":9723,"NA":9725},{"trials":9707,"activeCount":99},[],{"trials":9709,"activeCount":214,"soonestReadout":9714},[9710],{"nctId":9711,"briefTitle":9712,"status":294,"phases":9713,"primaryCompletion":9714,"completion":9714,"start":9715,"enrollment":1632,"conditions":9716,"interventions":9717},"NCT07611370","Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers",[87],"2027-06-30","2026-09-30",[1231,3048,29],[9704,9718],"Microencapsulated Sodium Propionate",{"trials":9720,"activeCount":99},[],{"trials":9722,"activeCount":99},[],{"trials":9724,"activeCount":99},[],{"trials":9726,"activeCount":99},[],{"intervention":9718,"totalTrials":214,"cells":9728},{"EARLY_PHASE1":9729,"PHASE1":9731,"PHASE2":9737,"PHASE3":9739,"PHASE4":9741,"NA":9743},{"trials":9730,"activeCount":99},[],{"trials":9732,"activeCount":214,"soonestReadout":9714},[9733],{"nctId":9711,"briefTitle":9712,"status":294,"phases":9734,"primaryCompletion":9714,"completion":9714,"start":9715,"enrollment":1632,"conditions":9735,"interventions":9736},[87],[1231,3048,29],[9704,9718],{"trials":9738,"activeCount":99},[],{"trials":9740,"activeCount":99},[],{"trials":9742,"activeCount":99},[],{"trials":9744,"activeCount":99},[],{"intervention":3554,"totalTrials":214,"cells":9746},{"EARLY_PHASE1":9747,"PHASE1":9749,"PHASE2":9755,"PHASE3":9757,"PHASE4":9759,"NA":9761},{"trials":9748,"activeCount":99},[],{"trials":9750,"activeCount":214,"soonestReadout":3550},[9751],{"nctId":3547,"briefTitle":3548,"status":130,"phases":9752,"primaryCompletion":3550,"completion":3550,"start":3551,"enrollment":363,"conditions":9753,"interventions":9754},[87],[1112],[3554,1149],{"trials":9756,"activeCount":99},[],{"trials":9758,"activeCount":99},[],{"trials":9760,"activeCount":99},[],{"trials":9762,"activeCount":99},[],{"intervention":1028,"totalTrials":214,"cells":9764},{"EARLY_PHASE1":9765,"PHASE1":9767,"PHASE2":9773,"PHASE3":9775,"PHASE4":9777,"NA":9779},{"trials":9766,"activeCount":99},[],{"trials":9768,"activeCount":214,"soonestReadout":1022},[9769],{"nctId":1019,"briefTitle":1020,"status":203,"phases":9770,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":919,"conditions":9771,"interventions":9772},[87],[1026],[1028,784,847],{"trials":9774,"activeCount":99},[],{"trials":9776,"activeCount":99},[],{"trials":9778,"activeCount":99},[],{"trials":9780,"activeCount":99},[],{"intervention":9782,"totalTrials":214,"cells":9783},"Oncolytic Virus CF33-expressing hNIS\u002FAnti-PD-L1 Antibody",{"EARLY_PHASE1":9784,"PHASE1":9786,"PHASE2":9796,"PHASE3":9798,"PHASE4":9800,"NA":9802},{"trials":9785,"activeCount":99},[],{"trials":9787,"activeCount":214,"soonestReadout":9792},[9788],{"nctId":9789,"briefTitle":9790,"status":130,"phases":9791,"primaryCompletion":9792,"completion":9792,"start":9793,"enrollment":95,"conditions":9794,"interventions":9795},"NCT05081492","CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer",[87],"2027-03-01","2021-10-18",[209,1960,3351],[9782],{"trials":9797,"activeCount":99},[],{"trials":9799,"activeCount":99},[],{"trials":9801,"activeCount":99},[],{"trials":9803,"activeCount":99},[],{"intervention":3870,"totalTrials":214,"cells":9805},{"EARLY_PHASE1":9806,"PHASE1":9808,"PHASE2":9814,"PHASE3":9816,"PHASE4":9818,"NA":9820},{"trials":9807,"activeCount":99},[],{"trials":9809,"activeCount":214,"soonestReadout":3866},[9810],{"nctId":3863,"briefTitle":3864,"status":203,"phases":9811,"primaryCompletion":3866,"completion":3866,"start":3867,"enrollment":298,"conditions":9812,"interventions":9813},[87],[320,1469,325],[84,170,3870],{"trials":9815,"activeCount":99},[],{"trials":9817,"activeCount":99},[],{"trials":9819,"activeCount":99},[],{"trials":9821,"activeCount":99},[],{"intervention":1085,"totalTrials":214,"cells":9823},{"EARLY_PHASE1":9824,"PHASE1":9826,"PHASE2":9832,"PHASE3":9834,"PHASE4":9836,"NA":9838},{"trials":9825,"activeCount":99},[],{"trials":9827,"activeCount":214,"soonestReadout":1080},[9828],{"nctId":1077,"briefTitle":1078,"status":203,"phases":9829,"primaryCompletion":1080,"completion":1080,"start":1081,"enrollment":404,"conditions":9830,"interventions":9831},[87],[1083],[1085,784,847],{"trials":9833,"activeCount":99},[],{"trials":9835,"activeCount":99},[],{"trials":9837,"activeCount":99},[],{"trials":9839,"activeCount":99},[],{"intervention":9841,"totalTrials":214,"cells":9842},"Immunotherapy",{"EARLY_PHASE1":9843,"PHASE1":9845,"PHASE2":9856,"PHASE3":9858,"PHASE4":9860,"NA":9862},{"trials":9844,"activeCount":99},[],{"trials":9846,"activeCount":214,"soonestReadout":9851},[9847],{"nctId":9848,"briefTitle":9849,"status":203,"phases":9850,"primaryCompletion":9851,"completion":9851,"start":9852,"enrollment":30,"conditions":9853,"interventions":9855},"NCT06130826","Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer",[87],"2026-09-05","2025-05-27",[6095,9854],"Colorectal Carcinoma",[9841],{"trials":9857,"activeCount":99},[],{"trials":9859,"activeCount":99},[],{"trials":9861,"activeCount":99},[],{"trials":9863,"activeCount":99},[],{"intervention":9865,"totalTrials":214,"cells":9866},"Asciminib",{"EARLY_PHASE1":9867,"PHASE1":9869,"PHASE2":9880,"PHASE3":9882,"PHASE4":9884,"NA":9886},{"trials":9868,"activeCount":99},[],{"trials":9870,"activeCount":214,"soonestReadout":9875},[9871],{"nctId":9872,"briefTitle":9873,"status":294,"phases":9874,"primaryCompletion":9875,"completion":9875,"start":9876,"enrollment":298,"conditions":9877,"interventions":9879},"NCT07040982","Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[87],"2028-06-13","2026-05-01",[9878],"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1",[9865],{"trials":9881,"activeCount":99},[],{"trials":9883,"activeCount":99},[],{"trials":9885,"activeCount":99},[],{"trials":9887,"activeCount":99},[],{"intervention":2185,"totalTrials":214,"cells":9889},{"EARLY_PHASE1":9890,"PHASE1":9892,"PHASE2":9898,"PHASE3":9900,"PHASE4":9902,"NA":9904},{"trials":9891,"activeCount":99},[],{"trials":9893,"activeCount":214,"soonestReadout":2181},[9894],{"nctId":2178,"briefTitle":2179,"status":130,"phases":9895,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":919,"conditions":9896,"interventions":9897},[87],[1847,1854],[838,2185],{"trials":9899,"activeCount":99},[],{"trials":9901,"activeCount":99},[],{"trials":9903,"activeCount":99},[],{"trials":9905,"activeCount":99},[],{"intervention":2197,"totalTrials":214,"cells":9907},{"EARLY_PHASE1":9908,"PHASE1":9910,"PHASE2":9916,"PHASE3":9918,"PHASE4":9920,"NA":9922},{"trials":9909,"activeCount":99},[],{"trials":9911,"activeCount":214,"soonestReadout":2190},[9912],{"nctId":2187,"briefTitle":2188,"status":130,"phases":9913,"primaryCompletion":2190,"completion":2190,"start":2191,"enrollment":177,"conditions":9914,"interventions":9915},[87],[2172,2193,2162,2173,2174,2194,1045,2175,1049,1052,2195,1057],[2197,2164,838],{"trials":9917,"activeCount":99},[],{"trials":9919,"activeCount":99},[],{"trials":9921,"activeCount":99},[],{"trials":9923,"activeCount":99},[],{"intervention":9925,"totalTrials":214,"cells":9926},"RNR inhibitor COH29",{"EARLY_PHASE1":9927,"PHASE1":9929,"PHASE2":9939,"PHASE3":9941,"PHASE4":9943,"NA":9945},{"trials":9928,"activeCount":99},[],{"trials":9930,"activeCount":214,"soonestReadout":9935},[9931],{"nctId":9932,"briefTitle":9933,"status":130,"phases":9934,"primaryCompletion":9935,"completion":949,"start":9936,"enrollment":1632,"conditions":9937,"interventions":9938},"NCT02112565","RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists",[87],"2018-11-23","2016-06-13",[24],[9925],{"trials":9940,"activeCount":99},[],{"trials":9942,"activeCount":99},[],{"trials":9944,"activeCount":99},[],{"trials":9946,"activeCount":99},[],{"intervention":9948,"totalTrials":214,"cells":9949},"Zirconium Zr 89-Df-Crefmirlimab",{"EARLY_PHASE1":9950,"PHASE1":9952,"PHASE2":9961,"PHASE3":9963,"PHASE4":9965,"NA":9967},{"trials":9951,"activeCount":99},[],{"trials":9953,"activeCount":214,"soonestReadout":1022},[9954],{"nctId":9955,"briefTitle":9956,"status":203,"phases":9957,"primaryCompletion":1022,"completion":1022,"start":9958,"enrollment":207,"conditions":9959,"interventions":9960},"NCT05371132","Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)",[87],"2022-06-20",[326,27],[9948],{"trials":9962,"activeCount":99},[],{"trials":9964,"activeCount":99},[],{"trials":9966,"activeCount":99},[],{"trials":9968,"activeCount":99},[],{"intervention":1119,"totalTrials":214,"cells":9970},{"EARLY_PHASE1":9971,"PHASE1":9973,"PHASE2":9979,"PHASE3":9981,"PHASE4":9983,"NA":9985},{"trials":9972,"activeCount":99},[],{"trials":9974,"activeCount":214,"soonestReadout":1109},[9975],{"nctId":1106,"briefTitle":1107,"status":130,"phases":9976,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":283,"conditions":9977,"interventions":9978},[87],[1112,1113,1114,1115,1116],[784,1118,1119,851,1120,1121],{"trials":9980,"activeCount":99},[],{"trials":9982,"activeCount":99},[],{"trials":9984,"activeCount":99},[],{"trials":9986,"activeCount":99},[],{"intervention":1121,"totalTrials":214,"cells":9988},{"EARLY_PHASE1":9989,"PHASE1":9991,"PHASE2":9997,"PHASE3":9999,"PHASE4":10001,"NA":10003},{"trials":9990,"activeCount":99},[],{"trials":9992,"activeCount":214,"soonestReadout":1109},[9993],{"nctId":1106,"briefTitle":1107,"status":130,"phases":9994,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":283,"conditions":9995,"interventions":9996},[87],[1112,1113,1114,1115,1116],[784,1118,1119,851,1120,1121],{"trials":9998,"activeCount":99},[],{"trials":10000,"activeCount":99},[],{"trials":10002,"activeCount":99},[],{"trials":10004,"activeCount":99},[],{"intervention":10006,"totalTrials":214,"cells":10007},"HER2(EQ)BBζ\u002FCD19t+ T cells",{"EARLY_PHASE1":10008,"PHASE1":10010,"PHASE2":10023,"PHASE3":10025,"PHASE4":10027,"NA":10029},{"trials":10009,"activeCount":99},[],{"trials":10011,"activeCount":214,"soonestReadout":10016},[10012],{"nctId":10013,"briefTitle":10014,"status":130,"phases":10015,"primaryCompletion":10016,"completion":10016,"start":10017,"enrollment":1945,"conditions":10018,"interventions":10022},"NCT03389230","Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma",[87],"2026-12-29","2018-08-14",[4601,4602,10019,10020,10021],"Recurrent Glioma","Refractory Glioma","WHO Grade III Glioma",[10006],{"trials":10024,"activeCount":99},[],{"trials":10026,"activeCount":99},[],{"trials":10028,"activeCount":99},[],{"trials":10030,"activeCount":99},[],{"intervention":1135,"totalTrials":214,"cells":10032},{"EARLY_PHASE1":10033,"PHASE1":10035,"PHASE2":10041,"PHASE3":10043,"PHASE4":10045,"NA":10047},{"trials":10034,"activeCount":99},[],{"trials":10036,"activeCount":214,"soonestReadout":1126},[10037],{"nctId":1123,"briefTitle":1124,"status":130,"phases":10038,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":30,"conditions":10039,"interventions":10040},[87],[859,1129],[784,1131,1132,1133,1134,1135,938,956,942],{"trials":10042,"activeCount":99},[],{"trials":10044,"activeCount":99},[],{"trials":10046,"activeCount":99},[],{"trials":10048,"activeCount":99},[],{"intervention":8634,"totalTrials":214,"cells":10050},{"EARLY_PHASE1":10051,"PHASE1":10053,"PHASE2":10059,"PHASE3":10061,"PHASE4":10063,"NA":10065},{"trials":10052,"activeCount":99},[],{"trials":10054,"activeCount":214,"soonestReadout":8629},[10055],{"nctId":8626,"briefTitle":8627,"status":203,"phases":10056,"primaryCompletion":8629,"completion":8629,"start":8630,"enrollment":298,"conditions":10057,"interventions":10058},[87],[8632,1073],[8634,8635],{"trials":10060,"activeCount":99},[],{"trials":10062,"activeCount":99},[],{"trials":10064,"activeCount":99},[],{"trials":10066,"activeCount":99},[],{"intervention":4979,"totalTrials":214,"cells":10068},{"EARLY_PHASE1":10069,"PHASE1":10071,"PHASE2":10077,"PHASE3":10079,"PHASE4":10081,"NA":10083},{"trials":10070,"activeCount":99},[],{"trials":10072,"activeCount":214,"soonestReadout":4974},[10073],{"nctId":4971,"briefTitle":4972,"status":130,"phases":10074,"primaryCompletion":4974,"completion":4974,"start":4975,"enrollment":4976,"conditions":10075,"interventions":10076},[87],[859,1173,1174],[4979,1176],{"trials":10078,"activeCount":99},[],{"trials":10080,"activeCount":99},[],{"trials":10082,"activeCount":99},[],{"trials":10084,"activeCount":99},[],{"intervention":1164,"totalTrials":214,"cells":10086},{"EARLY_PHASE1":10087,"PHASE1":10089,"PHASE2":10095,"PHASE3":10097,"PHASE4":10099,"NA":10101},{"trials":10088,"activeCount":99},[],{"trials":10090,"activeCount":214,"soonestReadout":1154},[10091],{"nctId":1151,"briefTitle":1152,"status":294,"phases":10092,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":404,"conditions":10093,"interventions":10094},[87],[1157,1158,1159,1160,1161,1162],[784,346,66,1164,938,1165,957],{"trials":10096,"activeCount":99},[],{"trials":10098,"activeCount":99},[],{"trials":10100,"activeCount":99},[],{"trials":10102,"activeCount":99},[],{"intervention":10104,"totalTrials":214,"cells":10105},"Chlorotoxin",{"EARLY_PHASE1":10106,"PHASE1":10108,"PHASE2":10117,"PHASE3":10119,"PHASE4":10121,"NA":10123},{"trials":10107,"activeCount":99},[],{"trials":10109,"activeCount":214,"soonestReadout":3081},[10110],{"nctId":10111,"briefTitle":10112,"status":130,"phases":10113,"primaryCompletion":3081,"completion":3081,"start":10114,"enrollment":1001,"conditions":10115,"interventions":10116},"NCT04214392","Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma",[87],"2020-02-26",[707,709,9126,710],[10104,10104],{"trials":10118,"activeCount":99},[],{"trials":10120,"activeCount":99},[],{"trials":10122,"activeCount":99},[],{"trials":10124,"activeCount":99},[],{"intervention":10126,"totalTrials":214,"cells":10127},"Autologous Anti-EGFR\u002FAnti-IL13Ralpha2 CAR T-cells",{"EARLY_PHASE1":10128,"PHASE1":10130,"PHASE2":10141,"PHASE3":10143,"PHASE4":10145,"NA":10147},{"trials":10129,"activeCount":99},[],{"trials":10131,"activeCount":214,"soonestReadout":10136},[10132],{"nctId":10133,"briefTitle":10134,"status":203,"phases":10135,"primaryCompletion":10136,"completion":10136,"start":10137,"enrollment":30,"conditions":10138,"interventions":10140},"NCT07544992","Locoregional Administration of Genetically Engineered Cells (EGFR\u002FIL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas",[87],"2031-11-04","2026-12-24",[7776,10139],"Recurrent Glioblastoma, IDH-Wildtype",[10126],{"trials":10142,"activeCount":99},[],{"trials":10144,"activeCount":99},[],{"trials":10146,"activeCount":99},[],{"trials":10148,"activeCount":99},[],{"intervention":10150,"totalTrials":214,"cells":10151},"Anti-CD33 CAR T-cells",{"EARLY_PHASE1":10152,"PHASE1":10154,"PHASE2":10164,"PHASE3":10166,"PHASE4":10168,"NA":10170},{"trials":10153,"activeCount":99},[],{"trials":10155,"activeCount":214,"soonestReadout":10160},[10156],{"nctId":10157,"briefTitle":10158,"status":203,"phases":10159,"primaryCompletion":10160,"completion":10160,"start":10161,"enrollment":22,"conditions":10162,"interventions":10163},"NCT05672147","CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia",[87],"2028-09-03","2023-12-07",[18,812,818,813],[10150],{"trials":10165,"activeCount":99},[],{"trials":10167,"activeCount":99},[],{"trials":10169,"activeCount":99},[],{"trials":10171,"activeCount":99},[],{"intervention":347,"totalTrials":214,"cells":10173},{"EARLY_PHASE1":10174,"PHASE1":10176,"PHASE2":10182,"PHASE3":10184,"PHASE4":10186,"NA":10188},{"trials":10175,"activeCount":99},[],{"trials":10177,"activeCount":214,"soonestReadout":314},[10178],{"nctId":311,"briefTitle":312,"status":203,"phases":10179,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":10180,"interventions":10181},[87],[318,319,320,321,322,323,324,325,326,327,328,329,330,331,303,332,333,334,335,336,337,338,339,340,341,342,343],[345,346,305,306,347,348,349],{"trials":10183,"activeCount":99},[],{"trials":10185,"activeCount":99},[],{"trials":10187,"activeCount":99},[],{"trials":10189,"activeCount":99},[],{"intervention":2711,"totalTrials":214,"cells":10191},{"EARLY_PHASE1":10192,"PHASE1":10194,"PHASE2":10200,"PHASE3":10202,"PHASE4":10204,"NA":10206},{"trials":10193,"activeCount":99},[],{"trials":10195,"activeCount":214,"soonestReadout":2705},[10196],{"nctId":2702,"briefTitle":2703,"status":130,"phases":10197,"primaryCompletion":2705,"completion":2705,"start":2706,"enrollment":283,"conditions":10198,"interventions":10199},[87],[2708],[2710,169,940,2711],{"trials":10201,"activeCount":99},[],{"trials":10203,"activeCount":99},[],{"trials":10205,"activeCount":99},[],{"trials":10207,"activeCount":99},[],{"intervention":10209,"totalTrials":214,"cells":10210},"Mezigdomide",{"EARLY_PHASE1":10211,"PHASE1":10213,"PHASE2":10222,"PHASE3":10224,"PHASE4":10226,"NA":10228},{"trials":10212,"activeCount":99},[],{"trials":10214,"activeCount":214,"soonestReadout":1797},[10215],{"nctId":10216,"briefTitle":10217,"status":203,"phases":10218,"primaryCompletion":1797,"completion":1797,"start":10219,"enrollment":795,"conditions":10220,"interventions":10221},"NCT06048250","Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma",[87],"2024-04-09",[6968],[10209],{"trials":10223,"activeCount":99},[],{"trials":10225,"activeCount":99},[],{"trials":10227,"activeCount":99},[],{"trials":10229,"activeCount":99},[],{"intervention":1622,"totalTrials":214,"cells":10231},{"EARLY_PHASE1":10232,"PHASE1":10234,"PHASE2":10240,"PHASE3":10242,"PHASE4":10244,"NA":10246},{"trials":10233,"activeCount":99},[],{"trials":10235,"activeCount":214,"soonestReadout":1618},[10236],{"nctId":1615,"briefTitle":1616,"status":203,"phases":10237,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":919,"conditions":10238,"interventions":10239},[87],[35,18,21],[847,849,1622,851,1623],{"trials":10241,"activeCount":99},[],{"trials":10243,"activeCount":99},[],{"trials":10245,"activeCount":99},[],{"trials":10247,"activeCount":99},[],{"intervention":10249,"totalTrials":214,"cells":10250},"Olutasidenib",{"EARLY_PHASE1":10251,"PHASE1":10253,"PHASE2":10262,"PHASE3":10264,"PHASE4":10266,"NA":10268},{"trials":10252,"activeCount":99},[],{"trials":10254,"activeCount":214,"soonestReadout":8043},[10255],{"nctId":10256,"briefTitle":10257,"status":203,"phases":10258,"primaryCompletion":8043,"completion":8043,"start":10259,"enrollment":795,"conditions":10260,"interventions":10261},"NCT06543381","Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant",[87],"2025-01-17",[18,1275,21],[10249],{"trials":10263,"activeCount":99},[],{"trials":10265,"activeCount":99},[],{"trials":10267,"activeCount":99},[],{"trials":10269,"activeCount":99},[],{"intervention":1234,"totalTrials":214,"cells":10271},{"EARLY_PHASE1":10272,"PHASE1":10274,"PHASE2":10280,"PHASE3":10282,"PHASE4":10284,"NA":10286},{"trials":10273,"activeCount":99},[],{"trials":10275,"activeCount":214,"soonestReadout":1228},[10276],{"nctId":1225,"briefTitle":1226,"status":203,"phases":10277,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":795,"conditions":10278,"interventions":10279},[87],[18,1231,21],[1233,784,1234,847,849,850,851],{"trials":10281,"activeCount":99},[],{"trials":10283,"activeCount":99},[],{"trials":10285,"activeCount":99},[],{"trials":10287,"activeCount":99},[],{"intervention":2379,"totalTrials":214,"cells":10289},{"EARLY_PHASE1":10290,"PHASE1":10292,"PHASE2":10298,"PHASE3":10300,"PHASE4":10302,"NA":10304},{"trials":10291,"activeCount":99},[],{"trials":10293,"activeCount":214,"soonestReadout":2374},[10294],{"nctId":2371,"briefTitle":2372,"status":130,"phases":10295,"primaryCompletion":2374,"completion":2374,"start":2375,"enrollment":486,"conditions":10296,"interventions":10297},[87],[35,18,21,813],[2378,823,2379,849,1148,2298],{"trials":10299,"activeCount":99},[],{"trials":10301,"activeCount":99},[],{"trials":10303,"activeCount":99},[],{"trials":10305,"activeCount":99},[],{"intervention":274,"totalTrials":576,"cells":10307},{"EARLY_PHASE1":10308,"PHASE1":10310,"PHASE2":10340,"PHASE3":10390,"PHASE4":10392,"NA":10394},{"trials":10309,"activeCount":99},[],{"trials":10311,"activeCount":214,"soonestReadout":79},[10312,10316,10320,10324,10332,10336],{"nctId":873,"briefTitle":874,"status":107,"phases":10313,"primaryCompletion":109,"completion":109,"start":876,"enrollment":9,"conditions":10314,"interventions":10315},[87],[878,879,880],[738,385,75,115,871,882,883,274],{"nctId":258,"briefTitle":259,"status":107,"phases":10317,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":10318,"interventions":10319},[87],[266],[268,269,250,270,271,272,273,274,275,276],{"nctId":8509,"briefTitle":8510,"status":107,"phases":10321,"primaryCompletion":8512,"completion":8512,"start":8513,"enrollment":498,"conditions":10322,"interventions":10323},[87],[32],[3317,2946,1332,274,8516,2345],{"nctId":10325,"briefTitle":10326,"status":107,"phases":10327,"primaryCompletion":10328,"completion":10328,"start":10329,"enrollment":283,"conditions":10330,"interventions":10331},"NCT00730613","Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma",[87],"2011-08","2002-02",[2744],[2862,274],{"nctId":2338,"briefTitle":2339,"status":107,"phases":10333,"primaryCompletion":2341,"completion":2341,"start":2342,"enrollment":404,"conditions":10334,"interventions":10335},[87],[32,1298],[1804,115,274,2345],{"nctId":77,"briefTitle":78,"status":130,"phases":10337,"primaryCompletion":79,"completion":8310,"start":8311,"enrollment":8312,"conditions":10338,"interventions":10339},[87],[124],[71,8315,273,274,275],{"trials":10341,"activeCount":99},[10342,10352,10356,10360,10364,10375,10379,10386],{"nctId":10343,"briefTitle":10344,"status":107,"phases":10345,"primaryCompletion":6142,"completion":6142,"start":10346,"enrollment":10347,"conditions":10348,"interventions":10350},"NCT00499655","Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer",[88],"2007-11",107,[3273,10349,3274],"Stage IIIB Non-small Cell Lung Cancer",[10351,903,1331,8516,387,274],"erlotinib hydrochloride",{"nctId":6160,"briefTitle":6161,"status":369,"phases":10353,"primaryCompletion":6163,"start":6164,"enrollment":1916,"conditions":10354,"interventions":10355},[88],[266],[6167,696,274,447,6168,2345],{"nctId":376,"briefTitle":377,"status":107,"phases":10357,"primaryCompletion":379,"completion":380,"start":381,"enrollment":177,"conditions":10358,"interventions":10359},[88],[383],[385,126,250,386,270,274,387],{"nctId":2948,"briefTitle":2949,"status":107,"phases":10361,"primaryCompletion":2951,"completion":2951,"start":2952,"enrollment":1666,"conditions":10362,"interventions":10363},[88],[2954,2955,976,2956,2957,2958],[1700,1775,273,274,71],{"nctId":10365,"briefTitle":10366,"status":369,"phases":10367,"primaryCompletion":2508,"start":10368,"enrollment":1945,"conditions":10369,"interventions":10373},"NCT00233948","Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma",[87,88],"2006-03",[10370,2317,10371,10372],"Adult Liposarcoma","Stage III Adult Soft Tissue Sarcoma","Stage IV Adult Soft Tissue Sarcoma",[10374,274,276,2345],"nelfinavir mesylate",{"nctId":8319,"briefTitle":8320,"status":369,"phases":10376,"primaryCompletion":987,"completion":987,"start":8322,"enrollment":214,"conditions":10377,"interventions":10378},[88],[664],[274,275,276],{"nctId":10380,"briefTitle":10381,"status":369,"phases":10382,"primaryCompletion":10383,"completion":10383,"start":6224,"enrollment":576,"conditions":10384,"interventions":10385},"NCT00723203","Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia",[88],"2010-09",[32],[8303,274,2345],{"nctId":7707,"briefTitle":7708,"status":369,"phases":10387,"primaryCompletion":7710,"completion":7710,"start":7711,"enrollment":283,"conditions":10388,"interventions":10389},[88],[5110],[385,386,274,2345],{"trials":10391,"activeCount":99},[],{"trials":10393,"activeCount":99},[],{"trials":10395,"activeCount":99},[10396,10403],{"nctId":10397,"briefTitle":10398,"status":107,"phases":10399,"primaryCompletion":10400,"completion":10400,"start":8322,"enrollment":2214,"conditions":10401,"interventions":10402},"NCT00806650","Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer",[],"2017-11-15",[3313],[274,387],{"nctId":10404,"briefTitle":10405,"status":107,"phases":10406,"primaryCompletion":10407,"completion":10407,"start":6164,"enrollment":10408,"conditions":10409,"interventions":10410},"NCT00898508","Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease",[],"2019-06-06",563,[15],[274,8516,7897,2345],{"intervention":10412,"totalTrials":214,"cells":10413},"AutoCD6-CAR Treg cells",{"EARLY_PHASE1":10414,"PHASE1":10423,"PHASE2":10425,"PHASE3":10427,"PHASE4":10429,"NA":10431},{"trials":10415,"activeCount":214,"soonestReadout":1826},[10416],{"nctId":10417,"briefTitle":10418,"status":294,"phases":10419,"primaryCompletion":1826,"completion":1826,"start":949,"enrollment":434,"conditions":10420,"interventions":10422},"NCT07395050","Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes",[86],[10421],"Stage 3 Type 1 Diabetes",[10412],{"trials":10424,"activeCount":99},[],{"trials":10426,"activeCount":99},[],{"trials":10428,"activeCount":99},[],{"trials":10430,"activeCount":99},[],{"trials":10432,"activeCount":99},[],{"intervention":10434,"totalTrials":214,"cells":10435},"Fluorothymidine F-18",{"EARLY_PHASE1":10436,"PHASE1":10447,"PHASE2":10449,"PHASE3":10451,"PHASE4":10453,"NA":10455},{"trials":10437,"activeCount":214,"soonestReadout":10442},[10438],{"nctId":10439,"briefTitle":10440,"status":203,"phases":10441,"primaryCompletion":10442,"completion":10442,"start":10443,"enrollment":10444,"conditions":10445,"interventions":10446},"NCT03422731","Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy",[86],"2026-11-06","2018-02-15",74,[35,18],[10434],{"trials":10448,"activeCount":99},[],{"trials":10450,"activeCount":99},[],{"trials":10452,"activeCount":99},[],{"trials":10454,"activeCount":99},[],{"trials":10456,"activeCount":99},[],{"intervention":10458,"totalTrials":214,"cells":10459},"Copper Cu 64 Anti-CEA Monoclonal Antibody M5A",{"EARLY_PHASE1":10460,"PHASE1":10471,"PHASE2":10473,"PHASE3":10475,"PHASE4":10477,"NA":10479},{"trials":10461,"activeCount":214,"soonestReadout":10466},[10462],{"nctId":10463,"briefTitle":10464,"status":203,"phases":10465,"primaryCompletion":10466,"completion":10466,"start":10467,"enrollment":795,"conditions":10468,"interventions":10470},"NCT05245786","An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer",[86],"2026-11-12","2022-08-31",[10469,457,2127,2129,2131],"Locally Advanced Rectal Carcinoma",[10458],{"trials":10472,"activeCount":99},[],{"trials":10474,"activeCount":99},[],{"trials":10476,"activeCount":99},[],{"trials":10478,"activeCount":99},[],{"trials":10480,"activeCount":99},[],{"intervention":10482,"totalTrials":214,"cells":10483},"Genetic Testing for Cancer Risk",{"EARLY_PHASE1":10484,"PHASE1":10494,"PHASE2":10496,"PHASE3":10498,"PHASE4":10500,"NA":10502},{"trials":10485,"activeCount":214,"soonestReadout":10490},[10486],{"nctId":10487,"briefTitle":10488,"status":130,"phases":10489,"primaryCompletion":10490,"completion":10490,"start":10491,"enrollment":4174,"conditions":10492,"interventions":10493},"NCT05868486","Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer",[86],"2026-10-19","2022-05-20",[3100,29],[10482],{"trials":10495,"activeCount":99},[],{"trials":10497,"activeCount":99},[],{"trials":10499,"activeCount":99},[],{"trials":10501,"activeCount":99},[],{"trials":10503,"activeCount":99},[],{"intervention":10505,"totalTrials":214,"cells":10506},"CMV\u002FHIV-CAR T Cells",{"EARLY_PHASE1":10507,"PHASE1":10517,"PHASE2":10519,"PHASE3":10521,"PHASE4":10523,"NA":10525},{"trials":10508,"activeCount":214,"soonestReadout":3108},[10509],{"nctId":10510,"briefTitle":10511,"status":203,"phases":10512,"primaryCompletion":3108,"completion":3108,"start":10513,"enrollment":795,"conditions":10514,"interventions":10516},"NCT06252402","CMV-specific HIV-CAR T Cells as Immunotherapy for HIV\u002FAIDS",[86],"2024-12-19",[10515],"HIV-1",[10505],{"trials":10518,"activeCount":99},[],{"trials":10520,"activeCount":99},[],{"trials":10522,"activeCount":99},[],{"trials":10524,"activeCount":99},[],{"trials":10526,"activeCount":99},[],{"intervention":10528,"totalTrials":214,"cells":10529},"Theanine",{"EARLY_PHASE1":10530,"PHASE1":10539,"PHASE2":10541,"PHASE3":10543,"PHASE4":10545,"NA":10547},{"trials":10531,"activeCount":214,"soonestReadout":10536},[10532],{"nctId":10533,"briefTitle":10534,"status":203,"phases":10535,"primaryCompletion":10536,"completion":10536,"start":496,"enrollment":2625,"conditions":10537,"interventions":10538},"NCT07220447","L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance",[86],"2027-07-09",[3048,29],[10528],{"trials":10540,"activeCount":99},[],{"trials":10542,"activeCount":99},[],{"trials":10544,"activeCount":99},[],{"trials":10546,"activeCount":99},[],{"trials":10548,"activeCount":99},[],{"intervention":387,"totalTrials":9,"cells":10550},{"EARLY_PHASE1":10551,"PHASE1":10553,"PHASE2":10570,"PHASE3":10584,"PHASE4":10586,"NA":10588},{"trials":10552,"activeCount":99},[],{"trials":10554,"activeCount":99},[10555,10559],{"nctId":8295,"briefTitle":8296,"status":107,"phases":10556,"primaryCompletion":8298,"completion":8299,"start":6240,"enrollment":95,"conditions":10557,"interventions":10558},[87],[32],[8302,8303,275,387,276],{"nctId":10560,"briefTitle":10561,"status":107,"phases":10562,"primaryCompletion":8298,"completion":8298,"start":6049,"enrollment":486,"conditions":10563,"interventions":10568},"NCT01234740","Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases",[87],[578,10564,579,580,581,582,10565,583,10566,10567],"Adult Anaplastic Ependymoma","Adult Mixed Glioma","Tumors Metastatic to Brain","Adult Anaplastic Oligoastrocytoma",[10569,387,276],"bafetinib",{"trials":10571,"activeCount":99},[10572,10576,10580],{"nctId":10343,"briefTitle":10344,"status":107,"phases":10573,"primaryCompletion":6142,"completion":6142,"start":10346,"enrollment":10347,"conditions":10574,"interventions":10575},[88],[3273,10349,3274],[10351,903,1331,8516,387,274],{"nctId":376,"briefTitle":377,"status":107,"phases":10577,"primaryCompletion":379,"completion":380,"start":381,"enrollment":177,"conditions":10578,"interventions":10579},[88],[383],[385,126,250,386,270,274,387],{"nctId":731,"briefTitle":732,"status":369,"phases":10581,"primaryCompletion":734,"start":735,"enrollment":486,"conditions":10582,"interventions":10583},[88],[664],[738,739,168,740,290,387],{"trials":10585,"activeCount":99},[],{"trials":10587,"activeCount":99},[],{"trials":10589,"activeCount":214,"soonestReadout":70},[10590,10594,10598],{"nctId":10397,"briefTitle":10398,"status":107,"phases":10591,"primaryCompletion":10400,"completion":10400,"start":8322,"enrollment":2214,"conditions":10592,"interventions":10593},[],[3313],[274,387],{"nctId":68,"briefTitle":69,"status":130,"phases":10595,"primaryCompletion":70,"completion":3550,"start":6049,"enrollment":8333,"conditions":10596,"interventions":10597},[],[8335,8336,8337,1800,808,1426,1427,1428,1429,1430,1431,8166,4043,1918,4044,8338,8339,2773,8340,1275,8341,8342,8343,8344,8345,8346,8347,8348,8349,8350,8351,2954,8352,8353,2873,8354,8355,8356,8357,2874,2875,8358,8359,8360,8361,2876,8362,8363,8364,8365,8366,8367,8368,8369,8370,2955,8371,8372,8373,4047,2777,1488,8374,8375,8376,1196,812,970,4048,4049,2877,2878,2388,4050,4051,4052,4053,1848,1849,2895,976,977,4054,978,5234,4581,989,8377,813,8378,845,2880,8379,8380,8381,8382,8383,8384,8385,8386,8387,8388,8389,8390,8391,8392,2956,8393,990,8394,8395,8396,8397,8398,8399,991,8400,8401,8402,8403,8404,8405,8406,8407,8408,8409,8410,8411,8412,8413,2957,8414,992,8415,8416,8417,8418,8419,8420,8421,8422,8423,8424,8425,8426,8427,8428,8429,2958,8430,8431,8432,8433,2882],[71,273,8435,8436,8437,275,387],{"nctId":10599,"briefTitle":10600,"status":369,"phases":10601,"primaryCompletion":4444,"completion":4444,"start":10602,"enrollment":10603,"conditions":10604,"interventions":10605},"NCT00813878","Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease",[],"2001-07",126,[15],[10606,387,7897],"protein analysis",{"intervention":8516,"totalTrials":195,"cells":10608},{"EARLY_PHASE1":10609,"PHASE1":10611,"PHASE2":10617,"PHASE3":10623,"PHASE4":10625,"NA":10627},{"trials":10610,"activeCount":99},[],{"trials":10612,"activeCount":99},[10613],{"nctId":8509,"briefTitle":8510,"status":107,"phases":10614,"primaryCompletion":8512,"completion":8512,"start":8513,"enrollment":498,"conditions":10615,"interventions":10616},[87],[32],[3317,2946,1332,274,8516,2345],{"trials":10618,"activeCount":99},[10619],{"nctId":10343,"briefTitle":10344,"status":107,"phases":10620,"primaryCompletion":6142,"completion":6142,"start":10346,"enrollment":10347,"conditions":10621,"interventions":10622},[88],[3273,10349,3274],[10351,903,1331,8516,387,274],{"trials":10624,"activeCount":99},[],{"trials":10626,"activeCount":99},[],{"trials":10628,"activeCount":214,"soonestReadout":10637},[10629,10633],{"nctId":10404,"briefTitle":10405,"status":107,"phases":10630,"primaryCompletion":10407,"completion":10407,"start":6164,"enrollment":10408,"conditions":10631,"interventions":10632},[],[15],[274,8516,7897,2345],{"nctId":10634,"briefTitle":10635,"status":130,"phases":10636,"primaryCompletion":10637,"completion":928,"start":50,"enrollment":36,"conditions":10638,"interventions":10639},"NCT01093612","Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer",[91],"2018-10-23",[15,144],[8516],{"intervention":8435,"totalTrials":283,"cells":10641},{"EARLY_PHASE1":10642,"PHASE1":10644,"PHASE2":10646,"PHASE3":10659,"PHASE4":10661,"NA":10663},{"trials":10643,"activeCount":99},[],{"trials":10645,"activeCount":99},[],{"trials":10647,"activeCount":99},[10648],{"nctId":10649,"briefTitle":10650,"status":107,"phases":10651,"primaryCompletion":10652,"completion":10652,"start":10653,"enrollment":10654,"conditions":10655,"interventions":10657},"NCT00530218","Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant",[88],"2010-02","1999-03",61,[8361,32,27,6968,10656,1371],"MDS",[10658],"Ganciclovir",{"trials":10660,"activeCount":99},[],{"trials":10662,"activeCount":99},[],{"trials":10664,"activeCount":214,"soonestReadout":70},[10665,10669],{"nctId":68,"briefTitle":69,"status":130,"phases":10666,"primaryCompletion":70,"completion":3550,"start":6049,"enrollment":8333,"conditions":10667,"interventions":10668},[],[8335,8336,8337,1800,808,1426,1427,1428,1429,1430,1431,8166,4043,1918,4044,8338,8339,2773,8340,1275,8341,8342,8343,8344,8345,8346,8347,8348,8349,8350,8351,2954,8352,8353,2873,8354,8355,8356,8357,2874,2875,8358,8359,8360,8361,2876,8362,8363,8364,8365,8366,8367,8368,8369,8370,2955,8371,8372,8373,4047,2777,1488,8374,8375,8376,1196,812,970,4048,4049,2877,2878,2388,4050,4051,4052,4053,1848,1849,2895,976,977,4054,978,5234,4581,989,8377,813,8378,845,2880,8379,8380,8381,8382,8383,8384,8385,8386,8387,8388,8389,8390,8391,8392,2956,8393,990,8394,8395,8396,8397,8398,8399,991,8400,8401,8402,8403,8404,8405,8406,8407,8408,8409,8410,8411,8412,8413,2957,8414,992,8415,8416,8417,8418,8419,8420,8421,8422,8423,8424,8425,8426,8427,8428,8429,2958,8430,8431,8432,8433,2882],[71,273,8435,8436,8437,275,387],{"nctId":8439,"briefTitle":8440,"status":107,"phases":10670,"primaryCompletion":2342,"completion":2342,"start":8442,"enrollment":4174,"conditions":10671,"interventions":10672},[91],[1295,32,27,1297,1298,1299,8444],[8435,275],{"intervention":8436,"totalTrials":214,"cells":10674},{"EARLY_PHASE1":10675,"PHASE1":10677,"PHASE2":10679,"PHASE3":10681,"PHASE4":10683,"NA":10685},{"trials":10676,"activeCount":99},[],{"trials":10678,"activeCount":99},[],{"trials":10680,"activeCount":99},[],{"trials":10682,"activeCount":99},[],{"trials":10684,"activeCount":99},[],{"trials":10686,"activeCount":214,"soonestReadout":70},[10687],{"nctId":68,"briefTitle":69,"status":130,"phases":10688,"primaryCompletion":70,"completion":3550,"start":6049,"enrollment":8333,"conditions":10689,"interventions":10690},[],[8335,8336,8337,1800,808,1426,1427,1428,1429,1430,1431,8166,4043,1918,4044,8338,8339,2773,8340,1275,8341,8342,8343,8344,8345,8346,8347,8348,8349,8350,8351,2954,8352,8353,2873,8354,8355,8356,8357,2874,2875,8358,8359,8360,8361,2876,8362,8363,8364,8365,8366,8367,8368,8369,8370,2955,8371,8372,8373,4047,2777,1488,8374,8375,8376,1196,812,970,4048,4049,2877,2878,2388,4050,4051,4052,4053,1848,1849,2895,976,977,4054,978,5234,4581,989,8377,813,8378,845,2880,8379,8380,8381,8382,8383,8384,8385,8386,8387,8388,8389,8390,8391,8392,2956,8393,990,8394,8395,8396,8397,8398,8399,991,8400,8401,8402,8403,8404,8405,8406,8407,8408,8409,8410,8411,8412,8413,2957,8414,992,8415,8416,8417,8418,8419,8420,8421,8422,8423,8424,8425,8426,8427,8428,8429,2958,8430,8431,8432,8433,2882],[71,273,8435,8436,8437,275,387],{"intervention":8437,"totalTrials":214,"cells":10692},{"EARLY_PHASE1":10693,"PHASE1":10695,"PHASE2":10697,"PHASE3":10699,"PHASE4":10701,"NA":10703},{"trials":10694,"activeCount":99},[],{"trials":10696,"activeCount":99},[],{"trials":10698,"activeCount":99},[],{"trials":10700,"activeCount":99},[],{"trials":10702,"activeCount":99},[],{"trials":10704,"activeCount":214,"soonestReadout":70},[10705],{"nctId":68,"briefTitle":69,"status":130,"phases":10706,"primaryCompletion":70,"completion":3550,"start":6049,"enrollment":8333,"conditions":10707,"interventions":10708},[],[8335,8336,8337,1800,808,1426,1427,1428,1429,1430,1431,8166,4043,1918,4044,8338,8339,2773,8340,1275,8341,8342,8343,8344,8345,8346,8347,8348,8349,8350,8351,2954,8352,8353,2873,8354,8355,8356,8357,2874,2875,8358,8359,8360,8361,2876,8362,8363,8364,8365,8366,8367,8368,8369,8370,2955,8371,8372,8373,4047,2777,1488,8374,8375,8376,1196,812,970,4048,4049,2877,2878,2388,4050,4051,4052,4053,1848,1849,2895,976,977,4054,978,5234,4581,989,8377,813,8378,845,2880,8379,8380,8381,8382,8383,8384,8385,8386,8387,8388,8389,8390,8391,8392,2956,8393,990,8394,8395,8396,8397,8398,8399,991,8400,8401,8402,8403,8404,8405,8406,8407,8408,8409,8410,8411,8412,8413,2957,8414,992,8415,8416,8417,8418,8419,8420,8421,8422,8423,8424,8425,8426,8427,8428,8429,2958,8430,8431,8432,8433,2882],[71,273,8435,8436,8437,275,387],{"intervention":230,"totalTrials":214,"cells":10710},{"EARLY_PHASE1":10711,"PHASE1":10713,"PHASE2":10715,"PHASE3":10717,"PHASE4":10719,"NA":10721},{"trials":10712,"activeCount":99},[],{"trials":10714,"activeCount":99},[],{"trials":10716,"activeCount":99},[],{"trials":10718,"activeCount":99},[],{"trials":10720,"activeCount":99},[],{"trials":10722,"activeCount":214,"soonestReadout":221},[10723],{"nctId":218,"briefTitle":219,"status":130,"phases":10724,"primaryCompletion":221,"completion":222,"start":223,"enrollment":207,"conditions":10725,"interventions":10726},[91],[225,137,226,227,138,228,144],[94,230],{"intervention":10728,"totalTrials":214,"cells":10729},"Fluoro Uracil",{"EARLY_PHASE1":10730,"PHASE1":10732,"PHASE2":10734,"PHASE3":10736,"PHASE4":10738,"NA":10740},{"trials":10731,"activeCount":99},[],{"trials":10733,"activeCount":99},[],{"trials":10735,"activeCount":99},[],{"trials":10737,"activeCount":99},[],{"trials":10739,"activeCount":99},[],{"trials":10741,"activeCount":214,"soonestReadout":3924},[10742],{"nctId":10743,"briefTitle":10744,"status":203,"phases":10745,"primaryCompletion":3924,"completion":3924,"start":10746,"enrollment":3926,"conditions":10747,"interventions":10749},"NCT06490003","Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma",[],"2004-06-01",[1905,3938,10748],"DNA Methylation",[10728],{"intervention":10751,"totalTrials":214,"cells":10752},"Cu 64 anti-CEA monoclonal antibody M5A IV",{"EARLY_PHASE1":10753,"PHASE1":10755,"PHASE2":10757,"PHASE3":10759,"PHASE4":10761,"NA":10763},{"trials":10754,"activeCount":99},[],{"trials":10756,"activeCount":99},[],{"trials":10758,"activeCount":99},[],{"trials":10760,"activeCount":99},[],{"trials":10762,"activeCount":99},[],{"trials":10764,"activeCount":214,"soonestReadout":10769},[10765],{"nctId":10766,"briefTitle":10767,"status":130,"phases":10768,"primaryCompletion":10769,"completion":163,"start":10770,"enrollment":404,"conditions":10771,"interventions":10776},"NCT02293954","Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer",[91],"2022-03-06","2015-11-11",[15,663,7863,7864,10772,10773,5110,395,7865,10774,10775,24],"Gastrointestinal Cancer","Liver and Intrahepatic Biliary Tract Cancer","Rectal Cancer","Thyroid Gland Medullary Carcinoma",[10751],{"intervention":10778,"totalTrials":214,"cells":10779},"sildenafil citrate",{"EARLY_PHASE1":10780,"PHASE1":10782,"PHASE2":10784,"PHASE3":10786,"PHASE4":10800,"NA":10802},{"trials":10781,"activeCount":99},[],{"trials":10783,"activeCount":99},[],{"trials":10785,"activeCount":99},[],{"trials":10787,"activeCount":99},[10788],{"nctId":10789,"briefTitle":10790,"status":369,"phases":10791,"primaryCompletion":10792,"completion":10792,"start":6242,"enrollment":10793,"conditions":10794,"interventions":10798},"NCT00544076","ED Recovery in Men Age \u003C\u002F=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer",[89],"2012-04",110,[124,10795,10796,10797],"Male Erectile Disorder","Stage I Prostate Cancer","Stage II Prostate Cancer",[10778,10799],"alprostadil",{"trials":10801,"activeCount":99},[],{"trials":10803,"activeCount":99},[],{"intervention":10799,"totalTrials":214,"cells":10805},{"EARLY_PHASE1":10806,"PHASE1":10808,"PHASE2":10810,"PHASE3":10812,"PHASE4":10818,"NA":10820},{"trials":10807,"activeCount":99},[],{"trials":10809,"activeCount":99},[],{"trials":10811,"activeCount":99},[],{"trials":10813,"activeCount":99},[10814],{"nctId":10789,"briefTitle":10790,"status":369,"phases":10815,"primaryCompletion":10792,"completion":10792,"start":6242,"enrollment":10793,"conditions":10816,"interventions":10817},[89],[124,10795,10796,10797],[10778,10799],{"trials":10819,"activeCount":99},[],{"trials":10821,"activeCount":99},[],{"intervention":1700,"totalTrials":486,"cells":10823},{"EARLY_PHASE1":10824,"PHASE1":10826,"PHASE2":10846,"PHASE3":10860,"PHASE4":10862,"NA":10864},{"trials":10825,"activeCount":99},[],{"trials":10827,"activeCount":99},[10828,10832,10838,10842],{"nctId":1689,"briefTitle":1690,"status":107,"phases":10829,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":36,"conditions":10830,"interventions":10831},[87],[1696,1697,1698,1102,1103],[1700,61,1306,1305],{"nctId":10833,"briefTitle":10834,"status":107,"phases":10835,"primaryCompletion":8512,"completion":8512,"start":176,"enrollment":1264,"conditions":10836,"interventions":10837},"NCT00541359","Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors",[87],[24],[1700,882],{"nctId":4027,"briefTitle":4028,"status":479,"phases":10839,"primaryCompletion":4030,"completion":4030,"start":4031,"enrollment":99,"conditions":10840,"interventions":10841},[87],[1698],[4034,1556,1354,1321,3267],{"nctId":6229,"briefTitle":6230,"status":107,"phases":10843,"primaryCompletion":6232,"completion":6232,"start":6233,"enrollment":890,"conditions":10844,"interventions":10845},[87],[2744,27,395,24],[1700,6214],{"trials":10847,"activeCount":99},[10848,10852,10856],{"nctId":2930,"briefTitle":2931,"status":107,"phases":10849,"primaryCompletion":2933,"completion":2934,"start":2935,"enrollment":919,"conditions":10850,"interventions":10851},[87,88],[27],[1775,1700,386],{"nctId":2948,"briefTitle":2949,"status":107,"phases":10853,"primaryCompletion":2951,"completion":2951,"start":2952,"enrollment":1666,"conditions":10854,"interventions":10855},[88],[2954,2955,976,2956,2957,2958],[1700,1775,273,274,71],{"nctId":2475,"briefTitle":2476,"status":107,"phases":10857,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":10858,"interventions":10859},[88],[1297,2482],[1700,2484,115,1502,1332,1331],{"trials":10861,"activeCount":99},[],{"trials":10863,"activeCount":99},[],{"trials":10865,"activeCount":99},[],{"intervention":276,"totalTrials":434,"cells":10867},{"EARLY_PHASE1":10868,"PHASE1":10870,"PHASE2":10884,"PHASE3":10898,"PHASE4":10900,"NA":10902},{"trials":10869,"activeCount":99},[],{"trials":10871,"activeCount":99},[10872,10876,10880],{"nctId":8295,"briefTitle":8296,"status":107,"phases":10873,"primaryCompletion":8298,"completion":8299,"start":6240,"enrollment":95,"conditions":10874,"interventions":10875},[87],[32],[8302,8303,275,387,276],{"nctId":258,"briefTitle":259,"status":107,"phases":10877,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":10878,"interventions":10879},[87],[266],[268,269,250,270,271,272,273,274,275,276],{"nctId":10560,"briefTitle":10561,"status":107,"phases":10881,"primaryCompletion":8298,"completion":8298,"start":6049,"enrollment":486,"conditions":10882,"interventions":10883},[87],[578,10564,579,580,581,582,10565,583,10566,10567],[10569,387,276],{"trials":10885,"activeCount":99},[10886,10890,10894],{"nctId":3305,"briefTitle":3306,"status":369,"phases":10887,"primaryCompletion":3308,"completion":3309,"start":3310,"enrollment":486,"conditions":10888,"interventions":10889},[87,88],[2744,3312,2745,3313,3314,27,3315,879,664,2747,2335],[114,3317,3318,740,447,276],{"nctId":10365,"briefTitle":10366,"status":369,"phases":10891,"primaryCompletion":2508,"start":10368,"enrollment":1945,"conditions":10892,"interventions":10893},[87,88],[10370,2317,10371,10372],[10374,274,276,2345],{"nctId":8319,"briefTitle":8320,"status":369,"phases":10895,"primaryCompletion":987,"completion":987,"start":8322,"enrollment":214,"conditions":10896,"interventions":10897},[88],[664],[274,275,276],{"trials":10899,"activeCount":99},[],{"trials":10901,"activeCount":99},[],{"trials":10903,"activeCount":99},[],{"intervention":2789,"totalTrials":498,"cells":10905},{"EARLY_PHASE1":10906,"PHASE1":10908,"PHASE2":10939,"PHASE3":10954,"PHASE4":10956,"NA":10958},{"trials":10907,"activeCount":99},[],{"trials":10909,"activeCount":99},[10910,10931,10935],{"nctId":10911,"briefTitle":10912,"status":107,"phases":10913,"primaryCompletion":10914,"completion":10914,"start":4041,"enrollment":434,"conditions":10915,"interventions":10929},"NCT01082926","Phase I Study of Cellular Immunotherapy for Recurrent\u002FRefractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2",[87],"2013-09",[10916,10917,10918,10919,10920,10921,10922,4601,10923,10924,10925,10926,10927,10928],"Anaplastic Astrocytoma","Anaplastic Ependymoma","Anaplastic Meningioma","Anaplastic Oligodendroglioma","Brain Stem Glioma","Ependymoblastoma","Giant Cell Glioblastoma","Gliosarcoma","Grade III Meningioma","Meningeal Hemangiopericytoma","Mixed Glioma","Pineal Gland Astrocytoma","Brain Tumor",[10930,2789],"therapeutic allogeneic lymphocytes",{"nctId":2855,"briefTitle":2856,"status":107,"phases":10932,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":498,"conditions":10933,"interventions":10934},[87],[27],[2789,1775,2862,61],{"nctId":1030,"briefTitle":1031,"status":479,"phases":10936,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":99,"conditions":10937,"interventions":10938},[87],[1036,1037,1038,1039,1040,1041,1042,323,326,1043,1044,1045,1046,1047,302,1048,1049,1050,303,1051,1052,1053,470,1054,1055,1056,1057],[1059,784,847,1060],{"trials":10940,"activeCount":99},[10941,10950],{"nctId":10942,"briefTitle":10943,"status":107,"phases":10944,"primaryCompletion":10945,"completion":10946,"start":10947,"enrollment":207,"conditions":10948,"interventions":10949},"NCT03007238","Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease",[88],"2018-10-16","2019-06-26","2017-01-18",[3405],[1059],{"nctId":2781,"briefTitle":2782,"status":107,"phases":10951,"primaryCompletion":2784,"completion":2785,"start":2786,"enrollment":1361,"conditions":10952,"interventions":10953},[88],[32],[2789,738,42,2391,894,2790],{"trials":10955,"activeCount":99},[],{"trials":10957,"activeCount":99},[],{"trials":10959,"activeCount":99},[],{"intervention":903,"totalTrials":195,"cells":10961},{"EARLY_PHASE1":10962,"PHASE1":10964,"PHASE2":10974,"PHASE3":10984,"PHASE4":10986,"NA":10988},{"trials":10963,"activeCount":99},[],{"trials":10965,"activeCount":99},[10966,10970],{"nctId":2663,"briefTitle":2664,"status":107,"phases":10967,"primaryCompletion":433,"completion":433,"start":2666,"enrollment":785,"conditions":10968,"interventions":10969},[87],[24],[903,894],{"nctId":896,"briefTitle":897,"status":107,"phases":10971,"primaryCompletion":433,"completion":433,"start":899,"enrollment":900,"conditions":10972,"interventions":10973},[87],[24],[903,75],{"trials":10975,"activeCount":99},[10976,10980],{"nctId":10343,"briefTitle":10344,"status":107,"phases":10977,"primaryCompletion":6142,"completion":6142,"start":10346,"enrollment":10347,"conditions":10978,"interventions":10979},[88],[3273,10349,3274],[10351,903,1331,8516,387,274],{"nctId":1377,"briefTitle":1378,"status":107,"phases":10981,"primaryCompletion":1380,"completion":1381,"start":1382,"enrollment":1383,"conditions":10982,"interventions":10983},[88],[878,880,1385],[75,903],{"trials":10985,"activeCount":99},[],{"trials":10987,"activeCount":99},[],{"trials":10989,"activeCount":99},[],{"intervention":3317,"totalTrials":195,"cells":10991},{"EARLY_PHASE1":10992,"PHASE1":10994,"PHASE2":11000,"PHASE3":11018,"PHASE4":11020,"NA":11022},{"trials":10993,"activeCount":99},[],{"trials":10995,"activeCount":99},[10996],{"nctId":8509,"briefTitle":8510,"status":107,"phases":10997,"primaryCompletion":8512,"completion":8512,"start":8513,"enrollment":498,"conditions":10998,"interventions":10999},[87],[32],[3317,2946,1332,274,8516,2345],{"trials":11001,"activeCount":99},[11002,11006,11014],{"nctId":3305,"briefTitle":3306,"status":369,"phases":11003,"primaryCompletion":3308,"completion":3309,"start":3310,"enrollment":486,"conditions":11004,"interventions":11005},[87,88],[2744,3312,2745,3313,3314,27,3315,879,664,2747,2335],[114,3317,3318,740,447,276],{"nctId":11007,"briefTitle":11008,"status":369,"phases":11009,"primaryCompletion":11010,"start":11011,"enrollment":486,"conditions":11012,"interventions":11013},"NCT00544908","Dasatinib in Treating Patients With Stage IV Pancreatic Cancer",[88],"2012-10","2007-09",[7865],[3317],{"nctId":4493,"briefTitle":4494,"status":369,"phases":11015,"primaryCompletion":4496,"completion":4496,"start":4497,"enrollment":404,"conditions":11016,"interventions":11017},[87,88],[1426,1427,1428,1429,1430,1431,812,813,819],[2391,2790,3317],{"trials":11019,"activeCount":99},[],{"trials":11021,"activeCount":99},[],{"trials":11023,"activeCount":99},[],{"intervention":1331,"totalTrials":283,"cells":11025},{"EARLY_PHASE1":11026,"PHASE1":11028,"PHASE2":11030,"PHASE3":11044,"PHASE4":11046,"NA":11048},{"trials":11027,"activeCount":99},[],{"trials":11029,"activeCount":99},[],{"trials":11031,"activeCount":99},[11032,11036,11040],{"nctId":10343,"briefTitle":10344,"status":107,"phases":11033,"primaryCompletion":6142,"completion":6142,"start":10346,"enrollment":10347,"conditions":11034,"interventions":11035},[88],[3273,10349,3274],[10351,903,1331,8516,387,274],{"nctId":1323,"briefTitle":1324,"status":107,"phases":11037,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1264,"conditions":11038,"interventions":11039},[87,88],[989,1329,990,991,992],[115,738,1331,1332,75,1333],{"nctId":2475,"briefTitle":2476,"status":107,"phases":11041,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":11042,"interventions":11043},[88],[1297,2482],[1700,2484,115,1502,1332,1331],{"trials":11045,"activeCount":99},[],{"trials":11047,"activeCount":99},[],{"trials":11049,"activeCount":99},[],{"intervention":446,"totalTrials":283,"cells":11051},{"EARLY_PHASE1":11052,"PHASE1":11054,"PHASE2":11076,"PHASE3":11082,"PHASE4":11084,"NA":11086},{"trials":11053,"activeCount":99},[],{"trials":11055,"activeCount":99},[11056,11064],{"nctId":11057,"briefTitle":11058,"status":107,"phases":11059,"primaryCompletion":11060,"completion":11060,"start":11061,"enrollment":264,"conditions":11062,"interventions":11063},"NCT00962507","Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma",[87],"2013-01","2009-07",[27,1297],[446,8303],{"nctId":11065,"briefTitle":11066,"status":107,"phases":11067,"primaryCompletion":11068,"completion":11069,"start":11070,"enrollment":22,"conditions":11071,"interventions":11074},"NCT02120469","Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer",[87],"2019-03-20","2020-03-03","2014-10-01",[1880,1883,11072,144,11073],"Progesterone Receptor-negative","Triple-negative Breast Carcinoma",[446,11075],"eribulin mesylate",{"trials":11077,"activeCount":99},[11078],{"nctId":429,"briefTitle":430,"status":107,"phases":11079,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":11080,"interventions":11081},[87,88],[436,437,438,439,440,441,442,443,444],[250,270,271,446,447],{"trials":11083,"activeCount":99},[],{"trials":11085,"activeCount":99},[],{"trials":11087,"activeCount":99},[],{"intervention":8303,"totalTrials":283,"cells":11089},{"EARLY_PHASE1":11090,"PHASE1":11092,"PHASE2":11102,"PHASE3":11108,"PHASE4":11110,"NA":11112},{"trials":11091,"activeCount":99},[],{"trials":11093,"activeCount":99},[11094,11098],{"nctId":11057,"briefTitle":11058,"status":107,"phases":11095,"primaryCompletion":11060,"completion":11060,"start":11061,"enrollment":264,"conditions":11096,"interventions":11097},[87],[27,1297],[446,8303],{"nctId":8295,"briefTitle":8296,"status":107,"phases":11099,"primaryCompletion":8298,"completion":8299,"start":6240,"enrollment":95,"conditions":11100,"interventions":11101},[87],[32],[8302,8303,275,387,276],{"trials":11103,"activeCount":99},[11104],{"nctId":10380,"briefTitle":10381,"status":369,"phases":11105,"primaryCompletion":10383,"completion":10383,"start":6224,"enrollment":576,"conditions":11106,"interventions":11107},[88],[32],[8303,274,2345],{"trials":11109,"activeCount":99},[],{"trials":11111,"activeCount":99},[],{"trials":11113,"activeCount":99},[],{"intervention":2790,"totalTrials":283,"cells":11115},{"EARLY_PHASE1":11116,"PHASE1":11118,"PHASE2":11120,"PHASE3":11134,"PHASE4":11136,"NA":11138},{"trials":11117,"activeCount":99},[],{"trials":11119,"activeCount":99},[],{"trials":11121,"activeCount":99},[11122,11126,11130],{"nctId":4473,"briefTitle":4474,"status":107,"phases":11123,"primaryCompletion":4476,"completion":4476,"start":393,"enrollment":4477,"conditions":11124,"interventions":11125},[88],[32],[2391,2790],{"nctId":2781,"briefTitle":2782,"status":107,"phases":11127,"primaryCompletion":2784,"completion":2785,"start":2786,"enrollment":1361,"conditions":11128,"interventions":11129},[88],[32],[2789,738,42,2391,894,2790],{"nctId":4493,"briefTitle":4494,"status":369,"phases":11131,"primaryCompletion":4496,"completion":4496,"start":4497,"enrollment":404,"conditions":11132,"interventions":11133},[87,88],[1426,1427,1428,1429,1430,1431,812,813,819],[2391,2790,3317],{"trials":11135,"activeCount":99},[],{"trials":11137,"activeCount":99},[],{"trials":11139,"activeCount":99},[],{"intervention":1332,"totalTrials":283,"cells":11141},{"EARLY_PHASE1":11142,"PHASE1":11144,"PHASE2":11150,"PHASE3":11160,"PHASE4":11162,"NA":11164},{"trials":11143,"activeCount":99},[],{"trials":11145,"activeCount":99},[11146],{"nctId":8509,"briefTitle":8510,"status":107,"phases":11147,"primaryCompletion":8512,"completion":8512,"start":8513,"enrollment":498,"conditions":11148,"interventions":11149},[87],[32],[3317,2946,1332,274,8516,2345],{"trials":11151,"activeCount":99},[11152,11156],{"nctId":1323,"briefTitle":1324,"status":107,"phases":11153,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1264,"conditions":11154,"interventions":11155},[87,88],[989,1329,990,991,992],[115,738,1331,1332,75,1333],{"nctId":2475,"briefTitle":2476,"status":107,"phases":11157,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":11158,"interventions":11159},[88],[1297,2482],[1700,2484,115,1502,1332,1331],{"trials":11161,"activeCount":99},[],{"trials":11163,"activeCount":99},[],{"trials":11165,"activeCount":99},[],{"intervention":447,"totalTrials":283,"cells":11167},{"EARLY_PHASE1":11168,"PHASE1":11170,"PHASE2":11172,"PHASE3":11186,"PHASE4":11188,"NA":11190},{"trials":11169,"activeCount":99},[],{"trials":11171,"activeCount":99},[],{"trials":11173,"activeCount":99},[11174,11178,11182],{"nctId":6160,"briefTitle":6161,"status":369,"phases":11175,"primaryCompletion":6163,"start":6164,"enrollment":1916,"conditions":11176,"interventions":11177},[88],[266],[6167,696,274,447,6168,2345],{"nctId":3305,"briefTitle":3306,"status":369,"phases":11179,"primaryCompletion":3308,"completion":3309,"start":3310,"enrollment":486,"conditions":11180,"interventions":11181},[87,88],[2744,3312,2745,3313,3314,27,3315,879,664,2747,2335],[114,3317,3318,740,447,276],{"nctId":429,"briefTitle":430,"status":107,"phases":11183,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":11184,"interventions":11185},[87,88],[436,437,438,439,440,441,442,443,444],[250,270,271,446,447],{"trials":11187,"activeCount":99},[],{"trials":11189,"activeCount":99},[],{"trials":11191,"activeCount":99},[],{"intervention":1909,"totalTrials":363,"cells":11193},{"EARLY_PHASE1":11194,"PHASE1":11196,"PHASE2":11198,"PHASE3":11208,"PHASE4":11210,"NA":11212},{"trials":11195,"activeCount":99},[],{"trials":11197,"activeCount":99},[],{"trials":11199,"activeCount":99},[11200,11204],{"nctId":1899,"briefTitle":1900,"status":479,"phases":11201,"primaryCompletion":1902,"completion":1902,"start":1903,"enrollment":99,"conditions":11202,"interventions":11203},[88],[1905,1906,1907],[1909,1480],{"nctId":2062,"briefTitle":2063,"status":479,"phases":11205,"primaryCompletion":2065,"completion":2065,"start":2066,"enrollment":99,"conditions":11206,"interventions":11207},[88],[2068],[1480,1909],{"trials":11209,"activeCount":99},[],{"trials":11211,"activeCount":99},[],{"trials":11213,"activeCount":99},[],{"intervention":11215,"totalTrials":363,"cells":11216},"temsirolimus",{"EARLY_PHASE1":11217,"PHASE1":11219,"PHASE2":11228,"PHASE3":11239,"PHASE4":11241,"NA":11243},{"trials":11218,"activeCount":99},[],{"trials":11220,"activeCount":99},[11221],{"nctId":11222,"briefTitle":11223,"status":107,"phases":11224,"primaryCompletion":11225,"completion":11225,"start":6050,"enrollment":1632,"conditions":11226,"interventions":11227},"NCT00784914","A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors",[87],"2010-11",[2744,395],[11215],{"trials":11229,"activeCount":99},[11230],{"nctId":11231,"briefTitle":11232,"status":107,"phases":11233,"primaryCompletion":11234,"completion":11234,"start":11235,"conditions":11236,"interventions":11238},"NCT00022464","CCI-779 in Treating Patients With Metastatic Melanoma",[88],"2005-09","2001-06",[11237],"Melanoma (Skin)",[11215],{"trials":11240,"activeCount":99},[],{"trials":11242,"activeCount":99},[],{"trials":11244,"activeCount":99},[],{"intervention":8302,"totalTrials":363,"cells":11246},{"EARLY_PHASE1":11247,"PHASE1":11249,"PHASE2":11255,"PHASE3":11264,"PHASE4":11266,"NA":11268},{"trials":11248,"activeCount":99},[],{"trials":11250,"activeCount":99},[11251],{"nctId":8295,"briefTitle":8296,"status":107,"phases":11252,"primaryCompletion":8298,"completion":8299,"start":6240,"enrollment":95,"conditions":11253,"interventions":11254},[87],[32],[8302,8303,275,387,276],{"trials":11256,"activeCount":99},[11257],{"nctId":11258,"briefTitle":11259,"status":107,"phases":11260,"primaryCompletion":1091,"completion":1091,"start":11261,"enrollment":188,"conditions":11262,"interventions":11263},"NCT00062205","Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor",[88],"2002-06",[664],[8302],{"trials":11265,"activeCount":99},[],{"trials":11267,"activeCount":99},[],{"trials":11269,"activeCount":99},[],{"intervention":397,"totalTrials":363,"cells":11271},{"EARLY_PHASE1":11272,"PHASE1":11274,"PHASE2":11276,"PHASE3":11286,"PHASE4":11288,"NA":11290},{"trials":11273,"activeCount":99},[],{"trials":11275,"activeCount":99},[],{"trials":11277,"activeCount":99},[11278,11282],{"nctId":7890,"briefTitle":7891,"status":107,"phases":11279,"primaryCompletion":7893,"completion":7893,"start":7894,"enrollment":576,"conditions":11280,"interventions":11281},[87,88],[226,285,286,287,288],[386,397,7897],{"nctId":389,"briefTitle":390,"status":107,"phases":11283,"primaryCompletion":392,"completion":392,"start":393,"enrollment":316,"conditions":11284,"interventions":11285},[88],[266,395],[397,250,270],{"trials":11287,"activeCount":99},[],{"trials":11289,"activeCount":99},[],{"trials":11291,"activeCount":99},[],{"intervention":923,"totalTrials":363,"cells":11293},{"EARLY_PHASE1":11294,"PHASE1":11296,"PHASE2":11302,"PHASE3":11308,"PHASE4":11310,"NA":11312},{"trials":11295,"activeCount":99},[],{"trials":11297,"activeCount":99},[11298],{"nctId":915,"briefTitle":916,"status":107,"phases":11299,"primaryCompletion":175,"completion":175,"start":918,"enrollment":919,"conditions":11300,"interventions":11301},[87],[921],[738,114,385,75,894,740,923,871],{"trials":11303,"activeCount":99},[11304],{"nctId":1335,"briefTitle":1336,"status":107,"phases":11305,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":16,"conditions":11306,"interventions":11307},[88],[15],[738,385,75,168,115,923,871,1343],{"trials":11309,"activeCount":99},[],{"trials":11311,"activeCount":99},[],{"trials":11313,"activeCount":99},[],{"intervention":1343,"totalTrials":363,"cells":11315},{"EARLY_PHASE1":11316,"PHASE1":11318,"PHASE2":11320,"PHASE3":11330,"PHASE4":11332,"NA":11334},{"trials":11317,"activeCount":99},[],{"trials":11319,"activeCount":99},[],{"trials":11321,"activeCount":99},[11322,11326],{"nctId":1335,"briefTitle":1336,"status":107,"phases":11323,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":16,"conditions":11324,"interventions":11325},[88],[15],[738,385,75,168,115,923,871,1343],{"nctId":3355,"briefTitle":3356,"status":107,"phases":11327,"primaryCompletion":3358,"completion":3358,"start":3359,"enrollment":2625,"conditions":11328,"interventions":11329},[88],[2744,395,24],[114,1343,882],{"trials":11331,"activeCount":99},[],{"trials":11333,"activeCount":99},[],{"trials":11335,"activeCount":99},[],{"intervention":739,"totalTrials":363,"cells":11337},{"EARLY_PHASE1":11338,"PHASE1":11340,"PHASE2":11346,"PHASE3":11352,"PHASE4":11354,"NA":11356},{"trials":11339,"activeCount":99},[],{"trials":11341,"activeCount":99},[11342],{"nctId":7654,"briefTitle":7655,"status":107,"phases":11343,"primaryCompletion":2342,"completion":2342,"start":7657,"enrollment":890,"conditions":11344,"interventions":11345},[87],[24],[385,739],{"trials":11347,"activeCount":99},[11348],{"nctId":731,"briefTitle":732,"status":369,"phases":11349,"primaryCompletion":734,"start":735,"enrollment":486,"conditions":11350,"interventions":11351},[88],[664],[738,739,168,740,290,387],{"trials":11353,"activeCount":99},[],{"trials":11355,"activeCount":99},[],{"trials":11357,"activeCount":99},[],{"intervention":1500,"totalTrials":363,"cells":11359},{"EARLY_PHASE1":11360,"PHASE1":11362,"PHASE2":11364,"PHASE3":11377,"PHASE4":11379,"NA":11381},{"trials":11361,"activeCount":99},[],{"trials":11363,"activeCount":99},[],{"trials":11365,"activeCount":99},[11366,11373],{"nctId":11367,"briefTitle":11368,"status":107,"phases":11369,"primaryCompletion":11370,"completion":11370,"start":3875,"conditions":11371,"interventions":11372},"NCT00006384","SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer",[88],"2007-02",[3313],[1500,3878],{"nctId":1492,"briefTitle":1493,"status":107,"phases":11374,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":11375,"interventions":11376},[88],[1297],[738,1500,42,75,115,1501,1502],{"trials":11378,"activeCount":99},[],{"trials":11380,"activeCount":99},[],{"trials":11382,"activeCount":99},[],{"intervention":3878,"totalTrials":363,"cells":11384},{"EARLY_PHASE1":11385,"PHASE1":11387,"PHASE2":11393,"PHASE3":11399,"PHASE4":11401,"NA":11403},{"trials":11386,"activeCount":99},[],{"trials":11388,"activeCount":99},[11389],{"nctId":3872,"briefTitle":3873,"status":107,"phases":11390,"start":3875,"conditions":11391,"interventions":11392},[87],[24],[871,3878],{"trials":11394,"activeCount":99},[11395],{"nctId":11367,"briefTitle":11368,"status":107,"phases":11396,"primaryCompletion":11370,"completion":11370,"start":3875,"conditions":11397,"interventions":11398},[88],[3313],[1500,3878],{"trials":11400,"activeCount":99},[],{"trials":11402,"activeCount":99},[],{"trials":11404,"activeCount":99},[],{"intervention":2573,"totalTrials":363,"cells":11406},{"EARLY_PHASE1":11407,"PHASE1":11409,"PHASE2":11415,"PHASE3":11425,"PHASE4":11427,"NA":11429},{"trials":11408,"activeCount":99},[],{"trials":11410,"activeCount":99},[11411],{"nctId":2566,"briefTitle":2567,"status":907,"phases":11412,"primaryCompletion":2569,"completion":2569,"start":2570,"enrollment":298,"conditions":11413,"interventions":11414},[87],[18,1003,818],[2573,956],{"trials":11416,"activeCount":99},[11417],{"nctId":11418,"briefTitle":11419,"status":107,"phases":11420,"primaryCompletion":11421,"completion":3799,"start":11422,"enrollment":404,"conditions":11423,"interventions":11424},"NCT02509546","8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[87,88],"2021-03-09","2015-09-02",[1801,1003,818],[2573],{"trials":11426,"activeCount":99},[],{"trials":11428,"activeCount":99},[],{"trials":11430,"activeCount":99},[],{"intervention":11432,"totalTrials":363,"cells":11433},"sorafenib tosylate",{"EARLY_PHASE1":11434,"PHASE1":11436,"PHASE2":11451,"PHASE3":11461,"PHASE4":11463,"NA":11465},{"trials":11435,"activeCount":99},[],{"trials":11437,"activeCount":99},[11438],{"nctId":11439,"briefTitle":11440,"status":107,"phases":11441,"primaryCompletion":11442,"completion":11442,"start":11443,"enrollment":36,"conditions":11444,"interventions":11450},"NCT01666756","Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer",[87],"2020-05-29","2014-06-11",[11445,11446,11447,11448,11449],"Adult Primary Hepatocellular Carcinoma","Advanced Adult Primary Liver Cancer","Advanced Adult Hepatocellular Carcinoma","BCLC Stage B Adult Hepatocellular Carcinoma","BCLC Stage C Adult Hepatocellular Carcinoma",[11432],{"trials":11452,"activeCount":99},[11453],{"nctId":11454,"briefTitle":11455,"status":107,"phases":11456,"primaryCompletion":11457,"completion":11457,"start":2363,"enrollment":3044,"conditions":11458,"interventions":11459},"NCT00828074","Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer",[87,88],"2014-04",[15],[11432,11460],"vinorelbine ditartrate",{"trials":11462,"activeCount":99},[],{"trials":11464,"activeCount":99},[],{"trials":11466,"activeCount":99},[],{"intervention":11468,"totalTrials":363,"cells":11469},"CMVpp65-A*0201 peptide vaccine",{"EARLY_PHASE1":11470,"PHASE1":11472,"PHASE2":11482,"PHASE3":11497,"PHASE4":11499,"NA":11501},{"trials":11471,"activeCount":99},[],{"trials":11473,"activeCount":99},[11474],{"nctId":11475,"briefTitle":11476,"status":107,"phases":11477,"primaryCompletion":11478,"completion":11478,"start":11479,"enrollment":3044,"conditions":11480,"interventions":11481},"NCT00712634","Cytomegalovirus Vaccine in Healthy Participants",[87],"2009-04","1997-11",[1372],[11468],{"trials":11483,"activeCount":99},[11484],{"nctId":11485,"briefTitle":11486,"status":107,"phases":11487,"primaryCompletion":11488,"completion":11489,"start":11490,"enrollment":10654,"conditions":11491,"interventions":11496},"NCT02396134","Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant",[88],"2018-03-04","2024-09-19","2015-05-21",[3085,1800,808,11492,11493,3086,3087,1145,11494,21,11495,2102,3036,1276],"Adult Hodgkin Lymphoma","Adult Non-Hodgkin Lymphoma","HLA-A*0201 Positive Cells Present","Adult Lymphoblastic Lymphoma",[11468],{"trials":11498,"activeCount":99},[],{"trials":11500,"activeCount":99},[],{"trials":11502,"activeCount":99},[],{"intervention":11504,"totalTrials":363,"cells":11505},"exemestane",{"EARLY_PHASE1":11506,"PHASE1":11508,"PHASE2":11510,"PHASE3":11523,"PHASE4":11525,"NA":11527},{"trials":11507,"activeCount":99},[],{"trials":11509,"activeCount":99},[],{"trials":11511,"activeCount":99},[11512,11519],{"nctId":11513,"briefTitle":11514,"status":107,"phases":11515,"primaryCompletion":10946,"completion":10946,"start":11516,"enrollment":1610,"conditions":11517,"interventions":11518},"NCT00810797","Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer",[88],"2008-12-02",[15],[11504],{"nctId":2071,"briefTitle":2072,"status":107,"phases":11520,"primaryCompletion":2074,"completion":2075,"start":2076,"enrollment":298,"conditions":11521,"interventions":11522},[88],[1880,2078,1883,1887,2079,144,1891],[2081,941,2082,2055,1480],{"trials":11524,"activeCount":99},[],{"trials":11526,"activeCount":99},[],{"trials":11528,"activeCount":99},[],{"intervention":11460,"totalTrials":363,"cells":11530},{"EARLY_PHASE1":11531,"PHASE1":11533,"PHASE2":11535,"PHASE3":11551,"PHASE4":11553,"NA":11555},{"trials":11532,"activeCount":99},[],{"trials":11534,"activeCount":99},[],{"trials":11536,"activeCount":99},[11537,11547],{"nctId":11538,"briefTitle":11539,"status":107,"phases":11540,"primaryCompletion":11541,"completion":11541,"start":11542,"enrollment":2051,"conditions":11543,"interventions":11544},"NCT00540982","Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction",[87,88],"2010-05-20","1997-02-20",[5110,24],[11545,11546,11460],"indocyanine green","lidocaine",{"nctId":11454,"briefTitle":11455,"status":107,"phases":11548,"primaryCompletion":11457,"completion":11457,"start":2363,"enrollment":3044,"conditions":11549,"interventions":11550},[87,88],[15],[11432,11460],{"trials":11552,"activeCount":99},[],{"trials":11554,"activeCount":99},[],{"trials":11556,"activeCount":99},[],{"intervention":4719,"totalTrials":363,"cells":11558},{"EARLY_PHASE1":11559,"PHASE1":11561,"PHASE2":11563,"PHASE3":11573,"PHASE4":11575,"NA":11577},{"trials":11560,"activeCount":99},[],{"trials":11562,"activeCount":99},[],{"trials":11564,"activeCount":99},[11565,11569],{"nctId":4709,"briefTitle":4710,"status":907,"phases":11566,"primaryCompletion":4712,"completion":4712,"start":4713,"enrollment":919,"conditions":11567,"interventions":11568},[88],[1848,1849,1850,4715,4716,4717],[2649,4719],{"nctId":6488,"briefTitle":6489,"status":479,"phases":11570,"primaryCompletion":6491,"completion":6491,"start":6492,"enrollment":99,"conditions":11571,"interventions":11572},[87,88],[973,1856],[4719,3813,3814],{"trials":11574,"activeCount":99},[],{"trials":11576,"activeCount":99},[],{"trials":11578,"activeCount":99},[],{"intervention":1502,"totalTrials":363,"cells":11580},{"EARLY_PHASE1":11581,"PHASE1":11583,"PHASE2":11585,"PHASE3":11595,"PHASE4":11597,"NA":11599},{"trials":11582,"activeCount":99},[],{"trials":11584,"activeCount":99},[],{"trials":11586,"activeCount":99},[11587,11591],{"nctId":1492,"briefTitle":1493,"status":107,"phases":11588,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":11589,"interventions":11590},[88],[1297],[738,1500,42,75,115,1501,1502],{"nctId":2475,"briefTitle":2476,"status":107,"phases":11592,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":11593,"interventions":11594},[88],[1297,2482],[1700,2484,115,1502,1332,1331],{"trials":11596,"activeCount":99},[],{"trials":11598,"activeCount":99},[],{"trials":11600,"activeCount":99},[],{"intervention":10351,"totalTrials":214,"cells":11602},{"EARLY_PHASE1":11603,"PHASE1":11605,"PHASE2":11607,"PHASE3":11613,"PHASE4":11615,"NA":11617},{"trials":11604,"activeCount":99},[],{"trials":11606,"activeCount":99},[],{"trials":11608,"activeCount":99},[11609],{"nctId":10343,"briefTitle":10344,"status":107,"phases":11610,"primaryCompletion":6142,"completion":6142,"start":10346,"enrollment":10347,"conditions":11611,"interventions":11612},[88],[3273,10349,3274],[10351,903,1331,8516,387,274],{"trials":11614,"activeCount":99},[],{"trials":11616,"activeCount":99},[],{"trials":11618,"activeCount":99},[],{"intervention":11620,"totalTrials":214,"cells":11621},"Neratinib",{"EARLY_PHASE1":11622,"PHASE1":11624,"PHASE2":11626,"PHASE3":11637,"PHASE4":11639,"NA":11641},{"trials":11623,"activeCount":99},[],{"trials":11625,"activeCount":99},[],{"trials":11627,"activeCount":99},[11628],{"nctId":11629,"briefTitle":11630,"status":107,"phases":11631,"primaryCompletion":11632,"completion":11633,"start":11634,"enrollment":890,"conditions":11635,"interventions":11636},"NCT02673398","Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer",[88],"2020-03-12","2022-09-22","2016-12-02",[157,1961],[11620],{"trials":11638,"activeCount":99},[],{"trials":11640,"activeCount":99},[],{"trials":11642,"activeCount":99},[],{"intervention":1963,"totalTrials":214,"cells":11644},{"EARLY_PHASE1":11645,"PHASE1":11647,"PHASE2":11649,"PHASE3":11655,"PHASE4":11657,"NA":11659},{"trials":11646,"activeCount":99},[],{"trials":11648,"activeCount":99},[],{"trials":11650,"activeCount":99},[11651],{"nctId":1952,"briefTitle":1953,"status":107,"phases":11652,"primaryCompletion":1955,"completion":1956,"start":1957,"enrollment":36,"conditions":11653,"interventions":11654},[88],[1959,1880,1883,1960,1887,1961],[1963,1480],{"trials":11656,"activeCount":99},[],{"trials":11658,"activeCount":99},[],{"trials":11660,"activeCount":99},[],{"intervention":1364,"totalTrials":214,"cells":11662},{"EARLY_PHASE1":11663,"PHASE1":11665,"PHASE2":11667,"PHASE3":11673,"PHASE4":11675,"NA":11677},{"trials":11664,"activeCount":99},[],{"trials":11666,"activeCount":99},[],{"trials":11668,"activeCount":99},[11669],{"nctId":1356,"briefTitle":1357,"status":107,"phases":11670,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":11671,"interventions":11672},[88],[27],[893,75,894,1364],{"trials":11674,"activeCount":99},[],{"trials":11676,"activeCount":99},[],{"trials":11678,"activeCount":99},[],{"intervention":6168,"totalTrials":214,"cells":11680},{"EARLY_PHASE1":11681,"PHASE1":11683,"PHASE2":11685,"PHASE3":11691,"PHASE4":11693,"NA":11695},{"trials":11682,"activeCount":99},[],{"trials":11684,"activeCount":99},[],{"trials":11686,"activeCount":99},[11687],{"nctId":6160,"briefTitle":6161,"status":369,"phases":11688,"primaryCompletion":6163,"start":6164,"enrollment":1916,"conditions":11689,"interventions":11690},[88],[266],[6167,696,274,447,6168,2345],{"trials":11692,"activeCount":99},[],{"trials":11694,"activeCount":99},[],{"trials":11696,"activeCount":99},[],{"intervention":1418,"totalTrials":214,"cells":11698},{"EARLY_PHASE1":11699,"PHASE1":11701,"PHASE2":11703,"PHASE3":11709,"PHASE4":11711,"NA":11713},{"trials":11700,"activeCount":99},[],{"trials":11702,"activeCount":99},[],{"trials":11704,"activeCount":99},[11705],{"nctId":1399,"briefTitle":1400,"status":107,"phases":11706,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":11707,"interventions":11708},[88],[1407,1408,1409,1410,1411,1231,1412,1413,1414,21,1276,1415,1102,1103,1416],[1233,784,823,1418,850,851],{"trials":11710,"activeCount":99},[],{"trials":11712,"activeCount":99},[],{"trials":11714,"activeCount":99},[],{"intervention":11716,"totalTrials":214,"cells":11717},"deferasirox",{"EARLY_PHASE1":11718,"PHASE1":11720,"PHASE2":11722,"PHASE3":11737,"PHASE4":11739,"NA":11741},{"trials":11719,"activeCount":99},[],{"trials":11721,"activeCount":99},[],{"trials":11723,"activeCount":99},[11724],{"nctId":11725,"briefTitle":11726,"status":369,"phases":11727,"primaryCompletion":2770,"completion":2770,"start":4039,"enrollment":214,"conditions":11728,"interventions":11736},"NCT01159067","Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload",[88],[11729,8336,1800,808,1426,1427,1428,1429,1430,1431,8339,2773,8340,1275,8341,8342,8355,11730,2874,8361,2876,8362,8363,8364,8365,8366,8367,8368,8369,8370,2955,8371,8372,11731,2777,1488,1196,812,970,4048,4049,2877,2388,4050,4051,4053,1848,1849,2895,2331,976,977,4054,2332,1385,2333,978,5234,4581,8377,813,8378,2880,990,991,11732,8401,8402,8403,8404,8405,8406,8407,8409,8411,8412,8413,11733,2957,8414,992,11734,8416,141,142,143,8417,8418,8419,8420,8421,8422,8423,144,8425,8427,8428,8429,2958,8430,11735,8432],"Iron Overload","Disseminated Neuroblastoma","Poor Prognosis Metastatic Gestational Trophoblastic Tumor","Stage II Ovarian Epithelial Cancer","Stage III Malignant Testicular Germ Cell Tumor","Stage III Ovarian Epithelial Cancer","Stage IV Ovarian Epithelial Cancer",[11716],{"trials":11738,"activeCount":99},[],{"trials":11740,"activeCount":99},[],{"trials":11742,"activeCount":99},[],{"intervention":11744,"totalTrials":214,"cells":11745},"Niraparib",{"EARLY_PHASE1":11746,"PHASE1":11748,"PHASE2":11750,"PHASE3":11761,"PHASE4":11763,"NA":11765},{"trials":11747,"activeCount":99},[],{"trials":11749,"activeCount":99},[],{"trials":11751,"activeCount":99},[11752],{"nctId":11753,"briefTitle":11754,"status":479,"phases":11755,"primaryCompletion":11756,"completion":11756,"start":1272,"enrollment":99,"conditions":11757,"interventions":11760},"NCT05672095","Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer",[87,88],"2026-11-27",[11758,1026,11759,3239,3240,3241],"Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma",[11744],{"trials":11762,"activeCount":99},[],{"trials":11764,"activeCount":99},[],{"trials":11766,"activeCount":99},[],{"intervention":11768,"totalTrials":214,"cells":11769},"pazopanib hydrochloride",{"EARLY_PHASE1":11770,"PHASE1":11772,"PHASE2":11774,"PHASE3":11787,"PHASE4":11789,"NA":11791},{"trials":11771,"activeCount":99},[],{"trials":11773,"activeCount":99},[],{"trials":11775,"activeCount":99},[11776],{"nctId":11777,"briefTitle":11778,"status":107,"phases":11779,"primaryCompletion":11780,"completion":11781,"start":11782,"enrollment":19,"conditions":11783,"interventions":11786},"NCT01157091","Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer",[88],"2013-10-17","2013-12-31","2010-12-08",[1971,11784,11785],"Recurrent Renal Cell Cancer","Stage IV Renal Cell Cancer",[11768],{"trials":11788,"activeCount":99},[],{"trials":11790,"activeCount":99},[],{"trials":11792,"activeCount":99},[],{"intervention":2618,"totalTrials":214,"cells":11794},{"EARLY_PHASE1":11795,"PHASE1":11797,"PHASE2":11799,"PHASE3":11805,"PHASE4":11807,"NA":11809},{"trials":11796,"activeCount":99},[],{"trials":11798,"activeCount":99},[],{"trials":11800,"activeCount":99},[11801],{"nctId":2609,"briefTitle":2610,"status":107,"phases":11802,"primaryCompletion":2612,"completion":2613,"start":2614,"enrollment":1632,"conditions":11803,"interventions":11804},[88],[1918,2616,1932],[2618,956],{"trials":11806,"activeCount":99},[],{"trials":11808,"activeCount":99},[],{"trials":11810,"activeCount":99},[],{"intervention":11812,"totalTrials":214,"cells":11813},"Multi-antigen CMV-Modified Vaccinia Ankara Vaccine",{"EARLY_PHASE1":11814,"PHASE1":11816,"PHASE2":11818,"PHASE3":11829,"PHASE4":11831,"NA":11833},{"trials":11815,"activeCount":99},[],{"trials":11817,"activeCount":99},[],{"trials":11819,"activeCount":99},[11820],{"nctId":11821,"briefTitle":11822,"status":479,"phases":11823,"primaryCompletion":11824,"completion":11824,"start":11825,"enrollment":99,"conditions":11826,"interventions":11828},"NCT03438344","Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant",[88],"2021-12","2018-12",[3085,1612,1194,11827,2102,3086,1185,1412,21,3036,1276,3035],"Bone Marrow Transplantation Recipient",[11812],{"trials":11830,"activeCount":99},[],{"trials":11832,"activeCount":99},[],{"trials":11834,"activeCount":99},[],{"intervention":11836,"totalTrials":214,"cells":11837},"chloroquinoxaline sulfonamide",{"EARLY_PHASE1":11838,"PHASE1":11840,"PHASE2":11842,"PHASE3":11852,"PHASE4":11854,"NA":11856},{"trials":11839,"activeCount":99},[],{"trials":11841,"activeCount":99},[],{"trials":11843,"activeCount":99},[11844],{"nctId":11845,"briefTitle":11846,"status":107,"phases":11847,"primaryCompletion":11848,"completion":11848,"start":11849,"conditions":11850,"interventions":11851},"NCT00008372","Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer",[88],"2002-09","2000-12",[5110],[11836],{"trials":11853,"activeCount":99},[],{"trials":11855,"activeCount":99},[],{"trials":11857,"activeCount":99},[],{"intervention":4628,"totalTrials":214,"cells":11859},{"EARLY_PHASE1":11860,"PHASE1":11862,"PHASE2":11864,"PHASE3":11870,"PHASE4":11872,"NA":11874},{"trials":11861,"activeCount":99},[],{"trials":11863,"activeCount":99},[],{"trials":11865,"activeCount":99},[11866],{"nctId":4620,"briefTitle":4621,"status":107,"phases":11867,"primaryCompletion":4623,"completion":4624,"start":4625,"enrollment":111,"conditions":11868,"interventions":11869},[87,88],[1103,1102],[4628,2484,4629],{"trials":11871,"activeCount":99},[],{"trials":11873,"activeCount":99},[],{"trials":11875,"activeCount":99},[],{"intervention":10374,"totalTrials":214,"cells":11877},{"EARLY_PHASE1":11878,"PHASE1":11880,"PHASE2":11882,"PHASE3":11888,"PHASE4":11890,"NA":11892},{"trials":11879,"activeCount":99},[],{"trials":11881,"activeCount":99},[],{"trials":11883,"activeCount":99},[11884],{"nctId":10365,"briefTitle":10366,"status":369,"phases":11885,"primaryCompletion":2508,"start":10368,"enrollment":1945,"conditions":11886,"interventions":11887},[87,88],[10370,2317,10371,10372],[10374,274,276,2345],{"trials":11889,"activeCount":99},[],{"trials":11891,"activeCount":99},[],{"trials":11893,"activeCount":99},[],{"intervention":11895,"totalTrials":214,"cells":11896},"Anti-CD123\u002FCD3 Monoclonal Antibody MGD006",{"EARLY_PHASE1":11897,"PHASE1":11899,"PHASE2":11901,"PHASE3":11911,"PHASE4":11913,"NA":11915},{"trials":11898,"activeCount":99},[],{"trials":11900,"activeCount":99},[],{"trials":11902,"activeCount":99},[11903],{"nctId":11904,"briefTitle":11905,"status":479,"phases":11906,"primaryCompletion":11907,"completion":11907,"start":11907,"enrollment":99,"conditions":11908,"interventions":11910},"NCT03739606","Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer",[88],"2020-10-20",[809,1407,1409,11909,816,1173,4574,4575,4576,2241,1174,4579,4582,2242,4584],"Hairy Cell Leukemia",[11895],{"trials":11912,"activeCount":99},[],{"trials":11914,"activeCount":99},[],{"trials":11916,"activeCount":99},[],{"intervention":1654,"totalTrials":214,"cells":11918},{"EARLY_PHASE1":11919,"PHASE1":11921,"PHASE2":11923,"PHASE3":11929,"PHASE4":11931,"NA":11933},{"trials":11920,"activeCount":99},[],{"trials":11922,"activeCount":99},[],{"trials":11924,"activeCount":99},[11925],{"nctId":1644,"briefTitle":1645,"status":107,"phases":11926,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":1650,"conditions":11927,"interventions":11928},[88],[1407,1652,21,1488,845],[847,1654,849,1149,851],{"trials":11930,"activeCount":99},[],{"trials":11932,"activeCount":99},[],{"trials":11934,"activeCount":99},[],{"intervention":427,"totalTrials":214,"cells":11936},{"EARLY_PHASE1":11937,"PHASE1":11939,"PHASE2":11941,"PHASE3":11947,"PHASE4":11949,"NA":11951},{"trials":11938,"activeCount":99},[],{"trials":11940,"activeCount":99},[],{"trials":11942,"activeCount":99},[11943],{"nctId":416,"briefTitle":417,"status":369,"phases":11944,"primaryCompletion":419,"completion":419,"start":420,"enrollment":214,"conditions":11945,"interventions":11946},[88],[422,423,424],[305,426,308,427],{"trials":11948,"activeCount":99},[],{"trials":11950,"activeCount":99},[],{"trials":11952,"activeCount":99},[],{"intervention":11954,"totalTrials":214,"cells":11955},"cyclodextrin-based polymer-camptothecin CRLX101",{"EARLY_PHASE1":11956,"PHASE1":11958,"PHASE2":11960,"PHASE3":11975,"PHASE4":11977,"NA":11979},{"trials":11957,"activeCount":99},[],{"trials":11959,"activeCount":99},[],{"trials":11961,"activeCount":99},[11962],{"nctId":11963,"briefTitle":11964,"status":107,"phases":11965,"primaryCompletion":11966,"completion":11966,"start":11967,"enrollment":207,"conditions":11968,"interventions":11974},"NCT01612546","Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery",[88],"2015-01-15","2012-11",[436,437,438,439,440,441,442,11969,11970,11971,11972,11973,443,444],"Squamous Cell Carcinoma of the Esophagus","Stage IIIB Esophageal Cancer","Stage IIIB Gastric Cancer","Stage IIIC Esophageal Cancer","Stage IIIC Gastric Cancer",[11954],{"trials":11976,"activeCount":99},[],{"trials":11978,"activeCount":99},[],{"trials":11980,"activeCount":99},[],{"intervention":11982,"totalTrials":214,"cells":11983},"isosulfan blue based lymphatic mapping",{"EARLY_PHASE1":11984,"PHASE1":11986,"PHASE2":11988,"PHASE3":11997,"PHASE4":11999,"NA":12001},{"trials":11985,"activeCount":99},[],{"trials":11987,"activeCount":99},[],{"trials":11989,"activeCount":99},[11990],{"nctId":11991,"briefTitle":11992,"status":369,"phases":11993,"primaryCompletion":392,"completion":392,"start":11994,"enrollment":2122,"conditions":11995,"interventions":11996},"NCT00932035","Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer",[87,88],"2009-06",[15],[11982],{"trials":11998,"activeCount":99},[],{"trials":12000,"activeCount":99},[],{"trials":12002,"activeCount":99},[],{"intervention":3353,"totalTrials":214,"cells":12004},{"EARLY_PHASE1":12005,"PHASE1":12007,"PHASE2":12009,"PHASE3":12015,"PHASE4":12017,"NA":12019},{"trials":12006,"activeCount":99},[],{"trials":12008,"activeCount":99},[],{"trials":12010,"activeCount":99},[12011],{"nctId":3344,"briefTitle":3345,"status":107,"phases":12012,"primaryCompletion":3347,"completion":3348,"start":3349,"enrollment":19,"conditions":12013,"interventions":12014},[87,88],[209,1960,3351],[2710,459,169,3353,170],{"trials":12016,"activeCount":99},[],{"trials":12018,"activeCount":99},[],{"trials":12020,"activeCount":99},[],{"intervention":12022,"totalTrials":214,"cells":12023},"mRNA COVID-19 Vaccine",{"EARLY_PHASE1":12024,"PHASE1":12026,"PHASE2":12028,"PHASE3":12039,"PHASE4":12041,"NA":12043},{"trials":12025,"activeCount":99},[],{"trials":12027,"activeCount":99},[],{"trials":12029,"activeCount":99},[12030],{"nctId":12031,"briefTitle":12032,"status":907,"phases":12033,"primaryCompletion":12034,"completion":12034,"start":3069,"enrollment":3110,"conditions":12035,"interventions":12037},"NCT05672355","A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia",[88],"2029-01-12",[2102,12036],"COVID-19 Infection",[12022,12038],"Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1",{"trials":12040,"activeCount":99},[],{"trials":12042,"activeCount":99},[],{"trials":12044,"activeCount":99},[],{"intervention":12038,"totalTrials":214,"cells":12046},{"EARLY_PHASE1":12047,"PHASE1":12049,"PHASE2":12051,"PHASE3":12057,"PHASE4":12059,"NA":12061},{"trials":12048,"activeCount":99},[],{"trials":12050,"activeCount":99},[],{"trials":12052,"activeCount":99},[12053],{"nctId":12031,"briefTitle":12032,"status":907,"phases":12054,"primaryCompletion":12034,"completion":12034,"start":3069,"enrollment":3110,"conditions":12055,"interventions":12056},[88],[2102,12036],[12022,12038],{"trials":12058,"activeCount":99},[],{"trials":12060,"activeCount":99},[],{"trials":12062,"activeCount":99},[],{"intervention":12064,"totalTrials":214,"cells":12065},"Aromatase Inhibitor",{"EARLY_PHASE1":12066,"PHASE1":12068,"PHASE2":12070,"PHASE3":12082,"PHASE4":12084,"NA":12086},{"trials":12067,"activeCount":99},[],{"trials":12069,"activeCount":99},[],{"trials":12071,"activeCount":99},[12072],{"nctId":12073,"briefTitle":12074,"status":107,"phases":12075,"primaryCompletion":12076,"completion":4663,"start":12077,"enrollment":363,"conditions":12078,"interventions":12080},"NCT03477396","Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer",[88],"2021-09-29","2018-06-14",[12079,1883,1961],"Estrogen Receptor and\u002For Progesterone Receptor Positive",[12064,12081],"Ribociclib",{"trials":12083,"activeCount":99},[],{"trials":12085,"activeCount":99},[],{"trials":12087,"activeCount":99},[],{"intervention":12081,"totalTrials":214,"cells":12089},{"EARLY_PHASE1":12090,"PHASE1":12092,"PHASE2":12094,"PHASE3":12100,"PHASE4":12102,"NA":12104},{"trials":12091,"activeCount":99},[],{"trials":12093,"activeCount":99},[],{"trials":12095,"activeCount":99},[12096],{"nctId":12073,"briefTitle":12074,"status":107,"phases":12097,"primaryCompletion":12076,"completion":4663,"start":12077,"enrollment":363,"conditions":12098,"interventions":12099},[88],[12079,1883,1961],[12064,12081],{"trials":12101,"activeCount":99},[],{"trials":12103,"activeCount":99},[],{"trials":12105,"activeCount":99},[],{"intervention":12107,"totalTrials":214,"cells":12108},"axitinib",{"EARLY_PHASE1":12109,"PHASE1":12111,"PHASE2":12113,"PHASE3":12124,"PHASE4":12126,"NA":12128},{"trials":12110,"activeCount":99},[],{"trials":12112,"activeCount":99},[],{"trials":12114,"activeCount":99},[12115],{"nctId":12116,"briefTitle":12117,"status":107,"phases":12118,"primaryCompletion":12119,"completion":12119,"start":12120,"enrollment":264,"conditions":12121,"interventions":12123},"NCT01385059","Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer",[88],"2013-10-09","2011-10-28",[12122,8649],"Stage III Prostate Cancer",[12107],{"trials":12125,"activeCount":99},[],{"trials":12127,"activeCount":99},[],{"trials":12129,"activeCount":99},[],{"intervention":11546,"totalTrials":214,"cells":12131},{"EARLY_PHASE1":12132,"PHASE1":12134,"PHASE2":12136,"PHASE3":12142,"PHASE4":12144,"NA":12146},{"trials":12133,"activeCount":99},[],{"trials":12135,"activeCount":99},[],{"trials":12137,"activeCount":99},[12138],{"nctId":11538,"briefTitle":11539,"status":107,"phases":12139,"primaryCompletion":11541,"completion":11541,"start":11542,"enrollment":2051,"conditions":12140,"interventions":12141},[87,88],[5110,24],[11545,11546,11460],{"trials":12143,"activeCount":99},[],{"trials":12145,"activeCount":99},[],{"trials":12147,"activeCount":99},[],{"intervention":180,"totalTrials":214,"cells":12149},{"EARLY_PHASE1":12150,"PHASE1":12152,"PHASE2":12154,"PHASE3":12160,"PHASE4":12162,"NA":12164},{"trials":12151,"activeCount":99},[],{"trials":12153,"activeCount":99},[],{"trials":12155,"activeCount":99},[12156],{"nctId":172,"briefTitle":173,"status":107,"phases":12157,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":12158,"interventions":12159},[87,88],[15],[94,126,180],{"trials":12161,"activeCount":99},[],{"trials":12163,"activeCount":99},[],{"trials":12165,"activeCount":99},[],{"intervention":3909,"totalTrials":214,"cells":12167},{"EARLY_PHASE1":12168,"PHASE1":12170,"PHASE2":12172,"PHASE3":12178,"PHASE4":12180,"NA":12182},{"trials":12169,"activeCount":99},[],{"trials":12171,"activeCount":99},[],{"trials":12173,"activeCount":99},[12174],{"nctId":3902,"briefTitle":3903,"status":107,"phases":12175,"primaryCompletion":3905,"completion":3905,"start":3906,"enrollment":3765,"conditions":12176,"interventions":12177},[88],[15],[871,3909],{"trials":12179,"activeCount":99},[],{"trials":12181,"activeCount":99},[],{"trials":12183,"activeCount":99},[],{"intervention":1501,"totalTrials":214,"cells":12185},{"EARLY_PHASE1":12186,"PHASE1":12188,"PHASE2":12190,"PHASE3":12196,"PHASE4":12198,"NA":12200},{"trials":12187,"activeCount":99},[],{"trials":12189,"activeCount":99},[],{"trials":12191,"activeCount":99},[12192],{"nctId":1492,"briefTitle":1493,"status":107,"phases":12193,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":12194,"interventions":12195},[88],[1297],[738,1500,42,75,115,1501,1502],{"trials":12197,"activeCount":99},[],{"trials":12199,"activeCount":99},[],{"trials":12201,"activeCount":99},[],{"intervention":12203,"totalTrials":363,"cells":12204},"5-Fluoro-2-Deoxycytidine",{"EARLY_PHASE1":12205,"PHASE1":12207,"PHASE2":12223,"PHASE3":12225,"PHASE4":12227,"NA":12229},{"trials":12206,"activeCount":99},[],{"trials":12208,"activeCount":99},[12209,12219],{"nctId":12210,"briefTitle":12211,"status":107,"phases":12212,"primaryCompletion":12213,"completion":12213,"start":12214,"enrollment":785,"conditions":12215,"interventions":12217},"NCT00359606","5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer",[87],"2012-06","1999-04",[12216],"Neoplasms",[12203,12218],"Tetrahydrouridine",{"nctId":8882,"briefTitle":8883,"status":107,"phases":12220,"primaryCompletion":8885,"completion":8885,"start":8886,"enrollment":890,"conditions":12221,"interventions":12222},[87],[8888,8355,2777,812,813,8378,819],[8890,8891,2345,8315],{"trials":12224,"activeCount":99},[],{"trials":12226,"activeCount":99},[],{"trials":12228,"activeCount":99},[],{"trials":12230,"activeCount":99},[],{"intervention":12218,"totalTrials":363,"cells":12232},{"EARLY_PHASE1":12233,"PHASE1":12235,"PHASE2":12245,"PHASE3":12247,"PHASE4":12249,"NA":12251},{"trials":12234,"activeCount":99},[],{"trials":12236,"activeCount":99},[12237,12241],{"nctId":12210,"briefTitle":12211,"status":107,"phases":12238,"primaryCompletion":12213,"completion":12213,"start":12214,"enrollment":785,"conditions":12239,"interventions":12240},[87],[12216],[12203,12218],{"nctId":8882,"briefTitle":8883,"status":107,"phases":12242,"primaryCompletion":8885,"completion":8885,"start":8886,"enrollment":890,"conditions":12243,"interventions":12244},[87],[8888,8355,2777,812,813,8378,819],[8890,8891,2345,8315],{"trials":12246,"activeCount":99},[],{"trials":12248,"activeCount":99},[],{"trials":12250,"activeCount":99},[],{"trials":12252,"activeCount":99},[],{"intervention":11075,"totalTrials":363,"cells":12254},{"EARLY_PHASE1":12255,"PHASE1":12269,"PHASE2":12275,"PHASE3":12277,"PHASE4":12279,"NA":12281},{"trials":12256,"activeCount":99},[12257],{"nctId":12258,"briefTitle":12259,"status":107,"phases":12260,"primaryCompletion":12261,"completion":12262,"start":12263,"enrollment":9,"conditions":12264,"interventions":12267},"NCT02338037","Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors",[86],"2017-08-04","2024-03-15","2015-05-19",[12265,12266],"Metastatic Malignant Neoplasm in the Adult Brain","Primary Brain Tumor",[12268],"Eribulin Mesylate",{"trials":12270,"activeCount":99},[12271],{"nctId":11065,"briefTitle":11066,"status":107,"phases":12272,"primaryCompletion":11068,"completion":11069,"start":11070,"enrollment":22,"conditions":12273,"interventions":12274},[87],[1880,1883,11072,144,11073],[446,11075],{"trials":12276,"activeCount":99},[],{"trials":12278,"activeCount":99},[],{"trials":12280,"activeCount":99},[],{"trials":12282,"activeCount":99},[],{"intervention":587,"totalTrials":363,"cells":12284},{"EARLY_PHASE1":12285,"PHASE1":12287,"PHASE2":12305,"PHASE3":12307,"PHASE4":12309,"NA":12311},{"trials":12286,"activeCount":99},[],{"trials":12288,"activeCount":99},[12289,12301],{"nctId":12290,"briefTitle":12291,"status":107,"phases":12292,"primaryCompletion":12293,"completion":12293,"start":4040,"enrollment":795,"conditions":12294,"interventions":12299},"NCT01172964","A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas",[87],"2015-02-11",[578,12295,12296,579,12297,580,581,582,10565,583,10567,12298],"Recurrent Grade III Glioma","Recurrent Grade IV Glioma","Adult Brain Tumor","Recurrent High Grade Glioma",[587,12300,586],"gene therapy",{"nctId":571,"briefTitle":572,"status":107,"phases":12302,"primaryCompletion":574,"completion":574,"start":575,"enrollment":576,"conditions":12303,"interventions":12304},[87],[578,579,580,581,582,583,584],[586,587,270],{"trials":12306,"activeCount":99},[],{"trials":12308,"activeCount":99},[],{"trials":12310,"activeCount":99},[],{"trials":12312,"activeCount":99},[],{"intervention":586,"totalTrials":363,"cells":12314},{"EARLY_PHASE1":12315,"PHASE1":12317,"PHASE2":12327,"PHASE3":12329,"PHASE4":12331,"NA":12333},{"trials":12316,"activeCount":99},[],{"trials":12318,"activeCount":99},[12319,12323],{"nctId":12290,"briefTitle":12291,"status":107,"phases":12320,"primaryCompletion":12293,"completion":12293,"start":4040,"enrollment":795,"conditions":12321,"interventions":12322},[87],[578,12295,12296,579,12297,580,581,582,10565,583,10567,12298],[587,12300,586],{"nctId":571,"briefTitle":572,"status":107,"phases":12324,"primaryCompletion":574,"completion":574,"start":575,"enrollment":576,"conditions":12325,"interventions":12326},[87],[578,579,580,581,582,583,584],[586,587,270],{"trials":12328,"activeCount":99},[],{"trials":12330,"activeCount":99},[],{"trials":12332,"activeCount":99},[],{"trials":12334,"activeCount":99},[],{"intervention":2862,"totalTrials":363,"cells":12336},{"EARLY_PHASE1":12337,"PHASE1":12339,"PHASE2":12349,"PHASE3":12351,"PHASE4":12353,"NA":12355},{"trials":12338,"activeCount":99},[],{"trials":12340,"activeCount":99},[12341,12345],{"nctId":2855,"briefTitle":2856,"status":107,"phases":12342,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":498,"conditions":12343,"interventions":12344},[87],[27],[2789,1775,2862,61],{"nctId":10325,"briefTitle":10326,"status":107,"phases":12346,"primaryCompletion":10328,"completion":10328,"start":10329,"enrollment":283,"conditions":12347,"interventions":12348},[87],[2744],[2862,274],{"trials":12350,"activeCount":99},[],{"trials":12352,"activeCount":99},[],{"trials":12354,"activeCount":99},[],{"trials":12356,"activeCount":99},[],{"intervention":12358,"totalTrials":363,"cells":12359},"tetanus-CMV fusion peptide vaccine",{"EARLY_PHASE1":12360,"PHASE1":12362,"PHASE2":12399,"PHASE3":12401,"PHASE4":12403,"NA":12405},{"trials":12361,"activeCount":99},[],{"trials":12363,"activeCount":99},[12364,12389],{"nctId":12365,"briefTitle":12366,"status":107,"phases":12367,"primaryCompletion":12368,"completion":12368,"start":12369,"enrollment":1610,"conditions":12370,"interventions":12388},"NCT01588015","Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant",[87],"2024-02-02","2012-10-29",[8336,1800,808,1426,1427,1428,1429,1430,1431,12371,4043,12372,1918,12373,8340,1275,8342,8343,8344,8348,8349,8350,8351,2954,8353,8354,8355,8356,8357,2874,8358,12374,2876,8362,8363,8367,8368,8369,8370,2955,8372,12375,8373,4047,2777,12376,12377,1488,8375,8376,1196,812,970,4048,2388,4051,4052,4053,1848,1849,2895,976,4054,978,5234,4581,989,8377,813,8378,8380,8381,8384,8386,8387,8388,8389,8390,8391,8392,2956,990,8395,12378,12379,8396,8397,8398,8399,991,12380,12381,8401,8402,8405,8407,8408,8409,8410,8411,8412,8413,2957,992,8416,12382,12383,8417,8418,8421,8423,8424,8425,8426,8427,8428,8429,2958,8432,12384,12385,12386,8433,819,12387,8167],"Adult Acute Promyelocytic Leukemia (M3)","Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma","B-cell Adult Acute Lymphoblastic Leukemia","Monoclonal Gammopathy of Undetermined Significance","Peripheral T-cell Lymphoma","Primary Central Nervous System Hodgkin Lymphoma","Primary Central Nervous System Non-Hodgkin Lymphoma","Stage IA Mycosis Fungoides\u002FSezary Syndrome","Stage IB Mycosis Fungoides\u002FSezary Syndrome","Stage IIA Mycosis Fungoides\u002FSezary Syndrome","Stage IIB Mycosis Fungoides\u002FSezary Syndrome","Stage IIIA Mycosis Fungoides\u002FSezary Syndrome","Stage IIIB Mycosis Fungoides\u002FSezary Syndrome","Stage IVA Mycosis Fungoides\u002FSezary Syndrome","Stage IVB Mycosis Fungoides\u002FSezary Syndrome","T-cell Adult Acute Lymphoblastic Leukemia","Untreated Hairy Cell Leukemia",[12358],{"nctId":12390,"briefTitle":12391,"status":107,"phases":12392,"primaryCompletion":10792,"completion":10792,"start":12393,"enrollment":12394,"conditions":12395,"interventions":12396},"NCT00722839","Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants",[87],"2006-12",68,[8444],[12397,12358,12398],"PADRE-CMV fusion peptide vaccine","agatolimod sodium",{"trials":12400,"activeCount":99},[],{"trials":12402,"activeCount":99},[],{"trials":12404,"activeCount":99},[],{"trials":12406,"activeCount":99},[],{"intervention":1147,"totalTrials":363,"cells":12408},{"EARLY_PHASE1":12409,"PHASE1":12411,"PHASE2":12421,"PHASE3":12423,"PHASE4":12425,"NA":12427},{"trials":12410,"activeCount":99},[],{"trials":12412,"activeCount":99},[12413,12417],{"nctId":1137,"briefTitle":1138,"status":907,"phases":12414,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":12415,"interventions":12416},[87],[1144,1145],[784,940,1147,1148,1149,851],{"nctId":1179,"briefTitle":1180,"status":479,"phases":12418,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":99,"conditions":12419,"interventions":12420},[87],[1145,1185],[784,940,1147,1148,1149,851],{"trials":12422,"activeCount":99},[],{"trials":12424,"activeCount":99},[],{"trials":12426,"activeCount":99},[],{"trials":12428,"activeCount":99},[],{"intervention":8696,"totalTrials":214,"cells":12430},{"EARLY_PHASE1":12431,"PHASE1":12433,"PHASE2":12439,"PHASE3":12441,"PHASE4":12443,"NA":12445},{"trials":12432,"activeCount":99},[],{"trials":12434,"activeCount":99},[12435],{"nctId":8665,"briefTitle":8666,"status":107,"phases":12436,"primaryCompletion":8668,"completion":8668,"start":8669,"enrollment":25,"conditions":12437,"interventions":12438},[87],[8671,323,8672,8673,8674,8675,8676,8677,8678,8679,8680,8681,8682,8683,8684,8685,8686,8687,8688,8689,8690,8691,8692,8693,8694],[8658,8696],{"trials":12440,"activeCount":99},[],{"trials":12442,"activeCount":99},[],{"trials":12444,"activeCount":99},[],{"trials":12446,"activeCount":99},[],{"intervention":3229,"totalTrials":214,"cells":12448},{"EARLY_PHASE1":12449,"PHASE1":12451,"PHASE2":12457,"PHASE3":12459,"PHASE4":12461,"NA":12463},{"trials":12450,"activeCount":99},[],{"trials":12452,"activeCount":99},[12453],{"nctId":3221,"briefTitle":3222,"status":107,"phases":12454,"primaryCompletion":3224,"completion":3224,"start":3225,"enrollment":3226,"conditions":12455,"interventions":12456},[87],[24],[114,871,3229],{"trials":12458,"activeCount":99},[],{"trials":12460,"activeCount":99},[],{"trials":12462,"activeCount":99},[],{"trials":12464,"activeCount":99},[],{"intervention":12466,"totalTrials":214,"cells":12467},"tumor-homing peptide iRGD",{"EARLY_PHASE1":12468,"PHASE1":12470,"PHASE2":12480,"PHASE3":12482,"PHASE4":12484,"NA":12486},{"trials":12469,"activeCount":99},[],{"trials":12471,"activeCount":99},[12472],{"nctId":12473,"briefTitle":12474,"status":479,"phases":12475,"primaryCompletion":432,"start":481,"enrollment":99,"conditions":12476,"interventions":12479},"NCT01741597","Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung",[87],[12477,12478,226,227,138,5199,144,5204],"Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas",[12466],{"trials":12481,"activeCount":99},[],{"trials":12483,"activeCount":99},[],{"trials":12485,"activeCount":99},[],{"trials":12487,"activeCount":99},[],{"intervention":870,"totalTrials":214,"cells":12489},{"EARLY_PHASE1":12490,"PHASE1":12492,"PHASE2":12498,"PHASE3":12500,"PHASE4":12502,"NA":12504},{"trials":12491,"activeCount":99},[],{"trials":12493,"activeCount":99},[12494],{"nctId":863,"briefTitle":864,"status":107,"phases":12495,"primaryCompletion":866,"completion":866,"start":867,"enrollment":795,"conditions":12496,"interventions":12497},[87],[15],[738,870,75,168,871],{"trials":12499,"activeCount":99},[],{"trials":12501,"activeCount":99},[],{"trials":12503,"activeCount":99},[],{"trials":12505,"activeCount":99},[],{"intervention":12507,"totalTrials":214,"cells":12508},"Gallium Ga 68-labeled PSMA-11",{"EARLY_PHASE1":12509,"PHASE1":12511,"PHASE2":12522,"PHASE3":12524,"PHASE4":12526,"NA":12528},{"trials":12510,"activeCount":99},[],{"trials":12512,"activeCount":99},[12513],{"nctId":12514,"briefTitle":12515,"status":107,"phases":12516,"primaryCompletion":12517,"completion":12517,"start":12518,"enrollment":1001,"conditions":12519,"interventions":12521},"NCT04216134","68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer",[87],"2022-12-09","2019-12-12",[12520],"Biochemically Recurrent Prostate Carcinoma",[12507],{"trials":12523,"activeCount":99},[],{"trials":12525,"activeCount":99},[],{"trials":12527,"activeCount":99},[],{"trials":12529,"activeCount":99},[],{"intervention":883,"totalTrials":214,"cells":12531},{"EARLY_PHASE1":12532,"PHASE1":12534,"PHASE2":12540,"PHASE3":12542,"PHASE4":12544,"NA":12546},{"trials":12533,"activeCount":99},[],{"trials":12535,"activeCount":99},[12536],{"nctId":873,"briefTitle":874,"status":107,"phases":12537,"primaryCompletion":109,"completion":109,"start":876,"enrollment":9,"conditions":12538,"interventions":12539},[87],[878,879,880],[738,385,75,115,871,882,883,274],{"trials":12541,"activeCount":99},[],{"trials":12543,"activeCount":99},[],{"trials":12545,"activeCount":99},[],{"trials":12547,"activeCount":99},[],{"intervention":269,"totalTrials":214,"cells":12549},{"EARLY_PHASE1":12550,"PHASE1":12552,"PHASE2":12558,"PHASE3":12560,"PHASE4":12562,"NA":12564},{"trials":12551,"activeCount":99},[],{"trials":12553,"activeCount":99},[12554],{"nctId":258,"briefTitle":259,"status":107,"phases":12555,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":12556,"interventions":12557},[87],[266],[268,269,250,270,271,272,273,274,275,276],{"trials":12559,"activeCount":99},[],{"trials":12561,"activeCount":99},[],{"trials":12563,"activeCount":99},[],{"trials":12565,"activeCount":99},[],{"intervention":272,"totalTrials":214,"cells":12567},{"EARLY_PHASE1":12568,"PHASE1":12570,"PHASE2":12576,"PHASE3":12578,"PHASE4":12580,"NA":12582},{"trials":12569,"activeCount":99},[],{"trials":12571,"activeCount":99},[12572],{"nctId":258,"briefTitle":259,"status":107,"phases":12573,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":12574,"interventions":12575},[87],[266],[268,269,250,270,271,272,273,274,275,276],{"trials":12577,"activeCount":99},[],{"trials":12579,"activeCount":99},[],{"trials":12581,"activeCount":99},[],{"trials":12583,"activeCount":99},[],{"intervention":3613,"totalTrials":214,"cells":12585},{"EARLY_PHASE1":12586,"PHASE1":12588,"PHASE2":12594,"PHASE3":12596,"PHASE4":12598,"NA":12600},{"trials":12587,"activeCount":99},[],{"trials":12589,"activeCount":99},[12590],{"nctId":3606,"briefTitle":3607,"status":107,"phases":12591,"primaryCompletion":3609,"completion":3609,"start":3610,"enrollment":1945,"conditions":12592,"interventions":12593},[87],[2241,2242],[1256,1535,3613,3614],{"trials":12595,"activeCount":99},[],{"trials":12597,"activeCount":99},[],{"trials":12599,"activeCount":99},[],{"trials":12601,"activeCount":99},[],{"intervention":3614,"totalTrials":214,"cells":12603},{"EARLY_PHASE1":12604,"PHASE1":12606,"PHASE2":12612,"PHASE3":12614,"PHASE4":12616,"NA":12618},{"trials":12605,"activeCount":99},[],{"trials":12607,"activeCount":99},[12608],{"nctId":3606,"briefTitle":3607,"status":107,"phases":12609,"primaryCompletion":3609,"completion":3609,"start":3610,"enrollment":1945,"conditions":12610,"interventions":12611},[87],[2241,2242],[1256,1535,3613,3614],{"trials":12613,"activeCount":99},[],{"trials":12615,"activeCount":99},[],{"trials":12617,"activeCount":99},[],{"trials":12619,"activeCount":99},[],{"intervention":4586,"totalTrials":214,"cells":12621},{"EARLY_PHASE1":12622,"PHASE1":12624,"PHASE2":12630,"PHASE3":12632,"PHASE4":12634,"NA":12636},{"trials":12623,"activeCount":99},[],{"trials":12625,"activeCount":99},[12626],{"nctId":4567,"briefTitle":4568,"status":107,"phases":12627,"primaryCompletion":4570,"completion":4570,"start":4571,"enrollment":1916,"conditions":12628,"interventions":12629},[87],[4573,951,4574,4575,974,4576,2241,4577,4578,952,4579,4580,4581,4582,2242,4583,4584],[4586,1354,4587,4588,4589,4590],{"trials":12631,"activeCount":99},[],{"trials":12633,"activeCount":99},[],{"trials":12635,"activeCount":99},[],{"trials":12637,"activeCount":99},[],{"intervention":4587,"totalTrials":214,"cells":12639},{"EARLY_PHASE1":12640,"PHASE1":12642,"PHASE2":12648,"PHASE3":12650,"PHASE4":12652,"NA":12654},{"trials":12641,"activeCount":99},[],{"trials":12643,"activeCount":99},[12644],{"nctId":4567,"briefTitle":4568,"status":107,"phases":12645,"primaryCompletion":4570,"completion":4570,"start":4571,"enrollment":1916,"conditions":12646,"interventions":12647},[87],[4573,951,4574,4575,974,4576,2241,4577,4578,952,4579,4580,4581,4582,2242,4583,4584],[4586,1354,4587,4588,4589,4590],{"trials":12649,"activeCount":99},[],{"trials":12651,"activeCount":99},[],{"trials":12653,"activeCount":99},[],{"trials":12655,"activeCount":99},[],{"intervention":4588,"totalTrials":214,"cells":12657},{"EARLY_PHASE1":12658,"PHASE1":12660,"PHASE2":12666,"PHASE3":12668,"PHASE4":12670,"NA":12672},{"trials":12659,"activeCount":99},[],{"trials":12661,"activeCount":99},[12662],{"nctId":4567,"briefTitle":4568,"status":107,"phases":12663,"primaryCompletion":4570,"completion":4570,"start":4571,"enrollment":1916,"conditions":12664,"interventions":12665},[87],[4573,951,4574,4575,974,4576,2241,4577,4578,952,4579,4580,4581,4582,2242,4583,4584],[4586,1354,4587,4588,4589,4590],{"trials":12667,"activeCount":99},[],{"trials":12669,"activeCount":99},[],{"trials":12671,"activeCount":99},[],{"trials":12673,"activeCount":99},[],{"intervention":4589,"totalTrials":214,"cells":12675},{"EARLY_PHASE1":12676,"PHASE1":12678,"PHASE2":12684,"PHASE3":12686,"PHASE4":12688,"NA":12690},{"trials":12677,"activeCount":99},[],{"trials":12679,"activeCount":99},[12680],{"nctId":4567,"briefTitle":4568,"status":107,"phases":12681,"primaryCompletion":4570,"completion":4570,"start":4571,"enrollment":1916,"conditions":12682,"interventions":12683},[87],[4573,951,4574,4575,974,4576,2241,4577,4578,952,4579,4580,4581,4582,2242,4583,4584],[4586,1354,4587,4588,4589,4590],{"trials":12685,"activeCount":99},[],{"trials":12687,"activeCount":99},[],{"trials":12689,"activeCount":99},[],{"trials":12691,"activeCount":99},[],{"intervention":4590,"totalTrials":214,"cells":12693},{"EARLY_PHASE1":12694,"PHASE1":12696,"PHASE2":12702,"PHASE3":12704,"PHASE4":12706,"NA":12708},{"trials":12695,"activeCount":99},[],{"trials":12697,"activeCount":99},[12698],{"nctId":4567,"briefTitle":4568,"status":107,"phases":12699,"primaryCompletion":4570,"completion":4570,"start":4571,"enrollment":1916,"conditions":12700,"interventions":12701},[87],[4573,951,4574,4575,974,4576,2241,4577,4578,952,4579,4580,4581,4582,2242,4583,4584],[4586,1354,4587,4588,4589,4590],{"trials":12703,"activeCount":99},[],{"trials":12705,"activeCount":99},[],{"trials":12707,"activeCount":99},[],{"trials":12709,"activeCount":99},[],{"intervention":12300,"totalTrials":214,"cells":12711},{"EARLY_PHASE1":12712,"PHASE1":12714,"PHASE2":12720,"PHASE3":12722,"PHASE4":12724,"NA":12726},{"trials":12713,"activeCount":99},[],{"trials":12715,"activeCount":99},[12716],{"nctId":12290,"briefTitle":12291,"status":107,"phases":12717,"primaryCompletion":12293,"completion":12293,"start":4040,"enrollment":795,"conditions":12718,"interventions":12719},[87],[578,12295,12296,579,12297,580,581,582,10565,583,10567,12298],[587,12300,586],{"trials":12721,"activeCount":99},[],{"trials":12723,"activeCount":99},[],{"trials":12725,"activeCount":99},[],{"trials":12727,"activeCount":99},[],{"intervention":8008,"totalTrials":214,"cells":12729},{"EARLY_PHASE1":12730,"PHASE1":12732,"PHASE2":12738,"PHASE3":12740,"PHASE4":12742,"NA":12744},{"trials":12731,"activeCount":99},[],{"trials":12733,"activeCount":99},[12734],{"nctId":8002,"briefTitle":8003,"status":479,"phases":12735,"primaryCompletion":8005,"completion":8005,"start":5545,"enrollment":99,"conditions":12736,"interventions":12737},[87],[18,21],[2555,8008],{"trials":12739,"activeCount":99},[],{"trials":12741,"activeCount":99},[],{"trials":12743,"activeCount":99},[],{"trials":12745,"activeCount":99},[],{"intervention":3276,"totalTrials":214,"cells":12747},{"EARLY_PHASE1":12748,"PHASE1":12750,"PHASE2":12756,"PHASE3":12758,"PHASE4":12760,"NA":12762},{"trials":12749,"activeCount":99},[],{"trials":12751,"activeCount":99},[12752],{"nctId":3269,"briefTitle":3270,"status":107,"phases":12753,"primaryCompletion":1721,"completion":1721,"start":2508,"enrollment":95,"conditions":12754,"interventions":12755},[87],[3273,3274],[3276,3277,114],{"trials":12757,"activeCount":99},[],{"trials":12759,"activeCount":99},[],{"trials":12761,"activeCount":99},[],{"trials":12763,"activeCount":99},[],{"intervention":3277,"totalTrials":214,"cells":12765},{"EARLY_PHASE1":12766,"PHASE1":12768,"PHASE2":12774,"PHASE3":12776,"PHASE4":12778,"NA":12780},{"trials":12767,"activeCount":99},[],{"trials":12769,"activeCount":99},[12770],{"nctId":3269,"briefTitle":3270,"status":107,"phases":12771,"primaryCompletion":1721,"completion":1721,"start":2508,"enrollment":95,"conditions":12772,"interventions":12773},[87],[3273,3274],[3276,3277,114],{"trials":12775,"activeCount":99},[],{"trials":12777,"activeCount":99},[],{"trials":12779,"activeCount":99},[],{"trials":12781,"activeCount":99},[],{"intervention":8527,"totalTrials":214,"cells":12783},{"EARLY_PHASE1":12784,"PHASE1":12786,"PHASE2":12792,"PHASE3":12794,"PHASE4":12796,"NA":12798},{"trials":12785,"activeCount":99},[],{"trials":12787,"activeCount":99},[12788],{"nctId":8518,"briefTitle":8519,"status":107,"phases":12789,"primaryCompletion":8521,"completion":8522,"start":8523,"enrollment":911,"conditions":12790,"interventions":12791},[87],[8525,138,144],[2946,8527],{"trials":12793,"activeCount":99},[],{"trials":12795,"activeCount":99},[],{"trials":12797,"activeCount":99},[],{"trials":12799,"activeCount":99},[],{"intervention":2533,"totalTrials":214,"cells":12801},{"EARLY_PHASE1":12802,"PHASE1":12804,"PHASE2":12810,"PHASE3":12812,"PHASE4":12814,"NA":12816},{"trials":12803,"activeCount":99},[],{"trials":12805,"activeCount":99},[12806],{"nctId":2526,"briefTitle":2527,"status":479,"phases":12807,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":99,"conditions":12808,"interventions":12809},[87],[1003],[2533,1212,2534,2535,2536,2537,956],{"trials":12811,"activeCount":99},[],{"trials":12813,"activeCount":99},[],{"trials":12815,"activeCount":99},[],{"trials":12817,"activeCount":99},[],{"intervention":2535,"totalTrials":214,"cells":12819},{"EARLY_PHASE1":12820,"PHASE1":12822,"PHASE2":12828,"PHASE3":12830,"PHASE4":12832,"NA":12834},{"trials":12821,"activeCount":99},[],{"trials":12823,"activeCount":99},[12824],{"nctId":2526,"briefTitle":2527,"status":479,"phases":12825,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":99,"conditions":12826,"interventions":12827},[87],[1003],[2533,1212,2534,2535,2536,2537,956],{"trials":12829,"activeCount":99},[],{"trials":12831,"activeCount":99},[],{"trials":12833,"activeCount":99},[],{"trials":12835,"activeCount":99},[],{"intervention":2536,"totalTrials":214,"cells":12837},{"EARLY_PHASE1":12838,"PHASE1":12840,"PHASE2":12846,"PHASE3":12848,"PHASE4":12850,"NA":12852},{"trials":12839,"activeCount":99},[],{"trials":12841,"activeCount":99},[12842],{"nctId":2526,"briefTitle":2527,"status":479,"phases":12843,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":99,"conditions":12844,"interventions":12845},[87],[1003],[2533,1212,2534,2535,2536,2537,956],{"trials":12847,"activeCount":99},[],{"trials":12849,"activeCount":99},[],{"trials":12851,"activeCount":99},[],{"trials":12853,"activeCount":99},[],{"intervention":2537,"totalTrials":214,"cells":12855},{"EARLY_PHASE1":12856,"PHASE1":12858,"PHASE2":12864,"PHASE3":12866,"PHASE4":12868,"NA":12870},{"trials":12857,"activeCount":99},[],{"trials":12859,"activeCount":99},[12860],{"nctId":2526,"briefTitle":2527,"status":479,"phases":12861,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":99,"conditions":12862,"interventions":12863},[87],[1003],[2533,1212,2534,2535,2536,2537,956],{"trials":12865,"activeCount":99},[],{"trials":12867,"activeCount":99},[],{"trials":12869,"activeCount":99},[],{"trials":12871,"activeCount":99},[],{"intervention":6227,"totalTrials":214,"cells":12873},{"EARLY_PHASE1":12874,"PHASE1":12876,"PHASE2":12882,"PHASE3":12884,"PHASE4":12886,"NA":12888},{"trials":12875,"activeCount":99},[],{"trials":12877,"activeCount":99},[12878],{"nctId":6221,"briefTitle":6222,"status":107,"phases":12879,"primaryCompletion":6163,"completion":6163,"start":6224,"enrollment":36,"conditions":12880,"interventions":12881},[87],[2744],[6227,6214],{"trials":12883,"activeCount":99},[],{"trials":12885,"activeCount":99},[],{"trials":12887,"activeCount":99},[],{"trials":12889,"activeCount":99},[],{"intervention":2852,"totalTrials":214,"cells":12891},{"EARLY_PHASE1":12892,"PHASE1":12894,"PHASE2":12900,"PHASE3":12902,"PHASE4":12904,"NA":12906},{"trials":12893,"activeCount":99},[],{"trials":12895,"activeCount":99},[12896],{"nctId":2844,"briefTitle":2845,"status":107,"phases":12897,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":576,"conditions":12898,"interventions":12899},[87],[972,976,1855,2639,2850],[2852,169,1257,1457,2244,939,2853],{"trials":12901,"activeCount":99},[],{"trials":12903,"activeCount":99},[],{"trials":12905,"activeCount":99},[],{"trials":12907,"activeCount":99},[],{"intervention":2853,"totalTrials":214,"cells":12909},{"EARLY_PHASE1":12910,"PHASE1":12912,"PHASE2":12918,"PHASE3":12920,"PHASE4":12922,"NA":12924},{"trials":12911,"activeCount":99},[],{"trials":12913,"activeCount":99},[12914],{"nctId":2844,"briefTitle":2845,"status":107,"phases":12915,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":576,"conditions":12916,"interventions":12917},[87],[972,976,1855,2639,2850],[2852,169,1257,1457,2244,939,2853],{"trials":12919,"activeCount":99},[],{"trials":12921,"activeCount":99},[],{"trials":12923,"activeCount":99},[],{"trials":12925,"activeCount":99},[],{"intervention":12927,"totalTrials":214,"cells":12928},"indocyanine green solution",{"EARLY_PHASE1":12929,"PHASE1":12931,"PHASE2":12942,"PHASE3":12944,"PHASE4":12946,"NA":12948},{"trials":12930,"activeCount":99},[],{"trials":12932,"activeCount":99},[12933],{"nctId":12934,"briefTitle":12935,"status":107,"phases":12936,"primaryCompletion":7893,"completion":7893,"start":12937,"enrollment":404,"conditions":12938,"interventions":12941},"NCT02119858","Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery",[87],"2014-07-25",[12939,12940],"Stage IIA Prostate Cancer","Stage IIB Prostate Cancer",[12927],{"trials":12943,"activeCount":99},[],{"trials":12945,"activeCount":99},[],{"trials":12947,"activeCount":99},[],{"trials":12949,"activeCount":99},[],{"intervention":3704,"totalTrials":214,"cells":12951},{"EARLY_PHASE1":12952,"PHASE1":12954,"PHASE2":12960,"PHASE3":12962,"PHASE4":12964,"NA":12966},{"trials":12953,"activeCount":99},[],{"trials":12955,"activeCount":99},[12956],{"nctId":3696,"briefTitle":3697,"status":107,"phases":12957,"primaryCompletion":3699,"completion":3699,"start":3700,"enrollment":3226,"conditions":12958,"interventions":12959},[87],[3702,3239,3240,3241,3242,1891],[2021,3266,3704],{"trials":12961,"activeCount":99},[],{"trials":12963,"activeCount":99},[],{"trials":12965,"activeCount":99},[],{"trials":12967,"activeCount":99},[],{"intervention":10930,"totalTrials":214,"cells":12969},{"EARLY_PHASE1":12970,"PHASE1":12972,"PHASE2":12978,"PHASE3":12980,"PHASE4":12982,"NA":12984},{"trials":12971,"activeCount":99},[],{"trials":12973,"activeCount":99},[12974],{"nctId":10911,"briefTitle":10912,"status":107,"phases":12975,"primaryCompletion":10914,"completion":10914,"start":4041,"enrollment":434,"conditions":12976,"interventions":12977},[87],[10916,10917,10918,10919,10920,10921,10922,4601,10923,10924,10925,10926,10927,10928],[10930,2789],{"trials":12979,"activeCount":99},[],{"trials":12981,"activeCount":99},[],{"trials":12983,"activeCount":99},[],{"trials":12985,"activeCount":99},[],{"intervention":12987,"totalTrials":214,"cells":12988},"Neural Stem Cells-expressing CRAd-S-pk7",{"EARLY_PHASE1":12989,"PHASE1":12991,"PHASE2":13002,"PHASE3":13004,"PHASE4":13006,"NA":13008},{"trials":12990,"activeCount":99},[],{"trials":12992,"activeCount":99},[12993],{"nctId":12994,"briefTitle":12995,"status":907,"phases":12996,"primaryCompletion":12997,"completion":12997,"start":12998,"enrollment":1610,"conditions":12999,"interventions":13001},"NCT05139056","Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas",[87],"2026-08-07","2023-05-02",[13000],"Currently Only Enrolling Glioblastoma Patients at First Recurrence",[12987],{"trials":13003,"activeCount":99},[],{"trials":13005,"activeCount":99},[],{"trials":13007,"activeCount":99},[],{"trials":13009,"activeCount":99},[],{"intervention":13011,"totalTrials":214,"cells":13012},"anti-PSMA monoclonal antibody MDX1201-A488",{"EARLY_PHASE1":13013,"PHASE1":13015,"PHASE2":13026,"PHASE3":13028,"PHASE4":13030,"NA":13032},{"trials":13014,"activeCount":99},[],{"trials":13016,"activeCount":99},[13017],{"nctId":13018,"briefTitle":13019,"status":107,"phases":13020,"primaryCompletion":13021,"completion":13022,"start":13023,"enrollment":486,"conditions":13024,"interventions":13025},"NCT02048150","Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer",[87],"2018-05-10","2023-02-01","2015-03-13",[8646,12940,12122,8649],[13011],{"trials":13027,"activeCount":99},[],{"trials":13029,"activeCount":99},[],{"trials":13031,"activeCount":99},[],{"trials":13033,"activeCount":99},[],{"intervention":13035,"totalTrials":214,"cells":13036},"Iodine I 124 Monoclonal Antibody M5A",{"EARLY_PHASE1":13037,"PHASE1":13039,"PHASE2":13050,"PHASE3":13052,"PHASE4":13054,"NA":13056},{"trials":13038,"activeCount":99},[],{"trials":13040,"activeCount":99},[13041],{"nctId":13042,"briefTitle":13043,"status":107,"phases":13044,"primaryCompletion":13045,"completion":13045,"start":13046,"enrollment":195,"conditions":13047,"interventions":13049},"NCT03993327","An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer",[87],"2024-06-04","2020-07-15",[13048,323,303,335,339,343],"Colorectal Carcinoma Metastatic in the Liver",[13035],{"trials":13051,"activeCount":99},[],{"trials":13053,"activeCount":99},[],{"trials":13055,"activeCount":99},[],{"trials":13057,"activeCount":99},[],{"intervention":13059,"totalTrials":214,"cells":13060},"Esomeprazole Magnesium",{"EARLY_PHASE1":13061,"PHASE1":13063,"PHASE2":13073,"PHASE3":13075,"PHASE4":13077,"NA":13079},{"trials":13062,"activeCount":99},[],{"trials":13064,"activeCount":99},[13065],{"nctId":13066,"briefTitle":13067,"status":107,"phases":13068,"primaryCompletion":10792,"completion":10792,"start":13069,"enrollment":207,"conditions":13070,"interventions":13072},"NCT01135472","Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers",[87],"2010-03",[13071],"Healthy",[13059],{"trials":13074,"activeCount":99},[],{"trials":13076,"activeCount":99},[],{"trials":13078,"activeCount":99},[],{"trials":13080,"activeCount":99},[],{"intervention":13082,"totalTrials":214,"cells":13083},"beta-glucan MM-10-001",{"EARLY_PHASE1":13084,"PHASE1":13086,"PHASE2":13097,"PHASE3":13099,"PHASE4":13101,"NA":13103},{"trials":13085,"activeCount":99},[],{"trials":13087,"activeCount":99},[13088],{"nctId":13089,"briefTitle":13090,"status":107,"phases":13091,"primaryCompletion":13092,"completion":13093,"start":13094,"enrollment":404,"conditions":13095,"interventions":13096},"NCT00857025","Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[87],"2010-11-24","2021-05-18","2008-11-21",[5110],[13082],{"trials":13098,"activeCount":99},[],{"trials":13100,"activeCount":99},[],{"trials":13102,"activeCount":99},[],{"trials":13104,"activeCount":99},[],{"intervention":13106,"totalTrials":214,"cells":13107},"Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A",{"EARLY_PHASE1":13108,"PHASE1":13110,"PHASE2":13120,"PHASE3":13122,"PHASE4":13124,"NA":13126},{"trials":13109,"activeCount":99},[],{"trials":13111,"activeCount":99},[13112],{"nctId":13113,"briefTitle":13114,"status":907,"phases":13115,"primaryCompletion":297,"completion":297,"start":13116,"enrollment":404,"conditions":13117,"interventions":13119},"NCT05204147","Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers",[87],"2022-06-02",[13118,395],"Advanced Cancer",[13106],{"trials":13121,"activeCount":99},[],{"trials":13123,"activeCount":99},[],{"trials":13125,"activeCount":99},[],{"trials":13127,"activeCount":99},[],{"intervention":4667,"totalTrials":214,"cells":13129},{"EARLY_PHASE1":13130,"PHASE1":13132,"PHASE2":13138,"PHASE3":13140,"PHASE4":13142,"NA":13144},{"trials":13131,"activeCount":99},[],{"trials":13133,"activeCount":99},[13134],{"nctId":4659,"briefTitle":4660,"status":107,"phases":13135,"primaryCompletion":4662,"completion":4663,"start":4664,"enrollment":1632,"conditions":13136,"interventions":13137},[87],[1102,1319,2442],[1556,4667],{"trials":13139,"activeCount":99},[],{"trials":13141,"activeCount":99},[],{"trials":13143,"activeCount":99},[],{"trials":13145,"activeCount":99},[],{"intervention":13147,"totalTrials":214,"cells":13148},"multi-CMV epitope modified vaccinia Ankara vaccine",{"EARLY_PHASE1":13149,"PHASE1":13151,"PHASE2":13162,"PHASE3":13164,"PHASE4":13166,"NA":13168},{"trials":13150,"activeCount":99},[],{"trials":13152,"activeCount":99},[13153],{"nctId":13154,"briefTitle":13155,"status":107,"phases":13156,"primaryCompletion":13157,"completion":13157,"start":13158,"enrollment":30,"conditions":13159,"interventions":13161},"NCT01941056","Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus",[87],"2017-07-28","2014-01-05",[8354,13160],"Healthy, no Evidence of Disease",[13147],{"trials":13163,"activeCount":99},[],{"trials":13165,"activeCount":99},[],{"trials":13167,"activeCount":99},[],{"trials":13169,"activeCount":99},[],{"intervention":1060,"totalTrials":214,"cells":13171},{"EARLY_PHASE1":13172,"PHASE1":13174,"PHASE2":13180,"PHASE3":13182,"PHASE4":13184,"NA":13186},{"trials":13173,"activeCount":99},[],{"trials":13175,"activeCount":99},[13176],{"nctId":1030,"briefTitle":1031,"status":479,"phases":13177,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":99,"conditions":13178,"interventions":13179},[87],[1036,1037,1038,1039,1040,1041,1042,323,326,1043,1044,1045,1046,1047,302,1048,1049,1050,303,1051,1052,1053,470,1054,1055,1056,1057],[1059,784,847,1060],{"trials":13181,"activeCount":99},[],{"trials":13183,"activeCount":99},[],{"trials":13185,"activeCount":99},[],{"trials":13187,"activeCount":99},[],{"intervention":13189,"totalTrials":214,"cells":13190},"CpG-STAT3 siRNA CAS3\u002FSS3",{"EARLY_PHASE1":13191,"PHASE1":13193,"PHASE2":13203,"PHASE3":13205,"PHASE4":13207,"NA":13209},{"trials":13192,"activeCount":99},[],{"trials":13194,"activeCount":99},[13195],{"nctId":13196,"briefTitle":13197,"status":479,"phases":13198,"primaryCompletion":13199,"completion":13199,"start":6093,"enrollment":99,"conditions":13200,"interventions":13202},"NCT04995536","CpG-STAT3 siRNA CAS3\u002FSS3 and Localized Radiation Therapy for the Treatment of Relapsed\u002FRefractory B-Cell NHL",[87],"2024-01-04",[3061,972,1848,1849,2895,1850,5486,976,977,978,3062,1855,4715,4716,13201,4717,2639,5236,5238,5489],"Refractory Grade 3 Follicular Lymphoma",[13189],{"trials":13204,"activeCount":99},[],{"trials":13206,"activeCount":99},[],{"trials":13208,"activeCount":99},[],{"trials":13210,"activeCount":99},[],{"intervention":12397,"totalTrials":214,"cells":13212},{"EARLY_PHASE1":13213,"PHASE1":13215,"PHASE2":13221,"PHASE3":13223,"PHASE4":13225,"NA":13227},{"trials":13214,"activeCount":99},[],{"trials":13216,"activeCount":99},[13217],{"nctId":12390,"briefTitle":12391,"status":107,"phases":13218,"primaryCompletion":10792,"completion":10792,"start":12393,"enrollment":12394,"conditions":13219,"interventions":13220},[87],[8444],[12397,12358,12398],{"trials":13222,"activeCount":99},[],{"trials":13224,"activeCount":99},[],{"trials":13226,"activeCount":99},[],{"trials":13228,"activeCount":99},[],{"intervention":12398,"totalTrials":214,"cells":13230},{"EARLY_PHASE1":13231,"PHASE1":13233,"PHASE2":13239,"PHASE3":13241,"PHASE4":13243,"NA":13245},{"trials":13232,"activeCount":99},[],{"trials":13234,"activeCount":99},[13235],{"nctId":12390,"briefTitle":12391,"status":107,"phases":13236,"primaryCompletion":10792,"completion":10792,"start":12393,"enrollment":12394,"conditions":13237,"interventions":13238},[87],[8444],[12397,12358,12398],{"trials":13240,"activeCount":99},[],{"trials":13242,"activeCount":99},[],{"trials":13244,"activeCount":99},[],{"trials":13246,"activeCount":99},[],{"intervention":10569,"totalTrials":214,"cells":13248},{"EARLY_PHASE1":13249,"PHASE1":13251,"PHASE2":13257,"PHASE3":13259,"PHASE4":13261,"NA":13263},{"trials":13250,"activeCount":99},[],{"trials":13252,"activeCount":99},[13253],{"nctId":10560,"briefTitle":10561,"status":107,"phases":13254,"primaryCompletion":8298,"completion":8298,"start":6049,"enrollment":486,"conditions":13255,"interventions":13256},[87],[578,10564,579,580,581,582,10565,583,10566,10567],[10569,387,276],{"trials":13258,"activeCount":99},[],{"trials":13260,"activeCount":99},[],{"trials":13262,"activeCount":99},[],{"trials":13264,"activeCount":99},[],{"intervention":7687,"totalTrials":214,"cells":13266},{"EARLY_PHASE1":13267,"PHASE1":13269,"PHASE2":13275,"PHASE3":13277,"PHASE4":13279,"NA":13281},{"trials":13268,"activeCount":99},[],{"trials":13270,"activeCount":99},[13271],{"nctId":7681,"briefTitle":7682,"status":107,"phases":13272,"primaryCompletion":6233,"completion":6050,"start":7684,"conditions":13273,"interventions":13274},[87],[24],[7687,385],{"trials":13276,"activeCount":99},[],{"trials":13278,"activeCount":99},[],{"trials":13280,"activeCount":99},[],{"trials":13282,"activeCount":99},[],{"intervention":8844,"totalTrials":214,"cells":13284},{"EARLY_PHASE1":13285,"PHASE1":13287,"PHASE2":13293,"PHASE3":13295,"PHASE4":13297,"NA":13299},{"trials":13286,"activeCount":99},[],{"trials":13288,"activeCount":99},[13289],{"nctId":8829,"briefTitle":8830,"status":107,"phases":13290,"primaryCompletion":8832,"completion":8832,"start":8833,"enrollment":283,"conditions":13291,"interventions":13292},[87],[8835,8836,8837,3088,8838,8839,971,1102,5234,1103,8840,8841,8842],[4119,8844],{"trials":13294,"activeCount":99},[],{"trials":13296,"activeCount":99},[],{"trials":13298,"activeCount":99},[],{"trials":13300,"activeCount":99},[],{"intervention":4604,"totalTrials":214,"cells":13302},{"EARLY_PHASE1":13303,"PHASE1":13305,"PHASE2":13311,"PHASE3":13313,"PHASE4":13315,"NA":13317},{"trials":13304,"activeCount":99},[],{"trials":13306,"activeCount":99},[13307],{"nctId":4596,"briefTitle":4597,"status":479,"phases":13308,"primaryCompletion":4599,"completion":4599,"start":1218,"enrollment":99,"conditions":13309,"interventions":13310},[87],[4601,4602],[4604,1354],{"trials":13312,"activeCount":99},[],{"trials":13314,"activeCount":99},[],{"trials":13316,"activeCount":99},[],{"trials":13318,"activeCount":99},[],{"intervention":1211,"totalTrials":214,"cells":13320},{"EARLY_PHASE1":13321,"PHASE1":13323,"PHASE2":13329,"PHASE3":13331,"PHASE4":13333,"NA":13335},{"trials":13322,"activeCount":99},[],{"trials":13324,"activeCount":99},[13325],{"nctId":1202,"briefTitle":1203,"status":479,"phases":13326,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":99,"conditions":13327,"interventions":13328},[87],[1003,1208,818,1209],[1211,784,1212,847],{"trials":13330,"activeCount":99},[],{"trials":13332,"activeCount":99},[],{"trials":13334,"activeCount":99},[],{"trials":13336,"activeCount":99},[],{"intervention":2884,"totalTrials":214,"cells":13338},{"EARLY_PHASE1":13339,"PHASE1":13341,"PHASE2":13347,"PHASE3":13349,"PHASE4":13351,"NA":13353},{"trials":13340,"activeCount":99},[],{"trials":13342,"activeCount":99},[13343],{"nctId":2868,"briefTitle":2869,"status":107,"phases":13344,"primaryCompletion":481,"completion":481,"start":2871,"enrollment":95,"conditions":13345,"interventions":13346},[87],[1918,2873,2874,2875,2876,2877,2878,1848,1849,977,2879,2880,2881,2882],[2884,1775,2345],{"trials":13348,"activeCount":99},[],{"trials":13350,"activeCount":99},[],{"trials":13352,"activeCount":99},[],{"trials":13354,"activeCount":99},[],{"intervention":13356,"totalTrials":214,"cells":13357},"tipifarnib",{"EARLY_PHASE1":13358,"PHASE1":13360,"PHASE2":13368,"PHASE3":13370,"PHASE4":13372,"NA":13374},{"trials":13359,"activeCount":99},[],{"trials":13361,"activeCount":99},[13362],{"nctId":13363,"briefTitle":13364,"status":107,"phases":13365,"primaryCompletion":8322,"completion":8322,"start":735,"conditions":13366,"interventions":13367},"NCT00025454","R115777 in Treating Patients With Advanced Solid Tumors",[87],[24],[13356],{"trials":13369,"activeCount":99},[],{"trials":13371,"activeCount":99},[],{"trials":13373,"activeCount":99},[],{"trials":13375,"activeCount":99},[],{"intervention":362,"totalTrials":214,"cells":13377},{"EARLY_PHASE1":13378,"PHASE1":13380,"PHASE2":13386,"PHASE3":13388,"PHASE4":13390,"NA":13392},{"trials":13379,"activeCount":99},[],{"trials":13381,"activeCount":99},[13382],{"nctId":351,"briefTitle":352,"status":107,"phases":13383,"primaryCompletion":354,"completion":354,"start":355,"enrollment":25,"conditions":13384,"interventions":13385},[87],[285,286,357,358,359,360],[362,270,250,271],{"trials":13387,"activeCount":99},[],{"trials":13389,"activeCount":99},[],{"trials":13391,"activeCount":99},[],{"trials":13393,"activeCount":99},[],{"intervention":2392,"totalTrials":214,"cells":13395},{"EARLY_PHASE1":13396,"PHASE1":13398,"PHASE2":13404,"PHASE3":13406,"PHASE4":13408,"NA":13410},{"trials":13397,"activeCount":99},[],{"trials":13399,"activeCount":99},[13400],{"nctId":2381,"briefTitle":2382,"status":107,"phases":13401,"primaryCompletion":2384,"completion":2385,"start":2386,"enrollment":890,"conditions":13402,"interventions":13403},[87],[2388],[2390,893,894,2391,115,2392],{"trials":13405,"activeCount":99},[],{"trials":13407,"activeCount":99},[],{"trials":13409,"activeCount":99},[],{"trials":13411,"activeCount":99},[],{"intervention":6380,"totalTrials":214,"cells":13413},{"EARLY_PHASE1":13414,"PHASE1":13420,"PHASE2":13422,"PHASE3":13424,"PHASE4":13426,"NA":13428},{"trials":13415,"activeCount":99},[13416],{"nctId":6373,"briefTitle":6374,"status":479,"phases":13417,"primaryCompletion":2048,"completion":2048,"start":6376,"enrollment":99,"conditions":13418,"interventions":13419},[86],[6095,6378,1879],[6368,6380],{"trials":13421,"activeCount":99},[],{"trials":13423,"activeCount":99},[],{"trials":13425,"activeCount":99},[],{"trials":13427,"activeCount":99},[],{"trials":13429,"activeCount":99},[],{"intervention":13431,"totalTrials":214,"cells":13432},"pHIV7-shI-TAR-CCR5RZ treated CD4 cells",{"EARLY_PHASE1":13433,"PHASE1":13442,"PHASE2":13444,"PHASE3":13446,"PHASE4":13448,"NA":13450},{"trials":13434,"activeCount":99},[13435],{"nctId":13436,"briefTitle":13437,"status":369,"phases":13438,"primaryCompletion":2341,"completion":2341,"start":987,"enrollment":498,"conditions":13439,"interventions":13441},"NCT01153646","Gene Transfer for HIV Using Autologous T Cells",[86],[13440],"HIV-1 Infection",[13431],{"trials":13443,"activeCount":99},[],{"trials":13445,"activeCount":99},[],{"trials":13447,"activeCount":99},[],{"trials":13449,"activeCount":99},[],{"trials":13451,"activeCount":99},[],{"intervention":13453,"totalTrials":214,"cells":13454},"Electron Beam Therapy",{"EARLY_PHASE1":13455,"PHASE1":13466,"PHASE2":13468,"PHASE3":13470,"PHASE4":13472,"NA":13474},{"trials":13456,"activeCount":99},[13457],{"nctId":13458,"briefTitle":13459,"status":479,"phases":13460,"primaryCompletion":13461,"completion":13461,"start":13462,"enrollment":99,"conditions":13463,"interventions":13465},"NCT05515692","Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease",[86],"2024-09-18","2024-06-30",[3100,29,13464],"Refractory Sclerodermatous Graft Versus Host Disease",[13453],{"trials":13467,"activeCount":99},[],{"trials":13469,"activeCount":99},[],{"trials":13471,"activeCount":99},[],{"trials":13473,"activeCount":99},[],{"trials":13475,"activeCount":99},[],{"intervention":13477,"totalTrials":214,"cells":13478},"Copper Cu-64-DOTA-alendronate",{"EARLY_PHASE1":13479,"PHASE1":13489,"PHASE2":13491,"PHASE3":13493,"PHASE4":13495,"NA":13497},{"trials":13480,"activeCount":99},[13481],{"nctId":13482,"briefTitle":13483,"status":107,"phases":13484,"primaryCompletion":2385,"completion":2385,"start":13485,"enrollment":214,"conditions":13486,"interventions":13488},"NCT03542695","64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy",[86],"2021-11-03",[6095,13487],"Calcification",[13477],{"trials":13490,"activeCount":99},[],{"trials":13492,"activeCount":99},[],{"trials":13494,"activeCount":99},[],{"trials":13496,"activeCount":99},[],{"trials":13498,"activeCount":99},[],{"intervention":13500,"totalTrials":214,"cells":13501},"Copper Cu 64-DOTA-pembrolizumab",{"EARLY_PHASE1":13502,"PHASE1":13512,"PHASE2":13514,"PHASE3":13516,"PHASE4":13518,"NA":13520},{"trials":13503,"activeCount":99},[13504],{"nctId":13505,"briefTitle":13506,"status":479,"phases":13507,"primaryCompletion":13508,"completion":13508,"start":13509,"enrollment":99,"conditions":13510,"interventions":13511},"NCT05728372","64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation",[86],"2026-11-08","2023-08-25",[326],[13500],{"trials":13513,"activeCount":99},[],{"trials":13515,"activeCount":99},[],{"trials":13517,"activeCount":99},[],{"trials":13519,"activeCount":99},[],{"trials":13521,"activeCount":99},[],{"intervention":2345,"totalTrials":95,"cells":13523},{"EARLY_PHASE1":13524,"PHASE1":13526,"PHASE2":13544,"PHASE3":13562,"PHASE4":13564,"NA":13566},{"trials":13525,"activeCount":99},[],{"trials":13527,"activeCount":99},[13528,13532,13536,13540],{"nctId":8509,"briefTitle":8510,"status":107,"phases":13529,"primaryCompletion":8512,"completion":8512,"start":8513,"enrollment":498,"conditions":13530,"interventions":13531},[87],[32],[3317,2946,1332,274,8516,2345],{"nctId":8882,"briefTitle":8883,"status":107,"phases":13533,"primaryCompletion":8885,"completion":8885,"start":8886,"enrollment":890,"conditions":13534,"interventions":13535},[87],[8888,8355,2777,812,813,8378,819],[8890,8891,2345,8315],{"nctId":2338,"briefTitle":2339,"status":107,"phases":13537,"primaryCompletion":2341,"completion":2341,"start":2342,"enrollment":404,"conditions":13538,"interventions":13539},[87],[32,1298],[1804,115,274,2345],{"nctId":2868,"briefTitle":2869,"status":107,"phases":13541,"primaryCompletion":481,"completion":481,"start":2871,"enrollment":95,"conditions":13542,"interventions":13543},[87],[1918,2873,2874,2875,2876,2877,2878,1848,1849,977,2879,2880,2881,2882],[2884,1775,2345],{"trials":13545,"activeCount":99},[13546,13550,13554,13558],{"nctId":6160,"briefTitle":6161,"status":369,"phases":13547,"primaryCompletion":6163,"start":6164,"enrollment":1916,"conditions":13548,"interventions":13549},[88],[266],[6167,696,274,447,6168,2345],{"nctId":10365,"briefTitle":10366,"status":369,"phases":13551,"primaryCompletion":2508,"start":10368,"enrollment":1945,"conditions":13552,"interventions":13553},[87,88],[10370,2317,10371,10372],[10374,274,276,2345],{"nctId":10380,"briefTitle":10381,"status":369,"phases":13555,"primaryCompletion":10383,"completion":10383,"start":6224,"enrollment":576,"conditions":13556,"interventions":13557},[88],[32],[8303,274,2345],{"nctId":7707,"briefTitle":7708,"status":369,"phases":13559,"primaryCompletion":7710,"completion":7710,"start":7711,"enrollment":283,"conditions":13560,"interventions":13561},[88],[5110],[385,386,274,2345],{"trials":13563,"activeCount":99},[],{"trials":13565,"activeCount":99},[],{"trials":13567,"activeCount":99},[13568],{"nctId":10404,"briefTitle":10405,"status":107,"phases":13569,"primaryCompletion":10407,"completion":10407,"start":6164,"enrollment":10408,"conditions":13570,"interventions":13571},[],[15],[274,8516,7897,2345],{"intervention":882,"totalTrials":498,"cells":13573},{"EARLY_PHASE1":13574,"PHASE1":13576,"PHASE2":13590,"PHASE3":13596,"PHASE4":13598,"NA":13600},{"trials":13575,"activeCount":99},[],{"trials":13577,"activeCount":99},[13578,13582,13586],{"nctId":873,"briefTitle":874,"status":107,"phases":13579,"primaryCompletion":109,"completion":109,"start":876,"enrollment":9,"conditions":13580,"interventions":13581},[87],[878,879,880],[738,385,75,115,871,882,883,274],{"nctId":10833,"briefTitle":10834,"status":107,"phases":13583,"primaryCompletion":8512,"completion":8512,"start":176,"enrollment":1264,"conditions":13584,"interventions":13585},[87],[24],[1700,882],{"nctId":2301,"briefTitle":2302,"status":107,"phases":13587,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":890,"conditions":13588,"interventions":13589},[87],[2308,2309,2310,2311,2312,2313,2314,2315,2316,583,2317,2318,2319,2320,2321,2322,2323,2324,2325,2326,2327,2328,2329,2330,2331,2332,2333,2334,24,2335],[42,115,882,738],{"trials":13591,"activeCount":99},[13592],{"nctId":3355,"briefTitle":3356,"status":107,"phases":13593,"primaryCompletion":3358,"completion":3358,"start":3359,"enrollment":2625,"conditions":13594,"interventions":13595},[88],[2744,395,24],[114,1343,882],{"trials":13597,"activeCount":99},[],{"trials":13599,"activeCount":99},[],{"trials":13601,"activeCount":99},[13602],{"nctId":2504,"briefTitle":2505,"status":479,"phases":13603,"primaryCompletion":2507,"start":2508,"enrollment":99,"conditions":13604,"interventions":13605},[91],[2510,2511,2512,2314,2325,2328,2513],[894,740,882,42,115],{"intervention":7897,"totalTrials":283,"cells":13607},{"EARLY_PHASE1":13608,"PHASE1":13610,"PHASE2":13612,"PHASE3":13618,"PHASE4":13620,"NA":13622},{"trials":13609,"activeCount":99},[],{"trials":13611,"activeCount":99},[],{"trials":13613,"activeCount":99},[13614],{"nctId":7890,"briefTitle":7891,"status":107,"phases":13615,"primaryCompletion":7893,"completion":7893,"start":7894,"enrollment":576,"conditions":13616,"interventions":13617},[87,88],[226,285,286,287,288],[386,397,7897],{"trials":13619,"activeCount":99},[],{"trials":13621,"activeCount":99},[],{"trials":13623,"activeCount":99},[13624,13628],{"nctId":10404,"briefTitle":10405,"status":107,"phases":13625,"primaryCompletion":10407,"completion":10407,"start":6164,"enrollment":10408,"conditions":13626,"interventions":13627},[],[15],[274,8516,7897,2345],{"nctId":10599,"briefTitle":10600,"status":369,"phases":13629,"primaryCompletion":4444,"completion":4444,"start":10602,"enrollment":10603,"conditions":13630,"interventions":13631},[],[15],[10606,387,7897],{"intervention":11545,"totalTrials":283,"cells":13633},{"EARLY_PHASE1":13634,"PHASE1":13636,"PHASE2":13647,"PHASE3":13653,"PHASE4":13655,"NA":13657},{"trials":13635,"activeCount":99},[],{"trials":13637,"activeCount":99},[13638],{"nctId":13639,"briefTitle":13640,"status":107,"phases":13641,"primaryCompletion":13642,"completion":13642,"start":3647,"enrollment":19,"conditions":13643,"interventions":13646},"NCT01281488","Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors",[87],"2017-10-09",[11784,13644,13645],"Stage I Renal Cell Cancer","Stage II Renal Cell Cancer",[11545],{"trials":13648,"activeCount":99},[13649],{"nctId":11538,"briefTitle":11539,"status":107,"phases":13650,"primaryCompletion":11541,"completion":11541,"start":11542,"enrollment":2051,"conditions":13651,"interventions":13652},[87,88],[5110,24],[11545,11546,11460],{"trials":13654,"activeCount":99},[],{"trials":13656,"activeCount":99},[],{"trials":13658,"activeCount":99},[13659],{"nctId":13660,"briefTitle":13661,"status":479,"phases":13662,"primaryCompletion":13663,"completion":13663,"start":4918,"enrollment":99,"conditions":13664,"interventions":13666},"NCT06672224","Indocyanine Green Fluoroscopy and SPY Angiography for the Assessment of Lymphatic Structure in Breast Cancer Patients at Risk for Breast Cancer-Related Lymphedema",[91],"2026-08-14",[13665,6095],"Breast Cancer-Related Lymphedema",[13667],"Indocyanine Green",{"intervention":7633,"totalTrials":363,"cells":13669},{"EARLY_PHASE1":13670,"PHASE1":13672,"PHASE2":13674,"PHASE3":13680,"PHASE4":13682,"NA":13684},{"trials":13671,"activeCount":99},[],{"trials":13673,"activeCount":99},[],{"trials":13675,"activeCount":99},[13676],{"nctId":2071,"briefTitle":2072,"status":107,"phases":13677,"primaryCompletion":2074,"completion":2075,"start":2076,"enrollment":298,"conditions":13678,"interventions":13679},[88],[1880,2078,1883,1887,2079,144,1891],[2081,941,2082,2055,1480],{"trials":13681,"activeCount":99},[],{"trials":13683,"activeCount":99},[],{"trials":13685,"activeCount":99},[13686],{"nctId":7628,"briefTitle":7629,"status":107,"phases":13687,"primaryCompletion":2341,"completion":2341,"start":3358,"enrollment":1509,"conditions":13688,"interventions":13689},[],[15],[7633,7634],{"intervention":10606,"totalTrials":214,"cells":13691},{"EARLY_PHASE1":13692,"PHASE1":13694,"PHASE2":13696,"PHASE3":13698,"PHASE4":13700,"NA":13702},{"trials":13693,"activeCount":99},[],{"trials":13695,"activeCount":99},[],{"trials":13697,"activeCount":99},[],{"trials":13699,"activeCount":99},[],{"trials":13701,"activeCount":99},[],{"trials":13703,"activeCount":99},[13704],{"nctId":10599,"briefTitle":10600,"status":369,"phases":13705,"primaryCompletion":4444,"completion":4444,"start":10602,"enrollment":10603,"conditions":13706,"interventions":13707},[],[15],[10606,387,7897],{"intervention":13709,"totalTrials":214,"cells":13710},"VEGF-TKI",{"EARLY_PHASE1":13711,"PHASE1":13713,"PHASE2":13715,"PHASE3":13717,"PHASE4":13719,"NA":13721},{"trials":13712,"activeCount":99},[],{"trials":13714,"activeCount":99},[],{"trials":13716,"activeCount":99},[],{"trials":13718,"activeCount":99},[],{"trials":13720,"activeCount":99},[],{"trials":13722,"activeCount":99},[13723],{"nctId":13724,"briefTitle":13725,"status":107,"phases":13726,"primaryCompletion":13727,"completion":13727,"start":13728,"enrollment":33,"conditions":13729,"interventions":13731},"NCT02944617","Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor",[91],"2021-12-19","2016-11-11",[13730,1045,11785],"Diarrhea",[13709],{"intervention":13733,"totalTrials":214,"cells":13734},"VWF\u002FFVIII concentrates",{"EARLY_PHASE1":13735,"PHASE1":13737,"PHASE2":13739,"PHASE3":13741,"PHASE4":13743,"NA":13745},{"trials":13736,"activeCount":99},[],{"trials":13738,"activeCount":99},[],{"trials":13740,"activeCount":99},[],{"trials":13742,"activeCount":99},[],{"trials":13744,"activeCount":99},[],{"trials":13746,"activeCount":99},[13747],{"nctId":13748,"briefTitle":13749,"status":107,"phases":13750,"primaryCompletion":13751,"completion":13751,"start":13752,"enrollment":283,"conditions":13753,"interventions":13755},"NCT01051076","Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)",[91],"2020-10-21","2009-11-03",[13754],"Severe Hemophilia A",[13733],{"intervention":13757,"totalTrials":214,"cells":13758},"Cyclophosphamide, Fludarabine, Rabbit ATG",{"EARLY_PHASE1":13759,"PHASE1":13761,"PHASE2":13763,"PHASE3":13765,"PHASE4":13767,"NA":13769},{"trials":13760,"activeCount":99},[],{"trials":13762,"activeCount":99},[],{"trials":13764,"activeCount":99},[],{"trials":13766,"activeCount":99},[],{"trials":13768,"activeCount":99},[],{"trials":13770,"activeCount":99},[13771],{"nctId":13772,"briefTitle":13773,"status":479,"phases":13774,"primaryCompletion":13775,"start":13776,"enrollment":99,"conditions":13777,"interventions":13779},"NCT01129323","Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia",[91],"2011-09","2009-11",[13778],"Severe Aplastic Anemia",[13757],{"intervention":13781,"totalTrials":214,"cells":13782},"FVIII Concentrates",{"EARLY_PHASE1":13783,"PHASE1":13785,"PHASE2":13787,"PHASE3":13789,"PHASE4":13791,"NA":13793},{"trials":13784,"activeCount":99},[],{"trials":13786,"activeCount":99},[],{"trials":13788,"activeCount":99},[],{"trials":13790,"activeCount":99},[],{"trials":13792,"activeCount":99},[],{"trials":13794,"activeCount":99},[13795],{"nctId":13796,"briefTitle":13797,"status":479,"phases":13798,"primaryCompletion":13799,"completion":13799,"start":13800,"enrollment":99,"conditions":13801,"interventions":13802},"NCT01051544","Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive",[91],"2020-06-25","2009-09-25",[13754],[13781,13803],"FVIII\u002FVWF concentrates",{"intervention":13803,"totalTrials":214,"cells":13805},{"EARLY_PHASE1":13806,"PHASE1":13808,"PHASE2":13810,"PHASE3":13812,"PHASE4":13814,"NA":13816},{"trials":13807,"activeCount":99},[],{"trials":13809,"activeCount":99},[],{"trials":13811,"activeCount":99},[],{"trials":13813,"activeCount":99},[],{"trials":13815,"activeCount":99},[],{"trials":13817,"activeCount":99},[13818],{"nctId":13796,"briefTitle":13797,"status":479,"phases":13819,"primaryCompletion":13799,"completion":13799,"start":13800,"enrollment":99,"conditions":13820,"interventions":13821},[91],[13754],[13781,13803],{"intervention":13823,"totalTrials":214,"cells":13824},"zoledronic acid",{"EARLY_PHASE1":13825,"PHASE1":13827,"PHASE2":13829,"PHASE3":13831,"PHASE4":13833,"NA":13835},{"trials":13826,"activeCount":99},[],{"trials":13828,"activeCount":99},[],{"trials":13830,"activeCount":99},[],{"trials":13832,"activeCount":99},[],{"trials":13834,"activeCount":99},[],{"trials":13836,"activeCount":99},[13837],{"nctId":13838,"briefTitle":13839,"status":369,"phases":13840,"primaryCompletion":13841,"completion":13842,"start":13843,"enrollment":95,"conditions":13844,"interventions":13850},"NCT01409811","Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid",[91],"2015-01-01","2015-02","2012-09-14",[13845,13846,13847,13848,13849,139,140],"Estrogen Receptor-positive Breast Cancer","Invasive Ductal Breast Carcinoma","Progesterone Receptor-positive Breast Cancer","Stage IA Breast Cancer","Stage IB Breast Cancer",[13823],{"intervention":484,"totalTrials":214,"cells":13852},{"EARLY_PHASE1":13853,"PHASE1":13855,"PHASE2":13857,"PHASE3":13859,"PHASE4":13861,"NA":13863},{"trials":13854,"activeCount":99},[],{"trials":13856,"activeCount":99},[],{"trials":13858,"activeCount":99},[],{"trials":13860,"activeCount":99},[],{"trials":13862,"activeCount":99},[],{"trials":13864,"activeCount":99},[13865],{"nctId":477,"briefTitle":478,"status":479,"phases":13866,"primaryCompletion":481,"start":281,"enrollment":99,"conditions":13867,"interventions":13868},[91],[285,286,357,358,359,360],[484,270,290,250],{"intervention":13870,"totalTrials":214,"cells":13871},"intraperitoneal chemotherapy",{"EARLY_PHASE1":13872,"PHASE1":13874,"PHASE2":13876,"PHASE3":13878,"PHASE4":13880,"NA":13882},{"trials":13873,"activeCount":99},[],{"trials":13875,"activeCount":99},[],{"trials":13877,"activeCount":99},[],{"trials":13879,"activeCount":99},[],{"trials":13881,"activeCount":99},[],{"trials":13883,"activeCount":99},[13884],{"nctId":13885,"briefTitle":13886,"status":107,"phases":13887,"primaryCompletion":6232,"completion":6232,"start":13888,"enrollment":2543,"conditions":13889,"interventions":13890},"NCT00804258","Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer",[],"2007-08",[879],[13870],{"intervention":13892,"totalTrials":214,"cells":13893},"trivalent influenza vaccine",{"EARLY_PHASE1":13894,"PHASE1":13896,"PHASE2":13898,"PHASE3":13900,"PHASE4":13902,"NA":13904},{"trials":13895,"activeCount":99},[],{"trials":13897,"activeCount":99},[],{"trials":13899,"activeCount":99},[],{"trials":13901,"activeCount":99},[],{"trials":13903,"activeCount":99},[],{"trials":13905,"activeCount":99},[13906],{"nctId":13907,"briefTitle":13908,"status":107,"phases":13909,"primaryCompletion":13910,"completion":13910,"start":13911,"enrollment":13912,"conditions":13913,"interventions":13915},"NCT00964821","Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant",[],"2013-05","2007-01",459,[1295,32,27,1297,1298,1299,13914],"Nonmalignant Neoplasm",[13892],{"intervention":13917,"totalTrials":214,"cells":13918},"immunosuppressive therapy",{"EARLY_PHASE1":13919,"PHASE1":13921,"PHASE2":13923,"PHASE3":13925,"PHASE4":13927,"NA":13929},{"trials":13920,"activeCount":99},[],{"trials":13922,"activeCount":99},[],{"trials":13924,"activeCount":99},[],{"trials":13926,"activeCount":99},[],{"trials":13928,"activeCount":99},[],{"trials":13930,"activeCount":99},[13931],{"nctId":13932,"briefTitle":13933,"status":369,"phases":13934,"primaryCompletion":13935,"completion":13935,"start":6050,"enrollment":1361,"conditions":13936,"interventions":13939},"NCT00813501","Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases",[],"2010-06",[1295,1231,1296,32,27,1297,1298,13937,3315,13938],"Myelodysplastic-Myeloproliferative Diseases","Therapy-related Toxicity",[13917]]